home  gsk gsk brianna migraine patient behind the science breaking through the pain barrier our latest research behind the science jamies story i control my asthma it doesn’t control me latest news gsk receives fda approval for a new selfinjectable formulation of benlysta belimumab for systemic lupus erythematosus  july  investors register now to watch our live investor event webcast on wednesday  july at pm bstam est d remodelled dna helix structure about us we want to help people do more feel better live longer today there are still millions of people without access to basic healthcare thousands of diseases without adequate treatments and millions more people who suffer from everyday ailments at gsk we want to change this read more press releases  july  phase ii study results showed comparable viral suppression rates at  weeks for a twodrug regimen of longacting cabotegravir and rilpivirine and a threedrug regimen in patients with hiv  july  gsk submits us regulatory filing of arnuity ellipta in children with asthma  july  gsk announces board and committee changes view all press releases london   share price at  lse price updated every  minutes nyse   share price at  nyse price updated every  minutes tweets from gsk gsk gsk icymi we’re delighted to welcome leading scientist  physician dr laurie glimcher to our board read more… twittercomiwebstatus… about  hours ago gsk gsk can you imagine a scientific discovery filling a basketball stadium martys hiv research did exactly that… twittercomiwebstatus… about  days ago gsk gsk flashbackfriday to  years ago when marty st clair discovered she’d made a scientific breakthrough in hiv resea… twittercomiwebstatus… about  days ago follow us on twitter find out more our products we research and develop a broad range of innovative products in three primary areas of pharmaceuticals vaccines and consumer healthcare career opportunities at gsk discover the work we do and the opportunities that exist from research and development through to making our products available to those who need them health for all our medicines vaccines and consumer healthcare products are improving quality of life for patients and consumers around the world careers  gsk gsk search  apply careers join us and help make a difference discover a range of opportunities to be part of an organisation that helps millions of people around the world to do more feel better live longer key information explore our business working at gsk graduates working at gsk in the words of our employees we’re a scienceled global healthcare company on a mission to improve the lives of people all over the world we have career opportunities at all levels of seniority across the business globally  discover your career with gsk here view video more about working at gsk our culture and values graduate stories  future leaders on global assignment our global assignment programme allows selected graduates to gain as much breadth of experience as possible hear some of their stories developing our people – employee voices one of our programmes is ‘leading business’ a leadership development programme for high potential senior leaders developing our people we attract and retain the most talented people by investing in training development support and learning opportunities explore our business discover the work we do and the opportunities that exist from research and development through to making our products available to those who need them our people products  gsk gsk ellipta inhaler production line ware uk products we make a wide range of prescription medicines vaccines and consumer healthcare products explore our three business area portfolios for more information we list many – but not all – of our products across a wide range of countries on the following pages key information our prescription medicines our vaccines our consumer healthcare products our products our prescription medicines our pharmaceuticals business discovers develops and makes medicines to treat a broad range of the worlds most common acute and chronic diseases our vaccines our vaccines business develops produces and distributes over  million vaccines every day to people across over  countries our consumer healthcare products our consumer healthcare business has a portfolio of some of the world’s most trusted and best selling products in pain relief oral health respiratory nutrition and skin health horlicks and boost consumer products for sale in a delhi store in march  we completed a part transaction with novartis which reshaped our business we acquired novartis’s vaccines business excluding influenza vaccines and combined our consumer healthcare businesses to create a new company in addition novartis acquired our marketed oncology portfolio and the rd activities related to it viiv healthcare viiv healthcare is an independent global specialist hiv company dedicated to delivering innovative new options for the care and treatment of people living with hivaids stiefel dermatology stiefel has a long history of excellence in dermatology and rd focused in acne psoriasis eczema atopic dermatitis and superficial skin infections contact us  gsk gsk jhanvi ghadge management trainee mumbai india contact us whether you’re a customer job seeker health professional or an investor you can find the best way to contact us from the list below if you are looking for contacts within a specific country or market you can search for specific contacts through our worldwide contact information please note we cannot respond to questions about general medical information or questions regarding your personal medical condition if you have questions about a specific medical condition please consult a healthcare professional you can contact us directly with a direct message dm on our global facebook and twitter channels find all our social channels on our social media page concerns about the behaviour of gsk employees or our suppliers can be raised by speaking up integrity line  which contact details are you looking for headquarters careers customerspatients media media contact details investors funding requests partnerships worldwide find out more global compliance report a possible side effect speak up integrity line download our code of conduct code of conduct policy english pdf  mb investors  gsk gsk investors our investor proposition gsk is a scienceled global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical vaccine and consumer healthcare products key information quarterly results shareholder information annual report  q  results and investor event  wednesday  july emma walmsley ceo and simon dingemans cfo we will announce our second quarter  results and host an investor event on wednesday  july  at the investor event emma walmsley ceo and simon dingemans cfo will speak about our key priorities and financial outlook q  results read the preannouncement aide memoire investor eventregister for the live webcast latest information q  results we released our first quarter results on  april  london   share price at  lse price updated every  minutes nyse   share price at  nyse price updated every  minutes latest press releases  july  phase ii study results showed comparable viral suppression rates at  weeks for a twodrug regimen of longacting cabotegravir and rilpivirine and a threedrug regimen in patients with hiv  july  gsk submits us regulatory filing of arnuity ellipta in children with asthma  july  gsk announces board and committee changes view all press releases shareholder information manage your shares dividend calculator annual general meeting corporate sponsored nominee service more shareholder information annual report and responsible business supplement  view our annual report  summary and download the full annual report and responsible business supplement about us  gsk gsk dr allan pamba vice president for east africa about us we want to help people do more feel better live longer today there are still millions of people without access to basic healthcare thousands of diseases without adequate treatments and millions more people who suffer from everyday ailments at gsk we want to change this key information what we do  annual report  responsible business supplement discover more about gsk as a global healthcare company we take on some of the world’s biggest healthcare challenges by delivering a sustainable business we provide health benefits to patients and consumers improved shareholder returns as well as supporting wider society    view video juliana mok hui gsk scientist singapore we have three worldleading businesses that research develop and manufacture innovative pharmaceutical medicines vaccines and consumer healthcare products we are committed to widening access to our products so more people can benefit no matter where they live in the world or what they can afford to pay our key achievements m in  we delivered more than  million doses of vaccines around the world st in the access to medicine index since launch in  bn we donated  billion albendazole tablets since  to eliminate two neglected tropical diseases siobhan taub sensodyne production line maidenhead uk each of our three businesses benefits from gsk’s commercial infrastructure integrated supply networks and significant global presence  at gsk we believe how we do business is as important as what we do – it’s what makes us different  so we are challenging industry norms by changing the way we work find out more corporate executive team the corporate executive team manages our activities and each member is responsible for a specific part of the business board of directors the board of directors is responsible for the groups system of corporate governance and is ultimately accountable for the groups activities strategy risk management and financial performance our history it began when plough court pharmacy was established in  discover gsks journey through the centuries that led to the organisation we know today search jobs and apply  gsk gsk search jobs and apply use our global job search tool below to discover the range of opportunities here at gsk also visit your local country gsk website where you may find more specific local careers information warning against fraudulent internet recruitment activities pdf more about working at gsk explore our business discover the work we do and the opportunities that exist from research and development through to making our products available to those who need them working at gsk our people are essential to our success we focus on building their capabilities and aim to support and empower them to be the best meet our people meet some of our employees across a range of roles varying in job type function and experience level our locations our extensive network of manufacturing sites rd centres and commercial operations stretch across the globe glaxosmithkline  wikipedia glaxosmithkline from wikipedia the free encyclopedia jump to navigation search glaxosmithkline gsks head office in brentford london type public limited company traded as lse gsk nyse gsk ftse  component industry pharmaceutical biotechnology consumer goods predecessor glaxo plc wellcome plc beecham group plc kline  french beckman companies smith plc founded december   years ago  headquarters brentford london united kingdom area served worldwide key people sir philip hampton chairman emma walmsley ceo products pharmaceuticals vaccines oral healthcare nutritional products overthecounter medicines revenue £ billion  operating income £ billion  net income £ billion  number of employees   subsidiaries stiefel laboratories website wwwgskcom glaxosmithkline plc gsk is a british pharmaceutical company headquartered in brentford london established in  by a merger of glaxo wellcome and smithkline beecham gsk was the worlds sixth largest pharmaceutical company as of  after pfizer novartis merck hoffmannla roche and sanofin  emma walmsley became ceo on  march  and is the first female ceo of the company the company has a primary listing on the london stock exchange and is a constituent of the ftse  index as of august  it had a market capitalisation of £ billion around  billion the fourth largest on the london stock exchange it has a secondary listing on the new york stock exchange gsks drugs and vaccines earned £ billion in  its topselling products that year were advair avodart flovent augmentin lovaza and lamictal gsks consumer products which earned £ billion in  include sensodyne and aquafresh toothpaste the maltedmilk drink horlicks abreva for cold sores breathe right nasal strips nicoderm and nicorette nicotine replacements and night nurse a cold remedy the company developed the first malaria vaccine rtss which it said in  it would make available for five percent above cost legacy products developed at gsk include several listed in the world health organization model list of essential medicines such as amoxicillin mercaptopurine pyrimethamine and zidovudine in  gsk pleaded guilty to promotion of drugs for unapproved uses failure to report safety data and kickbacks to physicians in the united states and agreed to pay a  billion £bn settlement the largest settlement in the country by a drug company contents  history  glaxo wellcome  smithkline beecham  glaxosmithkline  venture arms  research products  pharmaceuticals  malaria vaccine  consumer healthcare  facilities  scientific recognition  operations and acquisitions since   –  –present  philanthropy and social responsibility   criminal and civil settlement  overview  rosiglitazone avandia  paroxetine paxilseroxat  bupropion wellbutrin  other controversies  antitrust case over griseofulvin  ribena  sb pharmco puerto rico  china  market manipulation in the uk  miscellaneous  diagram of acquisition history  see also  notes  references  external links historyedit glaxo wellcomeedit the historic glaxo factory in bunnythorpe new zealand with the glaxo laboratories sign still visible glaxo was founded in the s as a general trading company in bunnythorpe new zealand by a londoner joseph edward nathan in  it began producing driedmilk baby food first known as defiance then as glaxo from lacto under the slogan glaxo builds bonny babies the glaxo laboratories sign is still visible right on what is now a car repair shop on the main street of bunnythorpe the companys first pharmaceutical product produced in  was vitamin d glaxo laboratories opened new units in london in  the company bought two companies joseph nathan and allen  hanburys in  and  respectively the scottish pharmacologist david jack was working for allen  hanburys when glaxo took it over he went on to lead the companys rd until  after the company bought meyer laboratories in  it began to play an important role in the us market in  the american arm glaxo inc moved to research triangle park us headquartersresearch and zebulon us manufacturing in north carolina burroughs wellcome  company was founded in  in london by the american pharmacists henry wellcome and silas burroughs the wellcome tropical research laboratories opened in  in the s burroughs wellcome established research and manufacturing facilities in tuckahoe new york which served as the us headquarters until the company moved to research triangle park in north carolina in  the nobel prize winning scientists gertrude b elion and george h hitchings worked there and invented drugs still used many years later such as mercaptopurine in  the wellcome company bought cooper mcdougall  robertson inc to become more active in animal health glaxo and burroughs wellcome merged in  to form glaxo wellcome glaxo restructured its rd operation that year cutting  jobs worldwide closing its rd facility in beckenham kent and opening a medicines research centre in stevenage hertfordshire also that year glaxo wellcome acquired the californiabased affymax a leader in the field of combinatorial chemistry by  glaxo wellcome had become the worlds thirdlargest pharmaceutical company by revenues behind novartis and merck with a global market share of around  per cent its products included imigran for the treatment of migraine salbutamol ventolin for the treatment of asthma zovirax for the treatment of coldsores and retrovir and epivir for the treatment of aids in  the company was the worlds largest manufacturer of drugs for the treatment of asthma and hivaids it employed  people including  in the uk had  operating companies and  manufacturing facilities worldwide and seven of its products were among the worlds top  bestselling pharmaceuticals the company had rd facilities in hertfordshire kent and london and manufacturing plants in scotland and the north of england it had rd centres in the us and japan and production facilities in the us europe and the far east smithkline beechamedit beechams clock tower constructed  part of the beechams factory st helens in  thomas beecham launched his beechams pills laxative in england giving birth to the beecham group in  beecham opened its first factory in st helens lancashire by the s beecham was extensively involved in pharmaceuticals john k smith opened his first pharmacy in philadelphia in  in  mahlon kline joined the business which  years later became smith kline  co in  it merged with french richard and company and in  changed its name to smith kline  french laboratories as it focused more on research years later it bought norden laboratories a business doing research into animal health and recherche et industrie thérapeutiques in belgium in  to focus on vaccines the company began to expand globally buying seven laboratories in canada and the united states in  in  it bought allergan a manufacturer of eye and skincare products smithkline  french merged with beckman inc in  and changed its name to smithkline beckman in  it bought its biggest competitor international clinical laboratories and in  merged with beecham to form smithkline beecham plc the headquarters moved from the united states to england to expand rd in the united states the company bought a new research center in  another opened in  in england at new frontiers science park harlow glaxosmithklineedit glaxo wellcome and smithkline beecham announced their intention to merge in january  the merger was completed in december that year forming glaxosmithkline gsk the companys global headquarters are at gsk house brentford london officially opened in  by thenprime minister tony blair the building was erected at a cost of £ million and as of  was home to  administrative staff venture armsedit sr one was established in  by smithkline beecham to invest in new biotechnology companies and continued operating after gsk was formed by  gsk had formed another subsidiary gsk ventures to outlicense or start new companies around drug candidates that it did not intend to develop further as of  sr one tended to invest only if the company aligned with gsks business sr one was led by  to  peter sears  to  brenda gavin  to  barbara dalton  to  maxine gowen   to  joyce lonergan   to  tamar howson  to  russell greig  to  christoph westphal  jens eckstein research productsedit further information list of glaxosmithkline products pharmaceuticalsedit gsk manufactures products for major disease areas such as asthma cancer infections diabetes and mental health its biggestselling in  were advair avodart flovent augmentin lovaza and lamictal its drugs and vaccines earned £ billion that year other topselling products include its asthmacopd inhalers advair ventolin and flovent its diphtheriatetanuspertussis vaccine infanrix and its hepatitis b vaccine the epilepsy drug lamictal and the antibacterial augmentin medicines historically discovered or developed at gsk and its legacy companies and now sold as generics include amoxicillin and amoxicillinclavulanate ticarcillinclavulanate mupirocin and ceftazidime for bacterial infections zidovudine for hiv infection valacyclovir for herpes virus infections albendazole for parasitic infections sumatriptan for migraine lamotrigine for epilepsy bupropion and paroxetine for major depressive disorder cimetidine and ranitidine for gastroesophageal reflux disorder mercaptopurine and thioguanine for the treatment of leukemia allopurinol for gout pyrimethamine for malaria and the antibacterial trimethoprim among these albendazole amoxicillin amoxicillinclavulanate allopurinol mercaptopurine mupriocin pyrimethamine ranitidine thioguanine trimethoprim and zidovudine are listed on the world health organizations list of essential medications malaria vaccineedit in  gsk applied for regulatory approval for the first malaria vaccine malaria is responsible for over  deaths annually mainly in africa known as rtss the vaccine was developed as a joint project with the path vaccines initiative and the bill and melinda gates foundation the company has committed to making the vaccine available in developing countries for five percent above the cost of production as of  rtss which uses gsks proprietary as adjuvant was being examined in a phase  trial in eight african countries path reported that in the month period following vaccination rtss conferred approximately  protection from clinical plasmodium falciparum disease in children aged  months and approximately  protection in children aged  weeks when administered in conjunction with expanded program for immunization epi vaccines in  glaxo said it had spent more than  million and expected to spend an additional  million before seeking regulatory approval a second generation malaria vaccine is being evaluated in phase  clinical trials consumer healthcareedit gsks consumer healthcare division which earned £ billion in  sells oral healthcare including aquafresh macleans and sensodyne toothpastes and drinks such as horlicks boost a chocolateflavoured malt drink sold in india and formerly lucozade and ribena sold in  to suntory for £bn other products include abreva to treat cold sores night nurse a cold remedy breathe right nasal strips and nicoderm and nicorette nicotine replacements in march  it recalled alli an overthecounter weightloss drug in the united states and puerto rico because of possible tampering following customer complaints facilitiesedit as of  gsk had offices in over  countries and employed over  people  in rd the companys single largest market is the united states its us headquarters are in the navy yard philadelphia and research triangle park north carolina its consumerproducts division is in moon township pennsylvania company facilities include rd sites england stevenage stockley park ware the us research triangle park north carolina and collegeville pennsylvania canada china croatia france and india gsk is also planning to open a rd centre in partnership with mclaren technology group at the mclaren technology campus centres for biopharmaceutical products the us marietta pennsylvania and hamilton montana belgium canada germany and hungary manufacturing sites for prescription products scotland irvine and montrose england ware barnard castle worthing and ulverston ireland cork the us bristol tennessee king of prussia pennsylvania zebulon north carolina as well as australia belgium france italy malaysia poland puerto rico romania and singapore manufacturing sites for consumer products england maidenhead ireland dungarvan the us aiken south carolina oak hill new york st louis missouri brazil canada and kenya scientific recognitionedit four glaxosmithkline scientists have been recognized by the nobel committee for their contributions to basic medical science andor therapeutics development henry dale a former student of paul ehrlich received the  nobel prize in medicine for his work on the chemical transmission of neural impulses dale served as a pharmacologist and then as director of the wellcome physiological research laboratories from  to  and later served as trustee and chairman of the board of the wellcome trust john vane of wellcome research laboratories shared the  nobel prize for medicine for his work on prostaglandin biology and the discovery of prostacyclin vane served as group research and development director for the wellcome foundation from  to  gertrude b elion and george hitchings both of the wellcome research laboratories shared the  nobel prize in medicine with sir james w black for their discoveries of important principles for drug treatment elliot and hitchings were responsible for the discovery of a plethora of important drugs including mercaptopurine and thioguanine for the treatment of leukemia the immunosuppressant azothioprine allopurinol for gout pyrimethamine for malaria the antibacterial trimethoprim acyclovir for herpes virus infection and nelarabine for cancer treatment operations and acquisitions since edit –edit andrew witty gsks ceo since may  gsk completed the acquisition of new jerseybased block drug in  for us billion in  gsk acquired the usbased consumer healthcare company cns inc whose products included breathe right nasal strips and fiberchoice dietary supplements for us million in cash chris gent previously ceo of vodafone was appointed chairman of the board in  gsk opened its first rd centre in china in  in shanghai initially focused on neurodegenerative diseases andrew witty became the chief executive officer in  witty joined glaxo in  and had been president of gsks pharmaceuticals europe since  in  gsk acquired stiefel laboratories then the worlds largest independent dermatology drug company for usbn in november the fda approved gsks vaccine for  hn influenza protection manufactured by the companys id biomedical corp in canada also in november  gsk formed a joint venture with pfizer to create viiv healthcare which specializes in hiv research in  the company acquired laboratorios phoenix an argentine pharmaceutical company for usm and the ukbased sports nutrition company maxinutrition for £ million us million –presentedit in  in a million deal prestige brands holdings took over  gsk brands with sales of  million including bc powder beano ecotrin fiber choice goodys powder sominex and tagamet in  the company announced that it would invest £ million in manufacturing facilities in ulverston northern england designating it as the site for a previously announced biotech plant in may that year it acquired cellzome a german biotech company for us million and in june worldwide rights to alitretinoin toctino an eczema drug for  million in  gsk acquired human genome sciences hgs for  billion the companies had collaborated on developing the lupus drug belimumab benlysta albiglutide for type  diabetes and darapladib for atherosclerosis in march  gsk paid  billion to raise its stake in its indian pharmaceutical unit glaxosmithkline pharmaceuticals to  percent as part of a move to focus on emerging markets in april  novartis and glaxo agreed on more than  billion in deals with novartis selling its vaccine business to gsk and buying gsks cancer business in february  gsk announced that it would acquire glycovaxyn a swiss pharmaceutical company for  million and in june that year that it would sell two meningitis drugs to pfizer nimenrix and mencevax for around  million philip hampton at that time chair of the royal bank of scotland became gsk chairman in september  in september  the company announced that witty would be succeeded as ceo by emma walmsley in march  walmsley was a management professional originally from lancashire with a background in marketing philanthropy and social responsibilityedit glaxosmithkline center city philadelphia since  glaxosmithkline has several times ranked first among pharmaceutical companies on the global access to medicines index which is funded by the bill and melinda gates foundation in  the human rights campaign an lgbtrights advocacy group gave gsk a score of  percent in its corporate equality index gsk has been active with the world health organization who in the global alliance to eliminate lymphatic filariasis gaelf around  million people globally are believed to be infected with lymphatic filariasis in  the company endorsed the london declaration on neglected tropical diseases it agreed to donate  million albendazole tablets to the who each year to fight soiltransmitted helminthiasis and to provide  million albendazole tablets every year for lymphatic filariasis until the disease is eradicated as of  over  billion treatments had been delivered and  of  countries in which the disease is considered endemic had progressed to the surveillance stage in  the company said it would cut drug prices by  percent in  of the poorest nations release intellectual property rights for substances and processes relevant to neglected disease into a patent pool to encourage new drug development and invest  percent of profits from the leastdeveloped countries in medical infrastructure for those countries médecins sans frontières welcomed the decision but criticized gsk for failing to include hiv patents in its patent pool and for not including middleincome countries in the initiative in  gsk licensed its hiv portfolio to the medicines patent pool for use in children and agreed to negotiate a license for dolutegravir an integrase inhibitor then in clinical development in  this license was extended to include dolutegravir and adults with hiv the licenses include countries in which  percent of adults and  percent of children with hiv live also in  gsk joined alltrials a british campaign to ensure that all clinical trials are registered and the results reported the company said it would make its past clinicaltrial reports available and future ones within a year of the studies end  criminal and civil settlementedit overviewedit in july  gsk pleaded guilty in the united states to criminal charges and agreed to pay  billion in what was the largest settlement until then between the justice department and a drug company the  billion included a criminal fine of  and forfeiture of  the remaining  billion covered a civil settlement with the government under the false claims act the investigation was launched largely on the basis of information from four whistleblowers who filed qui tam whistleblower lawsuits against the company under the false claims act the charges stemmed from gsks promotion of the antidepressants paxil paroxetine and wellbutrin bupropion for unapproved uses from – specifically as suitable for patients under the age of  and from its failure to report safety data about avandia rosiglitazone both in violation of the federal food drug and cosmetic act other drugs promoted for unapproved uses were two inhalers advair fluticasonesalmeterol and flovent fluticasone propionate as well as zofran ondansetron imitrex sumatriptan lotronex alosetron and valtrex valaciclovir the settlement also covered reporting false best prices and underpaying rebates owed under the medicaid drug rebate program and kickbacks to physicians to prescribe gsks drugs there were allexpensespaid spa treatments and hunting trips for doctors and their spouses speakers fees at conferences and payment for articles ghostwritten by the company and placed by physicians in medical journals the company set up a ghostwriting programme called caspper initially to produce articles about paxil but which was extended to cover avandia as part of the settlement gsk signed a fiveyear corporate integrity agreement with the department of health and human services which obliged the company to make major changes in the way it did business including changing its compensation programmes for its sales force and executives and to implement and maintain transparency in its research practices and publication policies it announced in  that it would no longer pay doctors to promote its drugs or attend medical conferences and that its sales staff would no longer have prescription targets rosiglitazone avandiaedit further information rosiglitazone § adverse effects and rosiglitazone § lawsuits rosiglitazone the  settlement included a criminal fine of  for failing to report safety data to the fda about avandia rosiglitazone a diabetes drug approved in  and a civil settlement of  million for making false claims about it the justice department said gsk had promoted rosiglitazone to physicians with misleading information including that it conferred cardiovascular benefits despite an fdamandated label warning of cardiovascular risks in  john buse a diabetes specialist told medical conferences that rosiglitazone might carry an increased risk of cardiovascular problems gsk threatened to sue him called his university head of department and persuaded him to sign a retraction gsk raised questions internally about the drugs safety in  and in  the company ghostwrote an article in circulation describing a gskfunded clinical trial that suggested rosiglitazone might have a beneficial effect on cardiovascular risk from  reports began to link the thiazolidinediones the class of drugs to which rosiglitazone belongs to heart failure in april that year gsk began a sixyear openlabel randomized trial known as record to examine rosiglitazone and cardiovascular events two gsk metaanalyses in  and  showed an increased risk of cardiovascular problems with rosiglitazone the information was passed to the fda and posted on the company website but not otherwise published by december  rosiglitazone had become the topselling diabetes drug with annual sales of us billion in june  the new england journal of medicine published a metaanalysis that associated the drug with an increased risk of heart attack gsk had reportedly tried to persuade one of the authors steven nissen not to publish it after receiving an advance copy from one of the journals peer reviewers a gsk consultant in july  fda scientists suggested that rosiglitazone had caused  excess heart attacks between  and  the fda placed restrictions on the drug including adding a boxed warning but did not withdraw it in  the fda rejected that the drug had caused excess heart attacks a senate finance committee inquiry concluded in  that gsk had sought to intimidate scientists who had concerns about rosiglitazone in february that year the company tried to halt publication of an editorial about the controversy by nissen in the european heart journal the results of gsks record trial were published in june  it confirmed an association between rosiglitazone and an increased risk of heart failure and fractures but not of heart attack and concluded that it does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucoselowering drugs steven nissan and kathy wolkski argued that the studys low event rates reduced its statistical power in september  rosiglitazone was suspended in europe the results of the record study were confirmed in  by the duke clinical research institute in an independent review required by the fda in november that year the fda lifted the restrictions it had placed on the drug the boxed warning about heart attack was removed the warning about heart failure remained in place paroxetine paxilseroxatedit main article study  paroxetine known as paxil and seroxat gsk was fined for promoting paxilseroxat paroxetine for treating depression in the unders although the drug had not been approved for pediatric use paxil had  billion worldwide sales in  the company conducted nine clinical trials between  and  none of which showed that paxil helped children with depression from  to  it promoted the drug for the unders paying physicians to go on allexpenses paid trips fivestar hotels and spas from  paxils label along with those of similar drugs included an fdamandated boxed warning that it might increase the risk of suicidal ideation and behaviour in patients under  an internal smithkline beecham document said in  about withheld data from two gsk studies it would be commercially unacceptable to include a statement that pediatric efficacy had not been demonstrated as this would undermine the profile of paroxetine the company ghostwrote an article published in  in the journal of the american academy of child and adolescent psychiatry that misreported the results of one of its clinical trials study  the article concluded that paxil was generally well tolerated and effective for major depression in adolescents the suppression of the research findings is the subject of side effects  by alison bass for  years gsk marketed paxil as nonhabit forming in   patients filed a classaction suit alleging they had suffered withdrawal symptoms and in  a los angeles court issued an injunction preventing gsk from advertising that the drug was not habit forming the court withdrew the injunction after the fda objected that the court had no jurisdiction over drug marketing that the fda had approved in  a world health organization committee reported that paxil was among the top  drugs and top three antidepressants for which dependence had been reportedn  bupropion wellbutrinedit the company was also fined for promoting wellbutrin bupropion – approved at the time for major depressive disorder and also sold as a smokingcessation aid zyban – for weight loss and the treatment of attention deficit hyperactivity disorder sexual dysfunction and substance addiction gsk paid doctors to promote these offlabel uses and set up supposedly independent advisory boards and continuing medical education programmes other controversiesedit antitrust case over griseofulvinedit in the s glaxo group ltd glaxo and imperial chemical industries ici each owned patents covering various aspects of the antifungal drug griseofulvin nn – they created a patent pool by crosslicensing their patents subject to express licensing restrictions that the chemical from which the finished form of the drug tablets and capsules was made must not be resold in bulk form and they licensed other drug companies to sell the drug in finished form and subject to similar restrictions– the effect and intent of the bulksale restriction was to keep the drug chemical out of the hands of small companies that might act as pricecutters and the effect was to maintain stable uniform prices the united states brought an antitrust suit against the two companies—united states v glaxo group ltd—charging them with violation of the sherman act and also seeking to have the patents declared invalid the trial court found that the defendants had engaged in several unlawful conspiracies but dismissed the part of the suit seeking invalidation of patents and refused to grant as relief mandatory sales of the bulk drug chemical and compulsory licensing of the patents the government appealed to the supreme court which reversed in united states v glaxo group ltd  us   ribenaedit old ribena bottle year unknown made by beecham products brentford middlesex the label states widely used in hospitals and clinics there were concerns in the s about the sugar and vitamin content of ribena a blackcurrantbased syrup and soft drink owned by gsk until  produced in england by hw carter  co from the s the companys unbranded syrup was distributed to children as a source of vitamin c during world war ii which gave the drink a reputation as good for health beecham bought h w carter in  in  the british advertising standards authority asa required gsk to withdraw its claim that ribena toothkind a lowersugar variety did not encourage tooth decay a company poster showed bottles of toothkind in place of the bristles on a toothbrush the asas ruling was upheld by the high court in  gsk was fined  in new zealand over its claim that readytodrink ribena contained high levels of vitamin c after it was found to contain no detectable vitamin c in  gsk sold ribena and another drink lucozade to the japanese multinational suntory for £ billion sb pharmco puerto ricoedit in  the us department of justice announced that gsk would pay a  million criminal fine and forfeiture and a civil settlement of  million under the false claims act the fines stemmed from production of improperly made and adulterated drugs from  to  at gsks subsidiary sb pharmco puerto rico inc in cidra puerto rico which at the time produced  billion of products each year the drugs involved were kytril an antiemetic bactroban used to treat skin infections paxil the antidepressant and avandamet a diabetes drug gsk closed the factory in  according to the new york times the case began in  when gsk sent experts to fix problems cited by the fda the lead inspector recommended recalls of defective products but they were not authorized she was fired in  and filed a whistleblower lawsuit in  federal marshals seized  billion worth of products the largest such seizure in history in the  settlement sb pharmco plead guilty to criminal charges and agreed to pay  million in a criminal fine and forfeiture at that time the largest such payment ever by a manufacturer of adulterated drugs and  million in civil penalties to settle the civil lawsuit chinaedit in  chinese authorities announced that since  gsk had funnelled hk billion in kickbacks to gsk managers doctors hospitals and others who prescribed their drugs using over  travel agencies and consulting firms chinese authorities arrested four gsk executives as part of a fourmonth investigation into claims that doctors were bribed with cash and sexual favours in  a chinese court found the company guilty of bribery and imposed a fine of  million mark reilly the british head of gsks chinese operations received a threeyear suspended prison sentence after a oneday trial held in secret reilly was reportedly deported from china and dismissed by the company market manipulation in the ukedit in february  the company was fined more than £ million by the competition and markets authority for paying generics uk alpharma and norton healthcare more than £m between  and  in order to keep generic varieties of paroxetine out of the nhs market the generics companies were fined a further £ million at the end of  when generics were available in the uk the price of paroxetine dropped  miscellaneousedit italian police sought bribery charges in may  against  doctors and  gsk employees gsk and its predecessor were accused of having spent £m on physicians pharmacists and others giving them cameras computers holidays and cash doctors were alleged to have received cash based on the number of patients they treated with a cancer drug topotecan hycamtin the following month prosecutors in munich accused – doctors of having accepted bribes from smithkline beecham between  and  the inquiry was opened over allegations that the company had given over  hospital doctors money and free trips all charges were dismissed by the verona court in january  in  in the united states gsk settled the largest tax dispute in irs history agreeing to pay  billion at issue were zantac and other products sold in – the case revolved around intracompany transfer pricing—determining the share of profit attributable to the us subsidiaries of gsk and subject to tax by the irs the uks serious fraud office sfo opened a criminal inquiry in  into gsks sales practices using powers granted by the bribery act  the sfo said it was collaborating with chinese authorities to investigate bringing charges in the uk related to gsks activities in china europe and the middle east also as of  the us department of justice was investigating gsk with reference to the foreign corrupt practices act diagram of acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list glaxosmithkline smithkline beecham plc renamed  smithkline beckman renamed  smithklinerit renamed  smith kline  french reorganized  into  smith kline and french laboratories french richards and company acq  smith kline and company founded  lever brothers angioseal div acq  recherche et industrie thérapeutiques acq  beckman instruments inc merged  sold  specialized instruments corp acq  offner electronics acq  allergan acq  sold  international clinical laboratories acq  reckitt  colman acq  stiefel laboratories acq  by smithkline beckman sanofisynthelabo acq  beecham group plc merged  norcliff thayer acq  beecham group ltd s e massengill company acq  beecham group ltd renamed  cl bencard acq  county chemicals acq  glaxo wellcome renamed  glaxo merged  glaxo founded  joseph nathan acq  allen  hanburys founded  acq  margarine unie angioseal div acq  meyer laboratories acq  affymax acq  burroughs wellcome merged  mcdougall  robertson inc acq  burroughs wellcome  company founded  block drug acq  cns inc acq  stiefel laboratories acq  laboratorios phoenix acq  maxinutrition acq  cellzome acq  human genome sciences acq  novartis vaccine div acq  gsk cancer division sold  to novartis glycovaxyn acq  see alsoedit companies portal list of toothpaste brands index of oral health and dental articles recherche et industrie thérapeutiques rit galvani bioelectronics notesedit  glaxo wellcome was formed from glaxos  acquisition of burroughs wellcome and smithkline beecham from the  merger of the beecham group and the smithkline beckman corporation  world health organization expert committee on drug dependence  the committee noted the striking number of reports on paroxetine and withdrawal syndrome  the representative of consumers international reported that a number of patients had experienced difficulty in withdrawing from ssris in general it was agreed that withdrawal was indeed a problem in some patients but there was a difference of opinion on the degree of dependence that was involved given the possibility that the need for treatment of resistant or relapsing disease could make these drugs indispensable for patient care the committee expressed concern about the possibility of inappropriate prescribing resulting in the risk of problems of withdrawal outweighing the benefits of treatment with ssris referencesedit  a b c annual report  pdf retrieved  april    glaxosmithkline statista retrieved  april    the worlds biggest public companies  ranking forbes  ftse allshare index ranking stockchallengecouk   a b c annual report  pdf glaxosmithkline retrieved  may    products glaxosmithkline plc retrieved  november    a b hester plumridge  july  glaxo files its entry in race for a malaria vaccine wall street journal  laura lorenzetti  july  glaxosmithkline seeks approval on firstever malaria vaccine fortune   a b c d e f g h i j k glaxosmithkline to plead guilty and pay  billion to resolve fraud allegations and failure to report safety data united states department of justice  july  katie thomas and michael s schmidt glaxo agrees to pay  billion in fraud settlement the new york times  july  simon neville glaxosmithkline fined bn after bribing doctors to increase drugs sales the guardian  july   r p t davenporthines judy slinn glaxo a history to  cambridge university press  pp –  david newton trademarked a history of wellknown brands from airtex to wrights coal tar the history press  p   a b c d david j ravenscraft william f long paths to creating value in pharmaceutical mergers in steven n kaplan ed mergers and productivity university of chicago press   a b c d e f gsk history glaxosmithkline archived from the original on  june  retrieved  april     the story of a town tricentennial committee  addition to factory the eastchester citizenbulletin  november   peter pennoyer anne walker the architecture of delano  aldrich w w norton  company  p   iconic burroughs wellcome headquarters open for rare public tour triangle modernist houses press release  october   katherine bouton the nobel pair the new york times  january   mark s lesney the ghosts of pharma past modern drug discovery january  pp –   face glaxos axe at wellcome the independent  june    magnus grimond  june  glaxo warns of redundancies the independent   magnus grimond  september  glaxo wellcome plans to axe  jobs the independent   glaxo to acquire affymax the new york times  january   outlook glaxo wellcome the independent  march    company of the week glaxo wellcome the independent  august    profile glaxo wellcome bbc news  january    the new alchemy – the drug industry’s flurry of mergers is based on a big gamble the economist  january    partners resolve their differences and unite at the second attempt nature  may    hall that glitters isnt shareholder gold the daily telegraph  july    a b reaume andrew  january  is corporate venture capital a prescription for success in the pharmaceutical industry the journal of private equity   – jstor    press release peter sears president of smithkline beechams venture capital fund appointed to avant immunotherapeutics board of directors avant via pr newswire may     a b salemi tom  july  dalton joins pfizer the in vivo blog   press release sr one announces new team expands fund premier evergreen fund made  new investments in   business wire sr one via businesswire february     a b c licking ellen  april  sr one posts help wanted ad again the in vivo blog   licking ellen  march  sr ones revolving door the in vivo blog   huang gregory t  april  christoph westphal leaving gsks sr one to focus on longwood founders fund xconomy   press release jens eckstein named president of sr one gsks venture healthcare group sr one via fiercebiotech september     mostrecognized brands antiinfectives december  drugscom   geddes am et al dec  introduction historical perspective and development of amoxicillinclavulanate int j antimicrob agents  suppl  s– pmid  doijijantimicag   brown ag aug  clavulanic acid a novel betalactamase inhibitora case study in drug discovery and development drug des deliv   – pmid    search food and drug administration   d m richards r n brogden february  ceftazidime a review of its antibacterial activity pharmacokinetic properties and therapeutic use drugs   – pmid  doi   a b mercaptopurine chemical  engineering news   a b c d george hitchings and gertrude elion chemical heritage foundation   a b elion gb  the purine path to chemotherapy science   – pmid  doiscience   a b lawrence k altman  february  gertrude elion drug developer dies at  the new york times   who model list of essential medicines th list pdf world health organization october    glaxo files its entry in race for a malaria vaccine wall street journal   press release malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children path   birkett a j et al april  malaria vaccine rd in the decade of vaccines breakthroughs challenges and opportunities vaccine  supplement  b– pmid  doijvaccine   malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children    press releases  media  glaxosmithkline archived from the original on  april    donald g mcneil jr  october  glaxos rts s malaria vaccine shows promise scientists say the new york times   product pipeline  gsk   a b angela monaghan ribena and lucozade sold to japanese drinks giant the guardian  september   majumdar ramanuj  product management in india rd ed phi learning p  isbn    aaron smith alli weightloss drug recalled for tampering cnn  march   about us what we do glaxosmithkline accessed  november  archived  october  at the wayback machine  sir henry dale  biographical   john r vane  biographical   maltzman js koretzky ga april  azathioprine old drug new actions j clin invest  – pmc   pmid  doijci   elion gb  acyclovir discovery mechanism of action and selectivity j med virol suppl  – pmid    koenig r  the legacy of great science the work of nobel laureate gertrude elion lives on oncologist   – pmid  doitheoncologist   glaxosmithkline completes the purchase of block drug for  billion pr newswire retrieved  august    rick stouffer  october  glaxo unit buys breathe right maker trib live   sir christopher gent to exit glaxosmithkline the daily telegraph  october   ben hirschler  may  glaxo china rd centre to target neurodegeneration reuters  david cyranoski  october  pharmaceutical futures made in china nature   corporate executive team glaxosmithkline retrieved  november  archived  october  at the wayback machine  andrew wittys journey from graduate to gsk ceo glaxosmithkline  august  andrew philip witty bloomberg  graham ruddick  april  glaxosmithkline buys stiefel for bn the daily telegraph   fda approves additional vaccine for  hn influenza virus us food and drug administration fda  november    andrew jack  april  companies  pharmaceuticals – gsk and pfizer to merge hiv portfolios financial times   gsk acquires laboratorios phoenix for m infogrok  paul sandle  december  update glaxo buys proteindrinks firm maxinutrition reuters   david ranii  december  gsk sells bc goodys and other brands news  observer archived from the original on  april    gsk confirms  mln stg uk investment plans reuters  march   european biotechnology news  may  gsk acquires cellzome  britains largest drugmaker glaxosmithkline will pay about €m in cash to acquire cellzome ag completely john carroll for fiercebiotech  may  gsk snags proteomics platform tech in m cellzome buyout  john carroll for fiercepharma  june  gsk continues deal spree with m pact for basilea eczema drug basilea pharmaceutica press release  june  basilea enters into global agreement with stiefel a gsk company for toctino® alitretinoin  matthew herper three lessons from glaxosmithklines purchase of human genome sciences forbes  july   hirschler ben  march  gsk pays  billion to lift indian unit stake to  percent reuters retrieved  march    chad bray david jolly novartis and glaxo agree to trade  billion in assets the new york times  april   jonathan d rockoff jeanne whalen marta falconi deal flurry shows drug makers swing toward specialization the wall street journal  april   gen  news highlightsgsk acquires glycovaxyn for m gen   pfizer buys two gsk meningitis vaccines for m gen retrieved  march    james quinn sir philip hampton to chair glaxo the daily telegraph  september   jon yeomans  september  emma walmsley becomes latest female ceo in ftse  as she replaces sir andrew witty at gsk daily telegraph london retrieved  september    access to medicine pdf archived from the original pdf on  february    human rights campaign profle buyers guide entry for glaxosmithkline accessed may    global alliance to eliminate lymphatic filariasis ifpmaorg archived from the original on  december    private and public partners unite to combat  neglected tropical diseases by  bill  melinda gates foundation  january   researchbased pharma pledges on neglected tropical diseases the pharma letter  january    global programme to eliminate lymphatic filariasis progress report  pdf world health organization  september  p    sarah boseley drug giant glaxosmithkline pledges cheap medicine for worlds poor the guardian  february   unitaid  february  unitaid statement on gsk patent pool for neglected diseases  tido von schoenangerer letter to the editor the guardian  february   glaxosmithkline unit joins patent pool for aids drugs  reuters   medicines patent pool viiv healthcare sign licence for the most recent hiv medicine to have received regulatory approval  medicines patent pool   ben goldacre bad pharma fourth estate   p   max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  jim edwards inside gsks cassper ghostwriting program cbs news  august   gsk to stop paying doctors in major marketing overhaul thomsonreuters  december   the intimidation of dr john buse and the diabetes drug avandia committee on finance united states senate november  pp –  max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  for internal concerns p  and attachment e pp – for ghostwriting p  and attachment h pp – for the ghostwriting attachment i p ff for cover letter to circulation attachment i p  for the ghostwritten article attachment i pp – haffner sm et al    effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type  diabetes mellitus circulation   – pmid  doicir   a b nissen se  the rise and fall of rosiglitazone european heart journal   – pmid  doieurheartjehq  see table  for timeline  a b philip d home et al rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type  diabetes record a multicentre randomised openlabel trial the lancet   june  pp – dois pmid  philip d home et al rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes record study design and protocol diabetologia  september  pp – dois pmid  record rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes clinicaltrialsgov  nissen se wolski k  effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes new england journal of medicine   – pmid  doinejmoa rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance   stephanie saul doctor accused of leak to drug maker the new york times  january  gardiner harris a faceoff on the safety of a drug for diabetes the new york times  february   a b staff report on glaxosmithkline and the diabetes drug avandia committee on finance united states senate january  grassley baucus release committee report on avandia the united states senate committee on finance  february  andrew clark glaxos handling of avandia concerns damned by us senate committee the guardian  february   david graham assessment of the cardiovascular risks and health benefits of rosiglitazone office of surveillance and epidemiology food and drug administration  july   fda adds boxed warning for heartrelated risks to antidiabetes drug avandia agency says drug to remain on market while safety assessment continues food and drug administration  november   a b fda drug safety communication fda requires removal of some prescribing and dispensing restrictions for rosiglitazonecontaining diabetes medicines food and drug administration  november   avandia prescribing information food and drug administration  thomas f lüscher ulf landmesser frank ruschitzka  april  standing firm—the european heart journal scientific controversies and the industry european heart journal   – doieurheartjehq  steven e nissen the rise and fall of rosiglitazone european heart journal  april  pp – doieurheartjehq pmid  moncef slaoui the rise and fall of rosiglitazone reply european heart journal  april  pp – doieurheartjehq pmid  michel komajda et al heart failure events with rosiglitazone in type  diabetes data from the record clinical trial european heart journal  april  pp – doieurheartjehp pmid   steven e nissen kathy wolski rosiglitazone revisitedan updated metaanalysis of risk for myocardial infarction and cardiovascular mortality archives of internal medicine  july  pp – that study was limited by low event rates which resulted in insufficient statistical power to confirm or refute evidence of an increased risk for ischemic myocardial events doiarchinternmed pmid   european medicines agency recommends suspension of avandia avandamet and avaglim european medicines agency  september   kenneth w mchaffey et al results of a reevaluation of cardiovascular outcomes in the record trial american heart journal  august  pp – doijahj pmid   fda requires removal of certain restrictions on the diabetes drug avandia food and drug administration  november  readjudication of the rosiglitazone evaluated for cardiovascular outcomes and regulation of glycemia in diabetes trial record joint meeting of the endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee food and drug administration – june  steven nissen steven nissen the hidden agenda behind the fdas new avandia hearings forbes  may  the fda responds to steve nissens criticism of upcoming avandia meeting forbes  may   a b w kondro b sibbald march  drug company experts advised staff to withhold data about ssri use in children canadian medical association journal    pmc   pmid  doicmaj   goldacre  p   kurt samson december  senate probe seeks industry payment data on individual academic researchers annals of neurology   a– pmid  doiana   letter showing authorship of study  drug industry document archive university of california san francisco isabel heck controversial paxil paper still under fire  years later the brown daily herald  april  jon n jureidini leemon b mchenry peter r mansfield clinical trials and drug promotion selective reporting of study  international journal of risk  safety in medicine   pp – doijrs company hid suicide link bbc news  january  secrets of the drug trials bbc panorama  january  goldacre  pp –  martin keller et al efficacy of paroxetine in the treatment of adolescent major depression a randomized controlled trial journal of the american academy of child and adolescent psychiatry  july  pp – pmid  doi  alison bass side effects a prosecutor a whistleblower and a bestselling antidepressant on trial algonquin books of chapel hill  marcia angell  january  drug companies  doctors a story of corruption the new york review of books     judge paxil ads cant say it isnt habitforming associated press  august    drug and device law december   the fdas amicus briefs on preemption ronald d white for the los angeles times august   us opposes order to pull paxil tv ads  a b who expert committee on drug dependence thirtythird report world health organization  pp    a b c d united states v glaxo group ltd  us    a b c d e lahatte gabrielle  reverse payments when the federal trade commission can attack the validity of underlying patents case western reserve journal of law technology  the internet  – retrieved  june    leslie christopher r  antitrust law and intellectual property rights cases and materials oxford university press pp – isbn    united states v glaxo group ltd at   jacobson jonathan m  antitrust law developments american bar association p  isbn    oliver thring consider squash and cordial the guardian  september  we have frank and vernon to thank for ribena the bristol post  september   linus gregoriadis makers of ribena lose fight over antidecay claims the daily telegraph  january   david eames  march  judge orders ribena to fess up the new zealand herald  tony jaques when an icon stumbles – the ribena issue mismanaged corporate communications an international journal   pp – michael regester judy larkin risk issues and crisis management in public relations kogan page publishers  p ff  glaxosmithkline to plead guilty  pay  million to resolve criminal and civil liability regarding manufacturing deficiencies at puerto rico plant us department of justice  october   a b glaxo to pay  million for sale of bad products the new york times  october    alice yan toh han shih  july  shanghai travel agents revenue surge led to arrests in gsk bribery case south china morning post  glaxosmithkline executives face china bribery probe bbc news  july    rupert neate and angela monaghan glaxosmithkline admits some staff in china involved in bribery the guardian  july  rupert neate gsk’s china crisis chief executive andrew witty speaks  as it happened the guardian  july  tom philips  july  chinese police allege glaxo sales reps trained to offer sexual bribes the daily telegraph   china fines glaxosmithkline nearly  million in bribery case  the new york times   malcolm moore denise roland china fines glaxo £m for bribery mark reilly sentenced the daily telegraph  september   watchdog fines gsk £m for paying to keep generic drugs out of uk market daily telegraph  february  retrieved  february    john hooper heather stewart over  doctors face charges in italian drugs scandal the guardian  may   jane burgermeister german prosecutors probe again into bribes by drug companies bmj   june  glaxo probed over doctor freebies bbc news  march   glaxosmithkline annual report pg  pdf retrieved    glaxosmithkline to settle tax dispute with us reuters  september  irs accepts settlement offer in largest transfer pricing dispute irs  september   julia kollewe  may  glaxosmithkline faces criminal investigation by serious fraud office the guardian   kirsten ridley uk fraud office liaising with china on gsk bribery case reuters  july   glaxosmithkline faces bribery claims in syria reuters  august  external linksedit official website glaxosmithkline companies grouped at opencorporates financial times quote profile and news london stock exchange quote regulatory filings and news new york stock exchange quote profile regulatory filings and news v t e glaxosmithkline subsidiaries glaxosmithkline pakistan glaxosmithkline pharmaceuticals ltd stiefel laboratories viiv healthcare  predecessors acquisitions allen  hanburys beecham group block drug burroughs wellcome glaxo glaxo wellcome human genome sciences recherche et industrie thérapeutiques reliant pharmaceuticals s e massengill company smithkline beecham smith kline  french products current pharmaceuticals advair alli augmentin avandia beconase boniva flixonase hycamtin lamictal paxilseroxat serlipet tagamet ventolin wellbutrinzyban zantac … more vaccines hepatyrix pandemrix twinrix other aquafresh horlicks nicoderm nicorette niquitin sensodyne tums … more former bc powder geritol goodys powder lucozade ribena people governance chris gent chair andrew witty ceo other thomas beecham silas m burroughs mahlon kline john k smith henry wellcome litigation canada v glaxosmithkline inc christopher v smithkline beecham corp glaxosmithkline services unlimited v commission united states v glaxo group ltd united states v glaxosmithkline other drug industry document archive glaxosmithkline prize side effects study  category v t e pharmaceutical and biotechnology industry in the united kingdom manufacturing in the united kingdom economy of the united kingdom companies current aah pharmaceuticals alliance boots astex astrazeneca medimmune btg cyclacel dechra pharmaceuticals ge healthcare genus glaxosmithkline hikma pharmaceuticals indivior macfarlan smith norbrook group oxford biomedica pfizer uk phytopharm proximagen shire silence therapeutics tbs gb unipath vectura group vernalis viiv healthcare defunct allen  hanburys amersham beecham group cambridge antibody technology celltech chiroscience distillers company fisons glaxo wellcome ici reliant pharmaceuticals renovo zeneca government and regulatory bodies commission on human medicines department of health european directorate for the quality of medicines european medicines agency medicines and healthcare products regulatory agency national collaborating centre for mental health national patient safety agency pharmaceutical price regulation scheme pharmaceutical society of northern ireland general pharmaceutical council scottish medicines consortium veterinary medicines directorate industry and professional bodies association of the british pharmaceutical industry chemical industries association european federation of biotechnology european federation of pharmaceutical industries and associations faculty of pharmaceutical medicine pharmacists defence association royal pharmaceutical society of great britain worshipful society of apothecaries books and journals bandolier bad pharma  british national formulary british national formulary for children monthly index of medical specialities side effects  the pharmaceutical journal other british approved name british pharmacopoeia drugscope european and developing countries clinical trials partnership european pharmacopoeia list of worlds largest pharmaceutical companies pharmaceutical services negotiating committee wellcome trust category v t e ftse  companies of the united kingdom   → ftse  i admiral group anglo american antofagasta ashtead group associated british foods astrazeneca aviva bae systems bhp bp babcock international barclays barratt developments british american tobacco british land bt group bunzl burberry carnival centrica cocacola hbc compass group convatec crh croda international dcc diageo direct line group easyjet experian fresnillo gs gkn glaxosmithkline glencore hammerson hargreaves lansdown hsbc imperial brands informa intercontinental hotels group international airlines group intertek itv johnson matthey kingfisher land securities group legal  general lloyds banking group london stock exchange group marks  spencer mediclinic international merlin entertainments micro focus international mondi morrisons national grid next old mutual paddy power betfair pearson persimmon provident prudential randgold resources royal bank of scotland reckitt benckiser relx group rentokil initial rio tinto group rollsroyce royal dutch shell royal mail rsa insurance group sage group j sainsbury schroders scottish mortgage investment trust segro severn trent shire sky smith  nephew smiths group smurfit kappa sse standard chartered standard life st jamess place taylor wimpey tesco tui unilever united utilities vodafone whitbread wolseley worldpay wpp v t e philadelphiaarea corporations including the delaware valley list of companies based in the philadelphia area philadelphiabased fortune  corporations rank in the  list comcast  aramark  crown holdings  delaware valleybased fortune  corporations rank in the  list amerisourcebergen  dupont  lincoln national  universal health services  campbell soup  ugi  burlington stores inc  other notable philadelphiabased businesses amorosos beneficial bank chemtura day  zimmermann fmc corporation independence blue cross pennsylvania real estate investment trust pep boys philadelphia media network radian group urban outfitters notable philadelphiabased professional partnerships ballard spahr blank rome cozen oconnor dechert drinker biddle  reath duane morris morgan lewis  bockius pepper hamilton saul ewing white and williams other notable delaware valleybased businesses actua corporation airgas alliedbarton ametek aqua america asplundh bentley systems brandywine realty trust boscovs carpenter technology cephalon chemours christiana care health system crozer keystone health system davids bridal duckduckgo epam systems enersys liberty property trust penn mutual penn national gaming ritas italian ice sei investments slm sungard susquehanna international group vanguard toll brothers triumph group unisys viropharma vishay intertechnology vwr wawa wilmington trust w l gore and associates wsfs bank notable delaware valleybased us headquarters of foreign businesses aberdeen asset management ace agustawestland astrazeneca delaware investments glaxosmithkline ing group keystone foods sap america siemens medical shire pharmaceuticals subaru teva pharmaceuticals td bank notable delaware valleybased division headquarters of us corporations acme cerberus capital management centocor johnson  johnson colonial penn conseco delmarva power exelon gsi commerce ebay hercules ashland mab paints sherwinwilliams mcneil laboratories jj neoware hewlettpackard peco exelon qvc liberty media rohm and haas dow chemical sunoco energy transfer tasty baking flowers foods retrieved from httpsenwikipediaorgwindexphptitleglaxosmithklineoldid categories biotechnology companies of the united kingdomcompanies based in the london borough of hounslowcompanies listed on the new york stock exchangedental companiesglaxosmithklinemedical controversiesmultinational companies headquartered in englandpharmaceutical companies established in british companies established in pharmaceutical companies of the united kingdomvaccine producersorphan drug companieslife sciences industry establishments in the united kingdombiotechnology companies established in companies formed by mergerhidden categories webarchive template wayback linksuse british english from september use dmy dates from september opencorporates groupings navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages العربيةcatalàčeštinadanskdeutschespañolesperantoفارسیfrançais한국어हिन्दीbahasa indonesiaíslenskaitalianoעבריתಕನ್ನಡlietuviųmagyarbahasa melayunederlandsnorsk bokmålnorsk nynorskpolskiportuguêsromânăрусскийscotsසිංහලсрпски  srpskisrpskohrvatski  српскохрватскиsuomisvenskaతెలుగుไทยtürkçeукраїнська edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view glaxosmithkline  wikipedia glaxosmithkline from wikipedia the free encyclopedia jump to navigation search glaxosmithkline gsks head office in brentford london type public limited company traded as lse gsk nyse gsk ftse  component industry pharmaceutical biotechnology consumer goods predecessor glaxo plc wellcome plc beecham group plc kline  french beckman companies smith plc founded december   years ago  headquarters brentford london united kingdom area served worldwide key people sir philip hampton chairman emma walmsley ceo products pharmaceuticals vaccines oral healthcare nutritional products overthecounter medicines revenue £ billion  operating income £ billion  net income £ billion  number of employees   subsidiaries stiefel laboratories website wwwgskcom glaxosmithkline plc gsk is a british pharmaceutical company headquartered in brentford london established in  by a merger of glaxo wellcome and smithkline beecham gsk was the worlds sixth largest pharmaceutical company as of  after pfizer novartis merck hoffmannla roche and sanofin  emma walmsley became ceo on  march  and is the first female ceo of the company the company has a primary listing on the london stock exchange and is a constituent of the ftse  index as of august  it had a market capitalisation of £ billion around  billion the fourth largest on the london stock exchange it has a secondary listing on the new york stock exchange gsks drugs and vaccines earned £ billion in  its topselling products that year were advair avodart flovent augmentin lovaza and lamictal gsks consumer products which earned £ billion in  include sensodyne and aquafresh toothpaste the maltedmilk drink horlicks abreva for cold sores breathe right nasal strips nicoderm and nicorette nicotine replacements and night nurse a cold remedy the company developed the first malaria vaccine rtss which it said in  it would make available for five percent above cost legacy products developed at gsk include several listed in the world health organization model list of essential medicines such as amoxicillin mercaptopurine pyrimethamine and zidovudine in  gsk pleaded guilty to promotion of drugs for unapproved uses failure to report safety data and kickbacks to physicians in the united states and agreed to pay a  billion £bn settlement the largest settlement in the country by a drug company contents  history  glaxo wellcome  smithkline beecham  glaxosmithkline  venture arms  research products  pharmaceuticals  malaria vaccine  consumer healthcare  facilities  scientific recognition  operations and acquisitions since   –  –present  philanthropy and social responsibility   criminal and civil settlement  overview  rosiglitazone avandia  paroxetine paxilseroxat  bupropion wellbutrin  other controversies  antitrust case over griseofulvin  ribena  sb pharmco puerto rico  china  market manipulation in the uk  miscellaneous  diagram of acquisition history  see also  notes  references  external links historyedit glaxo wellcomeedit the historic glaxo factory in bunnythorpe new zealand with the glaxo laboratories sign still visible glaxo was founded in the s as a general trading company in bunnythorpe new zealand by a londoner joseph edward nathan in  it began producing driedmilk baby food first known as defiance then as glaxo from lacto under the slogan glaxo builds bonny babies the glaxo laboratories sign is still visible right on what is now a car repair shop on the main street of bunnythorpe the companys first pharmaceutical product produced in  was vitamin d glaxo laboratories opened new units in london in  the company bought two companies joseph nathan and allen  hanburys in  and  respectively the scottish pharmacologist david jack was working for allen  hanburys when glaxo took it over he went on to lead the companys rd until  after the company bought meyer laboratories in  it began to play an important role in the us market in  the american arm glaxo inc moved to research triangle park us headquartersresearch and zebulon us manufacturing in north carolina burroughs wellcome  company was founded in  in london by the american pharmacists henry wellcome and silas burroughs the wellcome tropical research laboratories opened in  in the s burroughs wellcome established research and manufacturing facilities in tuckahoe new york which served as the us headquarters until the company moved to research triangle park in north carolina in  the nobel prize winning scientists gertrude b elion and george h hitchings worked there and invented drugs still used many years later such as mercaptopurine in  the wellcome company bought cooper mcdougall  robertson inc to become more active in animal health glaxo and burroughs wellcome merged in  to form glaxo wellcome glaxo restructured its rd operation that year cutting  jobs worldwide closing its rd facility in beckenham kent and opening a medicines research centre in stevenage hertfordshire also that year glaxo wellcome acquired the californiabased affymax a leader in the field of combinatorial chemistry by  glaxo wellcome had become the worlds thirdlargest pharmaceutical company by revenues behind novartis and merck with a global market share of around  per cent its products included imigran for the treatment of migraine salbutamol ventolin for the treatment of asthma zovirax for the treatment of coldsores and retrovir and epivir for the treatment of aids in  the company was the worlds largest manufacturer of drugs for the treatment of asthma and hivaids it employed  people including  in the uk had  operating companies and  manufacturing facilities worldwide and seven of its products were among the worlds top  bestselling pharmaceuticals the company had rd facilities in hertfordshire kent and london and manufacturing plants in scotland and the north of england it had rd centres in the us and japan and production facilities in the us europe and the far east smithkline beechamedit beechams clock tower constructed  part of the beechams factory st helens in  thomas beecham launched his beechams pills laxative in england giving birth to the beecham group in  beecham opened its first factory in st helens lancashire by the s beecham was extensively involved in pharmaceuticals john k smith opened his first pharmacy in philadelphia in  in  mahlon kline joined the business which  years later became smith kline  co in  it merged with french richard and company and in  changed its name to smith kline  french laboratories as it focused more on research years later it bought norden laboratories a business doing research into animal health and recherche et industrie thérapeutiques in belgium in  to focus on vaccines the company began to expand globally buying seven laboratories in canada and the united states in  in  it bought allergan a manufacturer of eye and skincare products smithkline  french merged with beckman inc in  and changed its name to smithkline beckman in  it bought its biggest competitor international clinical laboratories and in  merged with beecham to form smithkline beecham plc the headquarters moved from the united states to england to expand rd in the united states the company bought a new research center in  another opened in  in england at new frontiers science park harlow glaxosmithklineedit glaxo wellcome and smithkline beecham announced their intention to merge in january  the merger was completed in december that year forming glaxosmithkline gsk the companys global headquarters are at gsk house brentford london officially opened in  by thenprime minister tony blair the building was erected at a cost of £ million and as of  was home to  administrative staff venture armsedit sr one was established in  by smithkline beecham to invest in new biotechnology companies and continued operating after gsk was formed by  gsk had formed another subsidiary gsk ventures to outlicense or start new companies around drug candidates that it did not intend to develop further as of  sr one tended to invest only if the company aligned with gsks business sr one was led by  to  peter sears  to  brenda gavin  to  barbara dalton  to  maxine gowen   to  joyce lonergan   to  tamar howson  to  russell greig  to  christoph westphal  jens eckstein research productsedit further information list of glaxosmithkline products pharmaceuticalsedit gsk manufactures products for major disease areas such as asthma cancer infections diabetes and mental health its biggestselling in  were advair avodart flovent augmentin lovaza and lamictal its drugs and vaccines earned £ billion that year other topselling products include its asthmacopd inhalers advair ventolin and flovent its diphtheriatetanuspertussis vaccine infanrix and its hepatitis b vaccine the epilepsy drug lamictal and the antibacterial augmentin medicines historically discovered or developed at gsk and its legacy companies and now sold as generics include amoxicillin and amoxicillinclavulanate ticarcillinclavulanate mupirocin and ceftazidime for bacterial infections zidovudine for hiv infection valacyclovir for herpes virus infections albendazole for parasitic infections sumatriptan for migraine lamotrigine for epilepsy bupropion and paroxetine for major depressive disorder cimetidine and ranitidine for gastroesophageal reflux disorder mercaptopurine and thioguanine for the treatment of leukemia allopurinol for gout pyrimethamine for malaria and the antibacterial trimethoprim among these albendazole amoxicillin amoxicillinclavulanate allopurinol mercaptopurine mupriocin pyrimethamine ranitidine thioguanine trimethoprim and zidovudine are listed on the world health organizations list of essential medications malaria vaccineedit in  gsk applied for regulatory approval for the first malaria vaccine malaria is responsible for over  deaths annually mainly in africa known as rtss the vaccine was developed as a joint project with the path vaccines initiative and the bill and melinda gates foundation the company has committed to making the vaccine available in developing countries for five percent above the cost of production as of  rtss which uses gsks proprietary as adjuvant was being examined in a phase  trial in eight african countries path reported that in the month period following vaccination rtss conferred approximately  protection from clinical plasmodium falciparum disease in children aged  months and approximately  protection in children aged  weeks when administered in conjunction with expanded program for immunization epi vaccines in  glaxo said it had spent more than  million and expected to spend an additional  million before seeking regulatory approval a second generation malaria vaccine is being evaluated in phase  clinical trials consumer healthcareedit gsks consumer healthcare division which earned £ billion in  sells oral healthcare including aquafresh macleans and sensodyne toothpastes and drinks such as horlicks boost a chocolateflavoured malt drink sold in india and formerly lucozade and ribena sold in  to suntory for £bn other products include abreva to treat cold sores night nurse a cold remedy breathe right nasal strips and nicoderm and nicorette nicotine replacements in march  it recalled alli an overthecounter weightloss drug in the united states and puerto rico because of possible tampering following customer complaints facilitiesedit as of  gsk had offices in over  countries and employed over  people  in rd the companys single largest market is the united states its us headquarters are in the navy yard philadelphia and research triangle park north carolina its consumerproducts division is in moon township pennsylvania company facilities include rd sites england stevenage stockley park ware the us research triangle park north carolina and collegeville pennsylvania canada china croatia france and india gsk is also planning to open a rd centre in partnership with mclaren technology group at the mclaren technology campus centres for biopharmaceutical products the us marietta pennsylvania and hamilton montana belgium canada germany and hungary manufacturing sites for prescription products scotland irvine and montrose england ware barnard castle worthing and ulverston ireland cork the us bristol tennessee king of prussia pennsylvania zebulon north carolina as well as australia belgium france italy malaysia poland puerto rico romania and singapore manufacturing sites for consumer products england maidenhead ireland dungarvan the us aiken south carolina oak hill new york st louis missouri brazil canada and kenya scientific recognitionedit four glaxosmithkline scientists have been recognized by the nobel committee for their contributions to basic medical science andor therapeutics development henry dale a former student of paul ehrlich received the  nobel prize in medicine for his work on the chemical transmission of neural impulses dale served as a pharmacologist and then as director of the wellcome physiological research laboratories from  to  and later served as trustee and chairman of the board of the wellcome trust john vane of wellcome research laboratories shared the  nobel prize for medicine for his work on prostaglandin biology and the discovery of prostacyclin vane served as group research and development director for the wellcome foundation from  to  gertrude b elion and george hitchings both of the wellcome research laboratories shared the  nobel prize in medicine with sir james w black for their discoveries of important principles for drug treatment elliot and hitchings were responsible for the discovery of a plethora of important drugs including mercaptopurine and thioguanine for the treatment of leukemia the immunosuppressant azothioprine allopurinol for gout pyrimethamine for malaria the antibacterial trimethoprim acyclovir for herpes virus infection and nelarabine for cancer treatment operations and acquisitions since edit –edit andrew witty gsks ceo since may  gsk completed the acquisition of new jerseybased block drug in  for us billion in  gsk acquired the usbased consumer healthcare company cns inc whose products included breathe right nasal strips and fiberchoice dietary supplements for us million in cash chris gent previously ceo of vodafone was appointed chairman of the board in  gsk opened its first rd centre in china in  in shanghai initially focused on neurodegenerative diseases andrew witty became the chief executive officer in  witty joined glaxo in  and had been president of gsks pharmaceuticals europe since  in  gsk acquired stiefel laboratories then the worlds largest independent dermatology drug company for usbn in november the fda approved gsks vaccine for  hn influenza protection manufactured by the companys id biomedical corp in canada also in november  gsk formed a joint venture with pfizer to create viiv healthcare which specializes in hiv research in  the company acquired laboratorios phoenix an argentine pharmaceutical company for usm and the ukbased sports nutrition company maxinutrition for £ million us million –presentedit in  in a million deal prestige brands holdings took over  gsk brands with sales of  million including bc powder beano ecotrin fiber choice goodys powder sominex and tagamet in  the company announced that it would invest £ million in manufacturing facilities in ulverston northern england designating it as the site for a previously announced biotech plant in may that year it acquired cellzome a german biotech company for us million and in june worldwide rights to alitretinoin toctino an eczema drug for  million in  gsk acquired human genome sciences hgs for  billion the companies had collaborated on developing the lupus drug belimumab benlysta albiglutide for type  diabetes and darapladib for atherosclerosis in march  gsk paid  billion to raise its stake in its indian pharmaceutical unit glaxosmithkline pharmaceuticals to  percent as part of a move to focus on emerging markets in april  novartis and glaxo agreed on more than  billion in deals with novartis selling its vaccine business to gsk and buying gsks cancer business in february  gsk announced that it would acquire glycovaxyn a swiss pharmaceutical company for  million and in june that year that it would sell two meningitis drugs to pfizer nimenrix and mencevax for around  million philip hampton at that time chair of the royal bank of scotland became gsk chairman in september  in september  the company announced that witty would be succeeded as ceo by emma walmsley in march  walmsley was a management professional originally from lancashire with a background in marketing philanthropy and social responsibilityedit glaxosmithkline center city philadelphia since  glaxosmithkline has several times ranked first among pharmaceutical companies on the global access to medicines index which is funded by the bill and melinda gates foundation in  the human rights campaign an lgbtrights advocacy group gave gsk a score of  percent in its corporate equality index gsk has been active with the world health organization who in the global alliance to eliminate lymphatic filariasis gaelf around  million people globally are believed to be infected with lymphatic filariasis in  the company endorsed the london declaration on neglected tropical diseases it agreed to donate  million albendazole tablets to the who each year to fight soiltransmitted helminthiasis and to provide  million albendazole tablets every year for lymphatic filariasis until the disease is eradicated as of  over  billion treatments had been delivered and  of  countries in which the disease is considered endemic had progressed to the surveillance stage in  the company said it would cut drug prices by  percent in  of the poorest nations release intellectual property rights for substances and processes relevant to neglected disease into a patent pool to encourage new drug development and invest  percent of profits from the leastdeveloped countries in medical infrastructure for those countries médecins sans frontières welcomed the decision but criticized gsk for failing to include hiv patents in its patent pool and for not including middleincome countries in the initiative in  gsk licensed its hiv portfolio to the medicines patent pool for use in children and agreed to negotiate a license for dolutegravir an integrase inhibitor then in clinical development in  this license was extended to include dolutegravir and adults with hiv the licenses include countries in which  percent of adults and  percent of children with hiv live also in  gsk joined alltrials a british campaign to ensure that all clinical trials are registered and the results reported the company said it would make its past clinicaltrial reports available and future ones within a year of the studies end  criminal and civil settlementedit overviewedit in july  gsk pleaded guilty in the united states to criminal charges and agreed to pay  billion in what was the largest settlement until then between the justice department and a drug company the  billion included a criminal fine of  and forfeiture of  the remaining  billion covered a civil settlement with the government under the false claims act the investigation was launched largely on the basis of information from four whistleblowers who filed qui tam whistleblower lawsuits against the company under the false claims act the charges stemmed from gsks promotion of the antidepressants paxil paroxetine and wellbutrin bupropion for unapproved uses from – specifically as suitable for patients under the age of  and from its failure to report safety data about avandia rosiglitazone both in violation of the federal food drug and cosmetic act other drugs promoted for unapproved uses were two inhalers advair fluticasonesalmeterol and flovent fluticasone propionate as well as zofran ondansetron imitrex sumatriptan lotronex alosetron and valtrex valaciclovir the settlement also covered reporting false best prices and underpaying rebates owed under the medicaid drug rebate program and kickbacks to physicians to prescribe gsks drugs there were allexpensespaid spa treatments and hunting trips for doctors and their spouses speakers fees at conferences and payment for articles ghostwritten by the company and placed by physicians in medical journals the company set up a ghostwriting programme called caspper initially to produce articles about paxil but which was extended to cover avandia as part of the settlement gsk signed a fiveyear corporate integrity agreement with the department of health and human services which obliged the company to make major changes in the way it did business including changing its compensation programmes for its sales force and executives and to implement and maintain transparency in its research practices and publication policies it announced in  that it would no longer pay doctors to promote its drugs or attend medical conferences and that its sales staff would no longer have prescription targets rosiglitazone avandiaedit further information rosiglitazone § adverse effects and rosiglitazone § lawsuits rosiglitazone the  settlement included a criminal fine of  for failing to report safety data to the fda about avandia rosiglitazone a diabetes drug approved in  and a civil settlement of  million for making false claims about it the justice department said gsk had promoted rosiglitazone to physicians with misleading information including that it conferred cardiovascular benefits despite an fdamandated label warning of cardiovascular risks in  john buse a diabetes specialist told medical conferences that rosiglitazone might carry an increased risk of cardiovascular problems gsk threatened to sue him called his university head of department and persuaded him to sign a retraction gsk raised questions internally about the drugs safety in  and in  the company ghostwrote an article in circulation describing a gskfunded clinical trial that suggested rosiglitazone might have a beneficial effect on cardiovascular risk from  reports began to link the thiazolidinediones the class of drugs to which rosiglitazone belongs to heart failure in april that year gsk began a sixyear openlabel randomized trial known as record to examine rosiglitazone and cardiovascular events two gsk metaanalyses in  and  showed an increased risk of cardiovascular problems with rosiglitazone the information was passed to the fda and posted on the company website but not otherwise published by december  rosiglitazone had become the topselling diabetes drug with annual sales of us billion in june  the new england journal of medicine published a metaanalysis that associated the drug with an increased risk of heart attack gsk had reportedly tried to persuade one of the authors steven nissen not to publish it after receiving an advance copy from one of the journals peer reviewers a gsk consultant in july  fda scientists suggested that rosiglitazone had caused  excess heart attacks between  and  the fda placed restrictions on the drug including adding a boxed warning but did not withdraw it in  the fda rejected that the drug had caused excess heart attacks a senate finance committee inquiry concluded in  that gsk had sought to intimidate scientists who had concerns about rosiglitazone in february that year the company tried to halt publication of an editorial about the controversy by nissen in the european heart journal the results of gsks record trial were published in june  it confirmed an association between rosiglitazone and an increased risk of heart failure and fractures but not of heart attack and concluded that it does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucoselowering drugs steven nissan and kathy wolkski argued that the studys low event rates reduced its statistical power in september  rosiglitazone was suspended in europe the results of the record study were confirmed in  by the duke clinical research institute in an independent review required by the fda in november that year the fda lifted the restrictions it had placed on the drug the boxed warning about heart attack was removed the warning about heart failure remained in place paroxetine paxilseroxatedit main article study  paroxetine known as paxil and seroxat gsk was fined for promoting paxilseroxat paroxetine for treating depression in the unders although the drug had not been approved for pediatric use paxil had  billion worldwide sales in  the company conducted nine clinical trials between  and  none of which showed that paxil helped children with depression from  to  it promoted the drug for the unders paying physicians to go on allexpenses paid trips fivestar hotels and spas from  paxils label along with those of similar drugs included an fdamandated boxed warning that it might increase the risk of suicidal ideation and behaviour in patients under  an internal smithkline beecham document said in  about withheld data from two gsk studies it would be commercially unacceptable to include a statement that pediatric efficacy had not been demonstrated as this would undermine the profile of paroxetine the company ghostwrote an article published in  in the journal of the american academy of child and adolescent psychiatry that misreported the results of one of its clinical trials study  the article concluded that paxil was generally well tolerated and effective for major depression in adolescents the suppression of the research findings is the subject of side effects  by alison bass for  years gsk marketed paxil as nonhabit forming in   patients filed a classaction suit alleging they had suffered withdrawal symptoms and in  a los angeles court issued an injunction preventing gsk from advertising that the drug was not habit forming the court withdrew the injunction after the fda objected that the court had no jurisdiction over drug marketing that the fda had approved in  a world health organization committee reported that paxil was among the top  drugs and top three antidepressants for which dependence had been reportedn  bupropion wellbutrinedit the company was also fined for promoting wellbutrin bupropion – approved at the time for major depressive disorder and also sold as a smokingcessation aid zyban – for weight loss and the treatment of attention deficit hyperactivity disorder sexual dysfunction and substance addiction gsk paid doctors to promote these offlabel uses and set up supposedly independent advisory boards and continuing medical education programmes other controversiesedit antitrust case over griseofulvinedit in the s glaxo group ltd glaxo and imperial chemical industries ici each owned patents covering various aspects of the antifungal drug griseofulvin nn – they created a patent pool by crosslicensing their patents subject to express licensing restrictions that the chemical from which the finished form of the drug tablets and capsules was made must not be resold in bulk form and they licensed other drug companies to sell the drug in finished form and subject to similar restrictions– the effect and intent of the bulksale restriction was to keep the drug chemical out of the hands of small companies that might act as pricecutters and the effect was to maintain stable uniform prices the united states brought an antitrust suit against the two companies—united states v glaxo group ltd—charging them with violation of the sherman act and also seeking to have the patents declared invalid the trial court found that the defendants had engaged in several unlawful conspiracies but dismissed the part of the suit seeking invalidation of patents and refused to grant as relief mandatory sales of the bulk drug chemical and compulsory licensing of the patents the government appealed to the supreme court which reversed in united states v glaxo group ltd  us   ribenaedit old ribena bottle year unknown made by beecham products brentford middlesex the label states widely used in hospitals and clinics there were concerns in the s about the sugar and vitamin content of ribena a blackcurrantbased syrup and soft drink owned by gsk until  produced in england by hw carter  co from the s the companys unbranded syrup was distributed to children as a source of vitamin c during world war ii which gave the drink a reputation as good for health beecham bought h w carter in  in  the british advertising standards authority asa required gsk to withdraw its claim that ribena toothkind a lowersugar variety did not encourage tooth decay a company poster showed bottles of toothkind in place of the bristles on a toothbrush the asas ruling was upheld by the high court in  gsk was fined  in new zealand over its claim that readytodrink ribena contained high levels of vitamin c after it was found to contain no detectable vitamin c in  gsk sold ribena and another drink lucozade to the japanese multinational suntory for £ billion sb pharmco puerto ricoedit in  the us department of justice announced that gsk would pay a  million criminal fine and forfeiture and a civil settlement of  million under the false claims act the fines stemmed from production of improperly made and adulterated drugs from  to  at gsks subsidiary sb pharmco puerto rico inc in cidra puerto rico which at the time produced  billion of products each year the drugs involved were kytril an antiemetic bactroban used to treat skin infections paxil the antidepressant and avandamet a diabetes drug gsk closed the factory in  according to the new york times the case began in  when gsk sent experts to fix problems cited by the fda the lead inspector recommended recalls of defective products but they were not authorized she was fired in  and filed a whistleblower lawsuit in  federal marshals seized  billion worth of products the largest such seizure in history in the  settlement sb pharmco plead guilty to criminal charges and agreed to pay  million in a criminal fine and forfeiture at that time the largest such payment ever by a manufacturer of adulterated drugs and  million in civil penalties to settle the civil lawsuit chinaedit in  chinese authorities announced that since  gsk had funnelled hk billion in kickbacks to gsk managers doctors hospitals and others who prescribed their drugs using over  travel agencies and consulting firms chinese authorities arrested four gsk executives as part of a fourmonth investigation into claims that doctors were bribed with cash and sexual favours in  a chinese court found the company guilty of bribery and imposed a fine of  million mark reilly the british head of gsks chinese operations received a threeyear suspended prison sentence after a oneday trial held in secret reilly was reportedly deported from china and dismissed by the company market manipulation in the ukedit in february  the company was fined more than £ million by the competition and markets authority for paying generics uk alpharma and norton healthcare more than £m between  and  in order to keep generic varieties of paroxetine out of the nhs market the generics companies were fined a further £ million at the end of  when generics were available in the uk the price of paroxetine dropped  miscellaneousedit italian police sought bribery charges in may  against  doctors and  gsk employees gsk and its predecessor were accused of having spent £m on physicians pharmacists and others giving them cameras computers holidays and cash doctors were alleged to have received cash based on the number of patients they treated with a cancer drug topotecan hycamtin the following month prosecutors in munich accused – doctors of having accepted bribes from smithkline beecham between  and  the inquiry was opened over allegations that the company had given over  hospital doctors money and free trips all charges were dismissed by the verona court in january  in  in the united states gsk settled the largest tax dispute in irs history agreeing to pay  billion at issue were zantac and other products sold in – the case revolved around intracompany transfer pricing—determining the share of profit attributable to the us subsidiaries of gsk and subject to tax by the irs the uks serious fraud office sfo opened a criminal inquiry in  into gsks sales practices using powers granted by the bribery act  the sfo said it was collaborating with chinese authorities to investigate bringing charges in the uk related to gsks activities in china europe and the middle east also as of  the us department of justice was investigating gsk with reference to the foreign corrupt practices act diagram of acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list glaxosmithkline smithkline beecham plc renamed  smithkline beckman renamed  smithklinerit renamed  smith kline  french reorganized  into  smith kline and french laboratories french richards and company acq  smith kline and company founded  lever brothers angioseal div acq  recherche et industrie thérapeutiques acq  beckman instruments inc merged  sold  specialized instruments corp acq  offner electronics acq  allergan acq  sold  international clinical laboratories acq  reckitt  colman acq  stiefel laboratories acq  by smithkline beckman sanofisynthelabo acq  beecham group plc merged  norcliff thayer acq  beecham group ltd s e massengill company acq  beecham group ltd renamed  cl bencard acq  county chemicals acq  glaxo wellcome renamed  glaxo merged  glaxo founded  joseph nathan acq  allen  hanburys founded  acq  margarine unie angioseal div acq  meyer laboratories acq  affymax acq  burroughs wellcome merged  mcdougall  robertson inc acq  burroughs wellcome  company founded  block drug acq  cns inc acq  stiefel laboratories acq  laboratorios phoenix acq  maxinutrition acq  cellzome acq  human genome sciences acq  novartis vaccine div acq  gsk cancer division sold  to novartis glycovaxyn acq  see alsoedit companies portal list of toothpaste brands index of oral health and dental articles recherche et industrie thérapeutiques rit galvani bioelectronics notesedit  glaxo wellcome was formed from glaxos  acquisition of burroughs wellcome and smithkline beecham from the  merger of the beecham group and the smithkline beckman corporation  world health organization expert committee on drug dependence  the committee noted the striking number of reports on paroxetine and withdrawal syndrome  the representative of consumers international reported that a number of patients had experienced difficulty in withdrawing from ssris in general it was agreed that withdrawal was indeed a problem in some patients but there was a difference of opinion on the degree of dependence that was involved given the possibility that the need for treatment of resistant or relapsing disease could make these drugs indispensable for patient care the committee expressed concern about the possibility of inappropriate prescribing resulting in the risk of problems of withdrawal outweighing the benefits of treatment with ssris referencesedit  a b c annual report  pdf retrieved  april    glaxosmithkline statista retrieved  april    the worlds biggest public companies  ranking forbes  ftse allshare index ranking stockchallengecouk   a b c annual report  pdf glaxosmithkline retrieved  may    products glaxosmithkline plc retrieved  november    a b hester plumridge  july  glaxo files its entry in race for a malaria vaccine wall street journal  laura lorenzetti  july  glaxosmithkline seeks approval on firstever malaria vaccine fortune   a b c d e f g h i j k glaxosmithkline to plead guilty and pay  billion to resolve fraud allegations and failure to report safety data united states department of justice  july  katie thomas and michael s schmidt glaxo agrees to pay  billion in fraud settlement the new york times  july  simon neville glaxosmithkline fined bn after bribing doctors to increase drugs sales the guardian  july   r p t davenporthines judy slinn glaxo a history to  cambridge university press  pp –  david newton trademarked a history of wellknown brands from airtex to wrights coal tar the history press  p   a b c d david j ravenscraft william f long paths to creating value in pharmaceutical mergers in steven n kaplan ed mergers and productivity university of chicago press   a b c d e f gsk history glaxosmithkline archived from the original on  june  retrieved  april     the story of a town tricentennial committee  addition to factory the eastchester citizenbulletin  november   peter pennoyer anne walker the architecture of delano  aldrich w w norton  company  p   iconic burroughs wellcome headquarters open for rare public tour triangle modernist houses press release  october   katherine bouton the nobel pair the new york times  january   mark s lesney the ghosts of pharma past modern drug discovery january  pp –   face glaxos axe at wellcome the independent  june    magnus grimond  june  glaxo warns of redundancies the independent   magnus grimond  september  glaxo wellcome plans to axe  jobs the independent   glaxo to acquire affymax the new york times  january   outlook glaxo wellcome the independent  march    company of the week glaxo wellcome the independent  august    profile glaxo wellcome bbc news  january    the new alchemy – the drug industry’s flurry of mergers is based on a big gamble the economist  january    partners resolve their differences and unite at the second attempt nature  may    hall that glitters isnt shareholder gold the daily telegraph  july    a b reaume andrew  january  is corporate venture capital a prescription for success in the pharmaceutical industry the journal of private equity   – jstor    press release peter sears president of smithkline beechams venture capital fund appointed to avant immunotherapeutics board of directors avant via pr newswire may     a b salemi tom  july  dalton joins pfizer the in vivo blog   press release sr one announces new team expands fund premier evergreen fund made  new investments in   business wire sr one via businesswire february     a b c licking ellen  april  sr one posts help wanted ad again the in vivo blog   licking ellen  march  sr ones revolving door the in vivo blog   huang gregory t  april  christoph westphal leaving gsks sr one to focus on longwood founders fund xconomy   press release jens eckstein named president of sr one gsks venture healthcare group sr one via fiercebiotech september     mostrecognized brands antiinfectives december  drugscom   geddes am et al dec  introduction historical perspective and development of amoxicillinclavulanate int j antimicrob agents  suppl  s– pmid  doijijantimicag   brown ag aug  clavulanic acid a novel betalactamase inhibitora case study in drug discovery and development drug des deliv   – pmid    search food and drug administration   d m richards r n brogden february  ceftazidime a review of its antibacterial activity pharmacokinetic properties and therapeutic use drugs   – pmid  doi   a b mercaptopurine chemical  engineering news   a b c d george hitchings and gertrude elion chemical heritage foundation   a b elion gb  the purine path to chemotherapy science   – pmid  doiscience   a b lawrence k altman  february  gertrude elion drug developer dies at  the new york times   who model list of essential medicines th list pdf world health organization october    glaxo files its entry in race for a malaria vaccine wall street journal   press release malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children path   birkett a j et al april  malaria vaccine rd in the decade of vaccines breakthroughs challenges and opportunities vaccine  supplement  b– pmid  doijvaccine   malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children    press releases  media  glaxosmithkline archived from the original on  april    donald g mcneil jr  october  glaxos rts s malaria vaccine shows promise scientists say the new york times   product pipeline  gsk   a b angela monaghan ribena and lucozade sold to japanese drinks giant the guardian  september   majumdar ramanuj  product management in india rd ed phi learning p  isbn    aaron smith alli weightloss drug recalled for tampering cnn  march   about us what we do glaxosmithkline accessed  november  archived  october  at the wayback machine  sir henry dale  biographical   john r vane  biographical   maltzman js koretzky ga april  azathioprine old drug new actions j clin invest  – pmc   pmid  doijci   elion gb  acyclovir discovery mechanism of action and selectivity j med virol suppl  – pmid    koenig r  the legacy of great science the work of nobel laureate gertrude elion lives on oncologist   – pmid  doitheoncologist   glaxosmithkline completes the purchase of block drug for  billion pr newswire retrieved  august    rick stouffer  october  glaxo unit buys breathe right maker trib live   sir christopher gent to exit glaxosmithkline the daily telegraph  october   ben hirschler  may  glaxo china rd centre to target neurodegeneration reuters  david cyranoski  october  pharmaceutical futures made in china nature   corporate executive team glaxosmithkline retrieved  november  archived  october  at the wayback machine  andrew wittys journey from graduate to gsk ceo glaxosmithkline  august  andrew philip witty bloomberg  graham ruddick  april  glaxosmithkline buys stiefel for bn the daily telegraph   fda approves additional vaccine for  hn influenza virus us food and drug administration fda  november    andrew jack  april  companies  pharmaceuticals – gsk and pfizer to merge hiv portfolios financial times   gsk acquires laboratorios phoenix for m infogrok  paul sandle  december  update glaxo buys proteindrinks firm maxinutrition reuters   david ranii  december  gsk sells bc goodys and other brands news  observer archived from the original on  april    gsk confirms  mln stg uk investment plans reuters  march   european biotechnology news  may  gsk acquires cellzome  britains largest drugmaker glaxosmithkline will pay about €m in cash to acquire cellzome ag completely john carroll for fiercebiotech  may  gsk snags proteomics platform tech in m cellzome buyout  john carroll for fiercepharma  june  gsk continues deal spree with m pact for basilea eczema drug basilea pharmaceutica press release  june  basilea enters into global agreement with stiefel a gsk company for toctino® alitretinoin  matthew herper three lessons from glaxosmithklines purchase of human genome sciences forbes  july   hirschler ben  march  gsk pays  billion to lift indian unit stake to  percent reuters retrieved  march    chad bray david jolly novartis and glaxo agree to trade  billion in assets the new york times  april   jonathan d rockoff jeanne whalen marta falconi deal flurry shows drug makers swing toward specialization the wall street journal  april   gen  news highlightsgsk acquires glycovaxyn for m gen   pfizer buys two gsk meningitis vaccines for m gen retrieved  march    james quinn sir philip hampton to chair glaxo the daily telegraph  september   jon yeomans  september  emma walmsley becomes latest female ceo in ftse  as she replaces sir andrew witty at gsk daily telegraph london retrieved  september    access to medicine pdf archived from the original pdf on  february    human rights campaign profle buyers guide entry for glaxosmithkline accessed may    global alliance to eliminate lymphatic filariasis ifpmaorg archived from the original on  december    private and public partners unite to combat  neglected tropical diseases by  bill  melinda gates foundation  january   researchbased pharma pledges on neglected tropical diseases the pharma letter  january    global programme to eliminate lymphatic filariasis progress report  pdf world health organization  september  p    sarah boseley drug giant glaxosmithkline pledges cheap medicine for worlds poor the guardian  february   unitaid  february  unitaid statement on gsk patent pool for neglected diseases  tido von schoenangerer letter to the editor the guardian  february   glaxosmithkline unit joins patent pool for aids drugs  reuters   medicines patent pool viiv healthcare sign licence for the most recent hiv medicine to have received regulatory approval  medicines patent pool   ben goldacre bad pharma fourth estate   p   max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  jim edwards inside gsks cassper ghostwriting program cbs news  august   gsk to stop paying doctors in major marketing overhaul thomsonreuters  december   the intimidation of dr john buse and the diabetes drug avandia committee on finance united states senate november  pp –  max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  for internal concerns p  and attachment e pp – for ghostwriting p  and attachment h pp – for the ghostwriting attachment i p ff for cover letter to circulation attachment i p  for the ghostwritten article attachment i pp – haffner sm et al    effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type  diabetes mellitus circulation   – pmid  doicir   a b nissen se  the rise and fall of rosiglitazone european heart journal   – pmid  doieurheartjehq  see table  for timeline  a b philip d home et al rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type  diabetes record a multicentre randomised openlabel trial the lancet   june  pp – dois pmid  philip d home et al rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes record study design and protocol diabetologia  september  pp – dois pmid  record rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes clinicaltrialsgov  nissen se wolski k  effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes new england journal of medicine   – pmid  doinejmoa rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance   stephanie saul doctor accused of leak to drug maker the new york times  january  gardiner harris a faceoff on the safety of a drug for diabetes the new york times  february   a b staff report on glaxosmithkline and the diabetes drug avandia committee on finance united states senate january  grassley baucus release committee report on avandia the united states senate committee on finance  february  andrew clark glaxos handling of avandia concerns damned by us senate committee the guardian  february   david graham assessment of the cardiovascular risks and health benefits of rosiglitazone office of surveillance and epidemiology food and drug administration  july   fda adds boxed warning for heartrelated risks to antidiabetes drug avandia agency says drug to remain on market while safety assessment continues food and drug administration  november   a b fda drug safety communication fda requires removal of some prescribing and dispensing restrictions for rosiglitazonecontaining diabetes medicines food and drug administration  november   avandia prescribing information food and drug administration  thomas f lüscher ulf landmesser frank ruschitzka  april  standing firm—the european heart journal scientific controversies and the industry european heart journal   – doieurheartjehq  steven e nissen the rise and fall of rosiglitazone european heart journal  april  pp – doieurheartjehq pmid  moncef slaoui the rise and fall of rosiglitazone reply european heart journal  april  pp – doieurheartjehq pmid  michel komajda et al heart failure events with rosiglitazone in type  diabetes data from the record clinical trial european heart journal  april  pp – doieurheartjehp pmid   steven e nissen kathy wolski rosiglitazone revisitedan updated metaanalysis of risk for myocardial infarction and cardiovascular mortality archives of internal medicine  july  pp – that study was limited by low event rates which resulted in insufficient statistical power to confirm or refute evidence of an increased risk for ischemic myocardial events doiarchinternmed pmid   european medicines agency recommends suspension of avandia avandamet and avaglim european medicines agency  september   kenneth w mchaffey et al results of a reevaluation of cardiovascular outcomes in the record trial american heart journal  august  pp – doijahj pmid   fda requires removal of certain restrictions on the diabetes drug avandia food and drug administration  november  readjudication of the rosiglitazone evaluated for cardiovascular outcomes and regulation of glycemia in diabetes trial record joint meeting of the endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee food and drug administration – june  steven nissen steven nissen the hidden agenda behind the fdas new avandia hearings forbes  may  the fda responds to steve nissens criticism of upcoming avandia meeting forbes  may   a b w kondro b sibbald march  drug company experts advised staff to withhold data about ssri use in children canadian medical association journal    pmc   pmid  doicmaj   goldacre  p   kurt samson december  senate probe seeks industry payment data on individual academic researchers annals of neurology   a– pmid  doiana   letter showing authorship of study  drug industry document archive university of california san francisco isabel heck controversial paxil paper still under fire  years later the brown daily herald  april  jon n jureidini leemon b mchenry peter r mansfield clinical trials and drug promotion selective reporting of study  international journal of risk  safety in medicine   pp – doijrs company hid suicide link bbc news  january  secrets of the drug trials bbc panorama  january  goldacre  pp –  martin keller et al efficacy of paroxetine in the treatment of adolescent major depression a randomized controlled trial journal of the american academy of child and adolescent psychiatry  july  pp – pmid  doi  alison bass side effects a prosecutor a whistleblower and a bestselling antidepressant on trial algonquin books of chapel hill  marcia angell  january  drug companies  doctors a story of corruption the new york review of books     judge paxil ads cant say it isnt habitforming associated press  august    drug and device law december   the fdas amicus briefs on preemption ronald d white for the los angeles times august   us opposes order to pull paxil tv ads  a b who expert committee on drug dependence thirtythird report world health organization  pp    a b c d united states v glaxo group ltd  us    a b c d e lahatte gabrielle  reverse payments when the federal trade commission can attack the validity of underlying patents case western reserve journal of law technology  the internet  – retrieved  june    leslie christopher r  antitrust law and intellectual property rights cases and materials oxford university press pp – isbn    united states v glaxo group ltd at   jacobson jonathan m  antitrust law developments american bar association p  isbn    oliver thring consider squash and cordial the guardian  september  we have frank and vernon to thank for ribena the bristol post  september   linus gregoriadis makers of ribena lose fight over antidecay claims the daily telegraph  january   david eames  march  judge orders ribena to fess up the new zealand herald  tony jaques when an icon stumbles – the ribena issue mismanaged corporate communications an international journal   pp – michael regester judy larkin risk issues and crisis management in public relations kogan page publishers  p ff  glaxosmithkline to plead guilty  pay  million to resolve criminal and civil liability regarding manufacturing deficiencies at puerto rico plant us department of justice  october   a b glaxo to pay  million for sale of bad products the new york times  october    alice yan toh han shih  july  shanghai travel agents revenue surge led to arrests in gsk bribery case south china morning post  glaxosmithkline executives face china bribery probe bbc news  july    rupert neate and angela monaghan glaxosmithkline admits some staff in china involved in bribery the guardian  july  rupert neate gsk’s china crisis chief executive andrew witty speaks  as it happened the guardian  july  tom philips  july  chinese police allege glaxo sales reps trained to offer sexual bribes the daily telegraph   china fines glaxosmithkline nearly  million in bribery case  the new york times   malcolm moore denise roland china fines glaxo £m for bribery mark reilly sentenced the daily telegraph  september   watchdog fines gsk £m for paying to keep generic drugs out of uk market daily telegraph  february  retrieved  february    john hooper heather stewart over  doctors face charges in italian drugs scandal the guardian  may   jane burgermeister german prosecutors probe again into bribes by drug companies bmj   june  glaxo probed over doctor freebies bbc news  march   glaxosmithkline annual report pg  pdf retrieved    glaxosmithkline to settle tax dispute with us reuters  september  irs accepts settlement offer in largest transfer pricing dispute irs  september   julia kollewe  may  glaxosmithkline faces criminal investigation by serious fraud office the guardian   kirsten ridley uk fraud office liaising with china on gsk bribery case reuters  july   glaxosmithkline faces bribery claims in syria reuters  august  external linksedit official website glaxosmithkline companies grouped at opencorporates financial times quote profile and news london stock exchange quote regulatory filings and news new york stock exchange quote profile regulatory filings and news v t e glaxosmithkline subsidiaries glaxosmithkline pakistan glaxosmithkline pharmaceuticals ltd stiefel laboratories viiv healthcare  predecessors acquisitions allen  hanburys beecham group block drug burroughs wellcome glaxo glaxo wellcome human genome sciences recherche et industrie thérapeutiques reliant pharmaceuticals s e massengill company smithkline beecham smith kline  french products current pharmaceuticals advair alli augmentin avandia beconase boniva flixonase hycamtin lamictal paxilseroxat serlipet tagamet ventolin wellbutrinzyban zantac … more vaccines hepatyrix pandemrix twinrix other aquafresh horlicks nicoderm nicorette niquitin sensodyne tums … more former bc powder geritol goodys powder lucozade ribena people governance chris gent chair andrew witty ceo other thomas beecham silas m burroughs mahlon kline john k smith henry wellcome litigation canada v glaxosmithkline inc christopher v smithkline beecham corp glaxosmithkline services unlimited v commission united states v glaxo group ltd united states v glaxosmithkline other drug industry document archive glaxosmithkline prize side effects study  category v t e pharmaceutical and biotechnology industry in the united kingdom manufacturing in the united kingdom economy of the united kingdom companies current aah pharmaceuticals alliance boots astex astrazeneca medimmune btg cyclacel dechra pharmaceuticals ge healthcare genus glaxosmithkline hikma pharmaceuticals indivior macfarlan smith norbrook group oxford biomedica pfizer uk phytopharm proximagen shire silence therapeutics tbs gb unipath vectura group vernalis viiv healthcare defunct allen  hanburys amersham beecham group cambridge antibody technology celltech chiroscience distillers company fisons glaxo wellcome ici reliant pharmaceuticals renovo zeneca government and regulatory bodies commission on human medicines department of health european directorate for the quality of medicines european medicines agency medicines and healthcare products regulatory agency national collaborating centre for mental health national patient safety agency pharmaceutical price regulation scheme pharmaceutical society of northern ireland general pharmaceutical council scottish medicines consortium veterinary medicines directorate industry and professional bodies association of the british pharmaceutical industry chemical industries association european federation of biotechnology european federation of pharmaceutical industries and associations faculty of pharmaceutical medicine pharmacists defence association royal pharmaceutical society of great britain worshipful society of apothecaries books and journals bandolier bad pharma  british national formulary british national formulary for children monthly index of medical specialities side effects  the pharmaceutical journal other british approved name british pharmacopoeia drugscope european and developing countries clinical trials partnership european pharmacopoeia list of worlds largest pharmaceutical companies pharmaceutical services negotiating committee wellcome trust category v t e ftse  companies of the united kingdom   → ftse  i admiral group anglo american antofagasta ashtead group associated british foods astrazeneca aviva bae systems bhp bp babcock international barclays barratt developments british american tobacco british land bt group bunzl burberry carnival centrica cocacola hbc compass group convatec crh croda international dcc diageo direct line group easyjet experian fresnillo gs gkn glaxosmithkline glencore hammerson hargreaves lansdown hsbc imperial brands informa intercontinental hotels group international airlines group intertek itv johnson matthey kingfisher land securities group legal  general lloyds banking group london stock exchange group marks  spencer mediclinic international merlin entertainments micro focus international mondi morrisons national grid next old mutual paddy power betfair pearson persimmon provident prudential randgold resources royal bank of scotland reckitt benckiser relx group rentokil initial rio tinto group rollsroyce royal dutch shell royal mail rsa insurance group sage group j sainsbury schroders scottish mortgage investment trust segro severn trent shire sky smith  nephew smiths group smurfit kappa sse standard chartered standard life st jamess place taylor wimpey tesco tui unilever united utilities vodafone whitbread wolseley worldpay wpp v t e philadelphiaarea corporations including the delaware valley list of companies based in the philadelphia area philadelphiabased fortune  corporations rank in the  list comcast  aramark  crown holdings  delaware valleybased fortune  corporations rank in the  list amerisourcebergen  dupont  lincoln national  universal health services  campbell soup  ugi  burlington stores inc  other notable philadelphiabased businesses amorosos beneficial bank chemtura day  zimmermann fmc corporation independence blue cross pennsylvania real estate investment trust pep boys philadelphia media network radian group urban outfitters notable philadelphiabased professional partnerships ballard spahr blank rome cozen oconnor dechert drinker biddle  reath duane morris morgan lewis  bockius pepper hamilton saul ewing white and williams other notable delaware valleybased businesses actua corporation airgas alliedbarton ametek aqua america asplundh bentley systems brandywine realty trust boscovs carpenter technology cephalon chemours christiana care health system crozer keystone health system davids bridal duckduckgo epam systems enersys liberty property trust penn mutual penn national gaming ritas italian ice sei investments slm sungard susquehanna international group vanguard toll brothers triumph group unisys viropharma vishay intertechnology vwr wawa wilmington trust w l gore and associates wsfs bank notable delaware valleybased us headquarters of foreign businesses aberdeen asset management ace agustawestland astrazeneca delaware investments glaxosmithkline ing group keystone foods sap america siemens medical shire pharmaceuticals subaru teva pharmaceuticals td bank notable delaware valleybased division headquarters of us corporations acme cerberus capital management centocor johnson  johnson colonial penn conseco delmarva power exelon gsi commerce ebay hercules ashland mab paints sherwinwilliams mcneil laboratories jj neoware hewlettpackard peco exelon qvc liberty media rohm and haas dow chemical sunoco energy transfer tasty baking flowers foods retrieved from httpsenwikipediaorgwindexphptitleglaxosmithklineoldid categories biotechnology companies of the united kingdomcompanies based in the london borough of hounslowcompanies listed on the new york stock exchangedental companiesglaxosmithklinemedical controversiesmultinational companies headquartered in englandpharmaceutical companies established in british companies established in pharmaceutical companies of the united kingdomvaccine producersorphan drug companieslife sciences industry establishments in the united kingdombiotechnology companies established in companies formed by mergerhidden categories webarchive template wayback linksuse british english from september use dmy dates from september opencorporates groupings navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages العربيةcatalàčeštinadanskdeutschespañolesperantoفارسیfrançais한국어हिन्दीbahasa indonesiaíslenskaitalianoעבריתಕನ್ನಡlietuviųmagyarbahasa melayunederlandsnorsk bokmålnorsk nynorskpolskiportuguêsromânăрусскийscotsසිංහලсрпски  srpskisrpskohrvatski  српскохрватскиsuomisvenskaతెలుగుไทยtürkçeукраїнська edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view glaxosmithkline  wikipedia glaxosmithkline from wikipedia the free encyclopedia jump to navigation search glaxosmithkline gsks head office in brentford london type public limited company traded as lse gsk nyse gsk ftse  component industry pharmaceutical biotechnology consumer goods predecessor glaxo plc wellcome plc beecham group plc kline  french beckman companies smith plc founded december   years ago  headquarters brentford london united kingdom area served worldwide key people sir philip hampton chairman emma walmsley ceo products pharmaceuticals vaccines oral healthcare nutritional products overthecounter medicines revenue £ billion  operating income £ billion  net income £ billion  number of employees   subsidiaries stiefel laboratories website wwwgskcom glaxosmithkline plc gsk is a british pharmaceutical company headquartered in brentford london established in  by a merger of glaxo wellcome and smithkline beecham gsk was the worlds sixth largest pharmaceutical company as of  after pfizer novartis merck hoffmannla roche and sanofin  emma walmsley became ceo on  march  and is the first female ceo of the company the company has a primary listing on the london stock exchange and is a constituent of the ftse  index as of august  it had a market capitalisation of £ billion around  billion the fourth largest on the london stock exchange it has a secondary listing on the new york stock exchange gsks drugs and vaccines earned £ billion in  its topselling products that year were advair avodart flovent augmentin lovaza and lamictal gsks consumer products which earned £ billion in  include sensodyne and aquafresh toothpaste the maltedmilk drink horlicks abreva for cold sores breathe right nasal strips nicoderm and nicorette nicotine replacements and night nurse a cold remedy the company developed the first malaria vaccine rtss which it said in  it would make available for five percent above cost legacy products developed at gsk include several listed in the world health organization model list of essential medicines such as amoxicillin mercaptopurine pyrimethamine and zidovudine in  gsk pleaded guilty to promotion of drugs for unapproved uses failure to report safety data and kickbacks to physicians in the united states and agreed to pay a  billion £bn settlement the largest settlement in the country by a drug company contents  history  glaxo wellcome  smithkline beecham  glaxosmithkline  venture arms  research products  pharmaceuticals  malaria vaccine  consumer healthcare  facilities  scientific recognition  operations and acquisitions since   –  –present  philanthropy and social responsibility   criminal and civil settlement  overview  rosiglitazone avandia  paroxetine paxilseroxat  bupropion wellbutrin  other controversies  antitrust case over griseofulvin  ribena  sb pharmco puerto rico  china  market manipulation in the uk  miscellaneous  diagram of acquisition history  see also  notes  references  external links historyedit glaxo wellcomeedit the historic glaxo factory in bunnythorpe new zealand with the glaxo laboratories sign still visible glaxo was founded in the s as a general trading company in bunnythorpe new zealand by a londoner joseph edward nathan in  it began producing driedmilk baby food first known as defiance then as glaxo from lacto under the slogan glaxo builds bonny babies the glaxo laboratories sign is still visible right on what is now a car repair shop on the main street of bunnythorpe the companys first pharmaceutical product produced in  was vitamin d glaxo laboratories opened new units in london in  the company bought two companies joseph nathan and allen  hanburys in  and  respectively the scottish pharmacologist david jack was working for allen  hanburys when glaxo took it over he went on to lead the companys rd until  after the company bought meyer laboratories in  it began to play an important role in the us market in  the american arm glaxo inc moved to research triangle park us headquartersresearch and zebulon us manufacturing in north carolina burroughs wellcome  company was founded in  in london by the american pharmacists henry wellcome and silas burroughs the wellcome tropical research laboratories opened in  in the s burroughs wellcome established research and manufacturing facilities in tuckahoe new york which served as the us headquarters until the company moved to research triangle park in north carolina in  the nobel prize winning scientists gertrude b elion and george h hitchings worked there and invented drugs still used many years later such as mercaptopurine in  the wellcome company bought cooper mcdougall  robertson inc to become more active in animal health glaxo and burroughs wellcome merged in  to form glaxo wellcome glaxo restructured its rd operation that year cutting  jobs worldwide closing its rd facility in beckenham kent and opening a medicines research centre in stevenage hertfordshire also that year glaxo wellcome acquired the californiabased affymax a leader in the field of combinatorial chemistry by  glaxo wellcome had become the worlds thirdlargest pharmaceutical company by revenues behind novartis and merck with a global market share of around  per cent its products included imigran for the treatment of migraine salbutamol ventolin for the treatment of asthma zovirax for the treatment of coldsores and retrovir and epivir for the treatment of aids in  the company was the worlds largest manufacturer of drugs for the treatment of asthma and hivaids it employed  people including  in the uk had  operating companies and  manufacturing facilities worldwide and seven of its products were among the worlds top  bestselling pharmaceuticals the company had rd facilities in hertfordshire kent and london and manufacturing plants in scotland and the north of england it had rd centres in the us and japan and production facilities in the us europe and the far east smithkline beechamedit beechams clock tower constructed  part of the beechams factory st helens in  thomas beecham launched his beechams pills laxative in england giving birth to the beecham group in  beecham opened its first factory in st helens lancashire by the s beecham was extensively involved in pharmaceuticals john k smith opened his first pharmacy in philadelphia in  in  mahlon kline joined the business which  years later became smith kline  co in  it merged with french richard and company and in  changed its name to smith kline  french laboratories as it focused more on research years later it bought norden laboratories a business doing research into animal health and recherche et industrie thérapeutiques in belgium in  to focus on vaccines the company began to expand globally buying seven laboratories in canada and the united states in  in  it bought allergan a manufacturer of eye and skincare products smithkline  french merged with beckman inc in  and changed its name to smithkline beckman in  it bought its biggest competitor international clinical laboratories and in  merged with beecham to form smithkline beecham plc the headquarters moved from the united states to england to expand rd in the united states the company bought a new research center in  another opened in  in england at new frontiers science park harlow glaxosmithklineedit glaxo wellcome and smithkline beecham announced their intention to merge in january  the merger was completed in december that year forming glaxosmithkline gsk the companys global headquarters are at gsk house brentford london officially opened in  by thenprime minister tony blair the building was erected at a cost of £ million and as of  was home to  administrative staff venture armsedit sr one was established in  by smithkline beecham to invest in new biotechnology companies and continued operating after gsk was formed by  gsk had formed another subsidiary gsk ventures to outlicense or start new companies around drug candidates that it did not intend to develop further as of  sr one tended to invest only if the company aligned with gsks business sr one was led by  to  peter sears  to  brenda gavin  to  barbara dalton  to  maxine gowen   to  joyce lonergan   to  tamar howson  to  russell greig  to  christoph westphal  jens eckstein research productsedit further information list of glaxosmithkline products pharmaceuticalsedit gsk manufactures products for major disease areas such as asthma cancer infections diabetes and mental health its biggestselling in  were advair avodart flovent augmentin lovaza and lamictal its drugs and vaccines earned £ billion that year other topselling products include its asthmacopd inhalers advair ventolin and flovent its diphtheriatetanuspertussis vaccine infanrix and its hepatitis b vaccine the epilepsy drug lamictal and the antibacterial augmentin medicines historically discovered or developed at gsk and its legacy companies and now sold as generics include amoxicillin and amoxicillinclavulanate ticarcillinclavulanate mupirocin and ceftazidime for bacterial infections zidovudine for hiv infection valacyclovir for herpes virus infections albendazole for parasitic infections sumatriptan for migraine lamotrigine for epilepsy bupropion and paroxetine for major depressive disorder cimetidine and ranitidine for gastroesophageal reflux disorder mercaptopurine and thioguanine for the treatment of leukemia allopurinol for gout pyrimethamine for malaria and the antibacterial trimethoprim among these albendazole amoxicillin amoxicillinclavulanate allopurinol mercaptopurine mupriocin pyrimethamine ranitidine thioguanine trimethoprim and zidovudine are listed on the world health organizations list of essential medications malaria vaccineedit in  gsk applied for regulatory approval for the first malaria vaccine malaria is responsible for over  deaths annually mainly in africa known as rtss the vaccine was developed as a joint project with the path vaccines initiative and the bill and melinda gates foundation the company has committed to making the vaccine available in developing countries for five percent above the cost of production as of  rtss which uses gsks proprietary as adjuvant was being examined in a phase  trial in eight african countries path reported that in the month period following vaccination rtss conferred approximately  protection from clinical plasmodium falciparum disease in children aged  months and approximately  protection in children aged  weeks when administered in conjunction with expanded program for immunization epi vaccines in  glaxo said it had spent more than  million and expected to spend an additional  million before seeking regulatory approval a second generation malaria vaccine is being evaluated in phase  clinical trials consumer healthcareedit gsks consumer healthcare division which earned £ billion in  sells oral healthcare including aquafresh macleans and sensodyne toothpastes and drinks such as horlicks boost a chocolateflavoured malt drink sold in india and formerly lucozade and ribena sold in  to suntory for £bn other products include abreva to treat cold sores night nurse a cold remedy breathe right nasal strips and nicoderm and nicorette nicotine replacements in march  it recalled alli an overthecounter weightloss drug in the united states and puerto rico because of possible tampering following customer complaints facilitiesedit as of  gsk had offices in over  countries and employed over  people  in rd the companys single largest market is the united states its us headquarters are in the navy yard philadelphia and research triangle park north carolina its consumerproducts division is in moon township pennsylvania company facilities include rd sites england stevenage stockley park ware the us research triangle park north carolina and collegeville pennsylvania canada china croatia france and india gsk is also planning to open a rd centre in partnership with mclaren technology group at the mclaren technology campus centres for biopharmaceutical products the us marietta pennsylvania and hamilton montana belgium canada germany and hungary manufacturing sites for prescription products scotland irvine and montrose england ware barnard castle worthing and ulverston ireland cork the us bristol tennessee king of prussia pennsylvania zebulon north carolina as well as australia belgium france italy malaysia poland puerto rico romania and singapore manufacturing sites for consumer products england maidenhead ireland dungarvan the us aiken south carolina oak hill new york st louis missouri brazil canada and kenya scientific recognitionedit four glaxosmithkline scientists have been recognized by the nobel committee for their contributions to basic medical science andor therapeutics development henry dale a former student of paul ehrlich received the  nobel prize in medicine for his work on the chemical transmission of neural impulses dale served as a pharmacologist and then as director of the wellcome physiological research laboratories from  to  and later served as trustee and chairman of the board of the wellcome trust john vane of wellcome research laboratories shared the  nobel prize for medicine for his work on prostaglandin biology and the discovery of prostacyclin vane served as group research and development director for the wellcome foundation from  to  gertrude b elion and george hitchings both of the wellcome research laboratories shared the  nobel prize in medicine with sir james w black for their discoveries of important principles for drug treatment elliot and hitchings were responsible for the discovery of a plethora of important drugs including mercaptopurine and thioguanine for the treatment of leukemia the immunosuppressant azothioprine allopurinol for gout pyrimethamine for malaria the antibacterial trimethoprim acyclovir for herpes virus infection and nelarabine for cancer treatment operations and acquisitions since edit –edit andrew witty gsks ceo since may  gsk completed the acquisition of new jerseybased block drug in  for us billion in  gsk acquired the usbased consumer healthcare company cns inc whose products included breathe right nasal strips and fiberchoice dietary supplements for us million in cash chris gent previously ceo of vodafone was appointed chairman of the board in  gsk opened its first rd centre in china in  in shanghai initially focused on neurodegenerative diseases andrew witty became the chief executive officer in  witty joined glaxo in  and had been president of gsks pharmaceuticals europe since  in  gsk acquired stiefel laboratories then the worlds largest independent dermatology drug company for usbn in november the fda approved gsks vaccine for  hn influenza protection manufactured by the companys id biomedical corp in canada also in november  gsk formed a joint venture with pfizer to create viiv healthcare which specializes in hiv research in  the company acquired laboratorios phoenix an argentine pharmaceutical company for usm and the ukbased sports nutrition company maxinutrition for £ million us million –presentedit in  in a million deal prestige brands holdings took over  gsk brands with sales of  million including bc powder beano ecotrin fiber choice goodys powder sominex and tagamet in  the company announced that it would invest £ million in manufacturing facilities in ulverston northern england designating it as the site for a previously announced biotech plant in may that year it acquired cellzome a german biotech company for us million and in june worldwide rights to alitretinoin toctino an eczema drug for  million in  gsk acquired human genome sciences hgs for  billion the companies had collaborated on developing the lupus drug belimumab benlysta albiglutide for type  diabetes and darapladib for atherosclerosis in march  gsk paid  billion to raise its stake in its indian pharmaceutical unit glaxosmithkline pharmaceuticals to  percent as part of a move to focus on emerging markets in april  novartis and glaxo agreed on more than  billion in deals with novartis selling its vaccine business to gsk and buying gsks cancer business in february  gsk announced that it would acquire glycovaxyn a swiss pharmaceutical company for  million and in june that year that it would sell two meningitis drugs to pfizer nimenrix and mencevax for around  million philip hampton at that time chair of the royal bank of scotland became gsk chairman in september  in september  the company announced that witty would be succeeded as ceo by emma walmsley in march  walmsley was a management professional originally from lancashire with a background in marketing philanthropy and social responsibilityedit glaxosmithkline center city philadelphia since  glaxosmithkline has several times ranked first among pharmaceutical companies on the global access to medicines index which is funded by the bill and melinda gates foundation in  the human rights campaign an lgbtrights advocacy group gave gsk a score of  percent in its corporate equality index gsk has been active with the world health organization who in the global alliance to eliminate lymphatic filariasis gaelf around  million people globally are believed to be infected with lymphatic filariasis in  the company endorsed the london declaration on neglected tropical diseases it agreed to donate  million albendazole tablets to the who each year to fight soiltransmitted helminthiasis and to provide  million albendazole tablets every year for lymphatic filariasis until the disease is eradicated as of  over  billion treatments had been delivered and  of  countries in which the disease is considered endemic had progressed to the surveillance stage in  the company said it would cut drug prices by  percent in  of the poorest nations release intellectual property rights for substances and processes relevant to neglected disease into a patent pool to encourage new drug development and invest  percent of profits from the leastdeveloped countries in medical infrastructure for those countries médecins sans frontières welcomed the decision but criticized gsk for failing to include hiv patents in its patent pool and for not including middleincome countries in the initiative in  gsk licensed its hiv portfolio to the medicines patent pool for use in children and agreed to negotiate a license for dolutegravir an integrase inhibitor then in clinical development in  this license was extended to include dolutegravir and adults with hiv the licenses include countries in which  percent of adults and  percent of children with hiv live also in  gsk joined alltrials a british campaign to ensure that all clinical trials are registered and the results reported the company said it would make its past clinicaltrial reports available and future ones within a year of the studies end  criminal and civil settlementedit overviewedit in july  gsk pleaded guilty in the united states to criminal charges and agreed to pay  billion in what was the largest settlement until then between the justice department and a drug company the  billion included a criminal fine of  and forfeiture of  the remaining  billion covered a civil settlement with the government under the false claims act the investigation was launched largely on the basis of information from four whistleblowers who filed qui tam whistleblower lawsuits against the company under the false claims act the charges stemmed from gsks promotion of the antidepressants paxil paroxetine and wellbutrin bupropion for unapproved uses from – specifically as suitable for patients under the age of  and from its failure to report safety data about avandia rosiglitazone both in violation of the federal food drug and cosmetic act other drugs promoted for unapproved uses were two inhalers advair fluticasonesalmeterol and flovent fluticasone propionate as well as zofran ondansetron imitrex sumatriptan lotronex alosetron and valtrex valaciclovir the settlement also covered reporting false best prices and underpaying rebates owed under the medicaid drug rebate program and kickbacks to physicians to prescribe gsks drugs there were allexpensespaid spa treatments and hunting trips for doctors and their spouses speakers fees at conferences and payment for articles ghostwritten by the company and placed by physicians in medical journals the company set up a ghostwriting programme called caspper initially to produce articles about paxil but which was extended to cover avandia as part of the settlement gsk signed a fiveyear corporate integrity agreement with the department of health and human services which obliged the company to make major changes in the way it did business including changing its compensation programmes for its sales force and executives and to implement and maintain transparency in its research practices and publication policies it announced in  that it would no longer pay doctors to promote its drugs or attend medical conferences and that its sales staff would no longer have prescription targets rosiglitazone avandiaedit further information rosiglitazone § adverse effects and rosiglitazone § lawsuits rosiglitazone the  settlement included a criminal fine of  for failing to report safety data to the fda about avandia rosiglitazone a diabetes drug approved in  and a civil settlement of  million for making false claims about it the justice department said gsk had promoted rosiglitazone to physicians with misleading information including that it conferred cardiovascular benefits despite an fdamandated label warning of cardiovascular risks in  john buse a diabetes specialist told medical conferences that rosiglitazone might carry an increased risk of cardiovascular problems gsk threatened to sue him called his university head of department and persuaded him to sign a retraction gsk raised questions internally about the drugs safety in  and in  the company ghostwrote an article in circulation describing a gskfunded clinical trial that suggested rosiglitazone might have a beneficial effect on cardiovascular risk from  reports began to link the thiazolidinediones the class of drugs to which rosiglitazone belongs to heart failure in april that year gsk began a sixyear openlabel randomized trial known as record to examine rosiglitazone and cardiovascular events two gsk metaanalyses in  and  showed an increased risk of cardiovascular problems with rosiglitazone the information was passed to the fda and posted on the company website but not otherwise published by december  rosiglitazone had become the topselling diabetes drug with annual sales of us billion in june  the new england journal of medicine published a metaanalysis that associated the drug with an increased risk of heart attack gsk had reportedly tried to persuade one of the authors steven nissen not to publish it after receiving an advance copy from one of the journals peer reviewers a gsk consultant in july  fda scientists suggested that rosiglitazone had caused  excess heart attacks between  and  the fda placed restrictions on the drug including adding a boxed warning but did not withdraw it in  the fda rejected that the drug had caused excess heart attacks a senate finance committee inquiry concluded in  that gsk had sought to intimidate scientists who had concerns about rosiglitazone in february that year the company tried to halt publication of an editorial about the controversy by nissen in the european heart journal the results of gsks record trial were published in june  it confirmed an association between rosiglitazone and an increased risk of heart failure and fractures but not of heart attack and concluded that it does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucoselowering drugs steven nissan and kathy wolkski argued that the studys low event rates reduced its statistical power in september  rosiglitazone was suspended in europe the results of the record study were confirmed in  by the duke clinical research institute in an independent review required by the fda in november that year the fda lifted the restrictions it had placed on the drug the boxed warning about heart attack was removed the warning about heart failure remained in place paroxetine paxilseroxatedit main article study  paroxetine known as paxil and seroxat gsk was fined for promoting paxilseroxat paroxetine for treating depression in the unders although the drug had not been approved for pediatric use paxil had  billion worldwide sales in  the company conducted nine clinical trials between  and  none of which showed that paxil helped children with depression from  to  it promoted the drug for the unders paying physicians to go on allexpenses paid trips fivestar hotels and spas from  paxils label along with those of similar drugs included an fdamandated boxed warning that it might increase the risk of suicidal ideation and behaviour in patients under  an internal smithkline beecham document said in  about withheld data from two gsk studies it would be commercially unacceptable to include a statement that pediatric efficacy had not been demonstrated as this would undermine the profile of paroxetine the company ghostwrote an article published in  in the journal of the american academy of child and adolescent psychiatry that misreported the results of one of its clinical trials study  the article concluded that paxil was generally well tolerated and effective for major depression in adolescents the suppression of the research findings is the subject of side effects  by alison bass for  years gsk marketed paxil as nonhabit forming in   patients filed a classaction suit alleging they had suffered withdrawal symptoms and in  a los angeles court issued an injunction preventing gsk from advertising that the drug was not habit forming the court withdrew the injunction after the fda objected that the court had no jurisdiction over drug marketing that the fda had approved in  a world health organization committee reported that paxil was among the top  drugs and top three antidepressants for which dependence had been reportedn  bupropion wellbutrinedit the company was also fined for promoting wellbutrin bupropion – approved at the time for major depressive disorder and also sold as a smokingcessation aid zyban – for weight loss and the treatment of attention deficit hyperactivity disorder sexual dysfunction and substance addiction gsk paid doctors to promote these offlabel uses and set up supposedly independent advisory boards and continuing medical education programmes other controversiesedit antitrust case over griseofulvinedit in the s glaxo group ltd glaxo and imperial chemical industries ici each owned patents covering various aspects of the antifungal drug griseofulvin nn – they created a patent pool by crosslicensing their patents subject to express licensing restrictions that the chemical from which the finished form of the drug tablets and capsules was made must not be resold in bulk form and they licensed other drug companies to sell the drug in finished form and subject to similar restrictions– the effect and intent of the bulksale restriction was to keep the drug chemical out of the hands of small companies that might act as pricecutters and the effect was to maintain stable uniform prices the united states brought an antitrust suit against the two companies—united states v glaxo group ltd—charging them with violation of the sherman act and also seeking to have the patents declared invalid the trial court found that the defendants had engaged in several unlawful conspiracies but dismissed the part of the suit seeking invalidation of patents and refused to grant as relief mandatory sales of the bulk drug chemical and compulsory licensing of the patents the government appealed to the supreme court which reversed in united states v glaxo group ltd  us   ribenaedit old ribena bottle year unknown made by beecham products brentford middlesex the label states widely used in hospitals and clinics there were concerns in the s about the sugar and vitamin content of ribena a blackcurrantbased syrup and soft drink owned by gsk until  produced in england by hw carter  co from the s the companys unbranded syrup was distributed to children as a source of vitamin c during world war ii which gave the drink a reputation as good for health beecham bought h w carter in  in  the british advertising standards authority asa required gsk to withdraw its claim that ribena toothkind a lowersugar variety did not encourage tooth decay a company poster showed bottles of toothkind in place of the bristles on a toothbrush the asas ruling was upheld by the high court in  gsk was fined  in new zealand over its claim that readytodrink ribena contained high levels of vitamin c after it was found to contain no detectable vitamin c in  gsk sold ribena and another drink lucozade to the japanese multinational suntory for £ billion sb pharmco puerto ricoedit in  the us department of justice announced that gsk would pay a  million criminal fine and forfeiture and a civil settlement of  million under the false claims act the fines stemmed from production of improperly made and adulterated drugs from  to  at gsks subsidiary sb pharmco puerto rico inc in cidra puerto rico which at the time produced  billion of products each year the drugs involved were kytril an antiemetic bactroban used to treat skin infections paxil the antidepressant and avandamet a diabetes drug gsk closed the factory in  according to the new york times the case began in  when gsk sent experts to fix problems cited by the fda the lead inspector recommended recalls of defective products but they were not authorized she was fired in  and filed a whistleblower lawsuit in  federal marshals seized  billion worth of products the largest such seizure in history in the  settlement sb pharmco plead guilty to criminal charges and agreed to pay  million in a criminal fine and forfeiture at that time the largest such payment ever by a manufacturer of adulterated drugs and  million in civil penalties to settle the civil lawsuit chinaedit in  chinese authorities announced that since  gsk had funnelled hk billion in kickbacks to gsk managers doctors hospitals and others who prescribed their drugs using over  travel agencies and consulting firms chinese authorities arrested four gsk executives as part of a fourmonth investigation into claims that doctors were bribed with cash and sexual favours in  a chinese court found the company guilty of bribery and imposed a fine of  million mark reilly the british head of gsks chinese operations received a threeyear suspended prison sentence after a oneday trial held in secret reilly was reportedly deported from china and dismissed by the company market manipulation in the ukedit in february  the company was fined more than £ million by the competition and markets authority for paying generics uk alpharma and norton healthcare more than £m between  and  in order to keep generic varieties of paroxetine out of the nhs market the generics companies were fined a further £ million at the end of  when generics were available in the uk the price of paroxetine dropped  miscellaneousedit italian police sought bribery charges in may  against  doctors and  gsk employees gsk and its predecessor were accused of having spent £m on physicians pharmacists and others giving them cameras computers holidays and cash doctors were alleged to have received cash based on the number of patients they treated with a cancer drug topotecan hycamtin the following month prosecutors in munich accused – doctors of having accepted bribes from smithkline beecham between  and  the inquiry was opened over allegations that the company had given over  hospital doctors money and free trips all charges were dismissed by the verona court in january  in  in the united states gsk settled the largest tax dispute in irs history agreeing to pay  billion at issue were zantac and other products sold in – the case revolved around intracompany transfer pricing—determining the share of profit attributable to the us subsidiaries of gsk and subject to tax by the irs the uks serious fraud office sfo opened a criminal inquiry in  into gsks sales practices using powers granted by the bribery act  the sfo said it was collaborating with chinese authorities to investigate bringing charges in the uk related to gsks activities in china europe and the middle east also as of  the us department of justice was investigating gsk with reference to the foreign corrupt practices act diagram of acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list glaxosmithkline smithkline beecham plc renamed  smithkline beckman renamed  smithklinerit renamed  smith kline  french reorganized  into  smith kline and french laboratories french richards and company acq  smith kline and company founded  lever brothers angioseal div acq  recherche et industrie thérapeutiques acq  beckman instruments inc merged  sold  specialized instruments corp acq  offner electronics acq  allergan acq  sold  international clinical laboratories acq  reckitt  colman acq  stiefel laboratories acq  by smithkline beckman sanofisynthelabo acq  beecham group plc merged  norcliff thayer acq  beecham group ltd s e massengill company acq  beecham group ltd renamed  cl bencard acq  county chemicals acq  glaxo wellcome renamed  glaxo merged  glaxo founded  joseph nathan acq  allen  hanburys founded  acq  margarine unie angioseal div acq  meyer laboratories acq  affymax acq  burroughs wellcome merged  mcdougall  robertson inc acq  burroughs wellcome  company founded  block drug acq  cns inc acq  stiefel laboratories acq  laboratorios phoenix acq  maxinutrition acq  cellzome acq  human genome sciences acq  novartis vaccine div acq  gsk cancer division sold  to novartis glycovaxyn acq  see alsoedit companies portal list of toothpaste brands index of oral health and dental articles recherche et industrie thérapeutiques rit galvani bioelectronics notesedit  glaxo wellcome was formed from glaxos  acquisition of burroughs wellcome and smithkline beecham from the  merger of the beecham group and the smithkline beckman corporation  world health organization expert committee on drug dependence  the committee noted the striking number of reports on paroxetine and withdrawal syndrome  the representative of consumers international reported that a number of patients had experienced difficulty in withdrawing from ssris in general it was agreed that withdrawal was indeed a problem in some patients but there was a difference of opinion on the degree of dependence that was involved given the possibility that the need for treatment of resistant or relapsing disease could make these drugs indispensable for patient care the committee expressed concern about the possibility of inappropriate prescribing resulting in the risk of problems of withdrawal outweighing the benefits of treatment with ssris referencesedit  a b c annual report  pdf retrieved  april    glaxosmithkline statista retrieved  april    the worlds biggest public companies  ranking forbes  ftse allshare index ranking stockchallengecouk   a b c annual report  pdf glaxosmithkline retrieved  may    products glaxosmithkline plc retrieved  november    a b hester plumridge  july  glaxo files its entry in race for a malaria vaccine wall street journal  laura lorenzetti  july  glaxosmithkline seeks approval on firstever malaria vaccine fortune   a b c d e f g h i j k glaxosmithkline to plead guilty and pay  billion to resolve fraud allegations and failure to report safety data united states department of justice  july  katie thomas and michael s schmidt glaxo agrees to pay  billion in fraud settlement the new york times  july  simon neville glaxosmithkline fined bn after bribing doctors to increase drugs sales the guardian  july   r p t davenporthines judy slinn glaxo a history to  cambridge university press  pp –  david newton trademarked a history of wellknown brands from airtex to wrights coal tar the history press  p   a b c d david j ravenscraft william f long paths to creating value in pharmaceutical mergers in steven n kaplan ed mergers and productivity university of chicago press   a b c d e f gsk history glaxosmithkline archived from the original on  june  retrieved  april     the story of a town tricentennial committee  addition to factory the eastchester citizenbulletin  november   peter pennoyer anne walker the architecture of delano  aldrich w w norton  company  p   iconic burroughs wellcome headquarters open for rare public tour triangle modernist houses press release  october   katherine bouton the nobel pair the new york times  january   mark s lesney the ghosts of pharma past modern drug discovery january  pp –   face glaxos axe at wellcome the independent  june    magnus grimond  june  glaxo warns of redundancies the independent   magnus grimond  september  glaxo wellcome plans to axe  jobs the independent   glaxo to acquire affymax the new york times  january   outlook glaxo wellcome the independent  march    company of the week glaxo wellcome the independent  august    profile glaxo wellcome bbc news  january    the new alchemy – the drug industry’s flurry of mergers is based on a big gamble the economist  january    partners resolve their differences and unite at the second attempt nature  may    hall that glitters isnt shareholder gold the daily telegraph  july    a b reaume andrew  january  is corporate venture capital a prescription for success in the pharmaceutical industry the journal of private equity   – jstor    press release peter sears president of smithkline beechams venture capital fund appointed to avant immunotherapeutics board of directors avant via pr newswire may     a b salemi tom  july  dalton joins pfizer the in vivo blog   press release sr one announces new team expands fund premier evergreen fund made  new investments in   business wire sr one via businesswire february     a b c licking ellen  april  sr one posts help wanted ad again the in vivo blog   licking ellen  march  sr ones revolving door the in vivo blog   huang gregory t  april  christoph westphal leaving gsks sr one to focus on longwood founders fund xconomy   press release jens eckstein named president of sr one gsks venture healthcare group sr one via fiercebiotech september     mostrecognized brands antiinfectives december  drugscom   geddes am et al dec  introduction historical perspective and development of amoxicillinclavulanate int j antimicrob agents  suppl  s– pmid  doijijantimicag   brown ag aug  clavulanic acid a novel betalactamase inhibitora case study in drug discovery and development drug des deliv   – pmid    search food and drug administration   d m richards r n brogden february  ceftazidime a review of its antibacterial activity pharmacokinetic properties and therapeutic use drugs   – pmid  doi   a b mercaptopurine chemical  engineering news   a b c d george hitchings and gertrude elion chemical heritage foundation   a b elion gb  the purine path to chemotherapy science   – pmid  doiscience   a b lawrence k altman  february  gertrude elion drug developer dies at  the new york times   who model list of essential medicines th list pdf world health organization october    glaxo files its entry in race for a malaria vaccine wall street journal   press release malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children path   birkett a j et al april  malaria vaccine rd in the decade of vaccines breakthroughs challenges and opportunities vaccine  supplement  b– pmid  doijvaccine   malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children    press releases  media  glaxosmithkline archived from the original on  april    donald g mcneil jr  october  glaxos rts s malaria vaccine shows promise scientists say the new york times   product pipeline  gsk   a b angela monaghan ribena and lucozade sold to japanese drinks giant the guardian  september   majumdar ramanuj  product management in india rd ed phi learning p  isbn    aaron smith alli weightloss drug recalled for tampering cnn  march   about us what we do glaxosmithkline accessed  november  archived  october  at the wayback machine  sir henry dale  biographical   john r vane  biographical   maltzman js koretzky ga april  azathioprine old drug new actions j clin invest  – pmc   pmid  doijci   elion gb  acyclovir discovery mechanism of action and selectivity j med virol suppl  – pmid    koenig r  the legacy of great science the work of nobel laureate gertrude elion lives on oncologist   – pmid  doitheoncologist   glaxosmithkline completes the purchase of block drug for  billion pr newswire retrieved  august    rick stouffer  october  glaxo unit buys breathe right maker trib live   sir christopher gent to exit glaxosmithkline the daily telegraph  october   ben hirschler  may  glaxo china rd centre to target neurodegeneration reuters  david cyranoski  october  pharmaceutical futures made in china nature   corporate executive team glaxosmithkline retrieved  november  archived  october  at the wayback machine  andrew wittys journey from graduate to gsk ceo glaxosmithkline  august  andrew philip witty bloomberg  graham ruddick  april  glaxosmithkline buys stiefel for bn the daily telegraph   fda approves additional vaccine for  hn influenza virus us food and drug administration fda  november    andrew jack  april  companies  pharmaceuticals – gsk and pfizer to merge hiv portfolios financial times   gsk acquires laboratorios phoenix for m infogrok  paul sandle  december  update glaxo buys proteindrinks firm maxinutrition reuters   david ranii  december  gsk sells bc goodys and other brands news  observer archived from the original on  april    gsk confirms  mln stg uk investment plans reuters  march   european biotechnology news  may  gsk acquires cellzome  britains largest drugmaker glaxosmithkline will pay about €m in cash to acquire cellzome ag completely john carroll for fiercebiotech  may  gsk snags proteomics platform tech in m cellzome buyout  john carroll for fiercepharma  june  gsk continues deal spree with m pact for basilea eczema drug basilea pharmaceutica press release  june  basilea enters into global agreement with stiefel a gsk company for toctino® alitretinoin  matthew herper three lessons from glaxosmithklines purchase of human genome sciences forbes  july   hirschler ben  march  gsk pays  billion to lift indian unit stake to  percent reuters retrieved  march    chad bray david jolly novartis and glaxo agree to trade  billion in assets the new york times  april   jonathan d rockoff jeanne whalen marta falconi deal flurry shows drug makers swing toward specialization the wall street journal  april   gen  news highlightsgsk acquires glycovaxyn for m gen   pfizer buys two gsk meningitis vaccines for m gen retrieved  march    james quinn sir philip hampton to chair glaxo the daily telegraph  september   jon yeomans  september  emma walmsley becomes latest female ceo in ftse  as she replaces sir andrew witty at gsk daily telegraph london retrieved  september    access to medicine pdf archived from the original pdf on  february    human rights campaign profle buyers guide entry for glaxosmithkline accessed may    global alliance to eliminate lymphatic filariasis ifpmaorg archived from the original on  december    private and public partners unite to combat  neglected tropical diseases by  bill  melinda gates foundation  january   researchbased pharma pledges on neglected tropical diseases the pharma letter  january    global programme to eliminate lymphatic filariasis progress report  pdf world health organization  september  p    sarah boseley drug giant glaxosmithkline pledges cheap medicine for worlds poor the guardian  february   unitaid  february  unitaid statement on gsk patent pool for neglected diseases  tido von schoenangerer letter to the editor the guardian  february   glaxosmithkline unit joins patent pool for aids drugs  reuters   medicines patent pool viiv healthcare sign licence for the most recent hiv medicine to have received regulatory approval  medicines patent pool   ben goldacre bad pharma fourth estate   p   max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  jim edwards inside gsks cassper ghostwriting program cbs news  august   gsk to stop paying doctors in major marketing overhaul thomsonreuters  december   the intimidation of dr john buse and the diabetes drug avandia committee on finance united states senate november  pp –  max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  for internal concerns p  and attachment e pp – for ghostwriting p  and attachment h pp – for the ghostwriting attachment i p ff for cover letter to circulation attachment i p  for the ghostwritten article attachment i pp – haffner sm et al    effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type  diabetes mellitus circulation   – pmid  doicir   a b nissen se  the rise and fall of rosiglitazone european heart journal   – pmid  doieurheartjehq  see table  for timeline  a b philip d home et al rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type  diabetes record a multicentre randomised openlabel trial the lancet   june  pp – dois pmid  philip d home et al rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes record study design and protocol diabetologia  september  pp – dois pmid  record rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes clinicaltrialsgov  nissen se wolski k  effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes new england journal of medicine   – pmid  doinejmoa rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance   stephanie saul doctor accused of leak to drug maker the new york times  january  gardiner harris a faceoff on the safety of a drug for diabetes the new york times  february   a b staff report on glaxosmithkline and the diabetes drug avandia committee on finance united states senate january  grassley baucus release committee report on avandia the united states senate committee on finance  february  andrew clark glaxos handling of avandia concerns damned by us senate committee the guardian  february   david graham assessment of the cardiovascular risks and health benefits of rosiglitazone office of surveillance and epidemiology food and drug administration  july   fda adds boxed warning for heartrelated risks to antidiabetes drug avandia agency says drug to remain on market while safety assessment continues food and drug administration  november   a b fda drug safety communication fda requires removal of some prescribing and dispensing restrictions for rosiglitazonecontaining diabetes medicines food and drug administration  november   avandia prescribing information food and drug administration  thomas f lüscher ulf landmesser frank ruschitzka  april  standing firm—the european heart journal scientific controversies and the industry european heart journal   – doieurheartjehq  steven e nissen the rise and fall of rosiglitazone european heart journal  april  pp – doieurheartjehq pmid  moncef slaoui the rise and fall of rosiglitazone reply european heart journal  april  pp – doieurheartjehq pmid  michel komajda et al heart failure events with rosiglitazone in type  diabetes data from the record clinical trial european heart journal  april  pp – doieurheartjehp pmid   steven e nissen kathy wolski rosiglitazone revisitedan updated metaanalysis of risk for myocardial infarction and cardiovascular mortality archives of internal medicine  july  pp – that study was limited by low event rates which resulted in insufficient statistical power to confirm or refute evidence of an increased risk for ischemic myocardial events doiarchinternmed pmid   european medicines agency recommends suspension of avandia avandamet and avaglim european medicines agency  september   kenneth w mchaffey et al results of a reevaluation of cardiovascular outcomes in the record trial american heart journal  august  pp – doijahj pmid   fda requires removal of certain restrictions on the diabetes drug avandia food and drug administration  november  readjudication of the rosiglitazone evaluated for cardiovascular outcomes and regulation of glycemia in diabetes trial record joint meeting of the endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee food and drug administration – june  steven nissen steven nissen the hidden agenda behind the fdas new avandia hearings forbes  may  the fda responds to steve nissens criticism of upcoming avandia meeting forbes  may   a b w kondro b sibbald march  drug company experts advised staff to withhold data about ssri use in children canadian medical association journal    pmc   pmid  doicmaj   goldacre  p   kurt samson december  senate probe seeks industry payment data on individual academic researchers annals of neurology   a– pmid  doiana   letter showing authorship of study  drug industry document archive university of california san francisco isabel heck controversial paxil paper still under fire  years later the brown daily herald  april  jon n jureidini leemon b mchenry peter r mansfield clinical trials and drug promotion selective reporting of study  international journal of risk  safety in medicine   pp – doijrs company hid suicide link bbc news  january  secrets of the drug trials bbc panorama  january  goldacre  pp –  martin keller et al efficacy of paroxetine in the treatment of adolescent major depression a randomized controlled trial journal of the american academy of child and adolescent psychiatry  july  pp – pmid  doi  alison bass side effects a prosecutor a whistleblower and a bestselling antidepressant on trial algonquin books of chapel hill  marcia angell  january  drug companies  doctors a story of corruption the new york review of books     judge paxil ads cant say it isnt habitforming associated press  august    drug and device law december   the fdas amicus briefs on preemption ronald d white for the los angeles times august   us opposes order to pull paxil tv ads  a b who expert committee on drug dependence thirtythird report world health organization  pp    a b c d united states v glaxo group ltd  us    a b c d e lahatte gabrielle  reverse payments when the federal trade commission can attack the validity of underlying patents case western reserve journal of law technology  the internet  – retrieved  june    leslie christopher r  antitrust law and intellectual property rights cases and materials oxford university press pp – isbn    united states v glaxo group ltd at   jacobson jonathan m  antitrust law developments american bar association p  isbn    oliver thring consider squash and cordial the guardian  september  we have frank and vernon to thank for ribena the bristol post  september   linus gregoriadis makers of ribena lose fight over antidecay claims the daily telegraph  january   david eames  march  judge orders ribena to fess up the new zealand herald  tony jaques when an icon stumbles – the ribena issue mismanaged corporate communications an international journal   pp – michael regester judy larkin risk issues and crisis management in public relations kogan page publishers  p ff  glaxosmithkline to plead guilty  pay  million to resolve criminal and civil liability regarding manufacturing deficiencies at puerto rico plant us department of justice  october   a b glaxo to pay  million for sale of bad products the new york times  october    alice yan toh han shih  july  shanghai travel agents revenue surge led to arrests in gsk bribery case south china morning post  glaxosmithkline executives face china bribery probe bbc news  july    rupert neate and angela monaghan glaxosmithkline admits some staff in china involved in bribery the guardian  july  rupert neate gsk’s china crisis chief executive andrew witty speaks  as it happened the guardian  july  tom philips  july  chinese police allege glaxo sales reps trained to offer sexual bribes the daily telegraph   china fines glaxosmithkline nearly  million in bribery case  the new york times   malcolm moore denise roland china fines glaxo £m for bribery mark reilly sentenced the daily telegraph  september   watchdog fines gsk £m for paying to keep generic drugs out of uk market daily telegraph  february  retrieved  february    john hooper heather stewart over  doctors face charges in italian drugs scandal the guardian  may   jane burgermeister german prosecutors probe again into bribes by drug companies bmj   june  glaxo probed over doctor freebies bbc news  march   glaxosmithkline annual report pg  pdf retrieved    glaxosmithkline to settle tax dispute with us reuters  september  irs accepts settlement offer in largest transfer pricing dispute irs  september   julia kollewe  may  glaxosmithkline faces criminal investigation by serious fraud office the guardian   kirsten ridley uk fraud office liaising with china on gsk bribery case reuters  july   glaxosmithkline faces bribery claims in syria reuters  august  external linksedit official website glaxosmithkline companies grouped at opencorporates financial times quote profile and news london stock exchange quote regulatory filings and news new york stock exchange quote profile regulatory filings and news v t e glaxosmithkline subsidiaries glaxosmithkline pakistan glaxosmithkline pharmaceuticals ltd stiefel laboratories viiv healthcare  predecessors acquisitions allen  hanburys beecham group block drug burroughs wellcome glaxo glaxo wellcome human genome sciences recherche et industrie thérapeutiques reliant pharmaceuticals s e massengill company smithkline beecham smith kline  french products current pharmaceuticals advair alli augmentin avandia beconase boniva flixonase hycamtin lamictal paxilseroxat serlipet tagamet ventolin wellbutrinzyban zantac … more vaccines hepatyrix pandemrix twinrix other aquafresh horlicks nicoderm nicorette niquitin sensodyne tums … more former bc powder geritol goodys powder lucozade ribena people governance chris gent chair andrew witty ceo other thomas beecham silas m burroughs mahlon kline john k smith henry wellcome litigation canada v glaxosmithkline inc christopher v smithkline beecham corp glaxosmithkline services unlimited v commission united states v glaxo group ltd united states v glaxosmithkline other drug industry document archive glaxosmithkline prize side effects study  category v t e pharmaceutical and biotechnology industry in the united kingdom manufacturing in the united kingdom economy of the united kingdom companies current aah pharmaceuticals alliance boots astex astrazeneca medimmune btg cyclacel dechra pharmaceuticals ge healthcare genus glaxosmithkline hikma pharmaceuticals indivior macfarlan smith norbrook group oxford biomedica pfizer uk phytopharm proximagen shire silence therapeutics tbs gb unipath vectura group vernalis viiv healthcare defunct allen  hanburys amersham beecham group cambridge antibody technology celltech chiroscience distillers company fisons glaxo wellcome ici reliant pharmaceuticals renovo zeneca government and regulatory bodies commission on human medicines department of health european directorate for the quality of medicines european medicines agency medicines and healthcare products regulatory agency national collaborating centre for mental health national patient safety agency pharmaceutical price regulation scheme pharmaceutical society of northern ireland general pharmaceutical council scottish medicines consortium veterinary medicines directorate industry and professional bodies association of the british pharmaceutical industry chemical industries association european federation of biotechnology european federation of pharmaceutical industries and associations faculty of pharmaceutical medicine pharmacists defence association royal pharmaceutical society of great britain worshipful society of apothecaries books and journals bandolier bad pharma  british national formulary british national formulary for children monthly index of medical specialities side effects  the pharmaceutical journal other british approved name british pharmacopoeia drugscope european and developing countries clinical trials partnership european pharmacopoeia list of worlds largest pharmaceutical companies pharmaceutical services negotiating committee wellcome trust category v t e ftse  companies of the united kingdom   → ftse  i admiral group anglo american antofagasta ashtead group associated british foods astrazeneca aviva bae systems bhp bp babcock international barclays barratt developments british american tobacco british land bt group bunzl burberry carnival centrica cocacola hbc compass group convatec crh croda international dcc diageo direct line group easyjet experian fresnillo gs gkn glaxosmithkline glencore hammerson hargreaves lansdown hsbc imperial brands informa intercontinental hotels group international airlines group intertek itv johnson matthey kingfisher land securities group legal  general lloyds banking group london stock exchange group marks  spencer mediclinic international merlin entertainments micro focus international mondi morrisons national grid next old mutual paddy power betfair pearson persimmon provident prudential randgold resources royal bank of scotland reckitt benckiser relx group rentokil initial rio tinto group rollsroyce royal dutch shell royal mail rsa insurance group sage group j sainsbury schroders scottish mortgage investment trust segro severn trent shire sky smith  nephew smiths group smurfit kappa sse standard chartered standard life st jamess place taylor wimpey tesco tui unilever united utilities vodafone whitbread wolseley worldpay wpp v t e philadelphiaarea corporations including the delaware valley list of companies based in the philadelphia area philadelphiabased fortune  corporations rank in the  list comcast  aramark  crown holdings  delaware valleybased fortune  corporations rank in the  list amerisourcebergen  dupont  lincoln national  universal health services  campbell soup  ugi  burlington stores inc  other notable philadelphiabased businesses amorosos beneficial bank chemtura day  zimmermann fmc corporation independence blue cross pennsylvania real estate investment trust pep boys philadelphia media network radian group urban outfitters notable philadelphiabased professional partnerships ballard spahr blank rome cozen oconnor dechert drinker biddle  reath duane morris morgan lewis  bockius pepper hamilton saul ewing white and williams other notable delaware valleybased businesses actua corporation airgas alliedbarton ametek aqua america asplundh bentley systems brandywine realty trust boscovs carpenter technology cephalon chemours christiana care health system crozer keystone health system davids bridal duckduckgo epam systems enersys liberty property trust penn mutual penn national gaming ritas italian ice sei investments slm sungard susquehanna international group vanguard toll brothers triumph group unisys viropharma vishay intertechnology vwr wawa wilmington trust w l gore and associates wsfs bank notable delaware valleybased us headquarters of foreign businesses aberdeen asset management ace agustawestland astrazeneca delaware investments glaxosmithkline ing group keystone foods sap america siemens medical shire pharmaceuticals subaru teva pharmaceuticals td bank notable delaware valleybased division headquarters of us corporations acme cerberus capital management centocor johnson  johnson colonial penn conseco delmarva power exelon gsi commerce ebay hercules ashland mab paints sherwinwilliams mcneil laboratories jj neoware hewlettpackard peco exelon qvc liberty media rohm and haas dow chemical sunoco energy transfer tasty baking flowers foods retrieved from httpsenwikipediaorgwindexphptitleglaxosmithklineoldid categories biotechnology companies of the united kingdomcompanies based in the london borough of hounslowcompanies listed on the new york stock exchangedental companiesglaxosmithklinemedical controversiesmultinational companies headquartered in englandpharmaceutical companies established in british companies established in pharmaceutical companies of the united kingdomvaccine producersorphan drug companieslife sciences industry establishments in the united kingdombiotechnology companies established in companies formed by mergerhidden categories webarchive template wayback linksuse british english from september use dmy dates from september opencorporates groupings navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages العربيةcatalàčeštinadanskdeutschespañolesperantoفارسیfrançais한국어हिन्दीbahasa indonesiaíslenskaitalianoעבריתಕನ್ನಡlietuviųmagyarbahasa melayunederlandsnorsk bokmålnorsk nynorskpolskiportuguêsromânăрусскийscotsසිංහලсрпски  srpskisrpskohrvatski  српскохрватскиsuomisvenskaతెలుగుไทยtürkçeукраїнська edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view glaxosmithkline  wikipedia glaxosmithkline from wikipedia the free encyclopedia jump to navigation search glaxosmithkline gsks head office in brentford london type public limited company traded as lse gsk nyse gsk ftse  component industry pharmaceutical biotechnology consumer goods predecessor glaxo plc wellcome plc beecham group plc kline  french beckman companies smith plc founded december   years ago  headquarters brentford london united kingdom area served worldwide key people sir philip hampton chairman emma walmsley ceo products pharmaceuticals vaccines oral healthcare nutritional products overthecounter medicines revenue £ billion  operating income £ billion  net income £ billion  number of employees   subsidiaries stiefel laboratories website wwwgskcom glaxosmithkline plc gsk is a british pharmaceutical company headquartered in brentford london established in  by a merger of glaxo wellcome and smithkline beecham gsk was the worlds sixth largest pharmaceutical company as of  after pfizer novartis merck hoffmannla roche and sanofin  emma walmsley became ceo on  march  and is the first female ceo of the company the company has a primary listing on the london stock exchange and is a constituent of the ftse  index as of august  it had a market capitalisation of £ billion around  billion the fourth largest on the london stock exchange it has a secondary listing on the new york stock exchange gsks drugs and vaccines earned £ billion in  its topselling products that year were advair avodart flovent augmentin lovaza and lamictal gsks consumer products which earned £ billion in  include sensodyne and aquafresh toothpaste the maltedmilk drink horlicks abreva for cold sores breathe right nasal strips nicoderm and nicorette nicotine replacements and night nurse a cold remedy the company developed the first malaria vaccine rtss which it said in  it would make available for five percent above cost legacy products developed at gsk include several listed in the world health organization model list of essential medicines such as amoxicillin mercaptopurine pyrimethamine and zidovudine in  gsk pleaded guilty to promotion of drugs for unapproved uses failure to report safety data and kickbacks to physicians in the united states and agreed to pay a  billion £bn settlement the largest settlement in the country by a drug company contents  history  glaxo wellcome  smithkline beecham  glaxosmithkline  venture arms  research products  pharmaceuticals  malaria vaccine  consumer healthcare  facilities  scientific recognition  operations and acquisitions since   –  –present  philanthropy and social responsibility   criminal and civil settlement  overview  rosiglitazone avandia  paroxetine paxilseroxat  bupropion wellbutrin  other controversies  antitrust case over griseofulvin  ribena  sb pharmco puerto rico  china  market manipulation in the uk  miscellaneous  diagram of acquisition history  see also  notes  references  external links historyedit glaxo wellcomeedit the historic glaxo factory in bunnythorpe new zealand with the glaxo laboratories sign still visible glaxo was founded in the s as a general trading company in bunnythorpe new zealand by a londoner joseph edward nathan in  it began producing driedmilk baby food first known as defiance then as glaxo from lacto under the slogan glaxo builds bonny babies the glaxo laboratories sign is still visible right on what is now a car repair shop on the main street of bunnythorpe the companys first pharmaceutical product produced in  was vitamin d glaxo laboratories opened new units in london in  the company bought two companies joseph nathan and allen  hanburys in  and  respectively the scottish pharmacologist david jack was working for allen  hanburys when glaxo took it over he went on to lead the companys rd until  after the company bought meyer laboratories in  it began to play an important role in the us market in  the american arm glaxo inc moved to research triangle park us headquartersresearch and zebulon us manufacturing in north carolina burroughs wellcome  company was founded in  in london by the american pharmacists henry wellcome and silas burroughs the wellcome tropical research laboratories opened in  in the s burroughs wellcome established research and manufacturing facilities in tuckahoe new york which served as the us headquarters until the company moved to research triangle park in north carolina in  the nobel prize winning scientists gertrude b elion and george h hitchings worked there and invented drugs still used many years later such as mercaptopurine in  the wellcome company bought cooper mcdougall  robertson inc to become more active in animal health glaxo and burroughs wellcome merged in  to form glaxo wellcome glaxo restructured its rd operation that year cutting  jobs worldwide closing its rd facility in beckenham kent and opening a medicines research centre in stevenage hertfordshire also that year glaxo wellcome acquired the californiabased affymax a leader in the field of combinatorial chemistry by  glaxo wellcome had become the worlds thirdlargest pharmaceutical company by revenues behind novartis and merck with a global market share of around  per cent its products included imigran for the treatment of migraine salbutamol ventolin for the treatment of asthma zovirax for the treatment of coldsores and retrovir and epivir for the treatment of aids in  the company was the worlds largest manufacturer of drugs for the treatment of asthma and hivaids it employed  people including  in the uk had  operating companies and  manufacturing facilities worldwide and seven of its products were among the worlds top  bestselling pharmaceuticals the company had rd facilities in hertfordshire kent and london and manufacturing plants in scotland and the north of england it had rd centres in the us and japan and production facilities in the us europe and the far east smithkline beechamedit beechams clock tower constructed  part of the beechams factory st helens in  thomas beecham launched his beechams pills laxative in england giving birth to the beecham group in  beecham opened its first factory in st helens lancashire by the s beecham was extensively involved in pharmaceuticals john k smith opened his first pharmacy in philadelphia in  in  mahlon kline joined the business which  years later became smith kline  co in  it merged with french richard and company and in  changed its name to smith kline  french laboratories as it focused more on research years later it bought norden laboratories a business doing research into animal health and recherche et industrie thérapeutiques in belgium in  to focus on vaccines the company began to expand globally buying seven laboratories in canada and the united states in  in  it bought allergan a manufacturer of eye and skincare products smithkline  french merged with beckman inc in  and changed its name to smithkline beckman in  it bought its biggest competitor international clinical laboratories and in  merged with beecham to form smithkline beecham plc the headquarters moved from the united states to england to expand rd in the united states the company bought a new research center in  another opened in  in england at new frontiers science park harlow glaxosmithklineedit glaxo wellcome and smithkline beecham announced their intention to merge in january  the merger was completed in december that year forming glaxosmithkline gsk the companys global headquarters are at gsk house brentford london officially opened in  by thenprime minister tony blair the building was erected at a cost of £ million and as of  was home to  administrative staff venture armsedit sr one was established in  by smithkline beecham to invest in new biotechnology companies and continued operating after gsk was formed by  gsk had formed another subsidiary gsk ventures to outlicense or start new companies around drug candidates that it did not intend to develop further as of  sr one tended to invest only if the company aligned with gsks business sr one was led by  to  peter sears  to  brenda gavin  to  barbara dalton  to  maxine gowen   to  joyce lonergan   to  tamar howson  to  russell greig  to  christoph westphal  jens eckstein research productsedit further information list of glaxosmithkline products pharmaceuticalsedit gsk manufactures products for major disease areas such as asthma cancer infections diabetes and mental health its biggestselling in  were advair avodart flovent augmentin lovaza and lamictal its drugs and vaccines earned £ billion that year other topselling products include its asthmacopd inhalers advair ventolin and flovent its diphtheriatetanuspertussis vaccine infanrix and its hepatitis b vaccine the epilepsy drug lamictal and the antibacterial augmentin medicines historically discovered or developed at gsk and its legacy companies and now sold as generics include amoxicillin and amoxicillinclavulanate ticarcillinclavulanate mupirocin and ceftazidime for bacterial infections zidovudine for hiv infection valacyclovir for herpes virus infections albendazole for parasitic infections sumatriptan for migraine lamotrigine for epilepsy bupropion and paroxetine for major depressive disorder cimetidine and ranitidine for gastroesophageal reflux disorder mercaptopurine and thioguanine for the treatment of leukemia allopurinol for gout pyrimethamine for malaria and the antibacterial trimethoprim among these albendazole amoxicillin amoxicillinclavulanate allopurinol mercaptopurine mupriocin pyrimethamine ranitidine thioguanine trimethoprim and zidovudine are listed on the world health organizations list of essential medications malaria vaccineedit in  gsk applied for regulatory approval for the first malaria vaccine malaria is responsible for over  deaths annually mainly in africa known as rtss the vaccine was developed as a joint project with the path vaccines initiative and the bill and melinda gates foundation the company has committed to making the vaccine available in developing countries for five percent above the cost of production as of  rtss which uses gsks proprietary as adjuvant was being examined in a phase  trial in eight african countries path reported that in the month period following vaccination rtss conferred approximately  protection from clinical plasmodium falciparum disease in children aged  months and approximately  protection in children aged  weeks when administered in conjunction with expanded program for immunization epi vaccines in  glaxo said it had spent more than  million and expected to spend an additional  million before seeking regulatory approval a second generation malaria vaccine is being evaluated in phase  clinical trials consumer healthcareedit gsks consumer healthcare division which earned £ billion in  sells oral healthcare including aquafresh macleans and sensodyne toothpastes and drinks such as horlicks boost a chocolateflavoured malt drink sold in india and formerly lucozade and ribena sold in  to suntory for £bn other products include abreva to treat cold sores night nurse a cold remedy breathe right nasal strips and nicoderm and nicorette nicotine replacements in march  it recalled alli an overthecounter weightloss drug in the united states and puerto rico because of possible tampering following customer complaints facilitiesedit as of  gsk had offices in over  countries and employed over  people  in rd the companys single largest market is the united states its us headquarters are in the navy yard philadelphia and research triangle park north carolina its consumerproducts division is in moon township pennsylvania company facilities include rd sites england stevenage stockley park ware the us research triangle park north carolina and collegeville pennsylvania canada china croatia france and india gsk is also planning to open a rd centre in partnership with mclaren technology group at the mclaren technology campus centres for biopharmaceutical products the us marietta pennsylvania and hamilton montana belgium canada germany and hungary manufacturing sites for prescription products scotland irvine and montrose england ware barnard castle worthing and ulverston ireland cork the us bristol tennessee king of prussia pennsylvania zebulon north carolina as well as australia belgium france italy malaysia poland puerto rico romania and singapore manufacturing sites for consumer products england maidenhead ireland dungarvan the us aiken south carolina oak hill new york st louis missouri brazil canada and kenya scientific recognitionedit four glaxosmithkline scientists have been recognized by the nobel committee for their contributions to basic medical science andor therapeutics development henry dale a former student of paul ehrlich received the  nobel prize in medicine for his work on the chemical transmission of neural impulses dale served as a pharmacologist and then as director of the wellcome physiological research laboratories from  to  and later served as trustee and chairman of the board of the wellcome trust john vane of wellcome research laboratories shared the  nobel prize for medicine for his work on prostaglandin biology and the discovery of prostacyclin vane served as group research and development director for the wellcome foundation from  to  gertrude b elion and george hitchings both of the wellcome research laboratories shared the  nobel prize in medicine with sir james w black for their discoveries of important principles for drug treatment elliot and hitchings were responsible for the discovery of a plethora of important drugs including mercaptopurine and thioguanine for the treatment of leukemia the immunosuppressant azothioprine allopurinol for gout pyrimethamine for malaria the antibacterial trimethoprim acyclovir for herpes virus infection and nelarabine for cancer treatment operations and acquisitions since edit –edit andrew witty gsks ceo since may  gsk completed the acquisition of new jerseybased block drug in  for us billion in  gsk acquired the usbased consumer healthcare company cns inc whose products included breathe right nasal strips and fiberchoice dietary supplements for us million in cash chris gent previously ceo of vodafone was appointed chairman of the board in  gsk opened its first rd centre in china in  in shanghai initially focused on neurodegenerative diseases andrew witty became the chief executive officer in  witty joined glaxo in  and had been president of gsks pharmaceuticals europe since  in  gsk acquired stiefel laboratories then the worlds largest independent dermatology drug company for usbn in november the fda approved gsks vaccine for  hn influenza protection manufactured by the companys id biomedical corp in canada also in november  gsk formed a joint venture with pfizer to create viiv healthcare which specializes in hiv research in  the company acquired laboratorios phoenix an argentine pharmaceutical company for usm and the ukbased sports nutrition company maxinutrition for £ million us million –presentedit in  in a million deal prestige brands holdings took over  gsk brands with sales of  million including bc powder beano ecotrin fiber choice goodys powder sominex and tagamet in  the company announced that it would invest £ million in manufacturing facilities in ulverston northern england designating it as the site for a previously announced biotech plant in may that year it acquired cellzome a german biotech company for us million and in june worldwide rights to alitretinoin toctino an eczema drug for  million in  gsk acquired human genome sciences hgs for  billion the companies had collaborated on developing the lupus drug belimumab benlysta albiglutide for type  diabetes and darapladib for atherosclerosis in march  gsk paid  billion to raise its stake in its indian pharmaceutical unit glaxosmithkline pharmaceuticals to  percent as part of a move to focus on emerging markets in april  novartis and glaxo agreed on more than  billion in deals with novartis selling its vaccine business to gsk and buying gsks cancer business in february  gsk announced that it would acquire glycovaxyn a swiss pharmaceutical company for  million and in june that year that it would sell two meningitis drugs to pfizer nimenrix and mencevax for around  million philip hampton at that time chair of the royal bank of scotland became gsk chairman in september  in september  the company announced that witty would be succeeded as ceo by emma walmsley in march  walmsley was a management professional originally from lancashire with a background in marketing philanthropy and social responsibilityedit glaxosmithkline center city philadelphia since  glaxosmithkline has several times ranked first among pharmaceutical companies on the global access to medicines index which is funded by the bill and melinda gates foundation in  the human rights campaign an lgbtrights advocacy group gave gsk a score of  percent in its corporate equality index gsk has been active with the world health organization who in the global alliance to eliminate lymphatic filariasis gaelf around  million people globally are believed to be infected with lymphatic filariasis in  the company endorsed the london declaration on neglected tropical diseases it agreed to donate  million albendazole tablets to the who each year to fight soiltransmitted helminthiasis and to provide  million albendazole tablets every year for lymphatic filariasis until the disease is eradicated as of  over  billion treatments had been delivered and  of  countries in which the disease is considered endemic had progressed to the surveillance stage in  the company said it would cut drug prices by  percent in  of the poorest nations release intellectual property rights for substances and processes relevant to neglected disease into a patent pool to encourage new drug development and invest  percent of profits from the leastdeveloped countries in medical infrastructure for those countries médecins sans frontières welcomed the decision but criticized gsk for failing to include hiv patents in its patent pool and for not including middleincome countries in the initiative in  gsk licensed its hiv portfolio to the medicines patent pool for use in children and agreed to negotiate a license for dolutegravir an integrase inhibitor then in clinical development in  this license was extended to include dolutegravir and adults with hiv the licenses include countries in which  percent of adults and  percent of children with hiv live also in  gsk joined alltrials a british campaign to ensure that all clinical trials are registered and the results reported the company said it would make its past clinicaltrial reports available and future ones within a year of the studies end  criminal and civil settlementedit overviewedit in july  gsk pleaded guilty in the united states to criminal charges and agreed to pay  billion in what was the largest settlement until then between the justice department and a drug company the  billion included a criminal fine of  and forfeiture of  the remaining  billion covered a civil settlement with the government under the false claims act the investigation was launched largely on the basis of information from four whistleblowers who filed qui tam whistleblower lawsuits against the company under the false claims act the charges stemmed from gsks promotion of the antidepressants paxil paroxetine and wellbutrin bupropion for unapproved uses from – specifically as suitable for patients under the age of  and from its failure to report safety data about avandia rosiglitazone both in violation of the federal food drug and cosmetic act other drugs promoted for unapproved uses were two inhalers advair fluticasonesalmeterol and flovent fluticasone propionate as well as zofran ondansetron imitrex sumatriptan lotronex alosetron and valtrex valaciclovir the settlement also covered reporting false best prices and underpaying rebates owed under the medicaid drug rebate program and kickbacks to physicians to prescribe gsks drugs there were allexpensespaid spa treatments and hunting trips for doctors and their spouses speakers fees at conferences and payment for articles ghostwritten by the company and placed by physicians in medical journals the company set up a ghostwriting programme called caspper initially to produce articles about paxil but which was extended to cover avandia as part of the settlement gsk signed a fiveyear corporate integrity agreement with the department of health and human services which obliged the company to make major changes in the way it did business including changing its compensation programmes for its sales force and executives and to implement and maintain transparency in its research practices and publication policies it announced in  that it would no longer pay doctors to promote its drugs or attend medical conferences and that its sales staff would no longer have prescription targets rosiglitazone avandiaedit further information rosiglitazone § adverse effects and rosiglitazone § lawsuits rosiglitazone the  settlement included a criminal fine of  for failing to report safety data to the fda about avandia rosiglitazone a diabetes drug approved in  and a civil settlement of  million for making false claims about it the justice department said gsk had promoted rosiglitazone to physicians with misleading information including that it conferred cardiovascular benefits despite an fdamandated label warning of cardiovascular risks in  john buse a diabetes specialist told medical conferences that rosiglitazone might carry an increased risk of cardiovascular problems gsk threatened to sue him called his university head of department and persuaded him to sign a retraction gsk raised questions internally about the drugs safety in  and in  the company ghostwrote an article in circulation describing a gskfunded clinical trial that suggested rosiglitazone might have a beneficial effect on cardiovascular risk from  reports began to link the thiazolidinediones the class of drugs to which rosiglitazone belongs to heart failure in april that year gsk began a sixyear openlabel randomized trial known as record to examine rosiglitazone and cardiovascular events two gsk metaanalyses in  and  showed an increased risk of cardiovascular problems with rosiglitazone the information was passed to the fda and posted on the company website but not otherwise published by december  rosiglitazone had become the topselling diabetes drug with annual sales of us billion in june  the new england journal of medicine published a metaanalysis that associated the drug with an increased risk of heart attack gsk had reportedly tried to persuade one of the authors steven nissen not to publish it after receiving an advance copy from one of the journals peer reviewers a gsk consultant in july  fda scientists suggested that rosiglitazone had caused  excess heart attacks between  and  the fda placed restrictions on the drug including adding a boxed warning but did not withdraw it in  the fda rejected that the drug had caused excess heart attacks a senate finance committee inquiry concluded in  that gsk had sought to intimidate scientists who had concerns about rosiglitazone in february that year the company tried to halt publication of an editorial about the controversy by nissen in the european heart journal the results of gsks record trial were published in june  it confirmed an association between rosiglitazone and an increased risk of heart failure and fractures but not of heart attack and concluded that it does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucoselowering drugs steven nissan and kathy wolkski argued that the studys low event rates reduced its statistical power in september  rosiglitazone was suspended in europe the results of the record study were confirmed in  by the duke clinical research institute in an independent review required by the fda in november that year the fda lifted the restrictions it had placed on the drug the boxed warning about heart attack was removed the warning about heart failure remained in place paroxetine paxilseroxatedit main article study  paroxetine known as paxil and seroxat gsk was fined for promoting paxilseroxat paroxetine for treating depression in the unders although the drug had not been approved for pediatric use paxil had  billion worldwide sales in  the company conducted nine clinical trials between  and  none of which showed that paxil helped children with depression from  to  it promoted the drug for the unders paying physicians to go on allexpenses paid trips fivestar hotels and spas from  paxils label along with those of similar drugs included an fdamandated boxed warning that it might increase the risk of suicidal ideation and behaviour in patients under  an internal smithkline beecham document said in  about withheld data from two gsk studies it would be commercially unacceptable to include a statement that pediatric efficacy had not been demonstrated as this would undermine the profile of paroxetine the company ghostwrote an article published in  in the journal of the american academy of child and adolescent psychiatry that misreported the results of one of its clinical trials study  the article concluded that paxil was generally well tolerated and effective for major depression in adolescents the suppression of the research findings is the subject of side effects  by alison bass for  years gsk marketed paxil as nonhabit forming in   patients filed a classaction suit alleging they had suffered withdrawal symptoms and in  a los angeles court issued an injunction preventing gsk from advertising that the drug was not habit forming the court withdrew the injunction after the fda objected that the court had no jurisdiction over drug marketing that the fda had approved in  a world health organization committee reported that paxil was among the top  drugs and top three antidepressants for which dependence had been reportedn  bupropion wellbutrinedit the company was also fined for promoting wellbutrin bupropion – approved at the time for major depressive disorder and also sold as a smokingcessation aid zyban – for weight loss and the treatment of attention deficit hyperactivity disorder sexual dysfunction and substance addiction gsk paid doctors to promote these offlabel uses and set up supposedly independent advisory boards and continuing medical education programmes other controversiesedit antitrust case over griseofulvinedit in the s glaxo group ltd glaxo and imperial chemical industries ici each owned patents covering various aspects of the antifungal drug griseofulvin nn – they created a patent pool by crosslicensing their patents subject to express licensing restrictions that the chemical from which the finished form of the drug tablets and capsules was made must not be resold in bulk form and they licensed other drug companies to sell the drug in finished form and subject to similar restrictions– the effect and intent of the bulksale restriction was to keep the drug chemical out of the hands of small companies that might act as pricecutters and the effect was to maintain stable uniform prices the united states brought an antitrust suit against the two companies—united states v glaxo group ltd—charging them with violation of the sherman act and also seeking to have the patents declared invalid the trial court found that the defendants had engaged in several unlawful conspiracies but dismissed the part of the suit seeking invalidation of patents and refused to grant as relief mandatory sales of the bulk drug chemical and compulsory licensing of the patents the government appealed to the supreme court which reversed in united states v glaxo group ltd  us   ribenaedit old ribena bottle year unknown made by beecham products brentford middlesex the label states widely used in hospitals and clinics there were concerns in the s about the sugar and vitamin content of ribena a blackcurrantbased syrup and soft drink owned by gsk until  produced in england by hw carter  co from the s the companys unbranded syrup was distributed to children as a source of vitamin c during world war ii which gave the drink a reputation as good for health beecham bought h w carter in  in  the british advertising standards authority asa required gsk to withdraw its claim that ribena toothkind a lowersugar variety did not encourage tooth decay a company poster showed bottles of toothkind in place of the bristles on a toothbrush the asas ruling was upheld by the high court in  gsk was fined  in new zealand over its claim that readytodrink ribena contained high levels of vitamin c after it was found to contain no detectable vitamin c in  gsk sold ribena and another drink lucozade to the japanese multinational suntory for £ billion sb pharmco puerto ricoedit in  the us department of justice announced that gsk would pay a  million criminal fine and forfeiture and a civil settlement of  million under the false claims act the fines stemmed from production of improperly made and adulterated drugs from  to  at gsks subsidiary sb pharmco puerto rico inc in cidra puerto rico which at the time produced  billion of products each year the drugs involved were kytril an antiemetic bactroban used to treat skin infections paxil the antidepressant and avandamet a diabetes drug gsk closed the factory in  according to the new york times the case began in  when gsk sent experts to fix problems cited by the fda the lead inspector recommended recalls of defective products but they were not authorized she was fired in  and filed a whistleblower lawsuit in  federal marshals seized  billion worth of products the largest such seizure in history in the  settlement sb pharmco plead guilty to criminal charges and agreed to pay  million in a criminal fine and forfeiture at that time the largest such payment ever by a manufacturer of adulterated drugs and  million in civil penalties to settle the civil lawsuit chinaedit in  chinese authorities announced that since  gsk had funnelled hk billion in kickbacks to gsk managers doctors hospitals and others who prescribed their drugs using over  travel agencies and consulting firms chinese authorities arrested four gsk executives as part of a fourmonth investigation into claims that doctors were bribed with cash and sexual favours in  a chinese court found the company guilty of bribery and imposed a fine of  million mark reilly the british head of gsks chinese operations received a threeyear suspended prison sentence after a oneday trial held in secret reilly was reportedly deported from china and dismissed by the company market manipulation in the ukedit in february  the company was fined more than £ million by the competition and markets authority for paying generics uk alpharma and norton healthcare more than £m between  and  in order to keep generic varieties of paroxetine out of the nhs market the generics companies were fined a further £ million at the end of  when generics were available in the uk the price of paroxetine dropped  miscellaneousedit italian police sought bribery charges in may  against  doctors and  gsk employees gsk and its predecessor were accused of having spent £m on physicians pharmacists and others giving them cameras computers holidays and cash doctors were alleged to have received cash based on the number of patients they treated with a cancer drug topotecan hycamtin the following month prosecutors in munich accused – doctors of having accepted bribes from smithkline beecham between  and  the inquiry was opened over allegations that the company had given over  hospital doctors money and free trips all charges were dismissed by the verona court in january  in  in the united states gsk settled the largest tax dispute in irs history agreeing to pay  billion at issue were zantac and other products sold in – the case revolved around intracompany transfer pricing—determining the share of profit attributable to the us subsidiaries of gsk and subject to tax by the irs the uks serious fraud office sfo opened a criminal inquiry in  into gsks sales practices using powers granted by the bribery act  the sfo said it was collaborating with chinese authorities to investigate bringing charges in the uk related to gsks activities in china europe and the middle east also as of  the us department of justice was investigating gsk with reference to the foreign corrupt practices act diagram of acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list glaxosmithkline smithkline beecham plc renamed  smithkline beckman renamed  smithklinerit renamed  smith kline  french reorganized  into  smith kline and french laboratories french richards and company acq  smith kline and company founded  lever brothers angioseal div acq  recherche et industrie thérapeutiques acq  beckman instruments inc merged  sold  specialized instruments corp acq  offner electronics acq  allergan acq  sold  international clinical laboratories acq  reckitt  colman acq  stiefel laboratories acq  by smithkline beckman sanofisynthelabo acq  beecham group plc merged  norcliff thayer acq  beecham group ltd s e massengill company acq  beecham group ltd renamed  cl bencard acq  county chemicals acq  glaxo wellcome renamed  glaxo merged  glaxo founded  joseph nathan acq  allen  hanburys founded  acq  margarine unie angioseal div acq  meyer laboratories acq  affymax acq  burroughs wellcome merged  mcdougall  robertson inc acq  burroughs wellcome  company founded  block drug acq  cns inc acq  stiefel laboratories acq  laboratorios phoenix acq  maxinutrition acq  cellzome acq  human genome sciences acq  novartis vaccine div acq  gsk cancer division sold  to novartis glycovaxyn acq  see alsoedit companies portal list of toothpaste brands index of oral health and dental articles recherche et industrie thérapeutiques rit galvani bioelectronics notesedit  glaxo wellcome was formed from glaxos  acquisition of burroughs wellcome and smithkline beecham from the  merger of the beecham group and the smithkline beckman corporation  world health organization expert committee on drug dependence  the committee noted the striking number of reports on paroxetine and withdrawal syndrome  the representative of consumers international reported that a number of patients had experienced difficulty in withdrawing from ssris in general it was agreed that withdrawal was indeed a problem in some patients but there was a difference of opinion on the degree of dependence that was involved given the possibility that the need for treatment of resistant or relapsing disease could make these drugs indispensable for patient care the committee expressed concern about the possibility of inappropriate prescribing resulting in the risk of problems of withdrawal outweighing the benefits of treatment with ssris referencesedit  a b c annual report  pdf retrieved  april    glaxosmithkline statista retrieved  april    the worlds biggest public companies  ranking forbes  ftse allshare index ranking stockchallengecouk   a b c annual report  pdf glaxosmithkline retrieved  may    products glaxosmithkline plc retrieved  november    a b hester plumridge  july  glaxo files its entry in race for a malaria vaccine wall street journal  laura lorenzetti  july  glaxosmithkline seeks approval on firstever malaria vaccine fortune   a b c d e f g h i j k glaxosmithkline to plead guilty and pay  billion to resolve fraud allegations and failure to report safety data united states department of justice  july  katie thomas and michael s schmidt glaxo agrees to pay  billion in fraud settlement the new york times  july  simon neville glaxosmithkline fined bn after bribing doctors to increase drugs sales the guardian  july   r p t davenporthines judy slinn glaxo a history to  cambridge university press  pp –  david newton trademarked a history of wellknown brands from airtex to wrights coal tar the history press  p   a b c d david j ravenscraft william f long paths to creating value in pharmaceutical mergers in steven n kaplan ed mergers and productivity university of chicago press   a b c d e f gsk history glaxosmithkline archived from the original on  june  retrieved  april     the story of a town tricentennial committee  addition to factory the eastchester citizenbulletin  november   peter pennoyer anne walker the architecture of delano  aldrich w w norton  company  p   iconic burroughs wellcome headquarters open for rare public tour triangle modernist houses press release  october   katherine bouton the nobel pair the new york times  january   mark s lesney the ghosts of pharma past modern drug discovery january  pp –   face glaxos axe at wellcome the independent  june    magnus grimond  june  glaxo warns of redundancies the independent   magnus grimond  september  glaxo wellcome plans to axe  jobs the independent   glaxo to acquire affymax the new york times  january   outlook glaxo wellcome the independent  march    company of the week glaxo wellcome the independent  august    profile glaxo wellcome bbc news  january    the new alchemy – the drug industry’s flurry of mergers is based on a big gamble the economist  january    partners resolve their differences and unite at the second attempt nature  may    hall that glitters isnt shareholder gold the daily telegraph  july    a b reaume andrew  january  is corporate venture capital a prescription for success in the pharmaceutical industry the journal of private equity   – jstor    press release peter sears president of smithkline beechams venture capital fund appointed to avant immunotherapeutics board of directors avant via pr newswire may     a b salemi tom  july  dalton joins pfizer the in vivo blog   press release sr one announces new team expands fund premier evergreen fund made  new investments in   business wire sr one via businesswire february     a b c licking ellen  april  sr one posts help wanted ad again the in vivo blog   licking ellen  march  sr ones revolving door the in vivo blog   huang gregory t  april  christoph westphal leaving gsks sr one to focus on longwood founders fund xconomy   press release jens eckstein named president of sr one gsks venture healthcare group sr one via fiercebiotech september     mostrecognized brands antiinfectives december  drugscom   geddes am et al dec  introduction historical perspective and development of amoxicillinclavulanate int j antimicrob agents  suppl  s– pmid  doijijantimicag   brown ag aug  clavulanic acid a novel betalactamase inhibitora case study in drug discovery and development drug des deliv   – pmid    search food and drug administration   d m richards r n brogden february  ceftazidime a review of its antibacterial activity pharmacokinetic properties and therapeutic use drugs   – pmid  doi   a b mercaptopurine chemical  engineering news   a b c d george hitchings and gertrude elion chemical heritage foundation   a b elion gb  the purine path to chemotherapy science   – pmid  doiscience   a b lawrence k altman  february  gertrude elion drug developer dies at  the new york times   who model list of essential medicines th list pdf world health organization october    glaxo files its entry in race for a malaria vaccine wall street journal   press release malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children path   birkett a j et al april  malaria vaccine rd in the decade of vaccines breakthroughs challenges and opportunities vaccine  supplement  b– pmid  doijvaccine   malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children    press releases  media  glaxosmithkline archived from the original on  april    donald g mcneil jr  october  glaxos rts s malaria vaccine shows promise scientists say the new york times   product pipeline  gsk   a b angela monaghan ribena and lucozade sold to japanese drinks giant the guardian  september   majumdar ramanuj  product management in india rd ed phi learning p  isbn    aaron smith alli weightloss drug recalled for tampering cnn  march   about us what we do glaxosmithkline accessed  november  archived  october  at the wayback machine  sir henry dale  biographical   john r vane  biographical   maltzman js koretzky ga april  azathioprine old drug new actions j clin invest  – pmc   pmid  doijci   elion gb  acyclovir discovery mechanism of action and selectivity j med virol suppl  – pmid    koenig r  the legacy of great science the work of nobel laureate gertrude elion lives on oncologist   – pmid  doitheoncologist   glaxosmithkline completes the purchase of block drug for  billion pr newswire retrieved  august    rick stouffer  october  glaxo unit buys breathe right maker trib live   sir christopher gent to exit glaxosmithkline the daily telegraph  october   ben hirschler  may  glaxo china rd centre to target neurodegeneration reuters  david cyranoski  october  pharmaceutical futures made in china nature   corporate executive team glaxosmithkline retrieved  november  archived  october  at the wayback machine  andrew wittys journey from graduate to gsk ceo glaxosmithkline  august  andrew philip witty bloomberg  graham ruddick  april  glaxosmithkline buys stiefel for bn the daily telegraph   fda approves additional vaccine for  hn influenza virus us food and drug administration fda  november    andrew jack  april  companies  pharmaceuticals – gsk and pfizer to merge hiv portfolios financial times   gsk acquires laboratorios phoenix for m infogrok  paul sandle  december  update glaxo buys proteindrinks firm maxinutrition reuters   david ranii  december  gsk sells bc goodys and other brands news  observer archived from the original on  april    gsk confirms  mln stg uk investment plans reuters  march   european biotechnology news  may  gsk acquires cellzome  britains largest drugmaker glaxosmithkline will pay about €m in cash to acquire cellzome ag completely john carroll for fiercebiotech  may  gsk snags proteomics platform tech in m cellzome buyout  john carroll for fiercepharma  june  gsk continues deal spree with m pact for basilea eczema drug basilea pharmaceutica press release  june  basilea enters into global agreement with stiefel a gsk company for toctino® alitretinoin  matthew herper three lessons from glaxosmithklines purchase of human genome sciences forbes  july   hirschler ben  march  gsk pays  billion to lift indian unit stake to  percent reuters retrieved  march    chad bray david jolly novartis and glaxo agree to trade  billion in assets the new york times  april   jonathan d rockoff jeanne whalen marta falconi deal flurry shows drug makers swing toward specialization the wall street journal  april   gen  news highlightsgsk acquires glycovaxyn for m gen   pfizer buys two gsk meningitis vaccines for m gen retrieved  march    james quinn sir philip hampton to chair glaxo the daily telegraph  september   jon yeomans  september  emma walmsley becomes latest female ceo in ftse  as she replaces sir andrew witty at gsk daily telegraph london retrieved  september    access to medicine pdf archived from the original pdf on  february    human rights campaign profle buyers guide entry for glaxosmithkline accessed may    global alliance to eliminate lymphatic filariasis ifpmaorg archived from the original on  december    private and public partners unite to combat  neglected tropical diseases by  bill  melinda gates foundation  january   researchbased pharma pledges on neglected tropical diseases the pharma letter  january    global programme to eliminate lymphatic filariasis progress report  pdf world health organization  september  p    sarah boseley drug giant glaxosmithkline pledges cheap medicine for worlds poor the guardian  february   unitaid  february  unitaid statement on gsk patent pool for neglected diseases  tido von schoenangerer letter to the editor the guardian  february   glaxosmithkline unit joins patent pool for aids drugs  reuters   medicines patent pool viiv healthcare sign licence for the most recent hiv medicine to have received regulatory approval  medicines patent pool   ben goldacre bad pharma fourth estate   p   max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  jim edwards inside gsks cassper ghostwriting program cbs news  august   gsk to stop paying doctors in major marketing overhaul thomsonreuters  december   the intimidation of dr john buse and the diabetes drug avandia committee on finance united states senate november  pp –  max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  for internal concerns p  and attachment e pp – for ghostwriting p  and attachment h pp – for the ghostwriting attachment i p ff for cover letter to circulation attachment i p  for the ghostwritten article attachment i pp – haffner sm et al    effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type  diabetes mellitus circulation   – pmid  doicir   a b nissen se  the rise and fall of rosiglitazone european heart journal   – pmid  doieurheartjehq  see table  for timeline  a b philip d home et al rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type  diabetes record a multicentre randomised openlabel trial the lancet   june  pp – dois pmid  philip d home et al rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes record study design and protocol diabetologia  september  pp – dois pmid  record rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes clinicaltrialsgov  nissen se wolski k  effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes new england journal of medicine   – pmid  doinejmoa rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance   stephanie saul doctor accused of leak to drug maker the new york times  january  gardiner harris a faceoff on the safety of a drug for diabetes the new york times  february   a b staff report on glaxosmithkline and the diabetes drug avandia committee on finance united states senate january  grassley baucus release committee report on avandia the united states senate committee on finance  february  andrew clark glaxos handling of avandia concerns damned by us senate committee the guardian  february   david graham assessment of the cardiovascular risks and health benefits of rosiglitazone office of surveillance and epidemiology food and drug administration  july   fda adds boxed warning for heartrelated risks to antidiabetes drug avandia agency says drug to remain on market while safety assessment continues food and drug administration  november   a b fda drug safety communication fda requires removal of some prescribing and dispensing restrictions for rosiglitazonecontaining diabetes medicines food and drug administration  november   avandia prescribing information food and drug administration  thomas f lüscher ulf landmesser frank ruschitzka  april  standing firm—the european heart journal scientific controversies and the industry european heart journal   – doieurheartjehq  steven e nissen the rise and fall of rosiglitazone european heart journal  april  pp – doieurheartjehq pmid  moncef slaoui the rise and fall of rosiglitazone reply european heart journal  april  pp – doieurheartjehq pmid  michel komajda et al heart failure events with rosiglitazone in type  diabetes data from the record clinical trial european heart journal  april  pp – doieurheartjehp pmid   steven e nissen kathy wolski rosiglitazone revisitedan updated metaanalysis of risk for myocardial infarction and cardiovascular mortality archives of internal medicine  july  pp – that study was limited by low event rates which resulted in insufficient statistical power to confirm or refute evidence of an increased risk for ischemic myocardial events doiarchinternmed pmid   european medicines agency recommends suspension of avandia avandamet and avaglim european medicines agency  september   kenneth w mchaffey et al results of a reevaluation of cardiovascular outcomes in the record trial american heart journal  august  pp – doijahj pmid   fda requires removal of certain restrictions on the diabetes drug avandia food and drug administration  november  readjudication of the rosiglitazone evaluated for cardiovascular outcomes and regulation of glycemia in diabetes trial record joint meeting of the endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee food and drug administration – june  steven nissen steven nissen the hidden agenda behind the fdas new avandia hearings forbes  may  the fda responds to steve nissens criticism of upcoming avandia meeting forbes  may   a b w kondro b sibbald march  drug company experts advised staff to withhold data about ssri use in children canadian medical association journal    pmc   pmid  doicmaj   goldacre  p   kurt samson december  senate probe seeks industry payment data on individual academic researchers annals of neurology   a– pmid  doiana   letter showing authorship of study  drug industry document archive university of california san francisco isabel heck controversial paxil paper still under fire  years later the brown daily herald  april  jon n jureidini leemon b mchenry peter r mansfield clinical trials and drug promotion selective reporting of study  international journal of risk  safety in medicine   pp – doijrs company hid suicide link bbc news  january  secrets of the drug trials bbc panorama  january  goldacre  pp –  martin keller et al efficacy of paroxetine in the treatment of adolescent major depression a randomized controlled trial journal of the american academy of child and adolescent psychiatry  july  pp – pmid  doi  alison bass side effects a prosecutor a whistleblower and a bestselling antidepressant on trial algonquin books of chapel hill  marcia angell  january  drug companies  doctors a story of corruption the new york review of books     judge paxil ads cant say it isnt habitforming associated press  august    drug and device law december   the fdas amicus briefs on preemption ronald d white for the los angeles times august   us opposes order to pull paxil tv ads  a b who expert committee on drug dependence thirtythird report world health organization  pp    a b c d united states v glaxo group ltd  us    a b c d e lahatte gabrielle  reverse payments when the federal trade commission can attack the validity of underlying patents case western reserve journal of law technology  the internet  – retrieved  june    leslie christopher r  antitrust law and intellectual property rights cases and materials oxford university press pp – isbn    united states v glaxo group ltd at   jacobson jonathan m  antitrust law developments american bar association p  isbn    oliver thring consider squash and cordial the guardian  september  we have frank and vernon to thank for ribena the bristol post  september   linus gregoriadis makers of ribena lose fight over antidecay claims the daily telegraph  january   david eames  march  judge orders ribena to fess up the new zealand herald  tony jaques when an icon stumbles – the ribena issue mismanaged corporate communications an international journal   pp – michael regester judy larkin risk issues and crisis management in public relations kogan page publishers  p ff  glaxosmithkline to plead guilty  pay  million to resolve criminal and civil liability regarding manufacturing deficiencies at puerto rico plant us department of justice  october   a b glaxo to pay  million for sale of bad products the new york times  october    alice yan toh han shih  july  shanghai travel agents revenue surge led to arrests in gsk bribery case south china morning post  glaxosmithkline executives face china bribery probe bbc news  july    rupert neate and angela monaghan glaxosmithkline admits some staff in china involved in bribery the guardian  july  rupert neate gsk’s china crisis chief executive andrew witty speaks  as it happened the guardian  july  tom philips  july  chinese police allege glaxo sales reps trained to offer sexual bribes the daily telegraph   china fines glaxosmithkline nearly  million in bribery case  the new york times   malcolm moore denise roland china fines glaxo £m for bribery mark reilly sentenced the daily telegraph  september   watchdog fines gsk £m for paying to keep generic drugs out of uk market daily telegraph  february  retrieved  february    john hooper heather stewart over  doctors face charges in italian drugs scandal the guardian  may   jane burgermeister german prosecutors probe again into bribes by drug companies bmj   june  glaxo probed over doctor freebies bbc news  march   glaxosmithkline annual report pg  pdf retrieved    glaxosmithkline to settle tax dispute with us reuters  september  irs accepts settlement offer in largest transfer pricing dispute irs  september   julia kollewe  may  glaxosmithkline faces criminal investigation by serious fraud office the guardian   kirsten ridley uk fraud office liaising with china on gsk bribery case reuters  july   glaxosmithkline faces bribery claims in syria reuters  august  external linksedit official website glaxosmithkline companies grouped at opencorporates financial times quote profile and news london stock exchange quote regulatory filings and news new york stock exchange quote profile regulatory filings and news v t e glaxosmithkline subsidiaries glaxosmithkline pakistan glaxosmithkline pharmaceuticals ltd stiefel laboratories viiv healthcare  predecessors acquisitions allen  hanburys beecham group block drug burroughs wellcome glaxo glaxo wellcome human genome sciences recherche et industrie thérapeutiques reliant pharmaceuticals s e massengill company smithkline beecham smith kline  french products current pharmaceuticals advair alli augmentin avandia beconase boniva flixonase hycamtin lamictal paxilseroxat serlipet tagamet ventolin wellbutrinzyban zantac … more vaccines hepatyrix pandemrix twinrix other aquafresh horlicks nicoderm nicorette niquitin sensodyne tums … more former bc powder geritol goodys powder lucozade ribena people governance chris gent chair andrew witty ceo other thomas beecham silas m burroughs mahlon kline john k smith henry wellcome litigation canada v glaxosmithkline inc christopher v smithkline beecham corp glaxosmithkline services unlimited v commission united states v glaxo group ltd united states v glaxosmithkline other drug industry document archive glaxosmithkline prize side effects study  category v t e pharmaceutical and biotechnology industry in the united kingdom manufacturing in the united kingdom economy of the united kingdom companies current aah pharmaceuticals alliance boots astex astrazeneca medimmune btg cyclacel dechra pharmaceuticals ge healthcare genus glaxosmithkline hikma pharmaceuticals indivior macfarlan smith norbrook group oxford biomedica pfizer uk phytopharm proximagen shire silence therapeutics tbs gb unipath vectura group vernalis viiv healthcare defunct allen  hanburys amersham beecham group cambridge antibody technology celltech chiroscience distillers company fisons glaxo wellcome ici reliant pharmaceuticals renovo zeneca government and regulatory bodies commission on human medicines department of health european directorate for the quality of medicines european medicines agency medicines and healthcare products regulatory agency national collaborating centre for mental health national patient safety agency pharmaceutical price regulation scheme pharmaceutical society of northern ireland general pharmaceutical council scottish medicines consortium veterinary medicines directorate industry and professional bodies association of the british pharmaceutical industry chemical industries association european federation of biotechnology european federation of pharmaceutical industries and associations faculty of pharmaceutical medicine pharmacists defence association royal pharmaceutical society of great britain worshipful society of apothecaries books and journals bandolier bad pharma  british national formulary british national formulary for children monthly index of medical specialities side effects  the pharmaceutical journal other british approved name british pharmacopoeia drugscope european and developing countries clinical trials partnership european pharmacopoeia list of worlds largest pharmaceutical companies pharmaceutical services negotiating committee wellcome trust category v t e ftse  companies of the united kingdom   → ftse  i admiral group anglo american antofagasta ashtead group associated british foods astrazeneca aviva bae systems bhp bp babcock international barclays barratt developments british american tobacco british land bt group bunzl burberry carnival centrica cocacola hbc compass group convatec crh croda international dcc diageo direct line group easyjet experian fresnillo gs gkn glaxosmithkline glencore hammerson hargreaves lansdown hsbc imperial brands informa intercontinental hotels group international airlines group intertek itv johnson matthey kingfisher land securities group legal  general lloyds banking group london stock exchange group marks  spencer mediclinic international merlin entertainments micro focus international mondi morrisons national grid next old mutual paddy power betfair pearson persimmon provident prudential randgold resources royal bank of scotland reckitt benckiser relx group rentokil initial rio tinto group rollsroyce royal dutch shell royal mail rsa insurance group sage group j sainsbury schroders scottish mortgage investment trust segro severn trent shire sky smith  nephew smiths group smurfit kappa sse standard chartered standard life st jamess place taylor wimpey tesco tui unilever united utilities vodafone whitbread wolseley worldpay wpp v t e philadelphiaarea corporations including the delaware valley list of companies based in the philadelphia area philadelphiabased fortune  corporations rank in the  list comcast  aramark  crown holdings  delaware valleybased fortune  corporations rank in the  list amerisourcebergen  dupont  lincoln national  universal health services  campbell soup  ugi  burlington stores inc  other notable philadelphiabased businesses amorosos beneficial bank chemtura day  zimmermann fmc corporation independence blue cross pennsylvania real estate investment trust pep boys philadelphia media network radian group urban outfitters notable philadelphiabased professional partnerships ballard spahr blank rome cozen oconnor dechert drinker biddle  reath duane morris morgan lewis  bockius pepper hamilton saul ewing white and williams other notable delaware valleybased businesses actua corporation airgas alliedbarton ametek aqua america asplundh bentley systems brandywine realty trust boscovs carpenter technology cephalon chemours christiana care health system crozer keystone health system davids bridal duckduckgo epam systems enersys liberty property trust penn mutual penn national gaming ritas italian ice sei investments slm sungard susquehanna international group vanguard toll brothers triumph group unisys viropharma vishay intertechnology vwr wawa wilmington trust w l gore and associates wsfs bank notable delaware valleybased us headquarters of foreign businesses aberdeen asset management ace agustawestland astrazeneca delaware investments glaxosmithkline ing group keystone foods sap america siemens medical shire pharmaceuticals subaru teva pharmaceuticals td bank notable delaware valleybased division headquarters of us corporations acme cerberus capital management centocor johnson  johnson colonial penn conseco delmarva power exelon gsi commerce ebay hercules ashland mab paints sherwinwilliams mcneil laboratories jj neoware hewlettpackard peco exelon qvc liberty media rohm and haas dow chemical sunoco energy transfer tasty baking flowers foods retrieved from httpsenwikipediaorgwindexphptitleglaxosmithklineoldid categories biotechnology companies of the united kingdomcompanies based in the london borough of hounslowcompanies listed on the new york stock exchangedental companiesglaxosmithklinemedical controversiesmultinational companies headquartered in englandpharmaceutical companies established in british companies established in pharmaceutical companies of the united kingdomvaccine producersorphan drug companieslife sciences industry establishments in the united kingdombiotechnology companies established in companies formed by mergerhidden categories webarchive template wayback linksuse british english from september use dmy dates from september opencorporates groupings navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages العربيةcatalàčeštinadanskdeutschespañolesperantoفارسیfrançais한국어हिन्दीbahasa indonesiaíslenskaitalianoעבריתಕನ್ನಡlietuviųmagyarbahasa melayunederlandsnorsk bokmålnorsk nynorskpolskiportuguêsromânăрусскийscotsසිංහලсрпски  srpskisrpskohrvatski  српскохрватскиsuomisvenskaతెలుగుไทยtürkçeукраїнська edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view glaxosmithkline  wikipedia glaxosmithkline from wikipedia the free encyclopedia jump to navigation search glaxosmithkline gsks head office in brentford london type public limited company traded as lse gsk nyse gsk ftse  component industry pharmaceutical biotechnology consumer goods predecessor glaxo plc wellcome plc beecham group plc kline  french beckman companies smith plc founded december   years ago  headquarters brentford london united kingdom area served worldwide key people sir philip hampton chairman emma walmsley ceo products pharmaceuticals vaccines oral healthcare nutritional products overthecounter medicines revenue £ billion  operating income £ billion  net income £ billion  number of employees   subsidiaries stiefel laboratories website wwwgskcom glaxosmithkline plc gsk is a british pharmaceutical company headquartered in brentford london established in  by a merger of glaxo wellcome and smithkline beecham gsk was the worlds sixth largest pharmaceutical company as of  after pfizer novartis merck hoffmannla roche and sanofin  emma walmsley became ceo on  march  and is the first female ceo of the company the company has a primary listing on the london stock exchange and is a constituent of the ftse  index as of august  it had a market capitalisation of £ billion around  billion the fourth largest on the london stock exchange it has a secondary listing on the new york stock exchange gsks drugs and vaccines earned £ billion in  its topselling products that year were advair avodart flovent augmentin lovaza and lamictal gsks consumer products which earned £ billion in  include sensodyne and aquafresh toothpaste the maltedmilk drink horlicks abreva for cold sores breathe right nasal strips nicoderm and nicorette nicotine replacements and night nurse a cold remedy the company developed the first malaria vaccine rtss which it said in  it would make available for five percent above cost legacy products developed at gsk include several listed in the world health organization model list of essential medicines such as amoxicillin mercaptopurine pyrimethamine and zidovudine in  gsk pleaded guilty to promotion of drugs for unapproved uses failure to report safety data and kickbacks to physicians in the united states and agreed to pay a  billion £bn settlement the largest settlement in the country by a drug company contents  history  glaxo wellcome  smithkline beecham  glaxosmithkline  venture arms  research products  pharmaceuticals  malaria vaccine  consumer healthcare  facilities  scientific recognition  operations and acquisitions since   –  –present  philanthropy and social responsibility   criminal and civil settlement  overview  rosiglitazone avandia  paroxetine paxilseroxat  bupropion wellbutrin  other controversies  antitrust case over griseofulvin  ribena  sb pharmco puerto rico  china  market manipulation in the uk  miscellaneous  diagram of acquisition history  see also  notes  references  external links historyedit glaxo wellcomeedit the historic glaxo factory in bunnythorpe new zealand with the glaxo laboratories sign still visible glaxo was founded in the s as a general trading company in bunnythorpe new zealand by a londoner joseph edward nathan in  it began producing driedmilk baby food first known as defiance then as glaxo from lacto under the slogan glaxo builds bonny babies the glaxo laboratories sign is still visible right on what is now a car repair shop on the main street of bunnythorpe the companys first pharmaceutical product produced in  was vitamin d glaxo laboratories opened new units in london in  the company bought two companies joseph nathan and allen  hanburys in  and  respectively the scottish pharmacologist david jack was working for allen  hanburys when glaxo took it over he went on to lead the companys rd until  after the company bought meyer laboratories in  it began to play an important role in the us market in  the american arm glaxo inc moved to research triangle park us headquartersresearch and zebulon us manufacturing in north carolina burroughs wellcome  company was founded in  in london by the american pharmacists henry wellcome and silas burroughs the wellcome tropical research laboratories opened in  in the s burroughs wellcome established research and manufacturing facilities in tuckahoe new york which served as the us headquarters until the company moved to research triangle park in north carolina in  the nobel prize winning scientists gertrude b elion and george h hitchings worked there and invented drugs still used many years later such as mercaptopurine in  the wellcome company bought cooper mcdougall  robertson inc to become more active in animal health glaxo and burroughs wellcome merged in  to form glaxo wellcome glaxo restructured its rd operation that year cutting  jobs worldwide closing its rd facility in beckenham kent and opening a medicines research centre in stevenage hertfordshire also that year glaxo wellcome acquired the californiabased affymax a leader in the field of combinatorial chemistry by  glaxo wellcome had become the worlds thirdlargest pharmaceutical company by revenues behind novartis and merck with a global market share of around  per cent its products included imigran for the treatment of migraine salbutamol ventolin for the treatment of asthma zovirax for the treatment of coldsores and retrovir and epivir for the treatment of aids in  the company was the worlds largest manufacturer of drugs for the treatment of asthma and hivaids it employed  people including  in the uk had  operating companies and  manufacturing facilities worldwide and seven of its products were among the worlds top  bestselling pharmaceuticals the company had rd facilities in hertfordshire kent and london and manufacturing plants in scotland and the north of england it had rd centres in the us and japan and production facilities in the us europe and the far east smithkline beechamedit beechams clock tower constructed  part of the beechams factory st helens in  thomas beecham launched his beechams pills laxative in england giving birth to the beecham group in  beecham opened its first factory in st helens lancashire by the s beecham was extensively involved in pharmaceuticals john k smith opened his first pharmacy in philadelphia in  in  mahlon kline joined the business which  years later became smith kline  co in  it merged with french richard and company and in  changed its name to smith kline  french laboratories as it focused more on research years later it bought norden laboratories a business doing research into animal health and recherche et industrie thérapeutiques in belgium in  to focus on vaccines the company began to expand globally buying seven laboratories in canada and the united states in  in  it bought allergan a manufacturer of eye and skincare products smithkline  french merged with beckman inc in  and changed its name to smithkline beckman in  it bought its biggest competitor international clinical laboratories and in  merged with beecham to form smithkline beecham plc the headquarters moved from the united states to england to expand rd in the united states the company bought a new research center in  another opened in  in england at new frontiers science park harlow glaxosmithklineedit glaxo wellcome and smithkline beecham announced their intention to merge in january  the merger was completed in december that year forming glaxosmithkline gsk the companys global headquarters are at gsk house brentford london officially opened in  by thenprime minister tony blair the building was erected at a cost of £ million and as of  was home to  administrative staff venture armsedit sr one was established in  by smithkline beecham to invest in new biotechnology companies and continued operating after gsk was formed by  gsk had formed another subsidiary gsk ventures to outlicense or start new companies around drug candidates that it did not intend to develop further as of  sr one tended to invest only if the company aligned with gsks business sr one was led by  to  peter sears  to  brenda gavin  to  barbara dalton  to  maxine gowen   to  joyce lonergan   to  tamar howson  to  russell greig  to  christoph westphal  jens eckstein research productsedit further information list of glaxosmithkline products pharmaceuticalsedit gsk manufactures products for major disease areas such as asthma cancer infections diabetes and mental health its biggestselling in  were advair avodart flovent augmentin lovaza and lamictal its drugs and vaccines earned £ billion that year other topselling products include its asthmacopd inhalers advair ventolin and flovent its diphtheriatetanuspertussis vaccine infanrix and its hepatitis b vaccine the epilepsy drug lamictal and the antibacterial augmentin medicines historically discovered or developed at gsk and its legacy companies and now sold as generics include amoxicillin and amoxicillinclavulanate ticarcillinclavulanate mupirocin and ceftazidime for bacterial infections zidovudine for hiv infection valacyclovir for herpes virus infections albendazole for parasitic infections sumatriptan for migraine lamotrigine for epilepsy bupropion and paroxetine for major depressive disorder cimetidine and ranitidine for gastroesophageal reflux disorder mercaptopurine and thioguanine for the treatment of leukemia allopurinol for gout pyrimethamine for malaria and the antibacterial trimethoprim among these albendazole amoxicillin amoxicillinclavulanate allopurinol mercaptopurine mupriocin pyrimethamine ranitidine thioguanine trimethoprim and zidovudine are listed on the world health organizations list of essential medications malaria vaccineedit in  gsk applied for regulatory approval for the first malaria vaccine malaria is responsible for over  deaths annually mainly in africa known as rtss the vaccine was developed as a joint project with the path vaccines initiative and the bill and melinda gates foundation the company has committed to making the vaccine available in developing countries for five percent above the cost of production as of  rtss which uses gsks proprietary as adjuvant was being examined in a phase  trial in eight african countries path reported that in the month period following vaccination rtss conferred approximately  protection from clinical plasmodium falciparum disease in children aged  months and approximately  protection in children aged  weeks when administered in conjunction with expanded program for immunization epi vaccines in  glaxo said it had spent more than  million and expected to spend an additional  million before seeking regulatory approval a second generation malaria vaccine is being evaluated in phase  clinical trials consumer healthcareedit gsks consumer healthcare division which earned £ billion in  sells oral healthcare including aquafresh macleans and sensodyne toothpastes and drinks such as horlicks boost a chocolateflavoured malt drink sold in india and formerly lucozade and ribena sold in  to suntory for £bn other products include abreva to treat cold sores night nurse a cold remedy breathe right nasal strips and nicoderm and nicorette nicotine replacements in march  it recalled alli an overthecounter weightloss drug in the united states and puerto rico because of possible tampering following customer complaints facilitiesedit as of  gsk had offices in over  countries and employed over  people  in rd the companys single largest market is the united states its us headquarters are in the navy yard philadelphia and research triangle park north carolina its consumerproducts division is in moon township pennsylvania company facilities include rd sites england stevenage stockley park ware the us research triangle park north carolina and collegeville pennsylvania canada china croatia france and india gsk is also planning to open a rd centre in partnership with mclaren technology group at the mclaren technology campus centres for biopharmaceutical products the us marietta pennsylvania and hamilton montana belgium canada germany and hungary manufacturing sites for prescription products scotland irvine and montrose england ware barnard castle worthing and ulverston ireland cork the us bristol tennessee king of prussia pennsylvania zebulon north carolina as well as australia belgium france italy malaysia poland puerto rico romania and singapore manufacturing sites for consumer products england maidenhead ireland dungarvan the us aiken south carolina oak hill new york st louis missouri brazil canada and kenya scientific recognitionedit four glaxosmithkline scientists have been recognized by the nobel committee for their contributions to basic medical science andor therapeutics development henry dale a former student of paul ehrlich received the  nobel prize in medicine for his work on the chemical transmission of neural impulses dale served as a pharmacologist and then as director of the wellcome physiological research laboratories from  to  and later served as trustee and chairman of the board of the wellcome trust john vane of wellcome research laboratories shared the  nobel prize for medicine for his work on prostaglandin biology and the discovery of prostacyclin vane served as group research and development director for the wellcome foundation from  to  gertrude b elion and george hitchings both of the wellcome research laboratories shared the  nobel prize in medicine with sir james w black for their discoveries of important principles for drug treatment elliot and hitchings were responsible for the discovery of a plethora of important drugs including mercaptopurine and thioguanine for the treatment of leukemia the immunosuppressant azothioprine allopurinol for gout pyrimethamine for malaria the antibacterial trimethoprim acyclovir for herpes virus infection and nelarabine for cancer treatment operations and acquisitions since edit –edit andrew witty gsks ceo since may  gsk completed the acquisition of new jerseybased block drug in  for us billion in  gsk acquired the usbased consumer healthcare company cns inc whose products included breathe right nasal strips and fiberchoice dietary supplements for us million in cash chris gent previously ceo of vodafone was appointed chairman of the board in  gsk opened its first rd centre in china in  in shanghai initially focused on neurodegenerative diseases andrew witty became the chief executive officer in  witty joined glaxo in  and had been president of gsks pharmaceuticals europe since  in  gsk acquired stiefel laboratories then the worlds largest independent dermatology drug company for usbn in november the fda approved gsks vaccine for  hn influenza protection manufactured by the companys id biomedical corp in canada also in november  gsk formed a joint venture with pfizer to create viiv healthcare which specializes in hiv research in  the company acquired laboratorios phoenix an argentine pharmaceutical company for usm and the ukbased sports nutrition company maxinutrition for £ million us million –presentedit in  in a million deal prestige brands holdings took over  gsk brands with sales of  million including bc powder beano ecotrin fiber choice goodys powder sominex and tagamet in  the company announced that it would invest £ million in manufacturing facilities in ulverston northern england designating it as the site for a previously announced biotech plant in may that year it acquired cellzome a german biotech company for us million and in june worldwide rights to alitretinoin toctino an eczema drug for  million in  gsk acquired human genome sciences hgs for  billion the companies had collaborated on developing the lupus drug belimumab benlysta albiglutide for type  diabetes and darapladib for atherosclerosis in march  gsk paid  billion to raise its stake in its indian pharmaceutical unit glaxosmithkline pharmaceuticals to  percent as part of a move to focus on emerging markets in april  novartis and glaxo agreed on more than  billion in deals with novartis selling its vaccine business to gsk and buying gsks cancer business in february  gsk announced that it would acquire glycovaxyn a swiss pharmaceutical company for  million and in june that year that it would sell two meningitis drugs to pfizer nimenrix and mencevax for around  million philip hampton at that time chair of the royal bank of scotland became gsk chairman in september  in september  the company announced that witty would be succeeded as ceo by emma walmsley in march  walmsley was a management professional originally from lancashire with a background in marketing philanthropy and social responsibilityedit glaxosmithkline center city philadelphia since  glaxosmithkline has several times ranked first among pharmaceutical companies on the global access to medicines index which is funded by the bill and melinda gates foundation in  the human rights campaign an lgbtrights advocacy group gave gsk a score of  percent in its corporate equality index gsk has been active with the world health organization who in the global alliance to eliminate lymphatic filariasis gaelf around  million people globally are believed to be infected with lymphatic filariasis in  the company endorsed the london declaration on neglected tropical diseases it agreed to donate  million albendazole tablets to the who each year to fight soiltransmitted helminthiasis and to provide  million albendazole tablets every year for lymphatic filariasis until the disease is eradicated as of  over  billion treatments had been delivered and  of  countries in which the disease is considered endemic had progressed to the surveillance stage in  the company said it would cut drug prices by  percent in  of the poorest nations release intellectual property rights for substances and processes relevant to neglected disease into a patent pool to encourage new drug development and invest  percent of profits from the leastdeveloped countries in medical infrastructure for those countries médecins sans frontières welcomed the decision but criticized gsk for failing to include hiv patents in its patent pool and for not including middleincome countries in the initiative in  gsk licensed its hiv portfolio to the medicines patent pool for use in children and agreed to negotiate a license for dolutegravir an integrase inhibitor then in clinical development in  this license was extended to include dolutegravir and adults with hiv the licenses include countries in which  percent of adults and  percent of children with hiv live also in  gsk joined alltrials a british campaign to ensure that all clinical trials are registered and the results reported the company said it would make its past clinicaltrial reports available and future ones within a year of the studies end  criminal and civil settlementedit overviewedit in july  gsk pleaded guilty in the united states to criminal charges and agreed to pay  billion in what was the largest settlement until then between the justice department and a drug company the  billion included a criminal fine of  and forfeiture of  the remaining  billion covered a civil settlement with the government under the false claims act the investigation was launched largely on the basis of information from four whistleblowers who filed qui tam whistleblower lawsuits against the company under the false claims act the charges stemmed from gsks promotion of the antidepressants paxil paroxetine and wellbutrin bupropion for unapproved uses from – specifically as suitable for patients under the age of  and from its failure to report safety data about avandia rosiglitazone both in violation of the federal food drug and cosmetic act other drugs promoted for unapproved uses were two inhalers advair fluticasonesalmeterol and flovent fluticasone propionate as well as zofran ondansetron imitrex sumatriptan lotronex alosetron and valtrex valaciclovir the settlement also covered reporting false best prices and underpaying rebates owed under the medicaid drug rebate program and kickbacks to physicians to prescribe gsks drugs there were allexpensespaid spa treatments and hunting trips for doctors and their spouses speakers fees at conferences and payment for articles ghostwritten by the company and placed by physicians in medical journals the company set up a ghostwriting programme called caspper initially to produce articles about paxil but which was extended to cover avandia as part of the settlement gsk signed a fiveyear corporate integrity agreement with the department of health and human services which obliged the company to make major changes in the way it did business including changing its compensation programmes for its sales force and executives and to implement and maintain transparency in its research practices and publication policies it announced in  that it would no longer pay doctors to promote its drugs or attend medical conferences and that its sales staff would no longer have prescription targets rosiglitazone avandiaedit further information rosiglitazone § adverse effects and rosiglitazone § lawsuits rosiglitazone the  settlement included a criminal fine of  for failing to report safety data to the fda about avandia rosiglitazone a diabetes drug approved in  and a civil settlement of  million for making false claims about it the justice department said gsk had promoted rosiglitazone to physicians with misleading information including that it conferred cardiovascular benefits despite an fdamandated label warning of cardiovascular risks in  john buse a diabetes specialist told medical conferences that rosiglitazone might carry an increased risk of cardiovascular problems gsk threatened to sue him called his university head of department and persuaded him to sign a retraction gsk raised questions internally about the drugs safety in  and in  the company ghostwrote an article in circulation describing a gskfunded clinical trial that suggested rosiglitazone might have a beneficial effect on cardiovascular risk from  reports began to link the thiazolidinediones the class of drugs to which rosiglitazone belongs to heart failure in april that year gsk began a sixyear openlabel randomized trial known as record to examine rosiglitazone and cardiovascular events two gsk metaanalyses in  and  showed an increased risk of cardiovascular problems with rosiglitazone the information was passed to the fda and posted on the company website but not otherwise published by december  rosiglitazone had become the topselling diabetes drug with annual sales of us billion in june  the new england journal of medicine published a metaanalysis that associated the drug with an increased risk of heart attack gsk had reportedly tried to persuade one of the authors steven nissen not to publish it after receiving an advance copy from one of the journals peer reviewers a gsk consultant in july  fda scientists suggested that rosiglitazone had caused  excess heart attacks between  and  the fda placed restrictions on the drug including adding a boxed warning but did not withdraw it in  the fda rejected that the drug had caused excess heart attacks a senate finance committee inquiry concluded in  that gsk had sought to intimidate scientists who had concerns about rosiglitazone in february that year the company tried to halt publication of an editorial about the controversy by nissen in the european heart journal the results of gsks record trial were published in june  it confirmed an association between rosiglitazone and an increased risk of heart failure and fractures but not of heart attack and concluded that it does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucoselowering drugs steven nissan and kathy wolkski argued that the studys low event rates reduced its statistical power in september  rosiglitazone was suspended in europe the results of the record study were confirmed in  by the duke clinical research institute in an independent review required by the fda in november that year the fda lifted the restrictions it had placed on the drug the boxed warning about heart attack was removed the warning about heart failure remained in place paroxetine paxilseroxatedit main article study  paroxetine known as paxil and seroxat gsk was fined for promoting paxilseroxat paroxetine for treating depression in the unders although the drug had not been approved for pediatric use paxil had  billion worldwide sales in  the company conducted nine clinical trials between  and  none of which showed that paxil helped children with depression from  to  it promoted the drug for the unders paying physicians to go on allexpenses paid trips fivestar hotels and spas from  paxils label along with those of similar drugs included an fdamandated boxed warning that it might increase the risk of suicidal ideation and behaviour in patients under  an internal smithkline beecham document said in  about withheld data from two gsk studies it would be commercially unacceptable to include a statement that pediatric efficacy had not been demonstrated as this would undermine the profile of paroxetine the company ghostwrote an article published in  in the journal of the american academy of child and adolescent psychiatry that misreported the results of one of its clinical trials study  the article concluded that paxil was generally well tolerated and effective for major depression in adolescents the suppression of the research findings is the subject of side effects  by alison bass for  years gsk marketed paxil as nonhabit forming in   patients filed a classaction suit alleging they had suffered withdrawal symptoms and in  a los angeles court issued an injunction preventing gsk from advertising that the drug was not habit forming the court withdrew the injunction after the fda objected that the court had no jurisdiction over drug marketing that the fda had approved in  a world health organization committee reported that paxil was among the top  drugs and top three antidepressants for which dependence had been reportedn  bupropion wellbutrinedit the company was also fined for promoting wellbutrin bupropion – approved at the time for major depressive disorder and also sold as a smokingcessation aid zyban – for weight loss and the treatment of attention deficit hyperactivity disorder sexual dysfunction and substance addiction gsk paid doctors to promote these offlabel uses and set up supposedly independent advisory boards and continuing medical education programmes other controversiesedit antitrust case over griseofulvinedit in the s glaxo group ltd glaxo and imperial chemical industries ici each owned patents covering various aspects of the antifungal drug griseofulvin nn – they created a patent pool by crosslicensing their patents subject to express licensing restrictions that the chemical from which the finished form of the drug tablets and capsules was made must not be resold in bulk form and they licensed other drug companies to sell the drug in finished form and subject to similar restrictions– the effect and intent of the bulksale restriction was to keep the drug chemical out of the hands of small companies that might act as pricecutters and the effect was to maintain stable uniform prices the united states brought an antitrust suit against the two companies—united states v glaxo group ltd—charging them with violation of the sherman act and also seeking to have the patents declared invalid the trial court found that the defendants had engaged in several unlawful conspiracies but dismissed the part of the suit seeking invalidation of patents and refused to grant as relief mandatory sales of the bulk drug chemical and compulsory licensing of the patents the government appealed to the supreme court which reversed in united states v glaxo group ltd  us   ribenaedit old ribena bottle year unknown made by beecham products brentford middlesex the label states widely used in hospitals and clinics there were concerns in the s about the sugar and vitamin content of ribena a blackcurrantbased syrup and soft drink owned by gsk until  produced in england by hw carter  co from the s the companys unbranded syrup was distributed to children as a source of vitamin c during world war ii which gave the drink a reputation as good for health beecham bought h w carter in  in  the british advertising standards authority asa required gsk to withdraw its claim that ribena toothkind a lowersugar variety did not encourage tooth decay a company poster showed bottles of toothkind in place of the bristles on a toothbrush the asas ruling was upheld by the high court in  gsk was fined  in new zealand over its claim that readytodrink ribena contained high levels of vitamin c after it was found to contain no detectable vitamin c in  gsk sold ribena and another drink lucozade to the japanese multinational suntory for £ billion sb pharmco puerto ricoedit in  the us department of justice announced that gsk would pay a  million criminal fine and forfeiture and a civil settlement of  million under the false claims act the fines stemmed from production of improperly made and adulterated drugs from  to  at gsks subsidiary sb pharmco puerto rico inc in cidra puerto rico which at the time produced  billion of products each year the drugs involved were kytril an antiemetic bactroban used to treat skin infections paxil the antidepressant and avandamet a diabetes drug gsk closed the factory in  according to the new york times the case began in  when gsk sent experts to fix problems cited by the fda the lead inspector recommended recalls of defective products but they were not authorized she was fired in  and filed a whistleblower lawsuit in  federal marshals seized  billion worth of products the largest such seizure in history in the  settlement sb pharmco plead guilty to criminal charges and agreed to pay  million in a criminal fine and forfeiture at that time the largest such payment ever by a manufacturer of adulterated drugs and  million in civil penalties to settle the civil lawsuit chinaedit in  chinese authorities announced that since  gsk had funnelled hk billion in kickbacks to gsk managers doctors hospitals and others who prescribed their drugs using over  travel agencies and consulting firms chinese authorities arrested four gsk executives as part of a fourmonth investigation into claims that doctors were bribed with cash and sexual favours in  a chinese court found the company guilty of bribery and imposed a fine of  million mark reilly the british head of gsks chinese operations received a threeyear suspended prison sentence after a oneday trial held in secret reilly was reportedly deported from china and dismissed by the company market manipulation in the ukedit in february  the company was fined more than £ million by the competition and markets authority for paying generics uk alpharma and norton healthcare more than £m between  and  in order to keep generic varieties of paroxetine out of the nhs market the generics companies were fined a further £ million at the end of  when generics were available in the uk the price of paroxetine dropped  miscellaneousedit italian police sought bribery charges in may  against  doctors and  gsk employees gsk and its predecessor were accused of having spent £m on physicians pharmacists and others giving them cameras computers holidays and cash doctors were alleged to have received cash based on the number of patients they treated with a cancer drug topotecan hycamtin the following month prosecutors in munich accused – doctors of having accepted bribes from smithkline beecham between  and  the inquiry was opened over allegations that the company had given over  hospital doctors money and free trips all charges were dismissed by the verona court in january  in  in the united states gsk settled the largest tax dispute in irs history agreeing to pay  billion at issue were zantac and other products sold in – the case revolved around intracompany transfer pricing—determining the share of profit attributable to the us subsidiaries of gsk and subject to tax by the irs the uks serious fraud office sfo opened a criminal inquiry in  into gsks sales practices using powers granted by the bribery act  the sfo said it was collaborating with chinese authorities to investigate bringing charges in the uk related to gsks activities in china europe and the middle east also as of  the us department of justice was investigating gsk with reference to the foreign corrupt practices act diagram of acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list glaxosmithkline smithkline beecham plc renamed  smithkline beckman renamed  smithklinerit renamed  smith kline  french reorganized  into  smith kline and french laboratories french richards and company acq  smith kline and company founded  lever brothers angioseal div acq  recherche et industrie thérapeutiques acq  beckman instruments inc merged  sold  specialized instruments corp acq  offner electronics acq  allergan acq  sold  international clinical laboratories acq  reckitt  colman acq  stiefel laboratories acq  by smithkline beckman sanofisynthelabo acq  beecham group plc merged  norcliff thayer acq  beecham group ltd s e massengill company acq  beecham group ltd renamed  cl bencard acq  county chemicals acq  glaxo wellcome renamed  glaxo merged  glaxo founded  joseph nathan acq  allen  hanburys founded  acq  margarine unie angioseal div acq  meyer laboratories acq  affymax acq  burroughs wellcome merged  mcdougall  robertson inc acq  burroughs wellcome  company founded  block drug acq  cns inc acq  stiefel laboratories acq  laboratorios phoenix acq  maxinutrition acq  cellzome acq  human genome sciences acq  novartis vaccine div acq  gsk cancer division sold  to novartis glycovaxyn acq  see alsoedit companies portal list of toothpaste brands index of oral health and dental articles recherche et industrie thérapeutiques rit galvani bioelectronics notesedit  glaxo wellcome was formed from glaxos  acquisition of burroughs wellcome and smithkline beecham from the  merger of the beecham group and the smithkline beckman corporation  world health organization expert committee on drug dependence  the committee noted the striking number of reports on paroxetine and withdrawal syndrome  the representative of consumers international reported that a number of patients had experienced difficulty in withdrawing from ssris in general it was agreed that withdrawal was indeed a problem in some patients but there was a difference of opinion on the degree of dependence that was involved given the possibility that the need for treatment of resistant or relapsing disease could make these drugs indispensable for patient care the committee expressed concern about the possibility of inappropriate prescribing resulting in the risk of problems of withdrawal outweighing the benefits of treatment with ssris referencesedit  a b c annual report  pdf retrieved  april    glaxosmithkline statista retrieved  april    the worlds biggest public companies  ranking forbes  ftse allshare index ranking stockchallengecouk   a b c annual report  pdf glaxosmithkline retrieved  may    products glaxosmithkline plc retrieved  november    a b hester plumridge  july  glaxo files its entry in race for a malaria vaccine wall street journal  laura lorenzetti  july  glaxosmithkline seeks approval on firstever malaria vaccine fortune   a b c d e f g h i j k glaxosmithkline to plead guilty and pay  billion to resolve fraud allegations and failure to report safety data united states department of justice  july  katie thomas and michael s schmidt glaxo agrees to pay  billion in fraud settlement the new york times  july  simon neville glaxosmithkline fined bn after bribing doctors to increase drugs sales the guardian  july   r p t davenporthines judy slinn glaxo a history to  cambridge university press  pp –  david newton trademarked a history of wellknown brands from airtex to wrights coal tar the history press  p   a b c d david j ravenscraft william f long paths to creating value in pharmaceutical mergers in steven n kaplan ed mergers and productivity university of chicago press   a b c d e f gsk history glaxosmithkline archived from the original on  june  retrieved  april     the story of a town tricentennial committee  addition to factory the eastchester citizenbulletin  november   peter pennoyer anne walker the architecture of delano  aldrich w w norton  company  p   iconic burroughs wellcome headquarters open for rare public tour triangle modernist houses press release  october   katherine bouton the nobel pair the new york times  january   mark s lesney the ghosts of pharma past modern drug discovery january  pp –   face glaxos axe at wellcome the independent  june    magnus grimond  june  glaxo warns of redundancies the independent   magnus grimond  september  glaxo wellcome plans to axe  jobs the independent   glaxo to acquire affymax the new york times  january   outlook glaxo wellcome the independent  march    company of the week glaxo wellcome the independent  august    profile glaxo wellcome bbc news  january    the new alchemy – the drug industry’s flurry of mergers is based on a big gamble the economist  january    partners resolve their differences and unite at the second attempt nature  may    hall that glitters isnt shareholder gold the daily telegraph  july    a b reaume andrew  january  is corporate venture capital a prescription for success in the pharmaceutical industry the journal of private equity   – jstor    press release peter sears president of smithkline beechams venture capital fund appointed to avant immunotherapeutics board of directors avant via pr newswire may     a b salemi tom  july  dalton joins pfizer the in vivo blog   press release sr one announces new team expands fund premier evergreen fund made  new investments in   business wire sr one via businesswire february     a b c licking ellen  april  sr one posts help wanted ad again the in vivo blog   licking ellen  march  sr ones revolving door the in vivo blog   huang gregory t  april  christoph westphal leaving gsks sr one to focus on longwood founders fund xconomy   press release jens eckstein named president of sr one gsks venture healthcare group sr one via fiercebiotech september     mostrecognized brands antiinfectives december  drugscom   geddes am et al dec  introduction historical perspective and development of amoxicillinclavulanate int j antimicrob agents  suppl  s– pmid  doijijantimicag   brown ag aug  clavulanic acid a novel betalactamase inhibitora case study in drug discovery and development drug des deliv   – pmid    search food and drug administration   d m richards r n brogden february  ceftazidime a review of its antibacterial activity pharmacokinetic properties and therapeutic use drugs   – pmid  doi   a b mercaptopurine chemical  engineering news   a b c d george hitchings and gertrude elion chemical heritage foundation   a b elion gb  the purine path to chemotherapy science   – pmid  doiscience   a b lawrence k altman  february  gertrude elion drug developer dies at  the new york times   who model list of essential medicines th list pdf world health organization october    glaxo files its entry in race for a malaria vaccine wall street journal   press release malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children path   birkett a j et al april  malaria vaccine rd in the decade of vaccines breakthroughs challenges and opportunities vaccine  supplement  b– pmid  doijvaccine   malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children    press releases  media  glaxosmithkline archived from the original on  april    donald g mcneil jr  october  glaxos rts s malaria vaccine shows promise scientists say the new york times   product pipeline  gsk   a b angela monaghan ribena and lucozade sold to japanese drinks giant the guardian  september   majumdar ramanuj  product management in india rd ed phi learning p  isbn    aaron smith alli weightloss drug recalled for tampering cnn  march   about us what we do glaxosmithkline accessed  november  archived  october  at the wayback machine  sir henry dale  biographical   john r vane  biographical   maltzman js koretzky ga april  azathioprine old drug new actions j clin invest  – pmc   pmid  doijci   elion gb  acyclovir discovery mechanism of action and selectivity j med virol suppl  – pmid    koenig r  the legacy of great science the work of nobel laureate gertrude elion lives on oncologist   – pmid  doitheoncologist   glaxosmithkline completes the purchase of block drug for  billion pr newswire retrieved  august    rick stouffer  october  glaxo unit buys breathe right maker trib live   sir christopher gent to exit glaxosmithkline the daily telegraph  october   ben hirschler  may  glaxo china rd centre to target neurodegeneration reuters  david cyranoski  october  pharmaceutical futures made in china nature   corporate executive team glaxosmithkline retrieved  november  archived  october  at the wayback machine  andrew wittys journey from graduate to gsk ceo glaxosmithkline  august  andrew philip witty bloomberg  graham ruddick  april  glaxosmithkline buys stiefel for bn the daily telegraph   fda approves additional vaccine for  hn influenza virus us food and drug administration fda  november    andrew jack  april  companies  pharmaceuticals – gsk and pfizer to merge hiv portfolios financial times   gsk acquires laboratorios phoenix for m infogrok  paul sandle  december  update glaxo buys proteindrinks firm maxinutrition reuters   david ranii  december  gsk sells bc goodys and other brands news  observer archived from the original on  april    gsk confirms  mln stg uk investment plans reuters  march   european biotechnology news  may  gsk acquires cellzome  britains largest drugmaker glaxosmithkline will pay about €m in cash to acquire cellzome ag completely john carroll for fiercebiotech  may  gsk snags proteomics platform tech in m cellzome buyout  john carroll for fiercepharma  june  gsk continues deal spree with m pact for basilea eczema drug basilea pharmaceutica press release  june  basilea enters into global agreement with stiefel a gsk company for toctino® alitretinoin  matthew herper three lessons from glaxosmithklines purchase of human genome sciences forbes  july   hirschler ben  march  gsk pays  billion to lift indian unit stake to  percent reuters retrieved  march    chad bray david jolly novartis and glaxo agree to trade  billion in assets the new york times  april   jonathan d rockoff jeanne whalen marta falconi deal flurry shows drug makers swing toward specialization the wall street journal  april   gen  news highlightsgsk acquires glycovaxyn for m gen   pfizer buys two gsk meningitis vaccines for m gen retrieved  march    james quinn sir philip hampton to chair glaxo the daily telegraph  september   jon yeomans  september  emma walmsley becomes latest female ceo in ftse  as she replaces sir andrew witty at gsk daily telegraph london retrieved  september    access to medicine pdf archived from the original pdf on  february    human rights campaign profle buyers guide entry for glaxosmithkline accessed may    global alliance to eliminate lymphatic filariasis ifpmaorg archived from the original on  december    private and public partners unite to combat  neglected tropical diseases by  bill  melinda gates foundation  january   researchbased pharma pledges on neglected tropical diseases the pharma letter  january    global programme to eliminate lymphatic filariasis progress report  pdf world health organization  september  p    sarah boseley drug giant glaxosmithkline pledges cheap medicine for worlds poor the guardian  february   unitaid  february  unitaid statement on gsk patent pool for neglected diseases  tido von schoenangerer letter to the editor the guardian  february   glaxosmithkline unit joins patent pool for aids drugs  reuters   medicines patent pool viiv healthcare sign licence for the most recent hiv medicine to have received regulatory approval  medicines patent pool   ben goldacre bad pharma fourth estate   p   max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  jim edwards inside gsks cassper ghostwriting program cbs news  august   gsk to stop paying doctors in major marketing overhaul thomsonreuters  december   the intimidation of dr john buse and the diabetes drug avandia committee on finance united states senate november  pp –  max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  for internal concerns p  and attachment e pp – for ghostwriting p  and attachment h pp – for the ghostwriting attachment i p ff for cover letter to circulation attachment i p  for the ghostwritten article attachment i pp – haffner sm et al    effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type  diabetes mellitus circulation   – pmid  doicir   a b nissen se  the rise and fall of rosiglitazone european heart journal   – pmid  doieurheartjehq  see table  for timeline  a b philip d home et al rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type  diabetes record a multicentre randomised openlabel trial the lancet   june  pp – dois pmid  philip d home et al rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes record study design and protocol diabetologia  september  pp – dois pmid  record rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes clinicaltrialsgov  nissen se wolski k  effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes new england journal of medicine   – pmid  doinejmoa rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance   stephanie saul doctor accused of leak to drug maker the new york times  january  gardiner harris a faceoff on the safety of a drug for diabetes the new york times  february   a b staff report on glaxosmithkline and the diabetes drug avandia committee on finance united states senate january  grassley baucus release committee report on avandia the united states senate committee on finance  february  andrew clark glaxos handling of avandia concerns damned by us senate committee the guardian  february   david graham assessment of the cardiovascular risks and health benefits of rosiglitazone office of surveillance and epidemiology food and drug administration  july   fda adds boxed warning for heartrelated risks to antidiabetes drug avandia agency says drug to remain on market while safety assessment continues food and drug administration  november   a b fda drug safety communication fda requires removal of some prescribing and dispensing restrictions for rosiglitazonecontaining diabetes medicines food and drug administration  november   avandia prescribing information food and drug administration  thomas f lüscher ulf landmesser frank ruschitzka  april  standing firm—the european heart journal scientific controversies and the industry european heart journal   – doieurheartjehq  steven e nissen the rise and fall of rosiglitazone european heart journal  april  pp – doieurheartjehq pmid  moncef slaoui the rise and fall of rosiglitazone reply european heart journal  april  pp – doieurheartjehq pmid  michel komajda et al heart failure events with rosiglitazone in type  diabetes data from the record clinical trial european heart journal  april  pp – doieurheartjehp pmid   steven e nissen kathy wolski rosiglitazone revisitedan updated metaanalysis of risk for myocardial infarction and cardiovascular mortality archives of internal medicine  july  pp – that study was limited by low event rates which resulted in insufficient statistical power to confirm or refute evidence of an increased risk for ischemic myocardial events doiarchinternmed pmid   european medicines agency recommends suspension of avandia avandamet and avaglim european medicines agency  september   kenneth w mchaffey et al results of a reevaluation of cardiovascular outcomes in the record trial american heart journal  august  pp – doijahj pmid   fda requires removal of certain restrictions on the diabetes drug avandia food and drug administration  november  readjudication of the rosiglitazone evaluated for cardiovascular outcomes and regulation of glycemia in diabetes trial record joint meeting of the endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee food and drug administration – june  steven nissen steven nissen the hidden agenda behind the fdas new avandia hearings forbes  may  the fda responds to steve nissens criticism of upcoming avandia meeting forbes  may   a b w kondro b sibbald march  drug company experts advised staff to withhold data about ssri use in children canadian medical association journal    pmc   pmid  doicmaj   goldacre  p   kurt samson december  senate probe seeks industry payment data on individual academic researchers annals of neurology   a– pmid  doiana   letter showing authorship of study  drug industry document archive university of california san francisco isabel heck controversial paxil paper still under fire  years later the brown daily herald  april  jon n jureidini leemon b mchenry peter r mansfield clinical trials and drug promotion selective reporting of study  international journal of risk  safety in medicine   pp – doijrs company hid suicide link bbc news  january  secrets of the drug trials bbc panorama  january  goldacre  pp –  martin keller et al efficacy of paroxetine in the treatment of adolescent major depression a randomized controlled trial journal of the american academy of child and adolescent psychiatry  july  pp – pmid  doi  alison bass side effects a prosecutor a whistleblower and a bestselling antidepressant on trial algonquin books of chapel hill  marcia angell  january  drug companies  doctors a story of corruption the new york review of books     judge paxil ads cant say it isnt habitforming associated press  august    drug and device law december   the fdas amicus briefs on preemption ronald d white for the los angeles times august   us opposes order to pull paxil tv ads  a b who expert committee on drug dependence thirtythird report world health organization  pp    a b c d united states v glaxo group ltd  us    a b c d e lahatte gabrielle  reverse payments when the federal trade commission can attack the validity of underlying patents case western reserve journal of law technology  the internet  – retrieved  june    leslie christopher r  antitrust law and intellectual property rights cases and materials oxford university press pp – isbn    united states v glaxo group ltd at   jacobson jonathan m  antitrust law developments american bar association p  isbn    oliver thring consider squash and cordial the guardian  september  we have frank and vernon to thank for ribena the bristol post  september   linus gregoriadis makers of ribena lose fight over antidecay claims the daily telegraph  january   david eames  march  judge orders ribena to fess up the new zealand herald  tony jaques when an icon stumbles – the ribena issue mismanaged corporate communications an international journal   pp – michael regester judy larkin risk issues and crisis management in public relations kogan page publishers  p ff  glaxosmithkline to plead guilty  pay  million to resolve criminal and civil liability regarding manufacturing deficiencies at puerto rico plant us department of justice  october   a b glaxo to pay  million for sale of bad products the new york times  october    alice yan toh han shih  july  shanghai travel agents revenue surge led to arrests in gsk bribery case south china morning post  glaxosmithkline executives face china bribery probe bbc news  july    rupert neate and angela monaghan glaxosmithkline admits some staff in china involved in bribery the guardian  july  rupert neate gsk’s china crisis chief executive andrew witty speaks  as it happened the guardian  july  tom philips  july  chinese police allege glaxo sales reps trained to offer sexual bribes the daily telegraph   china fines glaxosmithkline nearly  million in bribery case  the new york times   malcolm moore denise roland china fines glaxo £m for bribery mark reilly sentenced the daily telegraph  september   watchdog fines gsk £m for paying to keep generic drugs out of uk market daily telegraph  february  retrieved  february    john hooper heather stewart over  doctors face charges in italian drugs scandal the guardian  may   jane burgermeister german prosecutors probe again into bribes by drug companies bmj   june  glaxo probed over doctor freebies bbc news  march   glaxosmithkline annual report pg  pdf retrieved    glaxosmithkline to settle tax dispute with us reuters  september  irs accepts settlement offer in largest transfer pricing dispute irs  september   julia kollewe  may  glaxosmithkline faces criminal investigation by serious fraud office the guardian   kirsten ridley uk fraud office liaising with china on gsk bribery case reuters  july   glaxosmithkline faces bribery claims in syria reuters  august  external linksedit official website glaxosmithkline companies grouped at opencorporates financial times quote profile and news london stock exchange quote regulatory filings and news new york stock exchange quote profile regulatory filings and news v t e glaxosmithkline subsidiaries glaxosmithkline pakistan glaxosmithkline pharmaceuticals ltd stiefel laboratories viiv healthcare  predecessors acquisitions allen  hanburys beecham group block drug burroughs wellcome glaxo glaxo wellcome human genome sciences recherche et industrie thérapeutiques reliant pharmaceuticals s e massengill company smithkline beecham smith kline  french products current pharmaceuticals advair alli augmentin avandia beconase boniva flixonase hycamtin lamictal paxilseroxat serlipet tagamet ventolin wellbutrinzyban zantac … more vaccines hepatyrix pandemrix twinrix other aquafresh horlicks nicoderm nicorette niquitin sensodyne tums … more former bc powder geritol goodys powder lucozade ribena people governance chris gent chair andrew witty ceo other thomas beecham silas m burroughs mahlon kline john k smith henry wellcome litigation canada v glaxosmithkline inc christopher v smithkline beecham corp glaxosmithkline services unlimited v commission united states v glaxo group ltd united states v glaxosmithkline other drug industry document archive glaxosmithkline prize side effects study  category v t e pharmaceutical and biotechnology industry in the united kingdom manufacturing in the united kingdom economy of the united kingdom companies current aah pharmaceuticals alliance boots astex astrazeneca medimmune btg cyclacel dechra pharmaceuticals ge healthcare genus glaxosmithkline hikma pharmaceuticals indivior macfarlan smith norbrook group oxford biomedica pfizer uk phytopharm proximagen shire silence therapeutics tbs gb unipath vectura group vernalis viiv healthcare defunct allen  hanburys amersham beecham group cambridge antibody technology celltech chiroscience distillers company fisons glaxo wellcome ici reliant pharmaceuticals renovo zeneca government and regulatory bodies commission on human medicines department of health european directorate for the quality of medicines european medicines agency medicines and healthcare products regulatory agency national collaborating centre for mental health national patient safety agency pharmaceutical price regulation scheme pharmaceutical society of northern ireland general pharmaceutical council scottish medicines consortium veterinary medicines directorate industry and professional bodies association of the british pharmaceutical industry chemical industries association european federation of biotechnology european federation of pharmaceutical industries and associations faculty of pharmaceutical medicine pharmacists defence association royal pharmaceutical society of great britain worshipful society of apothecaries books and journals bandolier bad pharma  british national formulary british national formulary for children monthly index of medical specialities side effects  the pharmaceutical journal other british approved name british pharmacopoeia drugscope european and developing countries clinical trials partnership european pharmacopoeia list of worlds largest pharmaceutical companies pharmaceutical services negotiating committee wellcome trust category v t e ftse  companies of the united kingdom   → ftse  i admiral group anglo american antofagasta ashtead group associated british foods astrazeneca aviva bae systems bhp bp babcock international barclays barratt developments british american tobacco british land bt group bunzl burberry carnival centrica cocacola hbc compass group convatec crh croda international dcc diageo direct line group easyjet experian fresnillo gs gkn glaxosmithkline glencore hammerson hargreaves lansdown hsbc imperial brands informa intercontinental hotels group international airlines group intertek itv johnson matthey kingfisher land securities group legal  general lloyds banking group london stock exchange group marks  spencer mediclinic international merlin entertainments micro focus international mondi morrisons national grid next old mutual paddy power betfair pearson persimmon provident prudential randgold resources royal bank of scotland reckitt benckiser relx group rentokil initial rio tinto group rollsroyce royal dutch shell royal mail rsa insurance group sage group j sainsbury schroders scottish mortgage investment trust segro severn trent shire sky smith  nephew smiths group smurfit kappa sse standard chartered standard life st jamess place taylor wimpey tesco tui unilever united utilities vodafone whitbread wolseley worldpay wpp v t e philadelphiaarea corporations including the delaware valley list of companies based in the philadelphia area philadelphiabased fortune  corporations rank in the  list comcast  aramark  crown holdings  delaware valleybased fortune  corporations rank in the  list amerisourcebergen  dupont  lincoln national  universal health services  campbell soup  ugi  burlington stores inc  other notable philadelphiabased businesses amorosos beneficial bank chemtura day  zimmermann fmc corporation independence blue cross pennsylvania real estate investment trust pep boys philadelphia media network radian group urban outfitters notable philadelphiabased professional partnerships ballard spahr blank rome cozen oconnor dechert drinker biddle  reath duane morris morgan lewis  bockius pepper hamilton saul ewing white and williams other notable delaware valleybased businesses actua corporation airgas alliedbarton ametek aqua america asplundh bentley systems brandywine realty trust boscovs carpenter technology cephalon chemours christiana care health system crozer keystone health system davids bridal duckduckgo epam systems enersys liberty property trust penn mutual penn national gaming ritas italian ice sei investments slm sungard susquehanna international group vanguard toll brothers triumph group unisys viropharma vishay intertechnology vwr wawa wilmington trust w l gore and associates wsfs bank notable delaware valleybased us headquarters of foreign businesses aberdeen asset management ace agustawestland astrazeneca delaware investments glaxosmithkline ing group keystone foods sap america siemens medical shire pharmaceuticals subaru teva pharmaceuticals td bank notable delaware valleybased division headquarters of us corporations acme cerberus capital management centocor johnson  johnson colonial penn conseco delmarva power exelon gsi commerce ebay hercules ashland mab paints sherwinwilliams mcneil laboratories jj neoware hewlettpackard peco exelon qvc liberty media rohm and haas dow chemical sunoco energy transfer tasty baking flowers foods retrieved from httpsenwikipediaorgwindexphptitleglaxosmithklineoldid categories biotechnology companies of the united kingdomcompanies based in the london borough of hounslowcompanies listed on the new york stock exchangedental companiesglaxosmithklinemedical controversiesmultinational companies headquartered in englandpharmaceutical companies established in british companies established in pharmaceutical companies of the united kingdomvaccine producersorphan drug companieslife sciences industry establishments in the united kingdombiotechnology companies established in companies formed by mergerhidden categories webarchive template wayback linksuse british english from september use dmy dates from september opencorporates groupings navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages العربيةcatalàčeštinadanskdeutschespañolesperantoفارسیfrançais한국어हिन्दीbahasa indonesiaíslenskaitalianoעבריתಕನ್ನಡlietuviųmagyarbahasa melayunederlandsnorsk bokmålnorsk nynorskpolskiportuguêsromânăрусскийscotsසිංහලсрпски  srpskisrpskohrvatski  српскохрватскиsuomisvenskaతెలుగుไทยtürkçeукраїнська edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view market report glaxosmithkline plc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing glaxosmithkline plc  product pipeline review   aug    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs glaxosmithkline plc  product pipeline review   provides an overview of the glaxosmithkline plcs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of glaxosmithkline plcs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasereport scopethe report provides brief overview of glaxosmithkline plc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of glaxosmithkline plcs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the glaxosmithkline plcs pipeline productsreasons to get this reportevaluate glaxosmithkline plcs strategic position with total access to detailed information on its product pipelineassess the growth potential of glaxosmithkline plc in its therapy areas of focusidentify new drug targets and therapeutic classes in the glaxosmithkline plcs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of glaxosmithkline plc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of glaxosmithkline plcdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of glaxosmithkline plc and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contents list of tables list of figures glaxosmithkline plc snapshot glaxosmithkline plc overview key information key facts glaxosmithkline plc  research and development overview key therapeutic areas glaxosmithkline plc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  partnered products pipeline products  outlicensed products glaxosmithkline plc  pipeline products glance glaxosmithkline plc  late stage pipeline products glaxosmithkline plc  clinical stage pipeline products glaxosmithkline plc  early stage pipeline products glaxosmithkline plc  unknown stage pipeline products glaxosmithkline plc  drug profiles gsk gsk meningococcal meningitis serotype b vaccine mepolizumab fluticasone furoate  vilanterol trifenatate fluticasone furoate  umeclidinium bromide  vilanterol trifenatate albiglutide alitretinoin ambrisentan belimumab bupropion hydrochloride er ebola strain zaire vaccine fluticasone furoate gska gska kd losmapimod measles strain schwarz  mumps strain rit   rubella strain wistar ra  vaccine ofatumumab recmagea  as retosiban tafenoquine succinate vilanterol trifenatate zanamivir fluticasone furoate  levocabastine hydrochloride afuresertib hydrochloride batefenterol cad camicinal danirixin daprodustat fluticasone furoate  umeclidinium bromide gepotidacin mesylate gsk gska gska gsk gsk gsk gska gsk gsk gsk gsk gsk gska gsk gska gska gska gsk gsk gska gsk gsk gsk gsk gsk levocabastine hydrochloride malaria vaccine mapatumumab maribavir meningococcal serotypes a b c y and w pentavalent vaccine nimenrix otelixizumab ozanezumab procvax respiratory syncytial virus vaccine rilapladib streptococcal pneumoniae vaccine streptococcus serogroup b trivalent vaccine trametinib dimethyl sulfoxide  dabrafenib mesylate  panitumumab trametinib dimethyl sulfoxide  uprosertib umeclidinium bromide afuresertib hydrochloride  trametinib dimethyl sulfoxide gska gsk gsk hiv strains c tv bivalent vaccine pazopanib hydrochloride  pembrolizumab tdenpiv amlodipine besylate  rosuvastatin calcium candesartan cilexetil  hydrochlorothiazide gahb diphtheria  pertussis acellular  tetanus vaccine ecoxynv epelsiban besylate exenatide extraintestinal pathogenic escherichia coli vaccine fmp fp glpg gska gsk gska gska gsk gsk  gsk gsk gsk gska gsk gsk gska gska gska gsk gsk gsk gska gska gska gsk gsk gsk gsk gsk gsk gsk gsk gsk gska gska gska gska gska gvxnsd hiv vaccine human immunodeficiency virus vaccine imp influenza strain hn vaccine montelukast sodium omipalisib rsv seasonal influenza vaccine staphylococcus aureus vaccine tercvax uprosertib meningococcal serotypes a c y and w quadrivalent vaccine antibody drug conjugates for cancer blysgel candida vaccine cell therapy to target fltl for autoimmune myocarditis gene therapy to activate collagen type vii for recessive dystrophic epidermolysis bullosa gsk gsk gsk gsk gsk gsk gskb gw hivaids vaccine influenza vaccine marburg vaccine meningitis vaccine meningococcal meningitis vaccine monoclonal antibodies to agonize ox receptors for cancer recombinant protein to antagonize ccr for graft versus host disease and multiple sclerosis small molecule  for malaria small molecule  to inhibit histone methyltransferases for cancer small molecule  for malaria small molecule  for tuberculosis small molecule  to inhibit histone methyltransferase for cancer small molecule  to inhibit histone methyltransferase for cancer small molecule for hypertension and insulin resistance small molecule to activate ampk for type  diabetes small molecules to inhibit inha for tuberculosis small molecules to inhibit ror gammat for multiple sclerosis and rheumatoid arthritis staphylococci aureus vaccine streptococci pneumoniae vaccine streptococcus serotype a vaccine tc tuberculosis vaccine vaccine for alzheimers disease vaccine for alzheimers disease vaccine for cancer antisense oligonucleotides for undisclosed indication bacterial multivalent vaccine bacterial vaccine drug for chronic liver disease drug to antagonize tcell receptor for cancer drugs to inhibit kynurenine monooxygenase for acute pancreatitis enterotoxigenic escherichia coli vaccine gska gsk gskj monoclonal antibodies to modulate inducible tcell costimulator for cancer proteins for musculoskeletal disorders pseudomonas aeruginosa vaccine small molecule for tuberculosis small molecule to antagonize ffa for undisclosed indication small molecule to inhibit atpase family aaa domaincontaining protein  for oncology small molecule to inhibit brpf for undisclosed indication small molecule to inhibit histone deacetylases for cancer small molecules for hiv infection small molecules for tuberculosis small molecules for undisclosed indication small molecules to inhibit falcipain for malaria small molecules to inhibit leucyltrna synthetase for tuberculosis small molecules to inhibit rna polymerase for hepatitis c streptococcus pyogenes vaccine west nile virus vaccine typhoid and paratyphoid fever vaccine glaxosmithkline plc  pipeline analysis glaxosmithkline plc  pipeline products by target glaxosmithkline plc  pipeline products by route of administration glaxosmithkline plc  pipeline products by molecule type glaxosmithkline plc  pipeline products by mechanism of action glaxosmithkline plc  recent pipeline updates glaxosmithkline plc  dormant projects glaxosmithkline plc  discontinued pipeline products discontinued pipeline product profiles glaxosmithkline plc  company statement glaxosmithkline plc  locations and subsidiaries head office other locations  subsidiaries glaxosmithkline plc  key manufacturing facilities appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesglaxosmithkline plc key information glaxosmithkline plc key facts glaxosmithkline plc  pipeline by indication  glaxosmithkline plc  pipeline by stage of development  glaxosmithkline plc  monotherapy products in pipeline  glaxosmithkline plc  combination treatment modalities in pipeline  glaxosmithkline plc  partnered products in pipeline  glaxosmithkline plc  partnered products combination treatment modalities  glaxosmithkline plc  outlicensed products in pipeline  glaxosmithkline plc  outlicensed products combination treatment modalities  glaxosmithkline plc  preregistration  glaxosmithkline plc  filing rejectedwithdrawn  glaxosmithkline plc  phase iii  glaxosmithkline plc  phase ii  glaxosmithkline plc  phase i  glaxosmithkline plc  indcta filed  glaxosmithkline plc  preclinical  glaxosmithkline plc  discovery  glaxosmithkline plc  unknown  glaxosmithkline plc  pipeline by target  glaxosmithkline plc  pipeline by route of administration  glaxosmithkline plc  pipeline by molecule type  glaxosmithkline plc  pipeline products by mechanism of action  glaxosmithkline plc  recent pipeline updates  glaxosmithkline plc  dormant developmental projects glaxosmithkline plc  discontinued pipeline products  glaxosmithkline plc other locations glaxosmithkline plc subsidiaries glaxosmithkline plc key manufacturing facilities list of figuresglaxosmithkline plc  pipeline by top  indication  glaxosmithkline plc  pipeline by stage of development  glaxosmithkline plc  monotherapy products in pipeline  glaxosmithkline plc  combination treatment modalities in pipeline  glaxosmithkline plc  partnered products in pipeline  glaxosmithkline plc  outlicensed products in pipeline  glaxosmithkline plc  pipeline by top  target  glaxosmithkline plc  pipeline by top  route of administration  glaxosmithkline plc  pipeline by top  molecule type  glaxosmithkline plc  pipeline products by top  mechanism of action   companies mentioned in this reportglaxosmithkline plc this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc home  gsk skip to content skip to search united states select a region africa algeria kenya morocco nigeria south africa tunisia asia  the middle east armenia azerbaijan bangladesh cambodia china egypt georgia hong kong india indonesia israel japan kazakhstan korea malaysia myanmar pakistan philippines saudi arabia singapore sri lanka taiwan thailand turkey united arab emirates uzbekistan vietnam australasia australia new zealand europe albania austria belarus belgium bosnia and herzegovina bulgaria croatia cyprus czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania luxembourg macedonia malta moldova netherlands norway poland portugal romania russia serbia slovakia slovenia spain sweden switzerland ukraine united kingdom north america canada mexico united states south  central america argentina brazil caribbean islands chile colombia costa rica dominican republic ecuador el salvador guatemala honduras jamaica nicaragua panama peru trinidad  tobago uruguay venezuela gsk global website wwwgskcom consumers consumers access to medicines our medicines and products contact us healthcare professionals healthcare professionals how we work with doctors clinical study register contact us investors media media gsk statement about ventolin hfa d inhaler press releases press kits press kits altius institute for biomedical sciences anoro™ ellipta™ arnuity™ ellipta®  incruse® ellipta® arzerra® ofatumumab bioelectronics breo® ellipta™ building bridges for asthma care copd materials flulaval® quadrivalent influenza virus and fluarix® quadrivalent influenza vaccine hepatitis b vaccination and diabetes influenza resources mekinist® trametinib in combination with tafinlar® dabrafenib melanoma resources navy yard nucala® mepolizumab our settlement with the us government partnership to help communities protect and care for children impacted by disasters promacta eltrombopag take  for meningitis take  for meningitis jamie schanbaum us paralympian and meningitis survivor anne geddes worldrenowned photographer nick springer us paralympian and meningitis survivor dr leonard friedland vp director of scientific affairs and public health vaccines north america at gsk tanzeum™ albiglutide the state of uncontrolled asthma in america world meningitis day world meningitis day jamie schanbaum meningococcal disease fact sheet hour of power rowing  cycling challenge knowledge gaps in vaccination against meningococcal disease us impact awards flulaval quadrivalent for infants  months and older infographics media contacts corporate reporting social media image and video library business to business business to business us supplier diversity us supplier diversity corporate commitment becoming a gsk supplier what we buy supplier development affiliations helpful links contact us contact us contact us our us locations patientsconsumers media investors shareholders employeesretirees business partnersvendors healthcare providers gsk integrity and compliance menu home brian johns goes boldly for people living with hiv we are a scienceled global healthcare company researching and developing innovative pharmaceuticals vaccines and consumer healthcare products read more about what we do news gsk receives fda approval for a new selfinjectable formulation of benlysta belimumab for systemic lupus erythematosus read more jamies story i control my asthma it doesn’t control me our news gsk submits us regulatory filing of arnuity ellipta in children with asthma  july  gsk announces board and committee changes  july  gsk receives fda approval for a new selfinjectable formulation of benlysta belimumab for systemic lupus erythematosus  july  corporate reporting read our annual report and responsible business supplement view our reporting archive reporting on our relationships our work with the healthcare and nonprofit communities gskus twitter feed latest tweets sean’s reality is why we’re committed to the relentless pursuit of better breathing for copd patients… twittercomiwebstatus…  hours ago copd patients doctors and researchers lock hands to embrace the national copdactionplan gousagovxnths httpstcorankdqq  days ago got any genius ideas natgeo chasinggenius submissions are still open winners can win k to change the world… twittercomiwebstatus…  days ago copd patients experience debilitating symptoms watch the walkinmyshoes challenge to understand httpstcomqmchexo  days ago follow us on twitter working at gsk gsk careers looking for a new job find out about working at gsk and how to apply for a job gsk careers search jobs and apply what we do information for investors share price london   share price at  nyse   share price at  lse and nyse price updated every    minutes respectively clinical trial information learn more about the clinical study register data transparency glaxosmithkline plc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies market research report glaxosmithkline plc  product pipeline review   published by global markets direct product code  published february   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license glaxosmithkline plc  product pipeline review   published february   content info  pages description summary global markets directs glaxosmithkline plc  product pipeline review   provides an overview of the glaxosmithkline plcs pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by glaxosmithkline plc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope the report provides a snapshot of the pipeline therapeutic landscape of glaxosmithkline plc the report provides overview of glaxosmithkline plc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses glaxosmithkline plcs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features glaxosmithkline plcs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy evaluate glaxosmithkline plcs strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for glaxosmithkline plc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding glaxosmithkline plcs pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures glaxosmithkline plc snapshot glaxosmithkline plc overview key information key facts glaxosmithkline plc  research and development overview key therapeutic areas glaxosmithkline plc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  partnered products pipeline products  outlicensed products glaxosmithkline plc  pipeline products glance glaxosmithkline plc  late stage pipeline products glaxosmithkline plc  clinical stage pipeline products glaxosmithkline plc  early stage pipeline products glaxosmithkline plc  unknown stage pipeline products glaxosmithkline plc  drug profiles gepirone hydrochloride er gsk gsk mepolizumab melanoma lysate vaccine fluticasone furoate  umeclidinium bromide  vilanterol trifenatate fluticasone furoate  vilanterol trifenatate measles strain schwarz  mumps strain rit   rubella strain wistar ra  vaccine albiglutide ambrisentan as  recmagea belimumab bupropion hydrochloride er ebola zaire vaccine fluticasone furoate gska inotersen sodium kd losmapimod meningococcal serotype b vaccine retosiban tafenoquine succinate vilanterol trifenatate zanamivir batefenterol succinate  fluticasone furoate fluticasone furoate  levocabastine hydrochloride alitretinoin batefenterol cad camicinal dabrafenib mesylate  panitumumab  trametinib dimethyl sulfoxide danirixin daprodustat fluticasone furoate  umeclidinium bromide gepotidacin mesylate group b streptococcus trivalent vaccine gska gska gsk gsk gsk gska gsk  gsk gsk gsk gsk gsk gsk gsk gska gska gska gsk gska gsk gska gsk gsk gvxnsd hepatitis c vaccine  malaria vaccine mapatumumab maribavir meningococcal serotypes a b c w y pentavalent vaccine otelixizumab respiratory syncytial virus vaccine rilapladib streptococcal pneumonia vaccine  umeclidinium bromide gska gsk gsk hiv strains c  tv bivalent vaccine pazopanib hydrochloride  pembrolizumab tdenpiv amlodipine besylate  rosuvastatin calcium candesartan cilexetil  hydrochlorothiazide diphtheria  pertussis acellular  tetanus vaccine gahb ecoxynv epelsiban besylate fp gsk gska gska gsk gsk gsk gsk gska gska gska gsk gsk gsk gsk gsk gsk gsk gsk gsk gsk gsk gsk gsk gsk gsk gska gska gska hepatitis c vaccine  hiv vaccine  hiv vaccine  imp influenza strain ahn vaccine influenza vaccine  montelukast sodium omipalisib oxytocin rsv staphylococcus aureus vaccine meningococcal serotypes a c w y tetravalent vaccine blysgel cellular immunotherapy to target fltl for autoimmune myocarditis gene therapy to activate lysyl hydroxylase for recessive dystrophic epidermolysis bullosa gsk gsk gsk gsk gsk gsk gsk gsk gsk gsk gska gska gsk gsk gskb gsk gskj gw hiv vaccine  influenza vaccine marburg vaccine meningococcal vaccine  monoclonal antibody conjugate for oncology raxibacumab recombinant protein to antagonize ccr for graft versus host disease and multiple sclerosis small molecule  for malaria small molecule  to inhibit histone methyltransferases for cancer small molecule  for malaria small molecule  for tuberculosis small molecule  to inhibit histone methyltransferases for cancer small molecule  to inhibit histone methyltransferases for cancer small molecule for hypertension and insulin resistance small molecule to activate ampk for type  diabetes small molecule to agonize sp for multiple sclerosis small molecules to inhibit inha for tuberculosis small molecules to inhibit ror gammat for multiple sclerosis and rheumatoid arthritis staphylococci aureus vaccine streptococcal pneumonia vaccine tc tuberculosis vaccine vaccine for alzheimers disease vaccine for cancer bacterial vaccine bacterial vaccine  drug for chronic liver disease drugs to antagonize tcell receptor for oncology drugs to inhibit kynurenine monooxygenase for acute pancreatitis gska gsk gsk gskj proteins for musculoskeletal disorders pseudomonas aeruginosa vaccine small molecule for tuberculosis small molecule to antagonize ffa for undisclosed indication small molecule to inhibit histone deacetylases for oncology small molecules for hiv infection small molecules for tuberculosis small molecules for undisclosed indication small molecules to antagonize folate receptor for tuberculosis small molecules to inhibit atpase family aaa domaincontaining protein  for oncology small molecules to inhibit falcipain for malaria small molecules to inhibit leucyltrna synthetase for tuberculosis small molecules to inhibit rna polymerase for hepatitis c paratyphoid  typhoid vaccine glaxosmithkline plc  pipeline analysis glaxosmithkline plc  pipeline products by target glaxosmithkline plc  pipeline products by route of administration glaxosmithkline plc  pipeline products by molecule type glaxosmithkline plc  pipeline products by mechanism of action glaxosmithkline plc  recent pipeline updates glaxosmithkline plc  dormant projects glaxosmithkline plc  discontinued pipeline products discontinued pipeline product profiles glaxosmithkline plc  company statement glaxosmithkline plc  locations and subsidiaries head office other locations  subsidiaries glaxosmithkline plc  key manufacturing facilities appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables glaxosmithkline plc key information glaxosmithkline plc key facts glaxosmithkline plc  pipeline by indication  glaxosmithkline plc  pipeline by stage of development  glaxosmithkline plc  monotherapy products in pipeline  glaxosmithkline plc  combination treatment modalities in pipeline  glaxosmithkline plc  partnered products in pipeline  glaxosmithkline plc  partnered products combination treatment modalities  glaxosmithkline plc  outlicensed products in pipeline  glaxosmithkline plc  outlicensed products combination treatment modalities  glaxosmithkline plc  preregistration  glaxosmithkline plc  filing rejectedwithdrawn  glaxosmithkline plc  phase iii  glaxosmithkline plc  phase ii  glaxosmithkline plc  phase i  glaxosmithkline plc  indcta filed  glaxosmithkline plc  preclinical  glaxosmithkline plc  discovery  glaxosmithkline plc  unknown  glaxosmithkline plc  pipeline by target  glaxosmithkline plc  pipeline by route of administration  glaxosmithkline plc  pipeline by molecule type  glaxosmithkline plc  pipeline products by mechanism of action  glaxosmithkline plc  recent pipeline updates  glaxosmithkline plc  dormant developmental projects glaxosmithkline plc  discontinued pipeline products  glaxosmithkline plc other locations glaxosmithkline plc subsidiaries glaxosmithkline plc key manufacturing facilities list of figures glaxosmithkline plc  pipeline by top  indication  glaxosmithkline plc  pipeline by stage of development  glaxosmithkline plc  monotherapy products in pipeline  glaxosmithkline plc  combination treatment modalities in pipeline  glaxosmithkline plc  partnered products in pipeline  glaxosmithkline plc  outlicensed products in pipeline  glaxosmithkline plc  pipeline by top  target  glaxosmithkline plc  pipeline by route of administration  glaxosmithkline plc  pipeline by top  molecule type  glaxosmithkline plc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved glaxosmithkline plc gsk company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile glaxosmithkline plc gsk related topics stocksstock screenerhealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse gsk on new york consolidated usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description glaxosmithkline plc incorporated on december   is a global healthcare company the company operates through three segments pharmaceuticals vaccines and consumer healthcare the company focuses on its research across six areas respiratory diseases human immunodeficiency virus hivinfectious diseases vaccines immunoinflammation oncology and rare diseases the company develops a range of prescription medicines vaccines and consumer healthcare productsthe companys medicines portfolio products include adartrel bactroban ceftin daraprim eumovate flixonase imigran jalyn lamictal malarone naramig otosporin ear drops pentostam relenza seretide tracrium ultiva valtrex wellbutrin and zantac its vaccines portfolio products include ambirix bexsero cervarix encepur fendrix havrix infanrix kinrix menhibrix pandemrix quinvaxem rabipur synflorix twinrix and varilrix its consumer healthcare products are categorized as pain relief oral health respiratory nutritiongastro intestinal and skin health its pain relief product category includes brands such as voltaren panadol and excedrin its oral health product category includes brands such as sensodyne parodontax polident biotene and aquafesh its respiratory product category includes brands such as flonase contac and smokers healthnicotinell its nutritiongastro intestinal product category includes brands such as horlicks eno and tums its skin health product category includes brands such as physiogel abreva zovirax lamisil and fenistilthe pharmaceuticals business discovers develops and commercializes medicines to treat a range of acute and chronic diseases it has a portfolio of medicines in respiratory and hiv its pharmaceuticals business includes respiratory hiv specialty products and classic and established products it focuses its research across respiratory hiv and infectious diseases immunoinflammation oncology and rare diseases it provides a range of inhaled respiratory products including nucala mepolizumab and its ellipta portfolio its global hiv business is managed through viiv healthcare its specialty products portfolio includes medicines such as benlysta a treatment for lupus disease and tanzeumeperzan for type ii diabetes its classic and established products include over  postpatent medicines in the areas of antiinfectives allergy neurosciences dermatology respiratory and urologythe vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people it delivers over two million vaccine doses per day to people living in over  countries its vaccines business has a portfolio of over  pediatric adolescent adult older people and travel vaccines that offer protection against over  different diseases these include bexsero its meningitis b vaccine menveo for meningitis a c w and y flu hepatitis synflorix for pneumococcal disease rotarix for rotavirus gastroenteritis and vaccines against diphtheria tetanus and whooping cough namely infanrixpediarix and boostrix the consumer healthcare business develops and markets products in wellness oral health nutrition and skin health categories its brands include otrivin panadol parodontax poligrip sensodyne theraflu and voltaren its nutrition business includes horlicks its skin health brands include abreva and zovirax » full overview of gsk company address glaxosmithkline plc  great west roadbrentford     tw gs p f  company web links home page officers  directors name compensation philip hampton  emma walmsley  simon dingemans  patrick vallance  roger connor  » more officers  directors glaxosmithkline plc news briefgsk and innoviva submit eu filing for extended use of relvar ellipta jul   briefglaxosmithkline submits eu filing for relvar ellipta extension jul   briefglaxosmithkline receives fda approval for new selfinjectable formulation of benlysta jul   glaxosmithklines new ceo prepares to trim drug pipeline jul   glaxosmithklines new ceo prepares to trim drug pipeline jul   » more gsk news related topics stocksstock screenerhealthcarepharmaceuticals glaxosmithkline plc common stock nysegsk glaxosmithkline plc common stock gsk product news news  stocknewscom     follow us stocktwits twitter glaxosmithkline plc common stock gsk product news news gsk – reports phase ii study results for latte study showed comparable viral suppression rates at  weeks jul    am  by stocknewscom staff product news key facts surrounding this news item gsk had a powr rating of a strong buy coming into today gsk was  above its day moving average coming into today gsk was  below its day moving average coming into today gsk was  below its day moving average coming into today gsk was  above its day moving average coming into today gsk was  above its day moving average coming into today gsk had returned  yeartodate leading up to today’s news versus a  return from the benchmark sp  during the same period more info about glaxosmithkline plc common stock gsk glaxosmithkline plc creates discovers develops manufactures and markets pharmaceutical products including vaccines overthecounter medicines and healthrelated consumer products worldwide the companys wellness products include panadol and panadol cold  flu eno and tums – antacids and nicorette us nicoderm niquitin cq and nicabate – treatment of nicotine withdrawal sensodyne – to ttreat and prevent dental sensitivity polident poligrip and corega to enhance comfort of fitted denture and aquafresh for the prevention of gum disease and bad breath the company was founded in  and is based the united kingdom view our full gsk ticker page with ratings news and more gsk at a glance gsk current powr rating™ overall powr rating™ gsk current price   more gsk ratings data and news gsk price reaction the day of this event jul  gsk open priceleading up to this eventgsk mo returnna gsk price chart more glaxosmithkline plc common stock gsk news view all eventdate symbol news detail start price end price change powr rating loading please wait view all gsk news page generated in  seconds gsk profile  glaxosmithkline plc stock  yahoo financehomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoreyahoosearchsearchus markets closedsp  dow  listenaetnas ceo mark bertolini on the future of the health care systembertolini shares how a lifethreatening injury shaped his views on health careglaxosmithkline plc gsknyse  nyse delayed price currency in usdadd to watchlist at close pm edt  after hours pm edtpeople also watchaznnvssnyllybmysummaryconversationsstatisticsprofilefinancialsoptionsholdershistorical dataanalystsglaxosmithkline plc great west roadbrentford tw gsunited kingdom   httpwwwgskcomsector healthcareindustry drug manufacturers  majorfull time employees key executivesnametitlepayexercisedagems emma walmsleychief exec officer  directornanamr simon p dingemanschief financial officer and exec directormkdr patrick j t vallancepres of rd and exec directornanamr daniel e troysr vp and gen counselnananamr nick hironssr vp of global ethics and compliancenananaamounts are as of december   and compensation values are for the last fiscal year ending on that date pay is salary bonuses etc exercised is the value of options exercised during the fiscal year currency in usddescriptionglaxosmithkline plc engages in the creation discovery development manufacture and marketing of vaccines overthecounter medicines and healthrelated consumer products worldwide it operates through four segments pharmaceuticals pharmaceuticals rd vaccines and consumer healthcare the company offers pharmaceutical products comprising medicines in the therapeutic areas such as respiratory antivirals central nervous system cardiovascular and urogenital metabolic antibacterials dermatology rare diseases immunoinflammation vaccines and hiv it also provides consumer healthcare products in wellness oral health nutrition and skin health categories under the otrivin panadol parodontax poligrip sensodyne theraflu and voltaren brand names the company offers its consumer healthcare products in the form of tablets caplets infant syrup drops topical gels nasal sprays effervescents lozenges gum and transdermal patches malted drinks and foods and topical creams and nonmedicated patches as well as toothpastes toothbrushes mouth rinses medicated mouthwashes gels and sprays denture adhesives and denture cleansers glaxosmithkline plc has a strategic drug discovery collaboration with exscientia limited to discover novel and selective small molecules for up to  diseaserelated targets across various therapeutic areas the company was founded in  and is headquartered in brentford the united kingdomcorporate governanceglaxosmithkline plc’s iss governance qualityscore as of july   is  the pillar scores are audit  board  shareholder rights  compensation corporate governance scores courtesy of institutional shareholder services iss scores indicate decile rank relative to index or region a decile score of  indicates lower governance risk while a  indicates higher governance riskyahoo small businessdata disclaimerhelpsuggestionsprivacyabout our adsterms updated glaxosmithkline plc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports glaxosmithkline plc  product pipeline review   glaxosmithkline plc  product pipeline review   wgr  may  global  pages global markets direct description table of content sample report enquiry before buy related reports glaxosmithkline plc  product pipeline review  summaryglobal markets direct’s ‘glaxosmithkline plc  product pipeline review  ’ provides an overview of the glaxosmithkline plc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of glaxosmithkline plc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of glaxosmithkline plc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of glaxosmithkline plc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the glaxosmithkline plc’s pipeline productsreasons to buy evaluate glaxosmithkline plc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of glaxosmithkline plc in its therapy areas of focus identify new drug targets and therapeutic classes in the glaxosmithkline plc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of glaxosmithkline plc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of glaxosmithkline plc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of glaxosmithkline plc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures glaxosmithkline plc snapshot glaxosmithkline plc overview key information key facts glaxosmithkline plc  research and development overview key therapeutic areas glaxosmithkline plc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  partnered products pipeline products  outlicensed products glaxosmithkline plc  pipeline products glance glaxosmithkline plc  late stage pipeline products glaxosmithkline plc  clinical stage pipeline products glaxosmithkline plc  early stage pipeline products glaxosmithkline plc  drug profiles umeclidinium bromide  vilanterol trifenatate eltrombopag olamine flu pandemic vaccine fluticasone furoate influenza virus vaccine quadrivalent tenofovir disoproxil fumarate trametinib dabrafenib  trametinib pazopanib hydrochloride fluticasone furoate  vilanterol trifenatate albiglutide alitretinoin ambrisentan astuprotimutr belimumab darapladib gska gska gska gsk gsk kd lapatinib ditosylate measles mumps and rubella vaccine live mepolizumab ofatumumab recmagea  as umeclidinium bromide vilanterol trifenatate zanamivir tafenoquine fluticasone furoate  levocabastine hydrochloride fluticasone furoate  umeclidinium ad afuresertib antisense oligonucleotide for transthyretin amyloidosis batefenterol camicinal dabrafenib danirixin dilmapimod fiboflapon firategrast foretinib gsk gsk gsk gsk gsk gsk gska gska gsk gsk gsk gska gska gsk gsk gsk gsk gsk gsk gsk gsk gsk gska gska gska gska gsk gsk gsk gsk gsk gsk levocabastine hydrochloride losmapimod mapatumumab maribavir nimenrix otelixizumab ozanezumab procvax recombinant vector vaccine for malaria retosiban rilapladib ronacaleret hydrochloride s pneumoniae next generation vaccine trametinib  dabrafenib  panitumumab trametinib  uprosertib afuresertib  trametinib gska gsk gsk amlodipine  enalapril maleate amlodipine  losartan amlodipine  rosuvastatin candesartan cilexetil  hydrochlorothiazide fluticasone furoate  umeclidinium  vilanterol ad ad adgrin vaccine  adjuvanted hiv vaccine denv piv epelsiban besylate exenatide fp glpg gska gsk gsk gska gska gsk gsk  trametinib gsk gsk gsk  gsk gsk  gsk gsk gska gska gska gska gska gsk gsk gsk gska gska gska gsk gsk gsk gsk gsk gska gska gsk gsk gsk gsk gsk gsk gsk gsk gska gska gska gska gska gska gska gsk gsk gska gska hiv prophylactic vaccine hiv vaccine omipalisib rsv tercvax uprosertib antibody drug conjugate for cancer blysgelonin fusion toxin for cancer cancer vaccine ebola and marburg vaccine gsk gsk gska gsk imp influenza vaccine monoclonal antibodies to activate ox receptors for cancer monophosphoryl lipid a vaccine for alzheimers disease proteosomebased vaccine for alzheimers disease small molecule to inhibit histone methyltransferases for cancer small molecule to inhibit histone methyltransferases for cancer small molecule to inhibit histone methyltransferases for cancer small molecules for malaria small molecules to inhibit gyrase for mycobacterium tuberculosis infections tuberculosis vaccine antibodies targeting an immune checkpoint for cancer drug for chronic liver disease drug to inhibit kynurenine monooxygenase for acute pancreatitis gskj small molecule for tuberculosis small molecule to inhibit histone deacetylases for cancer small molecules to inhibit falcipain for malaria small molecules to inhibit inha for tuberculosis small molecules to inhibit leucyltrna synthetase for tuberculosis small molecules to inhibit rna polymerase for hepatitis c glaxosmithkline plc  pipeline analysis glaxosmithkline plc  pipeline products by target glaxosmithkline plc  pipeline products by route of administration glaxosmithkline plc  pipeline products by molecule type glaxosmithkline plc  pipeline products by mechanism of action glaxosmithkline plc  recent pipeline updates glaxosmithkline plc  dormant projects glaxosmithkline plc  discontinued pipeline products discontinued pipeline product profiles glaxosmithkline plc  company statement glaxosmithkline plc  locations and subsidiaries head office other locations  subsidiaries glaxosmithkline plc  key manufacturing facilities appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesglaxosmithkline plc key information glaxosmithkline plc key facts glaxosmithkline plc  pipeline by indication  glaxosmithkline plc  pipeline by stage of development  glaxosmithkline plc  monotherapy products in pipeline  glaxosmithkline plc  combination treatment modalities in pipeline  glaxosmithkline plc  partnered products in pipeline  glaxosmithkline plc  partnered products combination treatment modalities  glaxosmithkline plc  outlicensed products in pipeline  glaxosmithkline plc  outlicensed products combination treatment modalities  glaxosmithkline plc  preregistration  glaxosmithkline plc  filing rejectedwithdrawn  glaxosmithkline plc  phase iii  glaxosmithkline plc  phase ii  glaxosmithkline plc  phase i  glaxosmithkline plc  preclinical  glaxosmithkline plc  discovery  glaxosmithkline plc  pipeline by target  glaxosmithkline plc  pipeline by route of administration  glaxosmithkline plc  pipeline by molecule type  glaxosmithkline plc  pipeline products by mechanism of action  glaxosmithkline plc  recent pipeline updates  glaxosmithkline plc  dormant developmental projects glaxosmithkline plc  discontinued pipeline products  glaxosmithkline plc other locations glaxosmithkline plc subsidiaries glaxosmithkline plc key manufacturing facilities list of figuresglaxosmithkline plc  pipeline by top  indication  glaxosmithkline plc  pipeline by stage of development  glaxosmithkline plc  monotherapy products in pipeline  glaxosmithkline plc  combination treatment modalities in pipeline  glaxosmithkline plc  partnered products in pipeline  glaxosmithkline plc  outlicensed products in pipeline  glaxosmithkline plc  pipeline by top  target  glaxosmithkline plc  pipeline by top  route of administration  glaxosmithkline plc  pipeline by top  molecule type  glaxosmithkline plc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send glaxosmithkline plc  iceiceicenyseaboutcontactsearchcloseno results foundhomepagetradeasset classesenergyinterest ratesagricultureequity derivativesmetalscredit derivativesfxcash equities product specsfutures  options specsotcview all products specs featured contractsglobal oil benchmarksbrent crude oills gasoilsugar no sterlingusdxeuriborcoffeehenry hubmsciwtinorth american crudeftsemarkets  exchangesice futures europeice futures usice futures canadaice endexice futures singaporeice otc energyice swap tradecreditexice credit tradebrokered marketsconnect to tradedirect market access  colocationweb  mobileapis  isvstrading tools  desktopsice connectprice discovery  executionrepository  confirmation servicesnews  alerts trading resources trading hours holiday calendar expiry dates all product codes vendor codesfeessubscriptions trading insights globalizing natural gas market drives liquidity in lng futures turn market messages into market data natural gas market commentary learn more about our marketscontact us clearclearing networkclearing risk managementcleared products  marketsclearing margin modelsclearing membershipice clear europerisk managementmembershipcircularsregulationoperationstechnologytreasury  bankingclient clearingcdsice clear usrisk managementmembershipnoticesregulationtechnologyice clear singaporerisk managementmembershipcircularsregulationtechnologytreasuryice clear creditmembershipcircularsregulationcds client clearingice clear netherlandsrisk managementmembershipnoticesoperationsregulationtechnologystatisticsice clear canadarisk managementmembershipnoticesregulationtechnologyclearing resources trading calendar holiday calendar fees margins expiry calendar subscriptions ice linkclearing insights emir and cds clearing the road ahead credit default swaps growth in clearing  futures how clearing mitigates risk learn more about clearing membershipcontact us data servicesoverviewpricing  analytics dataanalyticsevaluations  marktomarket dataice benchmark administrationindex servicesreference dataregulation compliancesecurities evaluationsexchange dataice realtime market dataice historical market datanyse dataquote vendors  data distributorsdesktops  toolsprice discovery  executionpost tradewealth managementnews  alertsconnectivity  feedssfti global market accesssfti low latency solutionscolocation and proximity hostingmanaged servicesindependent software vendorsconsolidated feedtick historydata resourcesevents webinars ice data services business practices agreements ice connectaccess your existing trading messaging market data and analytics tools using ice connect data insights  takeaways for overcoming mifid ii requirements see how technology is driving market data consumption get started with exchange traded derivatives reference data interested in ice data servicesrequest more information    benchmarksice liborcalculating ice liborpanel compositiongovernance  oversightnonpublication daysabout ibalicensing  datamarket statusgovernance  oversighthistorical dataholiday calendarice swap rateaccessing ratesmethodologyvenuescurrencies tenors  publication governance  oversightnonpublication dayslbma gold pricemethodologytechnologyauction processdirect participantsclient participationpublicationgovernance  oversightnonpublication daysisda simmmethodology  participationgovernance data reports  licencingpublication times days  holidays ice benchmark administration insights central clearing for the iba gold auction libor a path to global reform learn more about ice benchmark administrationcontact us reportssee all reportsfrequently accessed reports ice futures europe end of day commitments of traders daily mtd qtd ytd volume  oi ice libor historical rates insightsice educationeducation coursescourse calendarbooking termsknowledge centerthe information exchange building on a benchmark ice brent crude credit investing beyond the bond market learn about a dynamic oil landscape webiceloginglaxosmithkline plcglaxosmithkline plcproduct specsdownloaddescriptionphysically delivered option contract on uk single equities additional flexible products may be available for this equity please see iceblock only contracts here market specificationstrading screen product nameglaxosmithkline plctrading screen hub nameiceucontract symbolgxounit of tradingone option normally equals rights over  shares due to corporate action contract adjustments some equity options series may have a nonstandard contract sizequotationpence per shareminimum price movement pence per share  £last trading day london time third friday in expiry monthalgorithmpricetime trading algorithm with priority given to the first order at the best priceblock trade minimum contractsexercise dayexercise by  london time on any business daydelivery monthstarget group options  serial months out to two years longer dated expiries beyond two years with a maximum expiry of five years are available on ice block onlynon target group options  serial months out to one year longer dated expiries beyond one year with a maximum expiry of five years are available on ice block onlya list of target group and non target options can be found heresettlement datesettlement date is two business days following the day of exerciselast trading day block trades can be reported until  london timedeliverable specificationsdelivery will be  shares or other such number of shares as determined by the terms of the contractoption premiumpayable in full by the buyer on the business day following a transactionother informationin the united states these products may only be offered and sold to prescribed entities under specified conditionsstock exchangelondon stock exchangemic codeifloclearing venuesiceuloadingrelated productsi group plcarm holdings plcaberdeen asset management plcaggreko plcamec foster wheeler plctrading hourscitytradingpreopennew york am   am  london am   pm  singapore pm   pm  loadingcodesclearing admin namelse masterphysicalgxologicalgxogmifcrn acnreferencescorporate actionsretail brokers  useful contacts  informationnew strike price intervals for uk stock optionslist of contract details for equity productsequity derivatives infographicholidaysice webinarsfeatured reportsend of day reporthistorical daily volume and oihistorical monthly volumesice daily  mtdqtdytd volume and oi home  gsk gsk brianna migraine patient behind the science breaking through the pain barrier our latest research behind the science jamies story i control my asthma it doesn’t control me latest news gsk receives fda approval for a new selfinjectable formulation of benlysta belimumab for systemic lupus erythematosus  july  investors register now to watch our live investor event webcast on wednesday  july at pm bstam est d remodelled dna helix structure about us we want to help people do more feel better live longer today there are still millions of people without access to basic healthcare thousands of diseases without adequate treatments and millions more people who suffer from everyday ailments at gsk we want to change this read more press releases  july  phase ii study results showed comparable viral suppression rates at  weeks for a twodrug regimen of longacting cabotegravir and rilpivirine and a threedrug regimen in patients with hiv  july  gsk submits us regulatory filing of arnuity ellipta in children with asthma  july  gsk announces board and committee changes view all press releases london   share price at  lse price updated every  minutes nyse   share price at  nyse price updated every  minutes tweets from gsk gsk gsk icymi we’re delighted to welcome leading scientist  physician dr laurie glimcher to our board read more… twittercomiwebstatus… about  hours ago gsk gsk can you imagine a scientific discovery filling a basketball stadium martys hiv research did exactly that… twittercomiwebstatus… about  days ago gsk gsk flashbackfriday to  years ago when marty st clair discovered she’d made a scientific breakthrough in hiv resea… twittercomiwebstatus… about  days ago follow us on twitter find out more our products we research and develop a broad range of innovative products in three primary areas of pharmaceuticals vaccines and consumer healthcare career opportunities at gsk discover the work we do and the opportunities that exist from research and development through to making our products available to those who need them health for all our medicines vaccines and consumer healthcare products are improving quality of life for patients and consumers around the world glaxosmithkline  wikipedia glaxosmithkline from wikipedia the free encyclopedia jump to navigation search glaxosmithkline gsks head office in brentford london type public limited company traded as lse gsk nyse gsk ftse  component industry pharmaceutical biotechnology consumer goods predecessor glaxo plc wellcome plc beecham group plc kline  french beckman companies smith plc founded december   years ago  headquarters brentford london united kingdom area served worldwide key people sir philip hampton chairman emma walmsley ceo products pharmaceuticals vaccines oral healthcare nutritional products overthecounter medicines revenue £ billion  operating income £ billion  net income £ billion  number of employees   subsidiaries stiefel laboratories website wwwgskcom glaxosmithkline plc gsk is a british pharmaceutical company headquartered in brentford london established in  by a merger of glaxo wellcome and smithkline beecham gsk was the worlds sixth largest pharmaceutical company as of  after pfizer novartis merck hoffmannla roche and sanofin  emma walmsley became ceo on  march  and is the first female ceo of the company the company has a primary listing on the london stock exchange and is a constituent of the ftse  index as of august  it had a market capitalisation of £ billion around  billion the fourth largest on the london stock exchange it has a secondary listing on the new york stock exchange gsks drugs and vaccines earned £ billion in  its topselling products that year were advair avodart flovent augmentin lovaza and lamictal gsks consumer products which earned £ billion in  include sensodyne and aquafresh toothpaste the maltedmilk drink horlicks abreva for cold sores breathe right nasal strips nicoderm and nicorette nicotine replacements and night nurse a cold remedy the company developed the first malaria vaccine rtss which it said in  it would make available for five percent above cost legacy products developed at gsk include several listed in the world health organization model list of essential medicines such as amoxicillin mercaptopurine pyrimethamine and zidovudine in  gsk pleaded guilty to promotion of drugs for unapproved uses failure to report safety data and kickbacks to physicians in the united states and agreed to pay a  billion £bn settlement the largest settlement in the country by a drug company contents  history  glaxo wellcome  smithkline beecham  glaxosmithkline  venture arms  research products  pharmaceuticals  malaria vaccine  consumer healthcare  facilities  scientific recognition  operations and acquisitions since   –  –present  philanthropy and social responsibility   criminal and civil settlement  overview  rosiglitazone avandia  paroxetine paxilseroxat  bupropion wellbutrin  other controversies  antitrust case over griseofulvin  ribena  sb pharmco puerto rico  china  market manipulation in the uk  miscellaneous  diagram of acquisition history  see also  notes  references  external links historyedit glaxo wellcomeedit the historic glaxo factory in bunnythorpe new zealand with the glaxo laboratories sign still visible glaxo was founded in the s as a general trading company in bunnythorpe new zealand by a londoner joseph edward nathan in  it began producing driedmilk baby food first known as defiance then as glaxo from lacto under the slogan glaxo builds bonny babies the glaxo laboratories sign is still visible right on what is now a car repair shop on the main street of bunnythorpe the companys first pharmaceutical product produced in  was vitamin d glaxo laboratories opened new units in london in  the company bought two companies joseph nathan and allen  hanburys in  and  respectively the scottish pharmacologist david jack was working for allen  hanburys when glaxo took it over he went on to lead the companys rd until  after the company bought meyer laboratories in  it began to play an important role in the us market in  the american arm glaxo inc moved to research triangle park us headquartersresearch and zebulon us manufacturing in north carolina burroughs wellcome  company was founded in  in london by the american pharmacists henry wellcome and silas burroughs the wellcome tropical research laboratories opened in  in the s burroughs wellcome established research and manufacturing facilities in tuckahoe new york which served as the us headquarters until the company moved to research triangle park in north carolina in  the nobel prize winning scientists gertrude b elion and george h hitchings worked there and invented drugs still used many years later such as mercaptopurine in  the wellcome company bought cooper mcdougall  robertson inc to become more active in animal health glaxo and burroughs wellcome merged in  to form glaxo wellcome glaxo restructured its rd operation that year cutting  jobs worldwide closing its rd facility in beckenham kent and opening a medicines research centre in stevenage hertfordshire also that year glaxo wellcome acquired the californiabased affymax a leader in the field of combinatorial chemistry by  glaxo wellcome had become the worlds thirdlargest pharmaceutical company by revenues behind novartis and merck with a global market share of around  per cent its products included imigran for the treatment of migraine salbutamol ventolin for the treatment of asthma zovirax for the treatment of coldsores and retrovir and epivir for the treatment of aids in  the company was the worlds largest manufacturer of drugs for the treatment of asthma and hivaids it employed  people including  in the uk had  operating companies and  manufacturing facilities worldwide and seven of its products were among the worlds top  bestselling pharmaceuticals the company had rd facilities in hertfordshire kent and london and manufacturing plants in scotland and the north of england it had rd centres in the us and japan and production facilities in the us europe and the far east smithkline beechamedit beechams clock tower constructed  part of the beechams factory st helens in  thomas beecham launched his beechams pills laxative in england giving birth to the beecham group in  beecham opened its first factory in st helens lancashire by the s beecham was extensively involved in pharmaceuticals john k smith opened his first pharmacy in philadelphia in  in  mahlon kline joined the business which  years later became smith kline  co in  it merged with french richard and company and in  changed its name to smith kline  french laboratories as it focused more on research years later it bought norden laboratories a business doing research into animal health and recherche et industrie thérapeutiques in belgium in  to focus on vaccines the company began to expand globally buying seven laboratories in canada and the united states in  in  it bought allergan a manufacturer of eye and skincare products smithkline  french merged with beckman inc in  and changed its name to smithkline beckman in  it bought its biggest competitor international clinical laboratories and in  merged with beecham to form smithkline beecham plc the headquarters moved from the united states to england to expand rd in the united states the company bought a new research center in  another opened in  in england at new frontiers science park harlow glaxosmithklineedit glaxo wellcome and smithkline beecham announced their intention to merge in january  the merger was completed in december that year forming glaxosmithkline gsk the companys global headquarters are at gsk house brentford london officially opened in  by thenprime minister tony blair the building was erected at a cost of £ million and as of  was home to  administrative staff venture armsedit sr one was established in  by smithkline beecham to invest in new biotechnology companies and continued operating after gsk was formed by  gsk had formed another subsidiary gsk ventures to outlicense or start new companies around drug candidates that it did not intend to develop further as of  sr one tended to invest only if the company aligned with gsks business sr one was led by  to  peter sears  to  brenda gavin  to  barbara dalton  to  maxine gowen   to  joyce lonergan   to  tamar howson  to  russell greig  to  christoph westphal  jens eckstein research productsedit further information list of glaxosmithkline products pharmaceuticalsedit gsk manufactures products for major disease areas such as asthma cancer infections diabetes and mental health its biggestselling in  were advair avodart flovent augmentin lovaza and lamictal its drugs and vaccines earned £ billion that year other topselling products include its asthmacopd inhalers advair ventolin and flovent its diphtheriatetanuspertussis vaccine infanrix and its hepatitis b vaccine the epilepsy drug lamictal and the antibacterial augmentin medicines historically discovered or developed at gsk and its legacy companies and now sold as generics include amoxicillin and amoxicillinclavulanate ticarcillinclavulanate mupirocin and ceftazidime for bacterial infections zidovudine for hiv infection valacyclovir for herpes virus infections albendazole for parasitic infections sumatriptan for migraine lamotrigine for epilepsy bupropion and paroxetine for major depressive disorder cimetidine and ranitidine for gastroesophageal reflux disorder mercaptopurine and thioguanine for the treatment of leukemia allopurinol for gout pyrimethamine for malaria and the antibacterial trimethoprim among these albendazole amoxicillin amoxicillinclavulanate allopurinol mercaptopurine mupriocin pyrimethamine ranitidine thioguanine trimethoprim and zidovudine are listed on the world health organizations list of essential medications malaria vaccineedit in  gsk applied for regulatory approval for the first malaria vaccine malaria is responsible for over  deaths annually mainly in africa known as rtss the vaccine was developed as a joint project with the path vaccines initiative and the bill and melinda gates foundation the company has committed to making the vaccine available in developing countries for five percent above the cost of production as of  rtss which uses gsks proprietary as adjuvant was being examined in a phase  trial in eight african countries path reported that in the month period following vaccination rtss conferred approximately  protection from clinical plasmodium falciparum disease in children aged  months and approximately  protection in children aged  weeks when administered in conjunction with expanded program for immunization epi vaccines in  glaxo said it had spent more than  million and expected to spend an additional  million before seeking regulatory approval a second generation malaria vaccine is being evaluated in phase  clinical trials consumer healthcareedit gsks consumer healthcare division which earned £ billion in  sells oral healthcare including aquafresh macleans and sensodyne toothpastes and drinks such as horlicks boost a chocolateflavoured malt drink sold in india and formerly lucozade and ribena sold in  to suntory for £bn other products include abreva to treat cold sores night nurse a cold remedy breathe right nasal strips and nicoderm and nicorette nicotine replacements in march  it recalled alli an overthecounter weightloss drug in the united states and puerto rico because of possible tampering following customer complaints facilitiesedit as of  gsk had offices in over  countries and employed over  people  in rd the companys single largest market is the united states its us headquarters are in the navy yard philadelphia and research triangle park north carolina its consumerproducts division is in moon township pennsylvania company facilities include rd sites england stevenage stockley park ware the us research triangle park north carolina and collegeville pennsylvania canada china croatia france and india gsk is also planning to open a rd centre in partnership with mclaren technology group at the mclaren technology campus centres for biopharmaceutical products the us marietta pennsylvania and hamilton montana belgium canada germany and hungary manufacturing sites for prescription products scotland irvine and montrose england ware barnard castle worthing and ulverston ireland cork the us bristol tennessee king of prussia pennsylvania zebulon north carolina as well as australia belgium france italy malaysia poland puerto rico romania and singapore manufacturing sites for consumer products england maidenhead ireland dungarvan the us aiken south carolina oak hill new york st louis missouri brazil canada and kenya scientific recognitionedit four glaxosmithkline scientists have been recognized by the nobel committee for their contributions to basic medical science andor therapeutics development henry dale a former student of paul ehrlich received the  nobel prize in medicine for his work on the chemical transmission of neural impulses dale served as a pharmacologist and then as director of the wellcome physiological research laboratories from  to  and later served as trustee and chairman of the board of the wellcome trust john vane of wellcome research laboratories shared the  nobel prize for medicine for his work on prostaglandin biology and the discovery of prostacyclin vane served as group research and development director for the wellcome foundation from  to  gertrude b elion and george hitchings both of the wellcome research laboratories shared the  nobel prize in medicine with sir james w black for their discoveries of important principles for drug treatment elliot and hitchings were responsible for the discovery of a plethora of important drugs including mercaptopurine and thioguanine for the treatment of leukemia the immunosuppressant azothioprine allopurinol for gout pyrimethamine for malaria the antibacterial trimethoprim acyclovir for herpes virus infection and nelarabine for cancer treatment operations and acquisitions since edit –edit andrew witty gsks ceo since may  gsk completed the acquisition of new jerseybased block drug in  for us billion in  gsk acquired the usbased consumer healthcare company cns inc whose products included breathe right nasal strips and fiberchoice dietary supplements for us million in cash chris gent previously ceo of vodafone was appointed chairman of the board in  gsk opened its first rd centre in china in  in shanghai initially focused on neurodegenerative diseases andrew witty became the chief executive officer in  witty joined glaxo in  and had been president of gsks pharmaceuticals europe since  in  gsk acquired stiefel laboratories then the worlds largest independent dermatology drug company for usbn in november the fda approved gsks vaccine for  hn influenza protection manufactured by the companys id biomedical corp in canada also in november  gsk formed a joint venture with pfizer to create viiv healthcare which specializes in hiv research in  the company acquired laboratorios phoenix an argentine pharmaceutical company for usm and the ukbased sports nutrition company maxinutrition for £ million us million –presentedit in  in a million deal prestige brands holdings took over  gsk brands with sales of  million including bc powder beano ecotrin fiber choice goodys powder sominex and tagamet in  the company announced that it would invest £ million in manufacturing facilities in ulverston northern england designating it as the site for a previously announced biotech plant in may that year it acquired cellzome a german biotech company for us million and in june worldwide rights to alitretinoin toctino an eczema drug for  million in  gsk acquired human genome sciences hgs for  billion the companies had collaborated on developing the lupus drug belimumab benlysta albiglutide for type  diabetes and darapladib for atherosclerosis in march  gsk paid  billion to raise its stake in its indian pharmaceutical unit glaxosmithkline pharmaceuticals to  percent as part of a move to focus on emerging markets in april  novartis and glaxo agreed on more than  billion in deals with novartis selling its vaccine business to gsk and buying gsks cancer business in february  gsk announced that it would acquire glycovaxyn a swiss pharmaceutical company for  million and in june that year that it would sell two meningitis drugs to pfizer nimenrix and mencevax for around  million philip hampton at that time chair of the royal bank of scotland became gsk chairman in september  in september  the company announced that witty would be succeeded as ceo by emma walmsley in march  walmsley was a management professional originally from lancashire with a background in marketing philanthropy and social responsibilityedit glaxosmithkline center city philadelphia since  glaxosmithkline has several times ranked first among pharmaceutical companies on the global access to medicines index which is funded by the bill and melinda gates foundation in  the human rights campaign an lgbtrights advocacy group gave gsk a score of  percent in its corporate equality index gsk has been active with the world health organization who in the global alliance to eliminate lymphatic filariasis gaelf around  million people globally are believed to be infected with lymphatic filariasis in  the company endorsed the london declaration on neglected tropical diseases it agreed to donate  million albendazole tablets to the who each year to fight soiltransmitted helminthiasis and to provide  million albendazole tablets every year for lymphatic filariasis until the disease is eradicated as of  over  billion treatments had been delivered and  of  countries in which the disease is considered endemic had progressed to the surveillance stage in  the company said it would cut drug prices by  percent in  of the poorest nations release intellectual property rights for substances and processes relevant to neglected disease into a patent pool to encourage new drug development and invest  percent of profits from the leastdeveloped countries in medical infrastructure for those countries médecins sans frontières welcomed the decision but criticized gsk for failing to include hiv patents in its patent pool and for not including middleincome countries in the initiative in  gsk licensed its hiv portfolio to the medicines patent pool for use in children and agreed to negotiate a license for dolutegravir an integrase inhibitor then in clinical development in  this license was extended to include dolutegravir and adults with hiv the licenses include countries in which  percent of adults and  percent of children with hiv live also in  gsk joined alltrials a british campaign to ensure that all clinical trials are registered and the results reported the company said it would make its past clinicaltrial reports available and future ones within a year of the studies end  criminal and civil settlementedit overviewedit in july  gsk pleaded guilty in the united states to criminal charges and agreed to pay  billion in what was the largest settlement until then between the justice department and a drug company the  billion included a criminal fine of  and forfeiture of  the remaining  billion covered a civil settlement with the government under the false claims act the investigation was launched largely on the basis of information from four whistleblowers who filed qui tam whistleblower lawsuits against the company under the false claims act the charges stemmed from gsks promotion of the antidepressants paxil paroxetine and wellbutrin bupropion for unapproved uses from – specifically as suitable for patients under the age of  and from its failure to report safety data about avandia rosiglitazone both in violation of the federal food drug and cosmetic act other drugs promoted for unapproved uses were two inhalers advair fluticasonesalmeterol and flovent fluticasone propionate as well as zofran ondansetron imitrex sumatriptan lotronex alosetron and valtrex valaciclovir the settlement also covered reporting false best prices and underpaying rebates owed under the medicaid drug rebate program and kickbacks to physicians to prescribe gsks drugs there were allexpensespaid spa treatments and hunting trips for doctors and their spouses speakers fees at conferences and payment for articles ghostwritten by the company and placed by physicians in medical journals the company set up a ghostwriting programme called caspper initially to produce articles about paxil but which was extended to cover avandia as part of the settlement gsk signed a fiveyear corporate integrity agreement with the department of health and human services which obliged the company to make major changes in the way it did business including changing its compensation programmes for its sales force and executives and to implement and maintain transparency in its research practices and publication policies it announced in  that it would no longer pay doctors to promote its drugs or attend medical conferences and that its sales staff would no longer have prescription targets rosiglitazone avandiaedit further information rosiglitazone § adverse effects and rosiglitazone § lawsuits rosiglitazone the  settlement included a criminal fine of  for failing to report safety data to the fda about avandia rosiglitazone a diabetes drug approved in  and a civil settlement of  million for making false claims about it the justice department said gsk had promoted rosiglitazone to physicians with misleading information including that it conferred cardiovascular benefits despite an fdamandated label warning of cardiovascular risks in  john buse a diabetes specialist told medical conferences that rosiglitazone might carry an increased risk of cardiovascular problems gsk threatened to sue him called his university head of department and persuaded him to sign a retraction gsk raised questions internally about the drugs safety in  and in  the company ghostwrote an article in circulation describing a gskfunded clinical trial that suggested rosiglitazone might have a beneficial effect on cardiovascular risk from  reports began to link the thiazolidinediones the class of drugs to which rosiglitazone belongs to heart failure in april that year gsk began a sixyear openlabel randomized trial known as record to examine rosiglitazone and cardiovascular events two gsk metaanalyses in  and  showed an increased risk of cardiovascular problems with rosiglitazone the information was passed to the fda and posted on the company website but not otherwise published by december  rosiglitazone had become the topselling diabetes drug with annual sales of us billion in june  the new england journal of medicine published a metaanalysis that associated the drug with an increased risk of heart attack gsk had reportedly tried to persuade one of the authors steven nissen not to publish it after receiving an advance copy from one of the journals peer reviewers a gsk consultant in july  fda scientists suggested that rosiglitazone had caused  excess heart attacks between  and  the fda placed restrictions on the drug including adding a boxed warning but did not withdraw it in  the fda rejected that the drug had caused excess heart attacks a senate finance committee inquiry concluded in  that gsk had sought to intimidate scientists who had concerns about rosiglitazone in february that year the company tried to halt publication of an editorial about the controversy by nissen in the european heart journal the results of gsks record trial were published in june  it confirmed an association between rosiglitazone and an increased risk of heart failure and fractures but not of heart attack and concluded that it does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucoselowering drugs steven nissan and kathy wolkski argued that the studys low event rates reduced its statistical power in september  rosiglitazone was suspended in europe the results of the record study were confirmed in  by the duke clinical research institute in an independent review required by the fda in november that year the fda lifted the restrictions it had placed on the drug the boxed warning about heart attack was removed the warning about heart failure remained in place paroxetine paxilseroxatedit main article study  paroxetine known as paxil and seroxat gsk was fined for promoting paxilseroxat paroxetine for treating depression in the unders although the drug had not been approved for pediatric use paxil had  billion worldwide sales in  the company conducted nine clinical trials between  and  none of which showed that paxil helped children with depression from  to  it promoted the drug for the unders paying physicians to go on allexpenses paid trips fivestar hotels and spas from  paxils label along with those of similar drugs included an fdamandated boxed warning that it might increase the risk of suicidal ideation and behaviour in patients under  an internal smithkline beecham document said in  about withheld data from two gsk studies it would be commercially unacceptable to include a statement that pediatric efficacy had not been demonstrated as this would undermine the profile of paroxetine the company ghostwrote an article published in  in the journal of the american academy of child and adolescent psychiatry that misreported the results of one of its clinical trials study  the article concluded that paxil was generally well tolerated and effective for major depression in adolescents the suppression of the research findings is the subject of side effects  by alison bass for  years gsk marketed paxil as nonhabit forming in   patients filed a classaction suit alleging they had suffered withdrawal symptoms and in  a los angeles court issued an injunction preventing gsk from advertising that the drug was not habit forming the court withdrew the injunction after the fda objected that the court had no jurisdiction over drug marketing that the fda had approved in  a world health organization committee reported that paxil was among the top  drugs and top three antidepressants for which dependence had been reportedn  bupropion wellbutrinedit the company was also fined for promoting wellbutrin bupropion – approved at the time for major depressive disorder and also sold as a smokingcessation aid zyban – for weight loss and the treatment of attention deficit hyperactivity disorder sexual dysfunction and substance addiction gsk paid doctors to promote these offlabel uses and set up supposedly independent advisory boards and continuing medical education programmes other controversiesedit antitrust case over griseofulvinedit in the s glaxo group ltd glaxo and imperial chemical industries ici each owned patents covering various aspects of the antifungal drug griseofulvin nn – they created a patent pool by crosslicensing their patents subject to express licensing restrictions that the chemical from which the finished form of the drug tablets and capsules was made must not be resold in bulk form and they licensed other drug companies to sell the drug in finished form and subject to similar restrictions– the effect and intent of the bulksale restriction was to keep the drug chemical out of the hands of small companies that might act as pricecutters and the effect was to maintain stable uniform prices the united states brought an antitrust suit against the two companies—united states v glaxo group ltd—charging them with violation of the sherman act and also seeking to have the patents declared invalid the trial court found that the defendants had engaged in several unlawful conspiracies but dismissed the part of the suit seeking invalidation of patents and refused to grant as relief mandatory sales of the bulk drug chemical and compulsory licensing of the patents the government appealed to the supreme court which reversed in united states v glaxo group ltd  us   ribenaedit old ribena bottle year unknown made by beecham products brentford middlesex the label states widely used in hospitals and clinics there were concerns in the s about the sugar and vitamin content of ribena a blackcurrantbased syrup and soft drink owned by gsk until  produced in england by hw carter  co from the s the companys unbranded syrup was distributed to children as a source of vitamin c during world war ii which gave the drink a reputation as good for health beecham bought h w carter in  in  the british advertising standards authority asa required gsk to withdraw its claim that ribena toothkind a lowersugar variety did not encourage tooth decay a company poster showed bottles of toothkind in place of the bristles on a toothbrush the asas ruling was upheld by the high court in  gsk was fined  in new zealand over its claim that readytodrink ribena contained high levels of vitamin c after it was found to contain no detectable vitamin c in  gsk sold ribena and another drink lucozade to the japanese multinational suntory for £ billion sb pharmco puerto ricoedit in  the us department of justice announced that gsk would pay a  million criminal fine and forfeiture and a civil settlement of  million under the false claims act the fines stemmed from production of improperly made and adulterated drugs from  to  at gsks subsidiary sb pharmco puerto rico inc in cidra puerto rico which at the time produced  billion of products each year the drugs involved were kytril an antiemetic bactroban used to treat skin infections paxil the antidepressant and avandamet a diabetes drug gsk closed the factory in  according to the new york times the case began in  when gsk sent experts to fix problems cited by the fda the lead inspector recommended recalls of defective products but they were not authorized she was fired in  and filed a whistleblower lawsuit in  federal marshals seized  billion worth of products the largest such seizure in history in the  settlement sb pharmco plead guilty to criminal charges and agreed to pay  million in a criminal fine and forfeiture at that time the largest such payment ever by a manufacturer of adulterated drugs and  million in civil penalties to settle the civil lawsuit chinaedit in  chinese authorities announced that since  gsk had funnelled hk billion in kickbacks to gsk managers doctors hospitals and others who prescribed their drugs using over  travel agencies and consulting firms chinese authorities arrested four gsk executives as part of a fourmonth investigation into claims that doctors were bribed with cash and sexual favours in  a chinese court found the company guilty of bribery and imposed a fine of  million mark reilly the british head of gsks chinese operations received a threeyear suspended prison sentence after a oneday trial held in secret reilly was reportedly deported from china and dismissed by the company market manipulation in the ukedit in february  the company was fined more than £ million by the competition and markets authority for paying generics uk alpharma and norton healthcare more than £m between  and  in order to keep generic varieties of paroxetine out of the nhs market the generics companies were fined a further £ million at the end of  when generics were available in the uk the price of paroxetine dropped  miscellaneousedit italian police sought bribery charges in may  against  doctors and  gsk employees gsk and its predecessor were accused of having spent £m on physicians pharmacists and others giving them cameras computers holidays and cash doctors were alleged to have received cash based on the number of patients they treated with a cancer drug topotecan hycamtin the following month prosecutors in munich accused – doctors of having accepted bribes from smithkline beecham between  and  the inquiry was opened over allegations that the company had given over  hospital doctors money and free trips all charges were dismissed by the verona court in january  in  in the united states gsk settled the largest tax dispute in irs history agreeing to pay  billion at issue were zantac and other products sold in – the case revolved around intracompany transfer pricing—determining the share of profit attributable to the us subsidiaries of gsk and subject to tax by the irs the uks serious fraud office sfo opened a criminal inquiry in  into gsks sales practices using powers granted by the bribery act  the sfo said it was collaborating with chinese authorities to investigate bringing charges in the uk related to gsks activities in china europe and the middle east also as of  the us department of justice was investigating gsk with reference to the foreign corrupt practices act diagram of acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list glaxosmithkline smithkline beecham plc renamed  smithkline beckman renamed  smithklinerit renamed  smith kline  french reorganized  into  smith kline and french laboratories french richards and company acq  smith kline and company founded  lever brothers angioseal div acq  recherche et industrie thérapeutiques acq  beckman instruments inc merged  sold  specialized instruments corp acq  offner electronics acq  allergan acq  sold  international clinical laboratories acq  reckitt  colman acq  stiefel laboratories acq  by smithkline beckman sanofisynthelabo acq  beecham group plc merged  norcliff thayer acq  beecham group ltd s e massengill company acq  beecham group ltd renamed  cl bencard acq  county chemicals acq  glaxo wellcome renamed  glaxo merged  glaxo founded  joseph nathan acq  allen  hanburys founded  acq  margarine unie angioseal div acq  meyer laboratories acq  affymax acq  burroughs wellcome merged  mcdougall  robertson inc acq  burroughs wellcome  company founded  block drug acq  cns inc acq  stiefel laboratories acq  laboratorios phoenix acq  maxinutrition acq  cellzome acq  human genome sciences acq  novartis vaccine div acq  gsk cancer division sold  to novartis glycovaxyn acq  see alsoedit companies portal list of toothpaste brands index of oral health and dental articles recherche et industrie thérapeutiques rit galvani bioelectronics notesedit  glaxo wellcome was formed from glaxos  acquisition of burroughs wellcome and smithkline beecham from the  merger of the beecham group and the smithkline beckman corporation  world health organization expert committee on drug dependence  the committee noted the striking number of reports on paroxetine and withdrawal syndrome  the representative of consumers international reported that a number of patients had experienced difficulty in withdrawing from ssris in general it was agreed that withdrawal was indeed a problem in some patients but there was a difference of opinion on the degree of dependence that was involved given the possibility that the need for treatment of resistant or relapsing disease could make these drugs indispensable for patient care the committee expressed concern about the possibility of inappropriate prescribing resulting in the risk of problems of withdrawal outweighing the benefits of treatment with ssris referencesedit  a b c annual report  pdf retrieved  april    glaxosmithkline statista retrieved  april    the worlds biggest public companies  ranking forbes  ftse allshare index ranking stockchallengecouk   a b c annual report  pdf glaxosmithkline retrieved  may    products glaxosmithkline plc retrieved  november    a b hester plumridge  july  glaxo files its entry in race for a malaria vaccine wall street journal  laura lorenzetti  july  glaxosmithkline seeks approval on firstever malaria vaccine fortune   a b c d e f g h i j k glaxosmithkline to plead guilty and pay  billion to resolve fraud allegations and failure to report safety data united states department of justice  july  katie thomas and michael s schmidt glaxo agrees to pay  billion in fraud settlement the new york times  july  simon neville glaxosmithkline fined bn after bribing doctors to increase drugs sales the guardian  july   r p t davenporthines judy slinn glaxo a history to  cambridge university press  pp –  david newton trademarked a history of wellknown brands from airtex to wrights coal tar the history press  p   a b c d david j ravenscraft william f long paths to creating value in pharmaceutical mergers in steven n kaplan ed mergers and productivity university of chicago press   a b c d e f gsk history glaxosmithkline archived from the original on  june  retrieved  april     the story of a town tricentennial committee  addition to factory the eastchester citizenbulletin  november   peter pennoyer anne walker the architecture of delano  aldrich w w norton  company  p   iconic burroughs wellcome headquarters open for rare public tour triangle modernist houses press release  october   katherine bouton the nobel pair the new york times  january   mark s lesney the ghosts of pharma past modern drug discovery january  pp –   face glaxos axe at wellcome the independent  june    magnus grimond  june  glaxo warns of redundancies the independent   magnus grimond  september  glaxo wellcome plans to axe  jobs the independent   glaxo to acquire affymax the new york times  january   outlook glaxo wellcome the independent  march    company of the week glaxo wellcome the independent  august    profile glaxo wellcome bbc news  january    the new alchemy – the drug industry’s flurry of mergers is based on a big gamble the economist  january    partners resolve their differences and unite at the second attempt nature  may    hall that glitters isnt shareholder gold the daily telegraph  july    a b reaume andrew  january  is corporate venture capital a prescription for success in the pharmaceutical industry the journal of private equity   – jstor    press release peter sears president of smithkline beechams venture capital fund appointed to avant immunotherapeutics board of directors avant via pr newswire may     a b salemi tom  july  dalton joins pfizer the in vivo blog   press release sr one announces new team expands fund premier evergreen fund made  new investments in   business wire sr one via businesswire february     a b c licking ellen  april  sr one posts help wanted ad again the in vivo blog   licking ellen  march  sr ones revolving door the in vivo blog   huang gregory t  april  christoph westphal leaving gsks sr one to focus on longwood founders fund xconomy   press release jens eckstein named president of sr one gsks venture healthcare group sr one via fiercebiotech september     mostrecognized brands antiinfectives december  drugscom   geddes am et al dec  introduction historical perspective and development of amoxicillinclavulanate int j antimicrob agents  suppl  s– pmid  doijijantimicag   brown ag aug  clavulanic acid a novel betalactamase inhibitora case study in drug discovery and development drug des deliv   – pmid    search food and drug administration   d m richards r n brogden february  ceftazidime a review of its antibacterial activity pharmacokinetic properties and therapeutic use drugs   – pmid  doi   a b mercaptopurine chemical  engineering news   a b c d george hitchings and gertrude elion chemical heritage foundation   a b elion gb  the purine path to chemotherapy science   – pmid  doiscience   a b lawrence k altman  february  gertrude elion drug developer dies at  the new york times   who model list of essential medicines th list pdf world health organization october    glaxo files its entry in race for a malaria vaccine wall street journal   press release malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children path   birkett a j et al april  malaria vaccine rd in the decade of vaccines breakthroughs challenges and opportunities vaccine  supplement  b– pmid  doijvaccine   malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children    press releases  media  glaxosmithkline archived from the original on  april    donald g mcneil jr  october  glaxos rts s malaria vaccine shows promise scientists say the new york times   product pipeline  gsk   a b angela monaghan ribena and lucozade sold to japanese drinks giant the guardian  september   majumdar ramanuj  product management in india rd ed phi learning p  isbn    aaron smith alli weightloss drug recalled for tampering cnn  march   about us what we do glaxosmithkline accessed  november  archived  october  at the wayback machine  sir henry dale  biographical   john r vane  biographical   maltzman js koretzky ga april  azathioprine old drug new actions j clin invest  – pmc   pmid  doijci   elion gb  acyclovir discovery mechanism of action and selectivity j med virol suppl  – pmid    koenig r  the legacy of great science the work of nobel laureate gertrude elion lives on oncologist   – pmid  doitheoncologist   glaxosmithkline completes the purchase of block drug for  billion pr newswire retrieved  august    rick stouffer  october  glaxo unit buys breathe right maker trib live   sir christopher gent to exit glaxosmithkline the daily telegraph  october   ben hirschler  may  glaxo china rd centre to target neurodegeneration reuters  david cyranoski  october  pharmaceutical futures made in china nature   corporate executive team glaxosmithkline retrieved  november  archived  october  at the wayback machine  andrew wittys journey from graduate to gsk ceo glaxosmithkline  august  andrew philip witty bloomberg  graham ruddick  april  glaxosmithkline buys stiefel for bn the daily telegraph   fda approves additional vaccine for  hn influenza virus us food and drug administration fda  november    andrew jack  april  companies  pharmaceuticals – gsk and pfizer to merge hiv portfolios financial times   gsk acquires laboratorios phoenix for m infogrok  paul sandle  december  update glaxo buys proteindrinks firm maxinutrition reuters   david ranii  december  gsk sells bc goodys and other brands news  observer archived from the original on  april    gsk confirms  mln stg uk investment plans reuters  march   european biotechnology news  may  gsk acquires cellzome  britains largest drugmaker glaxosmithkline will pay about €m in cash to acquire cellzome ag completely john carroll for fiercebiotech  may  gsk snags proteomics platform tech in m cellzome buyout  john carroll for fiercepharma  june  gsk continues deal spree with m pact for basilea eczema drug basilea pharmaceutica press release  june  basilea enters into global agreement with stiefel a gsk company for toctino® alitretinoin  matthew herper three lessons from glaxosmithklines purchase of human genome sciences forbes  july   hirschler ben  march  gsk pays  billion to lift indian unit stake to  percent reuters retrieved  march    chad bray david jolly novartis and glaxo agree to trade  billion in assets the new york times  april   jonathan d rockoff jeanne whalen marta falconi deal flurry shows drug makers swing toward specialization the wall street journal  april   gen  news highlightsgsk acquires glycovaxyn for m gen   pfizer buys two gsk meningitis vaccines for m gen retrieved  march    james quinn sir philip hampton to chair glaxo the daily telegraph  september   jon yeomans  september  emma walmsley becomes latest female ceo in ftse  as she replaces sir andrew witty at gsk daily telegraph london retrieved  september    access to medicine pdf archived from the original pdf on  february    human rights campaign profle buyers guide entry for glaxosmithkline accessed may    global alliance to eliminate lymphatic filariasis ifpmaorg archived from the original on  december    private and public partners unite to combat  neglected tropical diseases by  bill  melinda gates foundation  january   researchbased pharma pledges on neglected tropical diseases the pharma letter  january    global programme to eliminate lymphatic filariasis progress report  pdf world health organization  september  p    sarah boseley drug giant glaxosmithkline pledges cheap medicine for worlds poor the guardian  february   unitaid  february  unitaid statement on gsk patent pool for neglected diseases  tido von schoenangerer letter to the editor the guardian  february   glaxosmithkline unit joins patent pool for aids drugs  reuters   medicines patent pool viiv healthcare sign licence for the most recent hiv medicine to have received regulatory approval  medicines patent pool   ben goldacre bad pharma fourth estate   p   max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  jim edwards inside gsks cassper ghostwriting program cbs news  august   gsk to stop paying doctors in major marketing overhaul thomsonreuters  december   the intimidation of dr john buse and the diabetes drug avandia committee on finance united states senate november  pp –  max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  for internal concerns p  and attachment e pp – for ghostwriting p  and attachment h pp – for the ghostwriting attachment i p ff for cover letter to circulation attachment i p  for the ghostwritten article attachment i pp – haffner sm et al    effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type  diabetes mellitus circulation   – pmid  doicir   a b nissen se  the rise and fall of rosiglitazone european heart journal   – pmid  doieurheartjehq  see table  for timeline  a b philip d home et al rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type  diabetes record a multicentre randomised openlabel trial the lancet   june  pp – dois pmid  philip d home et al rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes record study design and protocol diabetologia  september  pp – dois pmid  record rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes clinicaltrialsgov  nissen se wolski k  effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes new england journal of medicine   – pmid  doinejmoa rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance   stephanie saul doctor accused of leak to drug maker the new york times  january  gardiner harris a faceoff on the safety of a drug for diabetes the new york times  february   a b staff report on glaxosmithkline and the diabetes drug avandia committee on finance united states senate january  grassley baucus release committee report on avandia the united states senate committee on finance  february  andrew clark glaxos handling of avandia concerns damned by us senate committee the guardian  february   david graham assessment of the cardiovascular risks and health benefits of rosiglitazone office of surveillance and epidemiology food and drug administration  july   fda adds boxed warning for heartrelated risks to antidiabetes drug avandia agency says drug to remain on market while safety assessment continues food and drug administration  november   a b fda drug safety communication fda requires removal of some prescribing and dispensing restrictions for rosiglitazonecontaining diabetes medicines food and drug administration  november   avandia prescribing information food and drug administration  thomas f lüscher ulf landmesser frank ruschitzka  april  standing firm—the european heart journal scientific controversies and the industry european heart journal   – doieurheartjehq  steven e nissen the rise and fall of rosiglitazone european heart journal  april  pp – doieurheartjehq pmid  moncef slaoui the rise and fall of rosiglitazone reply european heart journal  april  pp – doieurheartjehq pmid  michel komajda et al heart failure events with rosiglitazone in type  diabetes data from the record clinical trial european heart journal  april  pp – doieurheartjehp pmid   steven e nissen kathy wolski rosiglitazone revisitedan updated metaanalysis of risk for myocardial infarction and cardiovascular mortality archives of internal medicine  july  pp – that study was limited by low event rates which resulted in insufficient statistical power to confirm or refute evidence of an increased risk for ischemic myocardial events doiarchinternmed pmid   european medicines agency recommends suspension of avandia avandamet and avaglim european medicines agency  september   kenneth w mchaffey et al results of a reevaluation of cardiovascular outcomes in the record trial american heart journal  august  pp – doijahj pmid   fda requires removal of certain restrictions on the diabetes drug avandia food and drug administration  november  readjudication of the rosiglitazone evaluated for cardiovascular outcomes and regulation of glycemia in diabetes trial record joint meeting of the endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee food and drug administration – june  steven nissen steven nissen the hidden agenda behind the fdas new avandia hearings forbes  may  the fda responds to steve nissens criticism of upcoming avandia meeting forbes  may   a b w kondro b sibbald march  drug company experts advised staff to withhold data about ssri use in children canadian medical association journal    pmc   pmid  doicmaj   goldacre  p   kurt samson december  senate probe seeks industry payment data on individual academic researchers annals of neurology   a– pmid  doiana   letter showing authorship of study  drug industry document archive university of california san francisco isabel heck controversial paxil paper still under fire  years later the brown daily herald  april  jon n jureidini leemon b mchenry peter r mansfield clinical trials and drug promotion selective reporting of study  international journal of risk  safety in medicine   pp – doijrs company hid suicide link bbc news  january  secrets of the drug trials bbc panorama  january  goldacre  pp –  martin keller et al efficacy of paroxetine in the treatment of adolescent major depression a randomized controlled trial journal of the american academy of child and adolescent psychiatry  july  pp – pmid  doi  alison bass side effects a prosecutor a whistleblower and a bestselling antidepressant on trial algonquin books of chapel hill  marcia angell  january  drug companies  doctors a story of corruption the new york review of books     judge paxil ads cant say it isnt habitforming associated press  august    drug and device law december   the fdas amicus briefs on preemption ronald d white for the los angeles times august   us opposes order to pull paxil tv ads  a b who expert committee on drug dependence thirtythird report world health organization  pp    a b c d united states v glaxo group ltd  us    a b c d e lahatte gabrielle  reverse payments when the federal trade commission can attack the validity of underlying patents case western reserve journal of law technology  the internet  – retrieved  june    leslie christopher r  antitrust law and intellectual property rights cases and materials oxford university press pp – isbn    united states v glaxo group ltd at   jacobson jonathan m  antitrust law developments american bar association p  isbn    oliver thring consider squash and cordial the guardian  september  we have frank and vernon to thank for ribena the bristol post  september   linus gregoriadis makers of ribena lose fight over antidecay claims the daily telegraph  january   david eames  march  judge orders ribena to fess up the new zealand herald  tony jaques when an icon stumbles – the ribena issue mismanaged corporate communications an international journal   pp – michael regester judy larkin risk issues and crisis management in public relations kogan page publishers  p ff  glaxosmithkline to plead guilty  pay  million to resolve criminal and civil liability regarding manufacturing deficiencies at puerto rico plant us department of justice  october   a b glaxo to pay  million for sale of bad products the new york times  october    alice yan toh han shih  july  shanghai travel agents revenue surge led to arrests in gsk bribery case south china morning post  glaxosmithkline executives face china bribery probe bbc news  july    rupert neate and angela monaghan glaxosmithkline admits some staff in china involved in bribery the guardian  july  rupert neate gsk’s china crisis chief executive andrew witty speaks  as it happened the guardian  july  tom philips  july  chinese police allege glaxo sales reps trained to offer sexual bribes the daily telegraph   china fines glaxosmithkline nearly  million in bribery case  the new york times   malcolm moore denise roland china fines glaxo £m for bribery mark reilly sentenced the daily telegraph  september   watchdog fines gsk £m for paying to keep generic drugs out of uk market daily telegraph  february  retrieved  february    john hooper heather stewart over  doctors face charges in italian drugs scandal the guardian  may   jane burgermeister german prosecutors probe again into bribes by drug companies bmj   june  glaxo probed over doctor freebies bbc news  march   glaxosmithkline annual report pg  pdf retrieved    glaxosmithkline to settle tax dispute with us reuters  september  irs accepts settlement offer in largest transfer pricing dispute irs  september   julia kollewe  may  glaxosmithkline faces criminal investigation by serious fraud office the guardian   kirsten ridley uk fraud office liaising with china on gsk bribery case reuters  july   glaxosmithkline faces bribery claims in syria reuters  august  external linksedit official website glaxosmithkline companies grouped at opencorporates financial times quote profile and news london stock exchange quote regulatory filings and news new york stock exchange quote profile regulatory filings and news v t e glaxosmithkline subsidiaries glaxosmithkline pakistan glaxosmithkline pharmaceuticals ltd stiefel laboratories viiv healthcare  predecessors acquisitions allen  hanburys beecham group block drug burroughs wellcome glaxo glaxo wellcome human genome sciences recherche et industrie thérapeutiques reliant pharmaceuticals s e massengill company smithkline beecham smith kline  french products current pharmaceuticals advair alli augmentin avandia beconase boniva flixonase hycamtin lamictal paxilseroxat serlipet tagamet ventolin wellbutrinzyban zantac … more vaccines hepatyrix pandemrix twinrix other aquafresh horlicks nicoderm nicorette niquitin sensodyne tums … more former bc powder geritol goodys powder lucozade ribena people governance chris gent chair andrew witty ceo other thomas beecham silas m burroughs mahlon kline john k smith henry wellcome litigation canada v glaxosmithkline inc christopher v smithkline beecham corp glaxosmithkline services unlimited v commission united states v glaxo group ltd united states v glaxosmithkline other drug industry document archive glaxosmithkline prize side effects study  category v t e pharmaceutical and biotechnology industry in the united kingdom manufacturing in the united kingdom economy of the united kingdom companies current aah pharmaceuticals alliance boots astex astrazeneca medimmune btg cyclacel dechra pharmaceuticals ge healthcare genus glaxosmithkline hikma pharmaceuticals indivior macfarlan smith norbrook group oxford biomedica pfizer uk phytopharm proximagen shire silence therapeutics tbs gb unipath vectura group vernalis viiv healthcare defunct allen  hanburys amersham beecham group cambridge antibody technology celltech chiroscience distillers company fisons glaxo wellcome ici reliant pharmaceuticals renovo zeneca government and regulatory bodies commission on human medicines department of health european directorate for the quality of medicines european medicines agency medicines and healthcare products regulatory agency national collaborating centre for mental health national patient safety agency pharmaceutical price regulation scheme pharmaceutical society of northern ireland general pharmaceutical council scottish medicines consortium veterinary medicines directorate industry and professional bodies association of the british pharmaceutical industry chemical industries association european federation of biotechnology european federation of pharmaceutical industries and associations faculty of pharmaceutical medicine pharmacists defence association royal pharmaceutical society of great britain worshipful society of apothecaries books and journals bandolier bad pharma  british national formulary british national formulary for children monthly index of medical specialities side effects  the pharmaceutical journal other british approved name british pharmacopoeia drugscope european and developing countries clinical trials partnership european pharmacopoeia list of worlds largest pharmaceutical companies pharmaceutical services negotiating committee wellcome trust category v t e ftse  companies of the united kingdom   → ftse  i admiral group anglo american antofagasta ashtead group associated british foods astrazeneca aviva bae systems bhp bp babcock international barclays barratt developments british american tobacco british land bt group bunzl burberry carnival centrica cocacola hbc compass group convatec crh croda international dcc diageo direct line group easyjet experian fresnillo gs gkn glaxosmithkline glencore hammerson hargreaves lansdown hsbc imperial brands informa intercontinental hotels group international airlines group intertek itv johnson matthey kingfisher land securities group legal  general lloyds banking group london stock exchange group marks  spencer mediclinic international merlin entertainments micro focus international mondi morrisons national grid next old mutual paddy power betfair pearson persimmon provident prudential randgold resources royal bank of scotland reckitt benckiser relx group rentokil initial rio tinto group rollsroyce royal dutch shell royal mail rsa insurance group sage group j sainsbury schroders scottish mortgage investment trust segro severn trent shire sky smith  nephew smiths group smurfit kappa sse standard chartered standard life st jamess place taylor wimpey tesco tui unilever united utilities vodafone whitbread wolseley worldpay wpp v t e philadelphiaarea corporations including the delaware valley list of companies based in the philadelphia area philadelphiabased fortune  corporations rank in the  list comcast  aramark  crown holdings  delaware valleybased fortune  corporations rank in the  list amerisourcebergen  dupont  lincoln national  universal health services  campbell soup  ugi  burlington stores inc  other notable philadelphiabased businesses amorosos beneficial bank chemtura day  zimmermann fmc corporation independence blue cross pennsylvania real estate investment trust pep boys philadelphia media network radian group urban outfitters notable philadelphiabased professional partnerships ballard spahr blank rome cozen oconnor dechert drinker biddle  reath duane morris morgan lewis  bockius pepper hamilton saul ewing white and williams other notable delaware valleybased businesses actua corporation airgas alliedbarton ametek aqua america asplundh bentley systems brandywine realty trust boscovs carpenter technology cephalon chemours christiana care health system crozer keystone health system davids bridal duckduckgo epam systems enersys liberty property trust penn mutual penn national gaming ritas italian ice sei investments slm sungard susquehanna international group vanguard toll brothers triumph group unisys viropharma vishay intertechnology vwr wawa wilmington trust w l gore and associates wsfs bank notable delaware valleybased us headquarters of foreign businesses aberdeen asset management ace agustawestland astrazeneca delaware investments glaxosmithkline ing group keystone foods sap america siemens medical shire pharmaceuticals subaru teva pharmaceuticals td bank notable delaware valleybased division headquarters of us corporations acme cerberus capital management centocor johnson  johnson colonial penn conseco delmarva power exelon gsi commerce ebay hercules ashland mab paints sherwinwilliams mcneil laboratories jj neoware hewlettpackard peco exelon qvc liberty media rohm and haas dow chemical sunoco energy transfer tasty baking flowers foods retrieved from httpsenwikipediaorgwindexphptitleglaxosmithklineoldid categories biotechnology companies of the united kingdomcompanies based in the london borough of hounslowcompanies listed on the new york stock exchangedental companiesglaxosmithklinemedical controversiesmultinational companies headquartered in englandpharmaceutical companies established in british companies established in pharmaceutical companies of the united kingdomvaccine producersorphan drug companieslife sciences industry establishments in the united kingdombiotechnology companies established in companies formed by mergerhidden categories webarchive template wayback linksuse british english from september use dmy dates from september opencorporates groupings navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages العربيةcatalàčeštinadanskdeutschespañolesperantoفارسیfrançais한국어हिन्दीbahasa indonesiaíslenskaitalianoעבריתಕನ್ನಡlietuviųmagyarbahasa melayunederlandsnorsk bokmålnorsk nynorskpolskiportuguêsromânăрусскийscotsසිංහලсрпски  srpskisrpskohrvatski  српскохрватскиsuomisvenskaతెలుగుไทยtürkçeукраїнська edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی     한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info home  gsk gsk brianna migraine patient behind the science breaking through the pain barrier our latest research behind the science jamies story i control my asthma it doesn’t control me latest news gsk receives fda approval for a new selfinjectable formulation of benlysta belimumab for systemic lupus erythematosus  july  investors register now to watch our live investor event webcast on wednesday  july at pm bstam est d remodelled dna helix structure about us we want to help people do more feel better live longer today there are still millions of people without access to basic healthcare thousands of diseases without adequate treatments and millions more people who suffer from everyday ailments at gsk we want to change this read more press releases  july  phase ii study results showed comparable viral suppression rates at  weeks for a twodrug regimen of longacting cabotegravir and rilpivirine and a threedrug regimen in patients with hiv  july  gsk submits us regulatory filing of arnuity ellipta in children with asthma  july  gsk announces board and committee changes view all press releases london   share price at  lse price updated every  minutes nyse   share price at  nyse price updated every  minutes tweets from gsk gsk gsk icymi we’re delighted to welcome leading scientist  physician dr laurie glimcher to our board read more… twittercomiwebstatus… about  hours ago gsk gsk can you imagine a scientific discovery filling a basketball stadium martys hiv research did exactly that… twittercomiwebstatus… about  days ago gsk gsk flashbackfriday to  years ago when marty st clair discovered she’d made a scientific breakthrough in hiv resea… twittercomiwebstatus… about  days ago follow us on twitter find out more our products we research and develop a broad range of innovative products in three primary areas of pharmaceuticals vaccines and consumer healthcare career opportunities at gsk discover the work we do and the opportunities that exist from research and development through to making our products available to those who need them health for all our medicines vaccines and consumer healthcare products are improving quality of life for patients and consumers around the world glaxosmithkline  wikipedia glaxosmithkline from wikipedia the free encyclopedia jump to navigation search glaxosmithkline gsks head office in brentford london type public limited company traded as lse gsk nyse gsk ftse  component industry pharmaceutical biotechnology consumer goods predecessor glaxo plc wellcome plc beecham group plc kline  french beckman companies smith plc founded december   years ago  headquarters brentford london united kingdom area served worldwide key people sir philip hampton chairman emma walmsley ceo products pharmaceuticals vaccines oral healthcare nutritional products overthecounter medicines revenue £ billion  operating income £ billion  net income £ billion  number of employees   subsidiaries stiefel laboratories website wwwgskcom glaxosmithkline plc gsk is a british pharmaceutical company headquartered in brentford london established in  by a merger of glaxo wellcome and smithkline beecham gsk was the worlds sixth largest pharmaceutical company as of  after pfizer novartis merck hoffmannla roche and sanofin  emma walmsley became ceo on  march  and is the first female ceo of the company the company has a primary listing on the london stock exchange and is a constituent of the ftse  index as of august  it had a market capitalisation of £ billion around  billion the fourth largest on the london stock exchange it has a secondary listing on the new york stock exchange gsks drugs and vaccines earned £ billion in  its topselling products that year were advair avodart flovent augmentin lovaza and lamictal gsks consumer products which earned £ billion in  include sensodyne and aquafresh toothpaste the maltedmilk drink horlicks abreva for cold sores breathe right nasal strips nicoderm and nicorette nicotine replacements and night nurse a cold remedy the company developed the first malaria vaccine rtss which it said in  it would make available for five percent above cost legacy products developed at gsk include several listed in the world health organization model list of essential medicines such as amoxicillin mercaptopurine pyrimethamine and zidovudine in  gsk pleaded guilty to promotion of drugs for unapproved uses failure to report safety data and kickbacks to physicians in the united states and agreed to pay a  billion £bn settlement the largest settlement in the country by a drug company contents  history  glaxo wellcome  smithkline beecham  glaxosmithkline  venture arms  research products  pharmaceuticals  malaria vaccine  consumer healthcare  facilities  scientific recognition  operations and acquisitions since   –  –present  philanthropy and social responsibility   criminal and civil settlement  overview  rosiglitazone avandia  paroxetine paxilseroxat  bupropion wellbutrin  other controversies  antitrust case over griseofulvin  ribena  sb pharmco puerto rico  china  market manipulation in the uk  miscellaneous  diagram of acquisition history  see also  notes  references  external links historyedit glaxo wellcomeedit the historic glaxo factory in bunnythorpe new zealand with the glaxo laboratories sign still visible glaxo was founded in the s as a general trading company in bunnythorpe new zealand by a londoner joseph edward nathan in  it began producing driedmilk baby food first known as defiance then as glaxo from lacto under the slogan glaxo builds bonny babies the glaxo laboratories sign is still visible right on what is now a car repair shop on the main street of bunnythorpe the companys first pharmaceutical product produced in  was vitamin d glaxo laboratories opened new units in london in  the company bought two companies joseph nathan and allen  hanburys in  and  respectively the scottish pharmacologist david jack was working for allen  hanburys when glaxo took it over he went on to lead the companys rd until  after the company bought meyer laboratories in  it began to play an important role in the us market in  the american arm glaxo inc moved to research triangle park us headquartersresearch and zebulon us manufacturing in north carolina burroughs wellcome  company was founded in  in london by the american pharmacists henry wellcome and silas burroughs the wellcome tropical research laboratories opened in  in the s burroughs wellcome established research and manufacturing facilities in tuckahoe new york which served as the us headquarters until the company moved to research triangle park in north carolina in  the nobel prize winning scientists gertrude b elion and george h hitchings worked there and invented drugs still used many years later such as mercaptopurine in  the wellcome company bought cooper mcdougall  robertson inc to become more active in animal health glaxo and burroughs wellcome merged in  to form glaxo wellcome glaxo restructured its rd operation that year cutting  jobs worldwide closing its rd facility in beckenham kent and opening a medicines research centre in stevenage hertfordshire also that year glaxo wellcome acquired the californiabased affymax a leader in the field of combinatorial chemistry by  glaxo wellcome had become the worlds thirdlargest pharmaceutical company by revenues behind novartis and merck with a global market share of around  per cent its products included imigran for the treatment of migraine salbutamol ventolin for the treatment of asthma zovirax for the treatment of coldsores and retrovir and epivir for the treatment of aids in  the company was the worlds largest manufacturer of drugs for the treatment of asthma and hivaids it employed  people including  in the uk had  operating companies and  manufacturing facilities worldwide and seven of its products were among the worlds top  bestselling pharmaceuticals the company had rd facilities in hertfordshire kent and london and manufacturing plants in scotland and the north of england it had rd centres in the us and japan and production facilities in the us europe and the far east smithkline beechamedit beechams clock tower constructed  part of the beechams factory st helens in  thomas beecham launched his beechams pills laxative in england giving birth to the beecham group in  beecham opened its first factory in st helens lancashire by the s beecham was extensively involved in pharmaceuticals john k smith opened his first pharmacy in philadelphia in  in  mahlon kline joined the business which  years later became smith kline  co in  it merged with french richard and company and in  changed its name to smith kline  french laboratories as it focused more on research years later it bought norden laboratories a business doing research into animal health and recherche et industrie thérapeutiques in belgium in  to focus on vaccines the company began to expand globally buying seven laboratories in canada and the united states in  in  it bought allergan a manufacturer of eye and skincare products smithkline  french merged with beckman inc in  and changed its name to smithkline beckman in  it bought its biggest competitor international clinical laboratories and in  merged with beecham to form smithkline beecham plc the headquarters moved from the united states to england to expand rd in the united states the company bought a new research center in  another opened in  in england at new frontiers science park harlow glaxosmithklineedit glaxo wellcome and smithkline beecham announced their intention to merge in january  the merger was completed in december that year forming glaxosmithkline gsk the companys global headquarters are at gsk house brentford london officially opened in  by thenprime minister tony blair the building was erected at a cost of £ million and as of  was home to  administrative staff venture armsedit sr one was established in  by smithkline beecham to invest in new biotechnology companies and continued operating after gsk was formed by  gsk had formed another subsidiary gsk ventures to outlicense or start new companies around drug candidates that it did not intend to develop further as of  sr one tended to invest only if the company aligned with gsks business sr one was led by  to  peter sears  to  brenda gavin  to  barbara dalton  to  maxine gowen   to  joyce lonergan   to  tamar howson  to  russell greig  to  christoph westphal  jens eckstein research productsedit further information list of glaxosmithkline products pharmaceuticalsedit gsk manufactures products for major disease areas such as asthma cancer infections diabetes and mental health its biggestselling in  were advair avodart flovent augmentin lovaza and lamictal its drugs and vaccines earned £ billion that year other topselling products include its asthmacopd inhalers advair ventolin and flovent its diphtheriatetanuspertussis vaccine infanrix and its hepatitis b vaccine the epilepsy drug lamictal and the antibacterial augmentin medicines historically discovered or developed at gsk and its legacy companies and now sold as generics include amoxicillin and amoxicillinclavulanate ticarcillinclavulanate mupirocin and ceftazidime for bacterial infections zidovudine for hiv infection valacyclovir for herpes virus infections albendazole for parasitic infections sumatriptan for migraine lamotrigine for epilepsy bupropion and paroxetine for major depressive disorder cimetidine and ranitidine for gastroesophageal reflux disorder mercaptopurine and thioguanine for the treatment of leukemia allopurinol for gout pyrimethamine for malaria and the antibacterial trimethoprim among these albendazole amoxicillin amoxicillinclavulanate allopurinol mercaptopurine mupriocin pyrimethamine ranitidine thioguanine trimethoprim and zidovudine are listed on the world health organizations list of essential medications malaria vaccineedit in  gsk applied for regulatory approval for the first malaria vaccine malaria is responsible for over  deaths annually mainly in africa known as rtss the vaccine was developed as a joint project with the path vaccines initiative and the bill and melinda gates foundation the company has committed to making the vaccine available in developing countries for five percent above the cost of production as of  rtss which uses gsks proprietary as adjuvant was being examined in a phase  trial in eight african countries path reported that in the month period following vaccination rtss conferred approximately  protection from clinical plasmodium falciparum disease in children aged  months and approximately  protection in children aged  weeks when administered in conjunction with expanded program for immunization epi vaccines in  glaxo said it had spent more than  million and expected to spend an additional  million before seeking regulatory approval a second generation malaria vaccine is being evaluated in phase  clinical trials consumer healthcareedit gsks consumer healthcare division which earned £ billion in  sells oral healthcare including aquafresh macleans and sensodyne toothpastes and drinks such as horlicks boost a chocolateflavoured malt drink sold in india and formerly lucozade and ribena sold in  to suntory for £bn other products include abreva to treat cold sores night nurse a cold remedy breathe right nasal strips and nicoderm and nicorette nicotine replacements in march  it recalled alli an overthecounter weightloss drug in the united states and puerto rico because of possible tampering following customer complaints facilitiesedit as of  gsk had offices in over  countries and employed over  people  in rd the companys single largest market is the united states its us headquarters are in the navy yard philadelphia and research triangle park north carolina its consumerproducts division is in moon township pennsylvania company facilities include rd sites england stevenage stockley park ware the us research triangle park north carolina and collegeville pennsylvania canada china croatia france and india gsk is also planning to open a rd centre in partnership with mclaren technology group at the mclaren technology campus centres for biopharmaceutical products the us marietta pennsylvania and hamilton montana belgium canada germany and hungary manufacturing sites for prescription products scotland irvine and montrose england ware barnard castle worthing and ulverston ireland cork the us bristol tennessee king of prussia pennsylvania zebulon north carolina as well as australia belgium france italy malaysia poland puerto rico romania and singapore manufacturing sites for consumer products england maidenhead ireland dungarvan the us aiken south carolina oak hill new york st louis missouri brazil canada and kenya scientific recognitionedit four glaxosmithkline scientists have been recognized by the nobel committee for their contributions to basic medical science andor therapeutics development henry dale a former student of paul ehrlich received the  nobel prize in medicine for his work on the chemical transmission of neural impulses dale served as a pharmacologist and then as director of the wellcome physiological research laboratories from  to  and later served as trustee and chairman of the board of the wellcome trust john vane of wellcome research laboratories shared the  nobel prize for medicine for his work on prostaglandin biology and the discovery of prostacyclin vane served as group research and development director for the wellcome foundation from  to  gertrude b elion and george hitchings both of the wellcome research laboratories shared the  nobel prize in medicine with sir james w black for their discoveries of important principles for drug treatment elliot and hitchings were responsible for the discovery of a plethora of important drugs including mercaptopurine and thioguanine for the treatment of leukemia the immunosuppressant azothioprine allopurinol for gout pyrimethamine for malaria the antibacterial trimethoprim acyclovir for herpes virus infection and nelarabine for cancer treatment operations and acquisitions since edit –edit andrew witty gsks ceo since may  gsk completed the acquisition of new jerseybased block drug in  for us billion in  gsk acquired the usbased consumer healthcare company cns inc whose products included breathe right nasal strips and fiberchoice dietary supplements for us million in cash chris gent previously ceo of vodafone was appointed chairman of the board in  gsk opened its first rd centre in china in  in shanghai initially focused on neurodegenerative diseases andrew witty became the chief executive officer in  witty joined glaxo in  and had been president of gsks pharmaceuticals europe since  in  gsk acquired stiefel laboratories then the worlds largest independent dermatology drug company for usbn in november the fda approved gsks vaccine for  hn influenza protection manufactured by the companys id biomedical corp in canada also in november  gsk formed a joint venture with pfizer to create viiv healthcare which specializes in hiv research in  the company acquired laboratorios phoenix an argentine pharmaceutical company for usm and the ukbased sports nutrition company maxinutrition for £ million us million –presentedit in  in a million deal prestige brands holdings took over  gsk brands with sales of  million including bc powder beano ecotrin fiber choice goodys powder sominex and tagamet in  the company announced that it would invest £ million in manufacturing facilities in ulverston northern england designating it as the site for a previously announced biotech plant in may that year it acquired cellzome a german biotech company for us million and in june worldwide rights to alitretinoin toctino an eczema drug for  million in  gsk acquired human genome sciences hgs for  billion the companies had collaborated on developing the lupus drug belimumab benlysta albiglutide for type  diabetes and darapladib for atherosclerosis in march  gsk paid  billion to raise its stake in its indian pharmaceutical unit glaxosmithkline pharmaceuticals to  percent as part of a move to focus on emerging markets in april  novartis and glaxo agreed on more than  billion in deals with novartis selling its vaccine business to gsk and buying gsks cancer business in february  gsk announced that it would acquire glycovaxyn a swiss pharmaceutical company for  million and in june that year that it would sell two meningitis drugs to pfizer nimenrix and mencevax for around  million philip hampton at that time chair of the royal bank of scotland became gsk chairman in september  in september  the company announced that witty would be succeeded as ceo by emma walmsley in march  walmsley was a management professional originally from lancashire with a background in marketing philanthropy and social responsibilityedit glaxosmithkline center city philadelphia since  glaxosmithkline has several times ranked first among pharmaceutical companies on the global access to medicines index which is funded by the bill and melinda gates foundation in  the human rights campaign an lgbtrights advocacy group gave gsk a score of  percent in its corporate equality index gsk has been active with the world health organization who in the global alliance to eliminate lymphatic filariasis gaelf around  million people globally are believed to be infected with lymphatic filariasis in  the company endorsed the london declaration on neglected tropical diseases it agreed to donate  million albendazole tablets to the who each year to fight soiltransmitted helminthiasis and to provide  million albendazole tablets every year for lymphatic filariasis until the disease is eradicated as of  over  billion treatments had been delivered and  of  countries in which the disease is considered endemic had progressed to the surveillance stage in  the company said it would cut drug prices by  percent in  of the poorest nations release intellectual property rights for substances and processes relevant to neglected disease into a patent pool to encourage new drug development and invest  percent of profits from the leastdeveloped countries in medical infrastructure for those countries médecins sans frontières welcomed the decision but criticized gsk for failing to include hiv patents in its patent pool and for not including middleincome countries in the initiative in  gsk licensed its hiv portfolio to the medicines patent pool for use in children and agreed to negotiate a license for dolutegravir an integrase inhibitor then in clinical development in  this license was extended to include dolutegravir and adults with hiv the licenses include countries in which  percent of adults and  percent of children with hiv live also in  gsk joined alltrials a british campaign to ensure that all clinical trials are registered and the results reported the company said it would make its past clinicaltrial reports available and future ones within a year of the studies end  criminal and civil settlementedit overviewedit in july  gsk pleaded guilty in the united states to criminal charges and agreed to pay  billion in what was the largest settlement until then between the justice department and a drug company the  billion included a criminal fine of  and forfeiture of  the remaining  billion covered a civil settlement with the government under the false claims act the investigation was launched largely on the basis of information from four whistleblowers who filed qui tam whistleblower lawsuits against the company under the false claims act the charges stemmed from gsks promotion of the antidepressants paxil paroxetine and wellbutrin bupropion for unapproved uses from – specifically as suitable for patients under the age of  and from its failure to report safety data about avandia rosiglitazone both in violation of the federal food drug and cosmetic act other drugs promoted for unapproved uses were two inhalers advair fluticasonesalmeterol and flovent fluticasone propionate as well as zofran ondansetron imitrex sumatriptan lotronex alosetron and valtrex valaciclovir the settlement also covered reporting false best prices and underpaying rebates owed under the medicaid drug rebate program and kickbacks to physicians to prescribe gsks drugs there were allexpensespaid spa treatments and hunting trips for doctors and their spouses speakers fees at conferences and payment for articles ghostwritten by the company and placed by physicians in medical journals the company set up a ghostwriting programme called caspper initially to produce articles about paxil but which was extended to cover avandia as part of the settlement gsk signed a fiveyear corporate integrity agreement with the department of health and human services which obliged the company to make major changes in the way it did business including changing its compensation programmes for its sales force and executives and to implement and maintain transparency in its research practices and publication policies it announced in  that it would no longer pay doctors to promote its drugs or attend medical conferences and that its sales staff would no longer have prescription targets rosiglitazone avandiaedit further information rosiglitazone § adverse effects and rosiglitazone § lawsuits rosiglitazone the  settlement included a criminal fine of  for failing to report safety data to the fda about avandia rosiglitazone a diabetes drug approved in  and a civil settlement of  million for making false claims about it the justice department said gsk had promoted rosiglitazone to physicians with misleading information including that it conferred cardiovascular benefits despite an fdamandated label warning of cardiovascular risks in  john buse a diabetes specialist told medical conferences that rosiglitazone might carry an increased risk of cardiovascular problems gsk threatened to sue him called his university head of department and persuaded him to sign a retraction gsk raised questions internally about the drugs safety in  and in  the company ghostwrote an article in circulation describing a gskfunded clinical trial that suggested rosiglitazone might have a beneficial effect on cardiovascular risk from  reports began to link the thiazolidinediones the class of drugs to which rosiglitazone belongs to heart failure in april that year gsk began a sixyear openlabel randomized trial known as record to examine rosiglitazone and cardiovascular events two gsk metaanalyses in  and  showed an increased risk of cardiovascular problems with rosiglitazone the information was passed to the fda and posted on the company website but not otherwise published by december  rosiglitazone had become the topselling diabetes drug with annual sales of us billion in june  the new england journal of medicine published a metaanalysis that associated the drug with an increased risk of heart attack gsk had reportedly tried to persuade one of the authors steven nissen not to publish it after receiving an advance copy from one of the journals peer reviewers a gsk consultant in july  fda scientists suggested that rosiglitazone had caused  excess heart attacks between  and  the fda placed restrictions on the drug including adding a boxed warning but did not withdraw it in  the fda rejected that the drug had caused excess heart attacks a senate finance committee inquiry concluded in  that gsk had sought to intimidate scientists who had concerns about rosiglitazone in february that year the company tried to halt publication of an editorial about the controversy by nissen in the european heart journal the results of gsks record trial were published in june  it confirmed an association between rosiglitazone and an increased risk of heart failure and fractures but not of heart attack and concluded that it does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucoselowering drugs steven nissan and kathy wolkski argued that the studys low event rates reduced its statistical power in september  rosiglitazone was suspended in europe the results of the record study were confirmed in  by the duke clinical research institute in an independent review required by the fda in november that year the fda lifted the restrictions it had placed on the drug the boxed warning about heart attack was removed the warning about heart failure remained in place paroxetine paxilseroxatedit main article study  paroxetine known as paxil and seroxat gsk was fined for promoting paxilseroxat paroxetine for treating depression in the unders although the drug had not been approved for pediatric use paxil had  billion worldwide sales in  the company conducted nine clinical trials between  and  none of which showed that paxil helped children with depression from  to  it promoted the drug for the unders paying physicians to go on allexpenses paid trips fivestar hotels and spas from  paxils label along with those of similar drugs included an fdamandated boxed warning that it might increase the risk of suicidal ideation and behaviour in patients under  an internal smithkline beecham document said in  about withheld data from two gsk studies it would be commercially unacceptable to include a statement that pediatric efficacy had not been demonstrated as this would undermine the profile of paroxetine the company ghostwrote an article published in  in the journal of the american academy of child and adolescent psychiatry that misreported the results of one of its clinical trials study  the article concluded that paxil was generally well tolerated and effective for major depression in adolescents the suppression of the research findings is the subject of side effects  by alison bass for  years gsk marketed paxil as nonhabit forming in   patients filed a classaction suit alleging they had suffered withdrawal symptoms and in  a los angeles court issued an injunction preventing gsk from advertising that the drug was not habit forming the court withdrew the injunction after the fda objected that the court had no jurisdiction over drug marketing that the fda had approved in  a world health organization committee reported that paxil was among the top  drugs and top three antidepressants for which dependence had been reportedn  bupropion wellbutrinedit the company was also fined for promoting wellbutrin bupropion – approved at the time for major depressive disorder and also sold as a smokingcessation aid zyban – for weight loss and the treatment of attention deficit hyperactivity disorder sexual dysfunction and substance addiction gsk paid doctors to promote these offlabel uses and set up supposedly independent advisory boards and continuing medical education programmes other controversiesedit antitrust case over griseofulvinedit in the s glaxo group ltd glaxo and imperial chemical industries ici each owned patents covering various aspects of the antifungal drug griseofulvin nn – they created a patent pool by crosslicensing their patents subject to express licensing restrictions that the chemical from which the finished form of the drug tablets and capsules was made must not be resold in bulk form and they licensed other drug companies to sell the drug in finished form and subject to similar restrictions– the effect and intent of the bulksale restriction was to keep the drug chemical out of the hands of small companies that might act as pricecutters and the effect was to maintain stable uniform prices the united states brought an antitrust suit against the two companies—united states v glaxo group ltd—charging them with violation of the sherman act and also seeking to have the patents declared invalid the trial court found that the defendants had engaged in several unlawful conspiracies but dismissed the part of the suit seeking invalidation of patents and refused to grant as relief mandatory sales of the bulk drug chemical and compulsory licensing of the patents the government appealed to the supreme court which reversed in united states v glaxo group ltd  us   ribenaedit old ribena bottle year unknown made by beecham products brentford middlesex the label states widely used in hospitals and clinics there were concerns in the s about the sugar and vitamin content of ribena a blackcurrantbased syrup and soft drink owned by gsk until  produced in england by hw carter  co from the s the companys unbranded syrup was distributed to children as a source of vitamin c during world war ii which gave the drink a reputation as good for health beecham bought h w carter in  in  the british advertising standards authority asa required gsk to withdraw its claim that ribena toothkind a lowersugar variety did not encourage tooth decay a company poster showed bottles of toothkind in place of the bristles on a toothbrush the asas ruling was upheld by the high court in  gsk was fined  in new zealand over its claim that readytodrink ribena contained high levels of vitamin c after it was found to contain no detectable vitamin c in  gsk sold ribena and another drink lucozade to the japanese multinational suntory for £ billion sb pharmco puerto ricoedit in  the us department of justice announced that gsk would pay a  million criminal fine and forfeiture and a civil settlement of  million under the false claims act the fines stemmed from production of improperly made and adulterated drugs from  to  at gsks subsidiary sb pharmco puerto rico inc in cidra puerto rico which at the time produced  billion of products each year the drugs involved were kytril an antiemetic bactroban used to treat skin infections paxil the antidepressant and avandamet a diabetes drug gsk closed the factory in  according to the new york times the case began in  when gsk sent experts to fix problems cited by the fda the lead inspector recommended recalls of defective products but they were not authorized she was fired in  and filed a whistleblower lawsuit in  federal marshals seized  billion worth of products the largest such seizure in history in the  settlement sb pharmco plead guilty to criminal charges and agreed to pay  million in a criminal fine and forfeiture at that time the largest such payment ever by a manufacturer of adulterated drugs and  million in civil penalties to settle the civil lawsuit chinaedit in  chinese authorities announced that since  gsk had funnelled hk billion in kickbacks to gsk managers doctors hospitals and others who prescribed their drugs using over  travel agencies and consulting firms chinese authorities arrested four gsk executives as part of a fourmonth investigation into claims that doctors were bribed with cash and sexual favours in  a chinese court found the company guilty of bribery and imposed a fine of  million mark reilly the british head of gsks chinese operations received a threeyear suspended prison sentence after a oneday trial held in secret reilly was reportedly deported from china and dismissed by the company market manipulation in the ukedit in february  the company was fined more than £ million by the competition and markets authority for paying generics uk alpharma and norton healthcare more than £m between  and  in order to keep generic varieties of paroxetine out of the nhs market the generics companies were fined a further £ million at the end of  when generics were available in the uk the price of paroxetine dropped  miscellaneousedit italian police sought bribery charges in may  against  doctors and  gsk employees gsk and its predecessor were accused of having spent £m on physicians pharmacists and others giving them cameras computers holidays and cash doctors were alleged to have received cash based on the number of patients they treated with a cancer drug topotecan hycamtin the following month prosecutors in munich accused – doctors of having accepted bribes from smithkline beecham between  and  the inquiry was opened over allegations that the company had given over  hospital doctors money and free trips all charges were dismissed by the verona court in january  in  in the united states gsk settled the largest tax dispute in irs history agreeing to pay  billion at issue were zantac and other products sold in – the case revolved around intracompany transfer pricing—determining the share of profit attributable to the us subsidiaries of gsk and subject to tax by the irs the uks serious fraud office sfo opened a criminal inquiry in  into gsks sales practices using powers granted by the bribery act  the sfo said it was collaborating with chinese authorities to investigate bringing charges in the uk related to gsks activities in china europe and the middle east also as of  the us department of justice was investigating gsk with reference to the foreign corrupt practices act diagram of acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list glaxosmithkline smithkline beecham plc renamed  smithkline beckman renamed  smithklinerit renamed  smith kline  french reorganized  into  smith kline and french laboratories french richards and company acq  smith kline and company founded  lever brothers angioseal div acq  recherche et industrie thérapeutiques acq  beckman instruments inc merged  sold  specialized instruments corp acq  offner electronics acq  allergan acq  sold  international clinical laboratories acq  reckitt  colman acq  stiefel laboratories acq  by smithkline beckman sanofisynthelabo acq  beecham group plc merged  norcliff thayer acq  beecham group ltd s e massengill company acq  beecham group ltd renamed  cl bencard acq  county chemicals acq  glaxo wellcome renamed  glaxo merged  glaxo founded  joseph nathan acq  allen  hanburys founded  acq  margarine unie angioseal div acq  meyer laboratories acq  affymax acq  burroughs wellcome merged  mcdougall  robertson inc acq  burroughs wellcome  company founded  block drug acq  cns inc acq  stiefel laboratories acq  laboratorios phoenix acq  maxinutrition acq  cellzome acq  human genome sciences acq  novartis vaccine div acq  gsk cancer division sold  to novartis glycovaxyn acq  see alsoedit companies portal list of toothpaste brands index of oral health and dental articles recherche et industrie thérapeutiques rit galvani bioelectronics notesedit  glaxo wellcome was formed from glaxos  acquisition of burroughs wellcome and smithkline beecham from the  merger of the beecham group and the smithkline beckman corporation  world health organization expert committee on drug dependence  the committee noted the striking number of reports on paroxetine and withdrawal syndrome  the representative of consumers international reported that a number of patients had experienced difficulty in withdrawing from ssris in general it was agreed that withdrawal was indeed a problem in some patients but there was a difference of opinion on the degree of dependence that was involved given the possibility that the need for treatment of resistant or relapsing disease could make these drugs indispensable for patient care the committee expressed concern about the possibility of inappropriate prescribing resulting in the risk of problems of withdrawal outweighing the benefits of treatment with ssris referencesedit  a b c annual report  pdf retrieved  april    glaxosmithkline statista retrieved  april    the worlds biggest public companies  ranking forbes  ftse allshare index ranking stockchallengecouk   a b c annual report  pdf glaxosmithkline retrieved  may    products glaxosmithkline plc retrieved  november    a b hester plumridge  july  glaxo files its entry in race for a malaria vaccine wall street journal  laura lorenzetti  july  glaxosmithkline seeks approval on firstever malaria vaccine fortune   a b c d e f g h i j k glaxosmithkline to plead guilty and pay  billion to resolve fraud allegations and failure to report safety data united states department of justice  july  katie thomas and michael s schmidt glaxo agrees to pay  billion in fraud settlement the new york times  july  simon neville glaxosmithkline fined bn after bribing doctors to increase drugs sales the guardian  july   r p t davenporthines judy slinn glaxo a history to  cambridge university press  pp –  david newton trademarked a history of wellknown brands from airtex to wrights coal tar the history press  p   a b c d david j ravenscraft william f long paths to creating value in pharmaceutical mergers in steven n kaplan ed mergers and productivity university of chicago press   a b c d e f gsk history glaxosmithkline archived from the original on  june  retrieved  april     the story of a town tricentennial committee  addition to factory the eastchester citizenbulletin  november   peter pennoyer anne walker the architecture of delano  aldrich w w norton  company  p   iconic burroughs wellcome headquarters open for rare public tour triangle modernist houses press release  october   katherine bouton the nobel pair the new york times  january   mark s lesney the ghosts of pharma past modern drug discovery january  pp –   face glaxos axe at wellcome the independent  june    magnus grimond  june  glaxo warns of redundancies the independent   magnus grimond  september  glaxo wellcome plans to axe  jobs the independent   glaxo to acquire affymax the new york times  january   outlook glaxo wellcome the independent  march    company of the week glaxo wellcome the independent  august    profile glaxo wellcome bbc news  january    the new alchemy – the drug industry’s flurry of mergers is based on a big gamble the economist  january    partners resolve their differences and unite at the second attempt nature  may    hall that glitters isnt shareholder gold the daily telegraph  july    a b reaume andrew  january  is corporate venture capital a prescription for success in the pharmaceutical industry the journal of private equity   – jstor    press release peter sears president of smithkline beechams venture capital fund appointed to avant immunotherapeutics board of directors avant via pr newswire may     a b salemi tom  july  dalton joins pfizer the in vivo blog   press release sr one announces new team expands fund premier evergreen fund made  new investments in   business wire sr one via businesswire february     a b c licking ellen  april  sr one posts help wanted ad again the in vivo blog   licking ellen  march  sr ones revolving door the in vivo blog   huang gregory t  april  christoph westphal leaving gsks sr one to focus on longwood founders fund xconomy   press release jens eckstein named president of sr one gsks venture healthcare group sr one via fiercebiotech september     mostrecognized brands antiinfectives december  drugscom   geddes am et al dec  introduction historical perspective and development of amoxicillinclavulanate int j antimicrob agents  suppl  s– pmid  doijijantimicag   brown ag aug  clavulanic acid a novel betalactamase inhibitora case study in drug discovery and development drug des deliv   – pmid    search food and drug administration   d m richards r n brogden february  ceftazidime a review of its antibacterial activity pharmacokinetic properties and therapeutic use drugs   – pmid  doi   a b mercaptopurine chemical  engineering news   a b c d george hitchings and gertrude elion chemical heritage foundation   a b elion gb  the purine path to chemotherapy science   – pmid  doiscience   a b lawrence k altman  february  gertrude elion drug developer dies at  the new york times   who model list of essential medicines th list pdf world health organization october    glaxo files its entry in race for a malaria vaccine wall street journal   press release malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children path   birkett a j et al april  malaria vaccine rd in the decade of vaccines breakthroughs challenges and opportunities vaccine  supplement  b– pmid  doijvaccine   malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children    press releases  media  glaxosmithkline archived from the original on  april    donald g mcneil jr  october  glaxos rts s malaria vaccine shows promise scientists say the new york times   product pipeline  gsk   a b angela monaghan ribena and lucozade sold to japanese drinks giant the guardian  september   majumdar ramanuj  product management in india rd ed phi learning p  isbn    aaron smith alli weightloss drug recalled for tampering cnn  march   about us what we do glaxosmithkline accessed  november  archived  october  at the wayback machine  sir henry dale  biographical   john r vane  biographical   maltzman js koretzky ga april  azathioprine old drug new actions j clin invest  – pmc   pmid  doijci   elion gb  acyclovir discovery mechanism of action and selectivity j med virol suppl  – pmid    koenig r  the legacy of great science the work of nobel laureate gertrude elion lives on oncologist   – pmid  doitheoncologist   glaxosmithkline completes the purchase of block drug for  billion pr newswire retrieved  august    rick stouffer  october  glaxo unit buys breathe right maker trib live   sir christopher gent to exit glaxosmithkline the daily telegraph  october   ben hirschler  may  glaxo china rd centre to target neurodegeneration reuters  david cyranoski  october  pharmaceutical futures made in china nature   corporate executive team glaxosmithkline retrieved  november  archived  october  at the wayback machine  andrew wittys journey from graduate to gsk ceo glaxosmithkline  august  andrew philip witty bloomberg  graham ruddick  april  glaxosmithkline buys stiefel for bn the daily telegraph   fda approves additional vaccine for  hn influenza virus us food and drug administration fda  november    andrew jack  april  companies  pharmaceuticals – gsk and pfizer to merge hiv portfolios financial times   gsk acquires laboratorios phoenix for m infogrok  paul sandle  december  update glaxo buys proteindrinks firm maxinutrition reuters   david ranii  december  gsk sells bc goodys and other brands news  observer archived from the original on  april    gsk confirms  mln stg uk investment plans reuters  march   european biotechnology news  may  gsk acquires cellzome  britains largest drugmaker glaxosmithkline will pay about €m in cash to acquire cellzome ag completely john carroll for fiercebiotech  may  gsk snags proteomics platform tech in m cellzome buyout  john carroll for fiercepharma  june  gsk continues deal spree with m pact for basilea eczema drug basilea pharmaceutica press release  june  basilea enters into global agreement with stiefel a gsk company for toctino® alitretinoin  matthew herper three lessons from glaxosmithklines purchase of human genome sciences forbes  july   hirschler ben  march  gsk pays  billion to lift indian unit stake to  percent reuters retrieved  march    chad bray david jolly novartis and glaxo agree to trade  billion in assets the new york times  april   jonathan d rockoff jeanne whalen marta falconi deal flurry shows drug makers swing toward specialization the wall street journal  april   gen  news highlightsgsk acquires glycovaxyn for m gen   pfizer buys two gsk meningitis vaccines for m gen retrieved  march    james quinn sir philip hampton to chair glaxo the daily telegraph  september   jon yeomans  september  emma walmsley becomes latest female ceo in ftse  as she replaces sir andrew witty at gsk daily telegraph london retrieved  september    access to medicine pdf archived from the original pdf on  february    human rights campaign profle buyers guide entry for glaxosmithkline accessed may    global alliance to eliminate lymphatic filariasis ifpmaorg archived from the original on  december    private and public partners unite to combat  neglected tropical diseases by  bill  melinda gates foundation  january   researchbased pharma pledges on neglected tropical diseases the pharma letter  january    global programme to eliminate lymphatic filariasis progress report  pdf world health organization  september  p    sarah boseley drug giant glaxosmithkline pledges cheap medicine for worlds poor the guardian  february   unitaid  february  unitaid statement on gsk patent pool for neglected diseases  tido von schoenangerer letter to the editor the guardian  february   glaxosmithkline unit joins patent pool for aids drugs  reuters   medicines patent pool viiv healthcare sign licence for the most recent hiv medicine to have received regulatory approval  medicines patent pool   ben goldacre bad pharma fourth estate   p   max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  jim edwards inside gsks cassper ghostwriting program cbs news  august   gsk to stop paying doctors in major marketing overhaul thomsonreuters  december   the intimidation of dr john buse and the diabetes drug avandia committee on finance united states senate november  pp –  max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  for internal concerns p  and attachment e pp – for ghostwriting p  and attachment h pp – for the ghostwriting attachment i p ff for cover letter to circulation attachment i p  for the ghostwritten article attachment i pp – haffner sm et al    effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type  diabetes mellitus circulation   – pmid  doicir   a b nissen se  the rise and fall of rosiglitazone european heart journal   – pmid  doieurheartjehq  see table  for timeline  a b philip d home et al rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type  diabetes record a multicentre randomised openlabel trial the lancet   june  pp – dois pmid  philip d home et al rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes record study design and protocol diabetologia  september  pp – dois pmid  record rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes clinicaltrialsgov  nissen se wolski k  effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes new england journal of medicine   – pmid  doinejmoa rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance   stephanie saul doctor accused of leak to drug maker the new york times  january  gardiner harris a faceoff on the safety of a drug for diabetes the new york times  february   a b staff report on glaxosmithkline and the diabetes drug avandia committee on finance united states senate january  grassley baucus release committee report on avandia the united states senate committee on finance  february  andrew clark glaxos handling of avandia concerns damned by us senate committee the guardian  february   david graham assessment of the cardiovascular risks and health benefits of rosiglitazone office of surveillance and epidemiology food and drug administration  july   fda adds boxed warning for heartrelated risks to antidiabetes drug avandia agency says drug to remain on market while safety assessment continues food and drug administration  november   a b fda drug safety communication fda requires removal of some prescribing and dispensing restrictions for rosiglitazonecontaining diabetes medicines food and drug administration  november   avandia prescribing information food and drug administration  thomas f lüscher ulf landmesser frank ruschitzka  april  standing firm—the european heart journal scientific controversies and the industry european heart journal   – doieurheartjehq  steven e nissen the rise and fall of rosiglitazone european heart journal  april  pp – doieurheartjehq pmid  moncef slaoui the rise and fall of rosiglitazone reply european heart journal  april  pp – doieurheartjehq pmid  michel komajda et al heart failure events with rosiglitazone in type  diabetes data from the record clinical trial european heart journal  april  pp – doieurheartjehp pmid   steven e nissen kathy wolski rosiglitazone revisitedan updated metaanalysis of risk for myocardial infarction and cardiovascular mortality archives of internal medicine  july  pp – that study was limited by low event rates which resulted in insufficient statistical power to confirm or refute evidence of an increased risk for ischemic myocardial events doiarchinternmed pmid   european medicines agency recommends suspension of avandia avandamet and avaglim european medicines agency  september   kenneth w mchaffey et al results of a reevaluation of cardiovascular outcomes in the record trial american heart journal  august  pp – doijahj pmid   fda requires removal of certain restrictions on the diabetes drug avandia food and drug administration  november  readjudication of the rosiglitazone evaluated for cardiovascular outcomes and regulation of glycemia in diabetes trial record joint meeting of the endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee food and drug administration – june  steven nissen steven nissen the hidden agenda behind the fdas new avandia hearings forbes  may  the fda responds to steve nissens criticism of upcoming avandia meeting forbes  may   a b w kondro b sibbald march  drug company experts advised staff to withhold data about ssri use in children canadian medical association journal    pmc   pmid  doicmaj   goldacre  p   kurt samson december  senate probe seeks industry payment data on individual academic researchers annals of neurology   a– pmid  doiana   letter showing authorship of study  drug industry document archive university of california san francisco isabel heck controversial paxil paper still under fire  years later the brown daily herald  april  jon n jureidini leemon b mchenry peter r mansfield clinical trials and drug promotion selective reporting of study  international journal of risk  safety in medicine   pp – doijrs company hid suicide link bbc news  january  secrets of the drug trials bbc panorama  january  goldacre  pp –  martin keller et al efficacy of paroxetine in the treatment of adolescent major depression a randomized controlled trial journal of the american academy of child and adolescent psychiatry  july  pp – pmid  doi  alison bass side effects a prosecutor a whistleblower and a bestselling antidepressant on trial algonquin books of chapel hill  marcia angell  january  drug companies  doctors a story of corruption the new york review of books     judge paxil ads cant say it isnt habitforming associated press  august    drug and device law december   the fdas amicus briefs on preemption ronald d white for the los angeles times august   us opposes order to pull paxil tv ads  a b who expert committee on drug dependence thirtythird report world health organization  pp    a b c d united states v glaxo group ltd  us    a b c d e lahatte gabrielle  reverse payments when the federal trade commission can attack the validity of underlying patents case western reserve journal of law technology  the internet  – retrieved  june    leslie christopher r  antitrust law and intellectual property rights cases and materials oxford university press pp – isbn    united states v glaxo group ltd at   jacobson jonathan m  antitrust law developments american bar association p  isbn    oliver thring consider squash and cordial the guardian  september  we have frank and vernon to thank for ribena the bristol post  september   linus gregoriadis makers of ribena lose fight over antidecay claims the daily telegraph  january   david eames  march  judge orders ribena to fess up the new zealand herald  tony jaques when an icon stumbles – the ribena issue mismanaged corporate communications an international journal   pp – michael regester judy larkin risk issues and crisis management in public relations kogan page publishers  p ff  glaxosmithkline to plead guilty  pay  million to resolve criminal and civil liability regarding manufacturing deficiencies at puerto rico plant us department of justice  october   a b glaxo to pay  million for sale of bad products the new york times  october    alice yan toh han shih  july  shanghai travel agents revenue surge led to arrests in gsk bribery case south china morning post  glaxosmithkline executives face china bribery probe bbc news  july    rupert neate and angela monaghan glaxosmithkline admits some staff in china involved in bribery the guardian  july  rupert neate gsk’s china crisis chief executive andrew witty speaks  as it happened the guardian  july  tom philips  july  chinese police allege glaxo sales reps trained to offer sexual bribes the daily telegraph   china fines glaxosmithkline nearly  million in bribery case  the new york times   malcolm moore denise roland china fines glaxo £m for bribery mark reilly sentenced the daily telegraph  september   watchdog fines gsk £m for paying to keep generic drugs out of uk market daily telegraph  february  retrieved  february    john hooper heather stewart over  doctors face charges in italian drugs scandal the guardian  may   jane burgermeister german prosecutors probe again into bribes by drug companies bmj   june  glaxo probed over doctor freebies bbc news  march   glaxosmithkline annual report pg  pdf retrieved    glaxosmithkline to settle tax dispute with us reuters  september  irs accepts settlement offer in largest transfer pricing dispute irs  september   julia kollewe  may  glaxosmithkline faces criminal investigation by serious fraud office the guardian   kirsten ridley uk fraud office liaising with china on gsk bribery case reuters  july   glaxosmithkline faces bribery claims in syria reuters  august  external linksedit official website glaxosmithkline companies grouped at opencorporates financial times quote profile and news london stock exchange quote regulatory filings and news new york stock exchange quote profile regulatory filings and news v t e glaxosmithkline subsidiaries glaxosmithkline pakistan glaxosmithkline pharmaceuticals ltd stiefel laboratories viiv healthcare  predecessors acquisitions allen  hanburys beecham group block drug burroughs wellcome glaxo glaxo wellcome human genome sciences recherche et industrie thérapeutiques reliant pharmaceuticals s e massengill company smithkline beecham smith kline  french products current pharmaceuticals advair alli augmentin avandia beconase boniva flixonase hycamtin lamictal paxilseroxat serlipet tagamet ventolin wellbutrinzyban zantac … more vaccines hepatyrix pandemrix twinrix other aquafresh horlicks nicoderm nicorette niquitin sensodyne tums … more former bc powder geritol goodys powder lucozade ribena people governance chris gent chair andrew witty ceo other thomas beecham silas m burroughs mahlon kline john k smith henry wellcome litigation canada v glaxosmithkline inc christopher v smithkline beecham corp glaxosmithkline services unlimited v commission united states v glaxo group ltd united states v glaxosmithkline other drug industry document archive glaxosmithkline prize side effects study  category v t e pharmaceutical and biotechnology industry in the united kingdom manufacturing in the united kingdom economy of the united kingdom companies current aah pharmaceuticals alliance boots astex astrazeneca medimmune btg cyclacel dechra pharmaceuticals ge healthcare genus glaxosmithkline hikma pharmaceuticals indivior macfarlan smith norbrook group oxford biomedica pfizer uk phytopharm proximagen shire silence therapeutics tbs gb unipath vectura group vernalis viiv healthcare defunct allen  hanburys amersham beecham group cambridge antibody technology celltech chiroscience distillers company fisons glaxo wellcome ici reliant pharmaceuticals renovo zeneca government and regulatory bodies commission on human medicines department of health european directorate for the quality of medicines european medicines agency medicines and healthcare products regulatory agency national collaborating centre for mental health national patient safety agency pharmaceutical price regulation scheme pharmaceutical society of northern ireland general pharmaceutical council scottish medicines consortium veterinary medicines directorate industry and professional bodies association of the british pharmaceutical industry chemical industries association european federation of biotechnology european federation of pharmaceutical industries and associations faculty of pharmaceutical medicine pharmacists defence association royal pharmaceutical society of great britain worshipful society of apothecaries books and journals bandolier bad pharma  british national formulary british national formulary for children monthly index of medical specialities side effects  the pharmaceutical journal other british approved name british pharmacopoeia drugscope european and developing countries clinical trials partnership european pharmacopoeia list of worlds largest pharmaceutical companies pharmaceutical services negotiating committee wellcome trust category v t e ftse  companies of the united kingdom   → ftse  i admiral group anglo american antofagasta ashtead group associated british foods astrazeneca aviva bae systems bhp bp babcock international barclays barratt developments british american tobacco british land bt group bunzl burberry carnival centrica cocacola hbc compass group convatec crh croda international dcc diageo direct line group easyjet experian fresnillo gs gkn glaxosmithkline glencore hammerson hargreaves lansdown hsbc imperial brands informa intercontinental hotels group international airlines group intertek itv johnson matthey kingfisher land securities group legal  general lloyds banking group london stock exchange group marks  spencer mediclinic international merlin entertainments micro focus international mondi morrisons national grid next old mutual paddy power betfair pearson persimmon provident prudential randgold resources royal bank of scotland reckitt benckiser relx group rentokil initial rio tinto group rollsroyce royal dutch shell royal mail rsa insurance group sage group j sainsbury schroders scottish mortgage investment trust segro severn trent shire sky smith  nephew smiths group smurfit kappa sse standard chartered standard life st jamess place taylor wimpey tesco tui unilever united utilities vodafone whitbread wolseley worldpay wpp v t e philadelphiaarea corporations including the delaware valley list of companies based in the philadelphia area philadelphiabased fortune  corporations rank in the  list comcast  aramark  crown holdings  delaware valleybased fortune  corporations rank in the  list amerisourcebergen  dupont  lincoln national  universal health services  campbell soup  ugi  burlington stores inc  other notable philadelphiabased businesses amorosos beneficial bank chemtura day  zimmermann fmc corporation independence blue cross pennsylvania real estate investment trust pep boys philadelphia media network radian group urban outfitters notable philadelphiabased professional partnerships ballard spahr blank rome cozen oconnor dechert drinker biddle  reath duane morris morgan lewis  bockius pepper hamilton saul ewing white and williams other notable delaware valleybased businesses actua corporation airgas alliedbarton ametek aqua america asplundh bentley systems brandywine realty trust boscovs carpenter technology cephalon chemours christiana care health system crozer keystone health system davids bridal duckduckgo epam systems enersys liberty property trust penn mutual penn national gaming ritas italian ice sei investments slm sungard susquehanna international group vanguard toll brothers triumph group unisys viropharma vishay intertechnology vwr wawa wilmington trust w l gore and associates wsfs bank notable delaware valleybased us headquarters of foreign businesses aberdeen asset management ace agustawestland astrazeneca delaware investments glaxosmithkline ing group keystone foods sap america siemens medical shire pharmaceuticals subaru teva pharmaceuticals td bank notable delaware valleybased division headquarters of us corporations acme cerberus capital management centocor johnson  johnson colonial penn conseco delmarva power exelon gsi commerce ebay hercules ashland mab paints sherwinwilliams mcneil laboratories jj neoware hewlettpackard peco exelon qvc liberty media rohm and haas dow chemical sunoco energy transfer tasty baking flowers foods retrieved from httpsenwikipediaorgwindexphptitleglaxosmithklineoldid categories biotechnology companies of the united kingdomcompanies based in the london borough of hounslowcompanies listed on the new york stock exchangedental companiesglaxosmithklinemedical controversiesmultinational companies headquartered in englandpharmaceutical companies established in british companies established in pharmaceutical companies of the united kingdomvaccine producersorphan drug companieslife sciences industry establishments in the united kingdombiotechnology companies established in companies formed by mergerhidden categories webarchive template wayback linksuse british english from september use dmy dates from september opencorporates groupings navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages العربيةcatalàčeštinadanskdeutschespañolesperantoفارسیfrançais한국어हिन्दीbahasa indonesiaíslenskaitalianoעבריתಕನ್ನಡlietuviųmagyarbahasa melayunederlandsnorsk bokmålnorsk nynorskpolskiportuguêsromânăрусскийscotsසිංහලсрпски  srpskisrpskohrvatski  српскохрватскиsuomisvenskaతెలుగుไทยtürkçeукраїнська edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view gsk gsk  twitter skip to content home home home current page about search query search twitter searches you follow follow following unfollow saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  language english bahasa indonesia bahasa melayu català čeština dansk deutsch english uk español filipino français hrvatski italiano magyar nederlands norsk polski português română slovenčina suomi svenska tiếng việt türkçe ελληνικά български език русский српски українська мова עִבְרִית العربية فارسی मराठी हिन्दी বাংলা ગુજરાતી தமிழ் ಕನ್ನಡ ภาษาไทย 한국어  简体 繁體 have an account log in have an account remember me · forgot password new to twitter sign up gskverified account gsk tweets tweets current page  following following  followers followers k likes likes    more likes unmute gsk mute gsk follow following unfollow blocked unblock pending cancel gskverified account gsk we’re a scienceled global healthcare company on a mission to help people to do more feel better live longer twitter code of conduct httpgsktoocpcfj  london uk gskcom joined april   photos and videos photos and videos tweets tweets tweets current page tweets  replies media you blocked gsk are you sure you want to view these tweets viewing tweets wont unblock gsk yes view profile close gsk followed gsk‏verified account gsk h hours ago more copy link to tweet embed tweet icymi we’re delighted to welcome leading scientist  physician dr laurie glimcher to our board read more httpgsktottoba pictwittercomljwhptl  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet embed video can you imagine a scientific discovery filling a basketball stadium martys hiv research did exactly that behindthesciencepictwittercomzquzkncxh  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet embed video flashbackfriday to  years ago when marty st clair discovered she’d made a scientific breakthrough in hiv researchpictwittercomcuncyitp  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk retweeted viiv healthcare‏verified account viivhc jul  more copy link to tweet embed tweet we are on our way to paris find out about our activities next week httpbitlyuhtm  ias positiveaction hivresearch hivpictwittercomukpbygkck  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet a great way to round off inclusionweek – we’re shortlisted in ethicalcorp resp biz awards well done team httpgsktouhgnn  ercbapictwittercomkxnarenrll  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk retweeted gsk us‏verified account gskus jul  more copy link to tweet embed tweet putting ourselves in someone else’s wheels for inclusionweek thanks to bridgesports for helping teach us the ability of disabilitypictwittercomrmmfmbybnm  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet why being an inclusive employer is good for business httpgsktoudtdr  inclusionweek thursdaythoughtspictwittercomaakqhgnwlk  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk retweeted gsk us‏verified account gskus jul  more copy link to tweet embed tweet tbt proud to share our history w nmajh as biochemist  nobelprize winner gertrudeelion is inducted to the only in america® hall of famepictwittercomogqvjacz  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet our people are key to what we do and the diversity of their backgrounds ideas and talents make us a better company inclusionweekpictwittercombunqslckw  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet meet ahsiya and hear her story of bravery and thursdaythoughts on leadership httpgsktovjqnyh pictwittercomjemajrss  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet we’re at the un high level political forum with globalcompact discussing how biz can help achieve the sustainable dev goals sdgs hlpfpictwittercomeafaua  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet being an inclusive employer means looking beyond the exterior thanks victoria for sharing your story to help endthestigma inclusionweekpictwittercomptovyhkwg  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet volunteering can do more than support local communities here’s what the stats tell us about our pulse programme charitytuesdaypictwittercombbqotzalr  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet with pride so this just happened at our global hq in london wetakepride in our lgbtq community inclusionweekpictwittercomuiloqiylzb  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet on charitytuesday we pay homage to our employees who have spent time supporting local communities across the pictwittercomekysvbwali  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet our who to every to help do more  feel better  and live longer worldemojiday  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet we’re dedicating this week to celebrating the diversity of our global workforce inclusive companies  better companies inclusionweekpictwittercomfwybrqt  replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet embed video come behindthescience to see how were using cutting edge tech to design the next generation of inhalers httpgsktouzyqi pictwittercomimpbttsf  replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet tbt  ever wondered what an inhaler looked like in the early s we explored our archive collection to find outpictwittercompqfbjkmn  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk‏verified account gsk jul  more copy link to tweet embed tweet jamie climbed the nd highest peak in africa despite having asthma find out how he did it httpgsktosvvrt  facesofgskpictwittercomzegvwaqahx  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo gsk hasnt tweeted yet back to top ↑ loading seems to be taking a while twitter may be over capacity or experiencing a momentary hiccup try again or visit twitter status for more information new to twitter sign up now to get your own personalized timeline sign up you may also like · refresh false   twitter about help center terms privacy policy cookies ads info close choose a trend location dismiss close previous next close go to a persons profile searches you follow follow following unfollow saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  close promote this tweet close block cancel block add a location to your tweets when you tweet with a location twitter stores that location you can switch location onoff before each tweet and always have the option to delete your location history learn more turn location on not now close share location results from send close your lists close create a new list list name description under  characters optional privacy public · anyone can follow this list private · only you can access this list save list close close copy link to tweet heres the url for this tweet copy it to easily share with friends close embed this tweet embed this video add this tweet to your website by copying the code below learn more add this video to your website by copying the code below learn more hmm there was a problem reaching the server try again include parent tweet include media by embedding twitter content in your website or app you are agreeing to the twitter developer agreement and developer policy preview close why youre seeing this ad close log in to twitter remember me · forgot password dont have an account sign up » close sign up for twitter not on twitter sign up tune into the things you care about and get updates as they happen sign up have an account log in » close twoway sending and receiving short codes country code for customers of united states  any canada  any united kingdom  vodafone orange  o brazil  nextel tim haiti  digicel voila ireland  vodafone o india  bharti airtel videocon reliance indonesia  axis  telkomsel indosat xl axiata italy  wind  vodafone » see sms short codes for other countries close confirmation close   close skip all welcome home this timeline is where you’ll spend most of your time getting instant updates about what matters to you tweets not working for you hover over the profile pic and click the following button to unfollow any account say a lot with a little when you see a tweet you love tap the heart — it lets the person who wrote it know you shared the love spread the word the fastest way to share someone else’s tweet with your followers is with a retweet tap the icon to send it instantly join the conversation add your thoughts about any tweet with a reply find a topic you’re passionate about and jump right in learn the latest get instant insight into what people are talking about now get more of what you love follow more accounts to get instant updates about topics you care about find whats happening see the latest conversations about any topic instantly never miss a moment catch up instantly on the best stories happening as they unfold back next next tweet from user glaxosmithkline  wikipedia glaxosmithkline from wikipedia the free encyclopedia jump to navigation search glaxosmithkline gsks head office in brentford london type public limited company traded as lse gsk nyse gsk ftse  component industry pharmaceutical biotechnology consumer goods predecessor glaxo plc wellcome plc beecham group plc kline  french beckman companies smith plc founded december   years ago  headquarters brentford london united kingdom area served worldwide key people sir philip hampton chairman emma walmsley ceo products pharmaceuticals vaccines oral healthcare nutritional products overthecounter medicines revenue £ billion  operating income £ billion  net income £ billion  number of employees   subsidiaries stiefel laboratories website wwwgskcom glaxosmithkline plc gsk is a british pharmaceutical company headquartered in brentford london established in  by a merger of glaxo wellcome and smithkline beecham gsk was the worlds sixth largest pharmaceutical company as of  after pfizer novartis merck hoffmannla roche and sanofin  emma walmsley became ceo on  march  and is the first female ceo of the company the company has a primary listing on the london stock exchange and is a constituent of the ftse  index as of august  it had a market capitalisation of £ billion around  billion the fourth largest on the london stock exchange it has a secondary listing on the new york stock exchange gsks drugs and vaccines earned £ billion in  its topselling products that year were advair avodart flovent augmentin lovaza and lamictal gsks consumer products which earned £ billion in  include sensodyne and aquafresh toothpaste the maltedmilk drink horlicks abreva for cold sores breathe right nasal strips nicoderm and nicorette nicotine replacements and night nurse a cold remedy the company developed the first malaria vaccine rtss which it said in  it would make available for five percent above cost legacy products developed at gsk include several listed in the world health organization model list of essential medicines such as amoxicillin mercaptopurine pyrimethamine and zidovudine in  gsk pleaded guilty to promotion of drugs for unapproved uses failure to report safety data and kickbacks to physicians in the united states and agreed to pay a  billion £bn settlement the largest settlement in the country by a drug company contents  history  glaxo wellcome  smithkline beecham  glaxosmithkline  venture arms  research products  pharmaceuticals  malaria vaccine  consumer healthcare  facilities  scientific recognition  operations and acquisitions since   –  –present  philanthropy and social responsibility   criminal and civil settlement  overview  rosiglitazone avandia  paroxetine paxilseroxat  bupropion wellbutrin  other controversies  antitrust case over griseofulvin  ribena  sb pharmco puerto rico  china  market manipulation in the uk  miscellaneous  diagram of acquisition history  see also  notes  references  external links historyedit glaxo wellcomeedit the historic glaxo factory in bunnythorpe new zealand with the glaxo laboratories sign still visible glaxo was founded in the s as a general trading company in bunnythorpe new zealand by a londoner joseph edward nathan in  it began producing driedmilk baby food first known as defiance then as glaxo from lacto under the slogan glaxo builds bonny babies the glaxo laboratories sign is still visible right on what is now a car repair shop on the main street of bunnythorpe the companys first pharmaceutical product produced in  was vitamin d glaxo laboratories opened new units in london in  the company bought two companies joseph nathan and allen  hanburys in  and  respectively the scottish pharmacologist david jack was working for allen  hanburys when glaxo took it over he went on to lead the companys rd until  after the company bought meyer laboratories in  it began to play an important role in the us market in  the american arm glaxo inc moved to research triangle park us headquartersresearch and zebulon us manufacturing in north carolina burroughs wellcome  company was founded in  in london by the american pharmacists henry wellcome and silas burroughs the wellcome tropical research laboratories opened in  in the s burroughs wellcome established research and manufacturing facilities in tuckahoe new york which served as the us headquarters until the company moved to research triangle park in north carolina in  the nobel prize winning scientists gertrude b elion and george h hitchings worked there and invented drugs still used many years later such as mercaptopurine in  the wellcome company bought cooper mcdougall  robertson inc to become more active in animal health glaxo and burroughs wellcome merged in  to form glaxo wellcome glaxo restructured its rd operation that year cutting  jobs worldwide closing its rd facility in beckenham kent and opening a medicines research centre in stevenage hertfordshire also that year glaxo wellcome acquired the californiabased affymax a leader in the field of combinatorial chemistry by  glaxo wellcome had become the worlds thirdlargest pharmaceutical company by revenues behind novartis and merck with a global market share of around  per cent its products included imigran for the treatment of migraine salbutamol ventolin for the treatment of asthma zovirax for the treatment of coldsores and retrovir and epivir for the treatment of aids in  the company was the worlds largest manufacturer of drugs for the treatment of asthma and hivaids it employed  people including  in the uk had  operating companies and  manufacturing facilities worldwide and seven of its products were among the worlds top  bestselling pharmaceuticals the company had rd facilities in hertfordshire kent and london and manufacturing plants in scotland and the north of england it had rd centres in the us and japan and production facilities in the us europe and the far east smithkline beechamedit beechams clock tower constructed  part of the beechams factory st helens in  thomas beecham launched his beechams pills laxative in england giving birth to the beecham group in  beecham opened its first factory in st helens lancashire by the s beecham was extensively involved in pharmaceuticals john k smith opened his first pharmacy in philadelphia in  in  mahlon kline joined the business which  years later became smith kline  co in  it merged with french richard and company and in  changed its name to smith kline  french laboratories as it focused more on research years later it bought norden laboratories a business doing research into animal health and recherche et industrie thérapeutiques in belgium in  to focus on vaccines the company began to expand globally buying seven laboratories in canada and the united states in  in  it bought allergan a manufacturer of eye and skincare products smithkline  french merged with beckman inc in  and changed its name to smithkline beckman in  it bought its biggest competitor international clinical laboratories and in  merged with beecham to form smithkline beecham plc the headquarters moved from the united states to england to expand rd in the united states the company bought a new research center in  another opened in  in england at new frontiers science park harlow glaxosmithklineedit glaxo wellcome and smithkline beecham announced their intention to merge in january  the merger was completed in december that year forming glaxosmithkline gsk the companys global headquarters are at gsk house brentford london officially opened in  by thenprime minister tony blair the building was erected at a cost of £ million and as of  was home to  administrative staff venture armsedit sr one was established in  by smithkline beecham to invest in new biotechnology companies and continued operating after gsk was formed by  gsk had formed another subsidiary gsk ventures to outlicense or start new companies around drug candidates that it did not intend to develop further as of  sr one tended to invest only if the company aligned with gsks business sr one was led by  to  peter sears  to  brenda gavin  to  barbara dalton  to  maxine gowen   to  joyce lonergan   to  tamar howson  to  russell greig  to  christoph westphal  jens eckstein research productsedit further information list of glaxosmithkline products pharmaceuticalsedit gsk manufactures products for major disease areas such as asthma cancer infections diabetes and mental health its biggestselling in  were advair avodart flovent augmentin lovaza and lamictal its drugs and vaccines earned £ billion that year other topselling products include its asthmacopd inhalers advair ventolin and flovent its diphtheriatetanuspertussis vaccine infanrix and its hepatitis b vaccine the epilepsy drug lamictal and the antibacterial augmentin medicines historically discovered or developed at gsk and its legacy companies and now sold as generics include amoxicillin and amoxicillinclavulanate ticarcillinclavulanate mupirocin and ceftazidime for bacterial infections zidovudine for hiv infection valacyclovir for herpes virus infections albendazole for parasitic infections sumatriptan for migraine lamotrigine for epilepsy bupropion and paroxetine for major depressive disorder cimetidine and ranitidine for gastroesophageal reflux disorder mercaptopurine and thioguanine for the treatment of leukemia allopurinol for gout pyrimethamine for malaria and the antibacterial trimethoprim among these albendazole amoxicillin amoxicillinclavulanate allopurinol mercaptopurine mupriocin pyrimethamine ranitidine thioguanine trimethoprim and zidovudine are listed on the world health organizations list of essential medications malaria vaccineedit in  gsk applied for regulatory approval for the first malaria vaccine malaria is responsible for over  deaths annually mainly in africa known as rtss the vaccine was developed as a joint project with the path vaccines initiative and the bill and melinda gates foundation the company has committed to making the vaccine available in developing countries for five percent above the cost of production as of  rtss which uses gsks proprietary as adjuvant was being examined in a phase  trial in eight african countries path reported that in the month period following vaccination rtss conferred approximately  protection from clinical plasmodium falciparum disease in children aged  months and approximately  protection in children aged  weeks when administered in conjunction with expanded program for immunization epi vaccines in  glaxo said it had spent more than  million and expected to spend an additional  million before seeking regulatory approval a second generation malaria vaccine is being evaluated in phase  clinical trials consumer healthcareedit gsks consumer healthcare division which earned £ billion in  sells oral healthcare including aquafresh macleans and sensodyne toothpastes and drinks such as horlicks boost a chocolateflavoured malt drink sold in india and formerly lucozade and ribena sold in  to suntory for £bn other products include abreva to treat cold sores night nurse a cold remedy breathe right nasal strips and nicoderm and nicorette nicotine replacements in march  it recalled alli an overthecounter weightloss drug in the united states and puerto rico because of possible tampering following customer complaints facilitiesedit as of  gsk had offices in over  countries and employed over  people  in rd the companys single largest market is the united states its us headquarters are in the navy yard philadelphia and research triangle park north carolina its consumerproducts division is in moon township pennsylvania company facilities include rd sites england stevenage stockley park ware the us research triangle park north carolina and collegeville pennsylvania canada china croatia france and india gsk is also planning to open a rd centre in partnership with mclaren technology group at the mclaren technology campus centres for biopharmaceutical products the us marietta pennsylvania and hamilton montana belgium canada germany and hungary manufacturing sites for prescription products scotland irvine and montrose england ware barnard castle worthing and ulverston ireland cork the us bristol tennessee king of prussia pennsylvania zebulon north carolina as well as australia belgium france italy malaysia poland puerto rico romania and singapore manufacturing sites for consumer products england maidenhead ireland dungarvan the us aiken south carolina oak hill new york st louis missouri brazil canada and kenya scientific recognitionedit four glaxosmithkline scientists have been recognized by the nobel committee for their contributions to basic medical science andor therapeutics development henry dale a former student of paul ehrlich received the  nobel prize in medicine for his work on the chemical transmission of neural impulses dale served as a pharmacologist and then as director of the wellcome physiological research laboratories from  to  and later served as trustee and chairman of the board of the wellcome trust john vane of wellcome research laboratories shared the  nobel prize for medicine for his work on prostaglandin biology and the discovery of prostacyclin vane served as group research and development director for the wellcome foundation from  to  gertrude b elion and george hitchings both of the wellcome research laboratories shared the  nobel prize in medicine with sir james w black for their discoveries of important principles for drug treatment elliot and hitchings were responsible for the discovery of a plethora of important drugs including mercaptopurine and thioguanine for the treatment of leukemia the immunosuppressant azothioprine allopurinol for gout pyrimethamine for malaria the antibacterial trimethoprim acyclovir for herpes virus infection and nelarabine for cancer treatment operations and acquisitions since edit –edit andrew witty gsks ceo since may  gsk completed the acquisition of new jerseybased block drug in  for us billion in  gsk acquired the usbased consumer healthcare company cns inc whose products included breathe right nasal strips and fiberchoice dietary supplements for us million in cash chris gent previously ceo of vodafone was appointed chairman of the board in  gsk opened its first rd centre in china in  in shanghai initially focused on neurodegenerative diseases andrew witty became the chief executive officer in  witty joined glaxo in  and had been president of gsks pharmaceuticals europe since  in  gsk acquired stiefel laboratories then the worlds largest independent dermatology drug company for usbn in november the fda approved gsks vaccine for  hn influenza protection manufactured by the companys id biomedical corp in canada also in november  gsk formed a joint venture with pfizer to create viiv healthcare which specializes in hiv research in  the company acquired laboratorios phoenix an argentine pharmaceutical company for usm and the ukbased sports nutrition company maxinutrition for £ million us million –presentedit in  in a million deal prestige brands holdings took over  gsk brands with sales of  million including bc powder beano ecotrin fiber choice goodys powder sominex and tagamet in  the company announced that it would invest £ million in manufacturing facilities in ulverston northern england designating it as the site for a previously announced biotech plant in may that year it acquired cellzome a german biotech company for us million and in june worldwide rights to alitretinoin toctino an eczema drug for  million in  gsk acquired human genome sciences hgs for  billion the companies had collaborated on developing the lupus drug belimumab benlysta albiglutide for type  diabetes and darapladib for atherosclerosis in march  gsk paid  billion to raise its stake in its indian pharmaceutical unit glaxosmithkline pharmaceuticals to  percent as part of a move to focus on emerging markets in april  novartis and glaxo agreed on more than  billion in deals with novartis selling its vaccine business to gsk and buying gsks cancer business in february  gsk announced that it would acquire glycovaxyn a swiss pharmaceutical company for  million and in june that year that it would sell two meningitis drugs to pfizer nimenrix and mencevax for around  million philip hampton at that time chair of the royal bank of scotland became gsk chairman in september  in september  the company announced that witty would be succeeded as ceo by emma walmsley in march  walmsley was a management professional originally from lancashire with a background in marketing philanthropy and social responsibilityedit glaxosmithkline center city philadelphia since  glaxosmithkline has several times ranked first among pharmaceutical companies on the global access to medicines index which is funded by the bill and melinda gates foundation in  the human rights campaign an lgbtrights advocacy group gave gsk a score of  percent in its corporate equality index gsk has been active with the world health organization who in the global alliance to eliminate lymphatic filariasis gaelf around  million people globally are believed to be infected with lymphatic filariasis in  the company endorsed the london declaration on neglected tropical diseases it agreed to donate  million albendazole tablets to the who each year to fight soiltransmitted helminthiasis and to provide  million albendazole tablets every year for lymphatic filariasis until the disease is eradicated as of  over  billion treatments had been delivered and  of  countries in which the disease is considered endemic had progressed to the surveillance stage in  the company said it would cut drug prices by  percent in  of the poorest nations release intellectual property rights for substances and processes relevant to neglected disease into a patent pool to encourage new drug development and invest  percent of profits from the leastdeveloped countries in medical infrastructure for those countries médecins sans frontières welcomed the decision but criticized gsk for failing to include hiv patents in its patent pool and for not including middleincome countries in the initiative in  gsk licensed its hiv portfolio to the medicines patent pool for use in children and agreed to negotiate a license for dolutegravir an integrase inhibitor then in clinical development in  this license was extended to include dolutegravir and adults with hiv the licenses include countries in which  percent of adults and  percent of children with hiv live also in  gsk joined alltrials a british campaign to ensure that all clinical trials are registered and the results reported the company said it would make its past clinicaltrial reports available and future ones within a year of the studies end  criminal and civil settlementedit overviewedit in july  gsk pleaded guilty in the united states to criminal charges and agreed to pay  billion in what was the largest settlement until then between the justice department and a drug company the  billion included a criminal fine of  and forfeiture of  the remaining  billion covered a civil settlement with the government under the false claims act the investigation was launched largely on the basis of information from four whistleblowers who filed qui tam whistleblower lawsuits against the company under the false claims act the charges stemmed from gsks promotion of the antidepressants paxil paroxetine and wellbutrin bupropion for unapproved uses from – specifically as suitable for patients under the age of  and from its failure to report safety data about avandia rosiglitazone both in violation of the federal food drug and cosmetic act other drugs promoted for unapproved uses were two inhalers advair fluticasonesalmeterol and flovent fluticasone propionate as well as zofran ondansetron imitrex sumatriptan lotronex alosetron and valtrex valaciclovir the settlement also covered reporting false best prices and underpaying rebates owed under the medicaid drug rebate program and kickbacks to physicians to prescribe gsks drugs there were allexpensespaid spa treatments and hunting trips for doctors and their spouses speakers fees at conferences and payment for articles ghostwritten by the company and placed by physicians in medical journals the company set up a ghostwriting programme called caspper initially to produce articles about paxil but which was extended to cover avandia as part of the settlement gsk signed a fiveyear corporate integrity agreement with the department of health and human services which obliged the company to make major changes in the way it did business including changing its compensation programmes for its sales force and executives and to implement and maintain transparency in its research practices and publication policies it announced in  that it would no longer pay doctors to promote its drugs or attend medical conferences and that its sales staff would no longer have prescription targets rosiglitazone avandiaedit further information rosiglitazone § adverse effects and rosiglitazone § lawsuits rosiglitazone the  settlement included a criminal fine of  for failing to report safety data to the fda about avandia rosiglitazone a diabetes drug approved in  and a civil settlement of  million for making false claims about it the justice department said gsk had promoted rosiglitazone to physicians with misleading information including that it conferred cardiovascular benefits despite an fdamandated label warning of cardiovascular risks in  john buse a diabetes specialist told medical conferences that rosiglitazone might carry an increased risk of cardiovascular problems gsk threatened to sue him called his university head of department and persuaded him to sign a retraction gsk raised questions internally about the drugs safety in  and in  the company ghostwrote an article in circulation describing a gskfunded clinical trial that suggested rosiglitazone might have a beneficial effect on cardiovascular risk from  reports began to link the thiazolidinediones the class of drugs to which rosiglitazone belongs to heart failure in april that year gsk began a sixyear openlabel randomized trial known as record to examine rosiglitazone and cardiovascular events two gsk metaanalyses in  and  showed an increased risk of cardiovascular problems with rosiglitazone the information was passed to the fda and posted on the company website but not otherwise published by december  rosiglitazone had become the topselling diabetes drug with annual sales of us billion in june  the new england journal of medicine published a metaanalysis that associated the drug with an increased risk of heart attack gsk had reportedly tried to persuade one of the authors steven nissen not to publish it after receiving an advance copy from one of the journals peer reviewers a gsk consultant in july  fda scientists suggested that rosiglitazone had caused  excess heart attacks between  and  the fda placed restrictions on the drug including adding a boxed warning but did not withdraw it in  the fda rejected that the drug had caused excess heart attacks a senate finance committee inquiry concluded in  that gsk had sought to intimidate scientists who had concerns about rosiglitazone in february that year the company tried to halt publication of an editorial about the controversy by nissen in the european heart journal the results of gsks record trial were published in june  it confirmed an association between rosiglitazone and an increased risk of heart failure and fractures but not of heart attack and concluded that it does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucoselowering drugs steven nissan and kathy wolkski argued that the studys low event rates reduced its statistical power in september  rosiglitazone was suspended in europe the results of the record study were confirmed in  by the duke clinical research institute in an independent review required by the fda in november that year the fda lifted the restrictions it had placed on the drug the boxed warning about heart attack was removed the warning about heart failure remained in place paroxetine paxilseroxatedit main article study  paroxetine known as paxil and seroxat gsk was fined for promoting paxilseroxat paroxetine for treating depression in the unders although the drug had not been approved for pediatric use paxil had  billion worldwide sales in  the company conducted nine clinical trials between  and  none of which showed that paxil helped children with depression from  to  it promoted the drug for the unders paying physicians to go on allexpenses paid trips fivestar hotels and spas from  paxils label along with those of similar drugs included an fdamandated boxed warning that it might increase the risk of suicidal ideation and behaviour in patients under  an internal smithkline beecham document said in  about withheld data from two gsk studies it would be commercially unacceptable to include a statement that pediatric efficacy had not been demonstrated as this would undermine the profile of paroxetine the company ghostwrote an article published in  in the journal of the american academy of child and adolescent psychiatry that misreported the results of one of its clinical trials study  the article concluded that paxil was generally well tolerated and effective for major depression in adolescents the suppression of the research findings is the subject of side effects  by alison bass for  years gsk marketed paxil as nonhabit forming in   patients filed a classaction suit alleging they had suffered withdrawal symptoms and in  a los angeles court issued an injunction preventing gsk from advertising that the drug was not habit forming the court withdrew the injunction after the fda objected that the court had no jurisdiction over drug marketing that the fda had approved in  a world health organization committee reported that paxil was among the top  drugs and top three antidepressants for which dependence had been reportedn  bupropion wellbutrinedit the company was also fined for promoting wellbutrin bupropion – approved at the time for major depressive disorder and also sold as a smokingcessation aid zyban – for weight loss and the treatment of attention deficit hyperactivity disorder sexual dysfunction and substance addiction gsk paid doctors to promote these offlabel uses and set up supposedly independent advisory boards and continuing medical education programmes other controversiesedit antitrust case over griseofulvinedit in the s glaxo group ltd glaxo and imperial chemical industries ici each owned patents covering various aspects of the antifungal drug griseofulvin nn – they created a patent pool by crosslicensing their patents subject to express licensing restrictions that the chemical from which the finished form of the drug tablets and capsules was made must not be resold in bulk form and they licensed other drug companies to sell the drug in finished form and subject to similar restrictions– the effect and intent of the bulksale restriction was to keep the drug chemical out of the hands of small companies that might act as pricecutters and the effect was to maintain stable uniform prices the united states brought an antitrust suit against the two companies—united states v glaxo group ltd—charging them with violation of the sherman act and also seeking to have the patents declared invalid the trial court found that the defendants had engaged in several unlawful conspiracies but dismissed the part of the suit seeking invalidation of patents and refused to grant as relief mandatory sales of the bulk drug chemical and compulsory licensing of the patents the government appealed to the supreme court which reversed in united states v glaxo group ltd  us   ribenaedit old ribena bottle year unknown made by beecham products brentford middlesex the label states widely used in hospitals and clinics there were concerns in the s about the sugar and vitamin content of ribena a blackcurrantbased syrup and soft drink owned by gsk until  produced in england by hw carter  co from the s the companys unbranded syrup was distributed to children as a source of vitamin c during world war ii which gave the drink a reputation as good for health beecham bought h w carter in  in  the british advertising standards authority asa required gsk to withdraw its claim that ribena toothkind a lowersugar variety did not encourage tooth decay a company poster showed bottles of toothkind in place of the bristles on a toothbrush the asas ruling was upheld by the high court in  gsk was fined  in new zealand over its claim that readytodrink ribena contained high levels of vitamin c after it was found to contain no detectable vitamin c in  gsk sold ribena and another drink lucozade to the japanese multinational suntory for £ billion sb pharmco puerto ricoedit in  the us department of justice announced that gsk would pay a  million criminal fine and forfeiture and a civil settlement of  million under the false claims act the fines stemmed from production of improperly made and adulterated drugs from  to  at gsks subsidiary sb pharmco puerto rico inc in cidra puerto rico which at the time produced  billion of products each year the drugs involved were kytril an antiemetic bactroban used to treat skin infections paxil the antidepressant and avandamet a diabetes drug gsk closed the factory in  according to the new york times the case began in  when gsk sent experts to fix problems cited by the fda the lead inspector recommended recalls of defective products but they were not authorized she was fired in  and filed a whistleblower lawsuit in  federal marshals seized  billion worth of products the largest such seizure in history in the  settlement sb pharmco plead guilty to criminal charges and agreed to pay  million in a criminal fine and forfeiture at that time the largest such payment ever by a manufacturer of adulterated drugs and  million in civil penalties to settle the civil lawsuit chinaedit in  chinese authorities announced that since  gsk had funnelled hk billion in kickbacks to gsk managers doctors hospitals and others who prescribed their drugs using over  travel agencies and consulting firms chinese authorities arrested four gsk executives as part of a fourmonth investigation into claims that doctors were bribed with cash and sexual favours in  a chinese court found the company guilty of bribery and imposed a fine of  million mark reilly the british head of gsks chinese operations received a threeyear suspended prison sentence after a oneday trial held in secret reilly was reportedly deported from china and dismissed by the company market manipulation in the ukedit in february  the company was fined more than £ million by the competition and markets authority for paying generics uk alpharma and norton healthcare more than £m between  and  in order to keep generic varieties of paroxetine out of the nhs market the generics companies were fined a further £ million at the end of  when generics were available in the uk the price of paroxetine dropped  miscellaneousedit italian police sought bribery charges in may  against  doctors and  gsk employees gsk and its predecessor were accused of having spent £m on physicians pharmacists and others giving them cameras computers holidays and cash doctors were alleged to have received cash based on the number of patients they treated with a cancer drug topotecan hycamtin the following month prosecutors in munich accused – doctors of having accepted bribes from smithkline beecham between  and  the inquiry was opened over allegations that the company had given over  hospital doctors money and free trips all charges were dismissed by the verona court in january  in  in the united states gsk settled the largest tax dispute in irs history agreeing to pay  billion at issue were zantac and other products sold in – the case revolved around intracompany transfer pricing—determining the share of profit attributable to the us subsidiaries of gsk and subject to tax by the irs the uks serious fraud office sfo opened a criminal inquiry in  into gsks sales practices using powers granted by the bribery act  the sfo said it was collaborating with chinese authorities to investigate bringing charges in the uk related to gsks activities in china europe and the middle east also as of  the us department of justice was investigating gsk with reference to the foreign corrupt practices act diagram of acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list glaxosmithkline smithkline beecham plc renamed  smithkline beckman renamed  smithklinerit renamed  smith kline  french reorganized  into  smith kline and french laboratories french richards and company acq  smith kline and company founded  lever brothers angioseal div acq  recherche et industrie thérapeutiques acq  beckman instruments inc merged  sold  specialized instruments corp acq  offner electronics acq  allergan acq  sold  international clinical laboratories acq  reckitt  colman acq  stiefel laboratories acq  by smithkline beckman sanofisynthelabo acq  beecham group plc merged  norcliff thayer acq  beecham group ltd s e massengill company acq  beecham group ltd renamed  cl bencard acq  county chemicals acq  glaxo wellcome renamed  glaxo merged  glaxo founded  joseph nathan acq  allen  hanburys founded  acq  margarine unie angioseal div acq  meyer laboratories acq  affymax acq  burroughs wellcome merged  mcdougall  robertson inc acq  burroughs wellcome  company founded  block drug acq  cns inc acq  stiefel laboratories acq  laboratorios phoenix acq  maxinutrition acq  cellzome acq  human genome sciences acq  novartis vaccine div acq  gsk cancer division sold  to novartis glycovaxyn acq  see alsoedit companies portal list of toothpaste brands index of oral health and dental articles recherche et industrie thérapeutiques rit galvani bioelectronics notesedit  glaxo wellcome was formed from glaxos  acquisition of burroughs wellcome and smithkline beecham from the  merger of the beecham group and the smithkline beckman corporation  world health organization expert committee on drug dependence  the committee noted the striking number of reports on paroxetine and withdrawal syndrome  the representative of consumers international reported that a number of patients had experienced difficulty in withdrawing from ssris in general it was agreed that withdrawal was indeed a problem in some patients but there was a difference of opinion on the degree of dependence that was involved given the possibility that the need for treatment of resistant or relapsing disease could make these drugs indispensable for patient care the committee expressed concern about the possibility of inappropriate prescribing resulting in the risk of problems of withdrawal outweighing the benefits of treatment with ssris referencesedit  a b c annual report  pdf retrieved  april    glaxosmithkline statista retrieved  april    the worlds biggest public companies  ranking forbes  ftse allshare index ranking stockchallengecouk   a b c annual report  pdf glaxosmithkline retrieved  may    products glaxosmithkline plc retrieved  november    a b hester plumridge  july  glaxo files its entry in race for a malaria vaccine wall street journal  laura lorenzetti  july  glaxosmithkline seeks approval on firstever malaria vaccine fortune   a b c d e f g h i j k glaxosmithkline to plead guilty and pay  billion to resolve fraud allegations and failure to report safety data united states department of justice  july  katie thomas and michael s schmidt glaxo agrees to pay  billion in fraud settlement the new york times  july  simon neville glaxosmithkline fined bn after bribing doctors to increase drugs sales the guardian  july   r p t davenporthines judy slinn glaxo a history to  cambridge university press  pp –  david newton trademarked a history of wellknown brands from airtex to wrights coal tar the history press  p   a b c d david j ravenscraft william f long paths to creating value in pharmaceutical mergers in steven n kaplan ed mergers and productivity university of chicago press   a b c d e f gsk history glaxosmithkline archived from the original on  june  retrieved  april     the story of a town tricentennial committee  addition to factory the eastchester citizenbulletin  november   peter pennoyer anne walker the architecture of delano  aldrich w w norton  company  p   iconic burroughs wellcome headquarters open for rare public tour triangle modernist houses press release  october   katherine bouton the nobel pair the new york times  january   mark s lesney the ghosts of pharma past modern drug discovery january  pp –   face glaxos axe at wellcome the independent  june    magnus grimond  june  glaxo warns of redundancies the independent   magnus grimond  september  glaxo wellcome plans to axe  jobs the independent   glaxo to acquire affymax the new york times  january   outlook glaxo wellcome the independent  march    company of the week glaxo wellcome the independent  august    profile glaxo wellcome bbc news  january    the new alchemy – the drug industry’s flurry of mergers is based on a big gamble the economist  january    partners resolve their differences and unite at the second attempt nature  may    hall that glitters isnt shareholder gold the daily telegraph  july    a b reaume andrew  january  is corporate venture capital a prescription for success in the pharmaceutical industry the journal of private equity   – jstor    press release peter sears president of smithkline beechams venture capital fund appointed to avant immunotherapeutics board of directors avant via pr newswire may     a b salemi tom  july  dalton joins pfizer the in vivo blog   press release sr one announces new team expands fund premier evergreen fund made  new investments in   business wire sr one via businesswire february     a b c licking ellen  april  sr one posts help wanted ad again the in vivo blog   licking ellen  march  sr ones revolving door the in vivo blog   huang gregory t  april  christoph westphal leaving gsks sr one to focus on longwood founders fund xconomy   press release jens eckstein named president of sr one gsks venture healthcare group sr one via fiercebiotech september     mostrecognized brands antiinfectives december  drugscom   geddes am et al dec  introduction historical perspective and development of amoxicillinclavulanate int j antimicrob agents  suppl  s– pmid  doijijantimicag   brown ag aug  clavulanic acid a novel betalactamase inhibitora case study in drug discovery and development drug des deliv   – pmid    search food and drug administration   d m richards r n brogden february  ceftazidime a review of its antibacterial activity pharmacokinetic properties and therapeutic use drugs   – pmid  doi   a b mercaptopurine chemical  engineering news   a b c d george hitchings and gertrude elion chemical heritage foundation   a b elion gb  the purine path to chemotherapy science   – pmid  doiscience   a b lawrence k altman  february  gertrude elion drug developer dies at  the new york times   who model list of essential medicines th list pdf world health organization october    glaxo files its entry in race for a malaria vaccine wall street journal   press release malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children path   birkett a j et al april  malaria vaccine rd in the decade of vaccines breakthroughs challenges and opportunities vaccine  supplement  b– pmid  doijvaccine   malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children malaria vaccine candidate reduces disease over  months of followup in latestage study of more than  infants and young children    press releases  media  glaxosmithkline archived from the original on  april    donald g mcneil jr  october  glaxos rts s malaria vaccine shows promise scientists say the new york times   product pipeline  gsk   a b angela monaghan ribena and lucozade sold to japanese drinks giant the guardian  september   majumdar ramanuj  product management in india rd ed phi learning p  isbn    aaron smith alli weightloss drug recalled for tampering cnn  march   about us what we do glaxosmithkline accessed  november  archived  october  at the wayback machine  sir henry dale  biographical   john r vane  biographical   maltzman js koretzky ga april  azathioprine old drug new actions j clin invest  – pmc   pmid  doijci   elion gb  acyclovir discovery mechanism of action and selectivity j med virol suppl  – pmid    koenig r  the legacy of great science the work of nobel laureate gertrude elion lives on oncologist   – pmid  doitheoncologist   glaxosmithkline completes the purchase of block drug for  billion pr newswire retrieved  august    rick stouffer  october  glaxo unit buys breathe right maker trib live   sir christopher gent to exit glaxosmithkline the daily telegraph  october   ben hirschler  may  glaxo china rd centre to target neurodegeneration reuters  david cyranoski  october  pharmaceutical futures made in china nature   corporate executive team glaxosmithkline retrieved  november  archived  october  at the wayback machine  andrew wittys journey from graduate to gsk ceo glaxosmithkline  august  andrew philip witty bloomberg  graham ruddick  april  glaxosmithkline buys stiefel for bn the daily telegraph   fda approves additional vaccine for  hn influenza virus us food and drug administration fda  november    andrew jack  april  companies  pharmaceuticals – gsk and pfizer to merge hiv portfolios financial times   gsk acquires laboratorios phoenix for m infogrok  paul sandle  december  update glaxo buys proteindrinks firm maxinutrition reuters   david ranii  december  gsk sells bc goodys and other brands news  observer archived from the original on  april    gsk confirms  mln stg uk investment plans reuters  march   european biotechnology news  may  gsk acquires cellzome  britains largest drugmaker glaxosmithkline will pay about €m in cash to acquire cellzome ag completely john carroll for fiercebiotech  may  gsk snags proteomics platform tech in m cellzome buyout  john carroll for fiercepharma  june  gsk continues deal spree with m pact for basilea eczema drug basilea pharmaceutica press release  june  basilea enters into global agreement with stiefel a gsk company for toctino® alitretinoin  matthew herper three lessons from glaxosmithklines purchase of human genome sciences forbes  july   hirschler ben  march  gsk pays  billion to lift indian unit stake to  percent reuters retrieved  march    chad bray david jolly novartis and glaxo agree to trade  billion in assets the new york times  april   jonathan d rockoff jeanne whalen marta falconi deal flurry shows drug makers swing toward specialization the wall street journal  april   gen  news highlightsgsk acquires glycovaxyn for m gen   pfizer buys two gsk meningitis vaccines for m gen retrieved  march    james quinn sir philip hampton to chair glaxo the daily telegraph  september   jon yeomans  september  emma walmsley becomes latest female ceo in ftse  as she replaces sir andrew witty at gsk daily telegraph london retrieved  september    access to medicine pdf archived from the original pdf on  february    human rights campaign profle buyers guide entry for glaxosmithkline accessed may    global alliance to eliminate lymphatic filariasis ifpmaorg archived from the original on  december    private and public partners unite to combat  neglected tropical diseases by  bill  melinda gates foundation  january   researchbased pharma pledges on neglected tropical diseases the pharma letter  january    global programme to eliminate lymphatic filariasis progress report  pdf world health organization  september  p    sarah boseley drug giant glaxosmithkline pledges cheap medicine for worlds poor the guardian  february   unitaid  february  unitaid statement on gsk patent pool for neglected diseases  tido von schoenangerer letter to the editor the guardian  february   glaxosmithkline unit joins patent pool for aids drugs  reuters   medicines patent pool viiv healthcare sign licence for the most recent hiv medicine to have received regulatory approval  medicines patent pool   ben goldacre bad pharma fourth estate   p   max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  jim edwards inside gsks cassper ghostwriting program cbs news  august   gsk to stop paying doctors in major marketing overhaul thomsonreuters  december   the intimidation of dr john buse and the diabetes drug avandia committee on finance united states senate november  pp –  max baucus chuck grassley finance committee letter to the fda regarding avandia united states senate finance committee  july  for internal concerns p  and attachment e pp – for ghostwriting p  and attachment h pp – for the ghostwriting attachment i p ff for cover letter to circulation attachment i p  for the ghostwritten article attachment i pp – haffner sm et al    effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type  diabetes mellitus circulation   – pmid  doicir   a b nissen se  the rise and fall of rosiglitazone european heart journal   – pmid  doieurheartjehq  see table  for timeline  a b philip d home et al rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type  diabetes record a multicentre randomised openlabel trial the lancet   june  pp – dois pmid  philip d home et al rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes record study design and protocol diabetologia  september  pp – dois pmid  record rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes clinicaltrialsgov  nissen se wolski k  effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes new england journal of medicine   – pmid  doinejmoa rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance   stephanie saul doctor accused of leak to drug maker the new york times  january  gardiner harris a faceoff on the safety of a drug for diabetes the new york times  february   a b staff report on glaxosmithkline and the diabetes drug avandia committee on finance united states senate january  grassley baucus release committee report on avandia the united states senate committee on finance  february  andrew clark glaxos handling of avandia concerns damned by us senate committee the guardian  february   david graham assessment of the cardiovascular risks and health benefits of rosiglitazone office of surveillance and epidemiology food and drug administration  july   fda adds boxed warning for heartrelated risks to antidiabetes drug avandia agency says drug to remain on market while safety assessment continues food and drug administration  november   a b fda drug safety communication fda requires removal of some prescribing and dispensing restrictions for rosiglitazonecontaining diabetes medicines food and drug administration  november   avandia prescribing information food and drug administration  thomas f lüscher ulf landmesser frank ruschitzka  april  standing firm—the european heart journal scientific controversies and the industry european heart journal   – doieurheartjehq  steven e nissen the rise and fall of rosiglitazone european heart journal  april  pp – doieurheartjehq pmid  moncef slaoui the rise and fall of rosiglitazone reply european heart journal  april  pp – doieurheartjehq pmid  michel komajda et al heart failure events with rosiglitazone in type  diabetes data from the record clinical trial european heart journal  april  pp – doieurheartjehp pmid   steven e nissen kathy wolski rosiglitazone revisitedan updated metaanalysis of risk for myocardial infarction and cardiovascular mortality archives of internal medicine  july  pp – that study was limited by low event rates which resulted in insufficient statistical power to confirm or refute evidence of an increased risk for ischemic myocardial events doiarchinternmed pmid   european medicines agency recommends suspension of avandia avandamet and avaglim european medicines agency  september   kenneth w mchaffey et al results of a reevaluation of cardiovascular outcomes in the record trial american heart journal  august  pp – doijahj pmid   fda requires removal of certain restrictions on the diabetes drug avandia food and drug administration  november  readjudication of the rosiglitazone evaluated for cardiovascular outcomes and regulation of glycemia in diabetes trial record joint meeting of the endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee food and drug administration – june  steven nissen steven nissen the hidden agenda behind the fdas new avandia hearings forbes  may  the fda responds to steve nissens criticism of upcoming avandia meeting forbes  may   a b w kondro b sibbald march  drug company experts advised staff to withhold data about ssri use in children canadian medical association journal    pmc   pmid  doicmaj   goldacre  p   kurt samson december  senate probe seeks industry payment data on individual academic researchers annals of neurology   a– pmid  doiana   letter showing authorship of study  drug industry document archive university of california san francisco isabel heck controversial paxil paper still under fire  years later the brown daily herald  april  jon n jureidini leemon b mchenry peter r mansfield clinical trials and drug promotion selective reporting of study  international journal of risk  safety in medicine   pp – doijrs company hid suicide link bbc news  january  secrets of the drug trials bbc panorama  january  goldacre  pp –  martin keller et al efficacy of paroxetine in the treatment of adolescent major depression a randomized controlled trial journal of the american academy of child and adolescent psychiatry  july  pp – pmid  doi  alison bass side effects a prosecutor a whistleblower and a bestselling antidepressant on trial algonquin books of chapel hill  marcia angell  january  drug companies  doctors a story of corruption the new york review of books     judge paxil ads cant say it isnt habitforming associated press  august    drug and device law december   the fdas amicus briefs on preemption ronald d white for the los angeles times august   us opposes order to pull paxil tv ads  a b who expert committee on drug dependence thirtythird report world health organization  pp    a b c d united states v glaxo group ltd  us    a b c d e lahatte gabrielle  reverse payments when the federal trade commission can attack the validity of underlying patents case western reserve journal of law technology  the internet  – retrieved  june    leslie christopher r  antitrust law and intellectual property rights cases and materials oxford university press pp – isbn    united states v glaxo group ltd at   jacobson jonathan m  antitrust law developments american bar association p  isbn    oliver thring consider squash and cordial the guardian  september  we have frank and vernon to thank for ribena the bristol post  september   linus gregoriadis makers of ribena lose fight over antidecay claims the daily telegraph  january   david eames  march  judge orders ribena to fess up the new zealand herald  tony jaques when an icon stumbles – the ribena issue mismanaged corporate communications an international journal   pp – michael regester judy larkin risk issues and crisis management in public relations kogan page publishers  p ff  glaxosmithkline to plead guilty  pay  million to resolve criminal and civil liability regarding manufacturing deficiencies at puerto rico plant us department of justice  october   a b glaxo to pay  million for sale of bad products the new york times  october    alice yan toh han shih  july  shanghai travel agents revenue surge led to arrests in gsk bribery case south china morning post  glaxosmithkline executives face china bribery probe bbc news  july    rupert neate and angela monaghan glaxosmithkline admits some staff in china involved in bribery the guardian  july  rupert neate gsk’s china crisis chief executive andrew witty speaks  as it happened the guardian  july  tom philips  july  chinese police allege glaxo sales reps trained to offer sexual bribes the daily telegraph   china fines glaxosmithkline nearly  million in bribery case  the new york times   malcolm moore denise roland china fines glaxo £m for bribery mark reilly sentenced the daily telegraph  september   watchdog fines gsk £m for paying to keep generic drugs out of uk market daily telegraph  february  retrieved  february    john hooper heather stewart over  doctors face charges in italian drugs scandal the guardian  may   jane burgermeister german prosecutors probe again into bribes by drug companies bmj   june  glaxo probed over doctor freebies bbc news  march   glaxosmithkline annual report pg  pdf retrieved    glaxosmithkline to settle tax dispute with us reuters  september  irs accepts settlement offer in largest transfer pricing dispute irs  september   julia kollewe  may  glaxosmithkline faces criminal investigation by serious fraud office the guardian   kirsten ridley uk fraud office liaising with china on gsk bribery case reuters  july   glaxosmithkline faces bribery claims in syria reuters  august  external linksedit official website glaxosmithkline companies grouped at opencorporates financial times quote profile and news london stock exchange quote regulatory filings and news new york stock exchange quote profile regulatory filings and news v t e glaxosmithkline subsidiaries glaxosmithkline pakistan glaxosmithkline pharmaceuticals ltd stiefel laboratories viiv healthcare  predecessors acquisitions allen  hanburys beecham group block drug burroughs wellcome glaxo glaxo wellcome human genome sciences recherche et industrie thérapeutiques reliant pharmaceuticals s e massengill company smithkline beecham smith kline  french products current pharmaceuticals advair alli augmentin avandia beconase boniva flixonase hycamtin lamictal paxilseroxat serlipet tagamet ventolin wellbutrinzyban zantac … more vaccines hepatyrix pandemrix twinrix other aquafresh horlicks nicoderm nicorette niquitin sensodyne tums … more former bc powder geritol goodys powder lucozade ribena people governance chris gent chair andrew witty ceo other thomas beecham silas m burroughs mahlon kline john k smith henry wellcome litigation canada v glaxosmithkline inc christopher v smithkline beecham corp glaxosmithkline services unlimited v commission united states v glaxo group ltd united states v glaxosmithkline other drug industry document archive glaxosmithkline prize side effects study  category v t e pharmaceutical and biotechnology industry in the united kingdom manufacturing in the united kingdom economy of the united kingdom companies current aah pharmaceuticals alliance boots astex astrazeneca medimmune btg cyclacel dechra pharmaceuticals ge healthcare genus glaxosmithkline hikma pharmaceuticals indivior macfarlan smith norbrook group oxford biomedica pfizer uk phytopharm proximagen shire silence therapeutics tbs gb unipath vectura group vernalis viiv healthcare defunct allen  hanburys amersham beecham group cambridge antibody technology celltech chiroscience distillers company fisons glaxo wellcome ici reliant pharmaceuticals renovo zeneca government and regulatory bodies commission on human medicines department of health european directorate for the quality of medicines european medicines agency medicines and healthcare products regulatory agency national collaborating centre for mental health national patient safety agency pharmaceutical price regulation scheme pharmaceutical society of northern ireland general pharmaceutical council scottish medicines consortium veterinary medicines directorate industry and professional bodies association of the british pharmaceutical industry chemical industries association european federation of biotechnology european federation of pharmaceutical industries and associations faculty of pharmaceutical medicine pharmacists defence association royal pharmaceutical society of great britain worshipful society of apothecaries books and journals bandolier bad pharma  british national formulary british national formulary for children monthly index of medical specialities side effects  the pharmaceutical journal other british approved name british pharmacopoeia drugscope european and developing countries clinical trials partnership european pharmacopoeia list of worlds largest pharmaceutical companies pharmaceutical services negotiating committee wellcome trust category v t e ftse  companies of the united kingdom   → ftse  i admiral group anglo american antofagasta ashtead group associated british foods astrazeneca aviva bae systems bhp bp babcock international barclays barratt developments british american tobacco british land bt group bunzl burberry carnival centrica cocacola hbc compass group convatec crh croda international dcc diageo direct line group easyjet experian fresnillo gs gkn glaxosmithkline glencore hammerson hargreaves lansdown hsbc imperial brands informa intercontinental hotels group international airlines group intertek itv johnson matthey kingfisher land securities group legal  general lloyds banking group london stock exchange group marks  spencer mediclinic international merlin entertainments micro focus international mondi morrisons national grid next old mutual paddy power betfair pearson persimmon provident prudential randgold resources royal bank of scotland reckitt benckiser relx group rentokil initial rio tinto group rollsroyce royal dutch shell royal mail rsa insurance group sage group j sainsbury schroders scottish mortgage investment trust segro severn trent shire sky smith  nephew smiths group smurfit kappa sse standard chartered standard life st jamess place taylor wimpey tesco tui unilever united utilities vodafone whitbread wolseley worldpay wpp v t e philadelphiaarea corporations including the delaware valley list of companies based in the philadelphia area philadelphiabased fortune  corporations rank in the  list comcast  aramark  crown holdings  delaware valleybased fortune  corporations rank in the  list amerisourcebergen  dupont  lincoln national  universal health services  campbell soup  ugi  burlington stores inc  other notable philadelphiabased businesses amorosos beneficial bank chemtura day  zimmermann fmc corporation independence blue cross pennsylvania real estate investment trust pep boys philadelphia media network radian group urban outfitters notable philadelphiabased professional partnerships ballard spahr blank rome cozen oconnor dechert drinker biddle  reath duane morris morgan lewis  bockius pepper hamilton saul ewing white and williams other notable delaware valleybased businesses actua corporation airgas alliedbarton ametek aqua america asplundh bentley systems brandywine realty trust boscovs carpenter technology cephalon chemours christiana care health system crozer keystone health system davids bridal duckduckgo epam systems enersys liberty property trust penn mutual penn national gaming ritas italian ice sei investments slm sungard susquehanna international group vanguard toll brothers triumph group unisys viropharma vishay intertechnology vwr wawa wilmington trust w l gore and associates wsfs bank notable delaware valleybased us headquarters of foreign businesses aberdeen asset management ace agustawestland astrazeneca delaware investments glaxosmithkline ing group keystone foods sap america siemens medical shire pharmaceuticals subaru teva pharmaceuticals td bank notable delaware valleybased division headquarters of us corporations acme cerberus capital management centocor johnson  johnson colonial penn conseco delmarva power exelon gsi commerce ebay hercules ashland mab paints sherwinwilliams mcneil laboratories jj neoware hewlettpackard peco exelon qvc liberty media rohm and haas dow chemical sunoco energy transfer tasty baking flowers foods retrieved from httpsenwikipediaorgwindexphptitleglaxosmithklineoldid categories biotechnology companies of the united kingdomcompanies based in the london borough of hounslowcompanies listed on the new york stock exchangedental companiesglaxosmithklinemedical controversiesmultinational companies headquartered in englandpharmaceutical companies established in british companies established in pharmaceutical companies of the united kingdomvaccine producersorphan drug companieslife sciences industry establishments in the united kingdombiotechnology companies established in companies formed by mergerhidden categories webarchive template wayback linksuse british english from september use dmy dates from september opencorporates groupings navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages العربيةcatalàčeštinadanskdeutschespañolesperantoفارسیfrançais한국어हिन्दीbahasa indonesiaíslenskaitalianoעבריתಕನ್ನಡlietuviųmagyarbahasa melayunederlandsnorsk bokmålnorsk nynorskpolskiportuguêsromânăрусскийscotsසිංහලсрпски  srpskisrpskohrvatski  српскохрватскиsuomisvenskaతెలుగుไทยtürkçeукраїнська edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view